methylphenidate profile

N-phenyl-4-(quinolin-2-ylmethyl)piperazine-1-carboxamide: a fatty acid amide hydrolase inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	11515763
CHEMBL ID	513789
SCHEMBL ID	3600412
MeSH ID	M0013660
PubMed CID	4158
CHEMBL ID	796
CHEBI ID	84276
CHEBI ID	6887
SCHEMBL ID	37178
MeSH ID	M0013660

Synonym
bdbm26741
pf-622
n-phenyl-4-(quinolin-2-ylmethyl)piperazine-1-carboxamide
CHEMBL513789
898235-65-9
SCHEMBL3600412
DTXSID00467917
faah inhibitor, pf-622
NCGC00388308-02
methyl phenyl(piperidin-2-yl)acetate
methylin
.alpha.-phenyl-2-piperidineacetic acid methyl ester
2-piperidineacetic acid, .alpha.-phenyl-, methyl ester
daytrana (tn)
methylphenidate (usan/inn)
D04999
dea no. 1724
einecs 204-028-6
alpha-phenyl-alpha-(2-piperidyl)acetic acid methyl ester
methylfenidan
methyl (2-phenyl-2-(2-piperidyl)acetate)
4311/b ciba
nci-c56280
methyl phenidate
metilfenidato [inn-spanish]
methylphenidatum [inn-latin]
metilfenidato [italian]
c 4311
plimasine
2-piperidineacetic acid, alpha-phenyl-, methyl ester
calocain
hsdb 3126
methylphenidate
C07196
113-45-1
methyl alpha-phenyl-alpha-(2-piperidyl)acetate
methylphenidan
DB00422
alpha-phenyl-2-piperidineacetic acid methyl ester
methyl phenidylacetate
methyl alpha-phenyl-alpha-2-piperidinylacetate
phenidylate
prc-063
chebi:84276 ,
methylphenidate extended release
CHEMBL796 ,
L001307
bdbm50062912
methyl 2-phenyl-2-piperidin-2-ylacetate
NCGC00248587-01
methylphenidatum
metilfenidato
methylphenidate [usan:inn:ban]
cotempla xr-odt
methyl phenidyl acetate
centedein
d-methylphenidate hcl
gtpl7236
methyl 2-phenyl-2-(piperidin-2-yl)acetate
jornay pm (a.k.a. hld200)
SCHEMBL37178
CS-4657
methyl alpha-piperid-2-ylphenylacetate
ritaline (salt/mix)
methyl .alpha.-phenyl-2-piperidineacetate
methyl .alpha.-phenyl-.alpha.-2-piperidinylacetate
methylin (salt/mix)
centedein (salt/mix)
methyl .alpha.-phenyl-.alpha.-(2-piperidyl)acetate
methyl .alpha.-phenyl-2-piperidine-acetate
centedrin (salt/mix)
rubifen
methyl phenyl(2-piperidinyl)acetate #
centedrine (salt/mix)
ritalin (salt/mix)
HY-B1091
AB01563134_01
DTXSID5023299 ,
SBI-0206868.P001
phenyl-piperidin-2-yl-acetic acid methyl ester
BCP18286
Q422112
BRD-A19585813-003-01-7
NCGC00248587-03
2-piperidineacetic acid, ?-phenyl-, methyl ester
methylphenidate (ii)
dtxcid003299
chebi:6887
metilfenidato (inn-spanish)
methylphenidate (mart.)
n06ba04
methylphenidate transdermal system
methylphenidatum (inn-latin)
rac-methyl (2r)-phenyl((2r)-piperidin-2-yl)acetate

Excerpt	Reference	Relevance
"Methylphenidate is a powerful central nervous system stimulant with a high potential for abuse in horse racing. "	( Detection of Methylphenidate in Equine Hair Using Liquid Chromatography-High-Resolution Mass Spectrometry. Alarcio, G; Arthur, RM; Clifford, A; Flores, L; Moeller, BC; Mosburg, M, 2021)	2.43
"Methylphenidate (MPH) is an important emerging pollutant found in effluents and wastewater. "	( Development and validation of a LC-PDA method for methylphenidate analysis in sewage. Bertol, CD; Freddo, N; Friedrich, MT; Nardi, J; Paixão, MCS; Rosano, VA; Rossato-Grando, LG; Vieira, BF, 2022)	2.42
"Methylphenidate is a first-line treatment for ADHD, and it is known to affect the subcortical and dopaminergic systems."	( Subcortical volumetric alterations as potential predictors of methylphenidate treatment response in youth with attention-deficit/hyperactivity disorder. Hwang, CS; Kim, JS; Kim, JW; Lee, KH, )	1.09
"Methylphenidate (MPH) is a psychostimulant, beneficial in attention deficit hyperactivity disorder (ADHD). "	( Effect of Methylphenidate and buspirone-methylphenidate co-administration on biochemical and hematological parameters in rats: Implications for safe and confrontational use. Alam, N; Ikram, R; Kashif, SS; Khan, SS; Khatoon, H; Naeem, S; Siddiqui, T, 2021)	2.47
"Methylphenidate (MPH) is a central nervous system (CNS) stimulant known for its effectiveness in the treatment of Attention Deficit Hyperactivity Disorder (ADHD), a neuropsychiatric condition that has a high incidence in childhood and affects behavior and cognition. "	( Evidence of methylphenidate effect on mitochondria, redox homeostasis, and inflammatory aspects: Insights from animal studies. Foschiera, LN; Schmitz, F; Wyse, ATS, 2022)	2.54
"Methylphenidate is a first-line treatment for ADHD; its contribution to sleep problems in adult ADHD is currently unclear. "	( Effects of methylphenidate on subjective sleep parameters in adults with ADHD: a prospective, non-randomized, non-blinded 6-week trial. Fagerlund, B; Glenthøj, B; Habekost, T; Jepsen, JRM; le Sommer, J; Low, AM; Vangkilde, S, 2023)	2.74
"Methylphenidate is a widely used first-line treatment for attention deficit/hyperactivity disorder (ADHD), but the underlying circuit mechanisms are poorly understood. "	( Methylphenidate remediates aberrant brain network dynamics in children with attention-deficit/hyperactivity disorder: A randomized controlled trial. Cai, W; Makita, K; Menon, V; Mizuno, Y; Supekar, K; Takiguchi, S; Tomoda, A, 2022)	3.61
"Methylphenidate (MP) is a psychostimulant chronically prescribed for the treatment of attention deficit hyperactivity disorder (ADHD). "	( Abstinence following intermittent methylphenidate exposure dose-dependently modifies brain glucose metabolism in the rat brain. Arnavut, E; Hadjiargyrou, M; Hamilton, J; Komatsu, D; Sajjad, M; Thanos, PK; Yao, R, 2022)	2.44
"Methylphenidate (MPD) is a psychostimulant that is widely prescribed to treat attention deficit-hyperactivity disorder, but it is abused recreationally as well. "	( Age differences to methylphenidate-NAc neuronal and behavioral recordings from freely behaving animals. Dafny, N; Kabani, A; Medina, AC; Reyes-Vasquez, C, 2022)	2.49
"Methylphenidate is a 'prescription only' drug against attention disorders which is increasingly used by adults. "	( General practice database on mortality in adults on methylphenidate: cohort study. Cheung, K; Stricker, B; Verhamme, K, 2022)	2.41
"Methylphenidate is a stimulant used to treat attention deficit and hyperactivity disorder (ADHD). "	( Pre-clinical evidence that methylphenidate increases motivation and/or reward preference to search for high value rewards. Baltazar, G; Da Cunha, C; Esaki, JY; Fuentes, R; Levcik, D; Pochapski, JA; Pulido, LN; Sanchez, WN; Stresser, JL; Sugi, A, 2023)	2.65
"Methylphenidate (MPH) is a chiral compound with two chiral centers."	( Chiral separation and quantitation of methylphenidate, ethylphenidate, and ritalinic acid in blood using supercritical fluid chromatography. Kronstrand, R; Smith, C; Swortwood, MJ; Vikingsson, S, 2023)	1.9
"Methylphenidate (MPH) is a central nervous stimulant, which is mainly used in attention deficit hyperactivity disorder (ADHD) and narcolepsy. "	( Characteristics and outcomes of cases with methylphenidate abuse, dependence or withdrawal: an analysis of spontaneous reports in EudraVigilance. Bachmann, CJ; Hartmayer, LT; Hoffmann, F; Jobski, K, 2023)	2.62
"Methylphenidate (MPH) is a psychostimulant which inhibits the uptake of dopamine and norepinephrine transporters, DAT and NET, and is mostly used to treat Attention Deficit/Hyperactivity Disorder. "	( An exploratory analysis of the performance of methylphenidate regimens based on a PKPD model of dopamine and norepinephrine transporter occupancy. Nekka, F; Robaey, P; Soufsaf, S, 2023)	2.61
"Methylphenidate (MPD) is a psychostimulant used to treat attention deficit hyperactivity disorder. "	( Methylphenidate induces a different response in the dorsal raphe as compared to ventral tegmental area and locus coeruleus: behavioral and concomitant neuronal recordings in adult rats. Claussen, C; Dafny, N; Jones, Z; Tang, B; Yuan, A, 2023)	3.8
"Methylphenidate is a widely used and effective treatment for attention-deficit/hyperactivity disorder (ADHD), yet the underlying neural mechanisms and their relationship to changes in behavior are not fully understood. "	( Bayesian dynamical system analysis of the effects of methylphenidate in children with attention-deficit/hyperactivity disorder: a randomized trial. Cai, W; Menon, V; Mizuno, Y; Tomoda, A, 2023)	2.6
"Methylphenidate is an effective first-line treatment for attention-deficit/hyperactivity disorder (ADHD). "	( The Adverse Effects and Nonmedical Use of Methylphenidate Before and After the Outbreak of COVID-19: Machine Learning Analysis. Kim, E; Lee, H; Oh, S; Park, S; Purja, S; Shin, H; Yuniar, CT, 2023)	2.62
"Methylphenidate (MPH) is a central nervous system stimulant that is mainly used for Attention-Deficit/Hyperactivity Disorder (ADHD). "	( Methylphenidate exposure in juvenile period elicits locomotion changes and anxiolytic-like behavior in adulthood: Evidence using zebrafish as a translational model. Barcellos, LJG; Berton, N; Biazus, IC; do Prado, L; Fortuna, M; Freddo, N; Nardi, J; Oliveira, AP; Pompermaier, A; Rossato-Grando, LG; Siqueira, L; Soares, SM; Tamagno, WA; Varela, ACC, 2024)	4.33
"Methylphenidate is an established treatment for attention-deficit hyperactivity disorder that also has abuse potential. "	( Role of homeostatic feedback mechanisms in modulating methylphenidate actions on phasic dopamine signaling in the striatum of awake behaving rats. Burrell, MH; Fuller, JA; Hyland, BI; Lipski, J; Liyanagama, K; Wickens, JR; Yee, AG, 2019)	2.21
"Methylphenidate (MPH) is a piperidine similar to amphetamines, and is indicated for attention deficit hyperactivity disorder. "	( Methylphenidate and stuttering. Azzouz, B; Claustre, G; Djerada, Z; Herlem, E; Morel, A; Trenque, A; Trenque, T, 2019)	3.4
"Methylphenidate (MP) is a commonly prescribed psychostimulant to individuals with Attention Deficit Hyperactivity Disorder, and is often used illicitly among healthy individuals with intermittent breaks to coincide with breaks from school. "	( Brief and extended abstinence from chronic oral methylphenidate treatment produces reversible behavioral and physiological effects. Carias, E; Connor, C; Hadjiargyrou, M; Kalinowski, L; Komatsu, DE; Mackintosh, M; Martin, C; Popoola, D; Richer, K; Smith, L; Somanesan, R; Thanos, PK, 2020)	2.26
"Methylphenidate (MPH), which is a psychostimulant drug, has been often prescribed for the treatment of ADHD in patients."	( Effects of medications on ventricular repolarization in children with attention deficit hyperactivity disorder. Akpinar, M; Esedova, C; İrdem, A; Türkmenoğlu, YE; Uysal, T, 2020)	1.28
"Methylphenidate is a first-line treatment for ADHD, however no previous meta-analysis has evaluated its overall efficacy for ADHD in children with comorbid intellectual disability (ID) or borderline intellectual functioning."	( Therapeutic effects of methylphenidate for attention-deficit/hyperactivity disorder in children with borderline intellectual functioning or intellectual disability: A systematic review and meta-analysis. Carvalho, AF; Chen, TY; Chen, YW; Cheng, YS; Li, DJ; Lin, PY; Stubbs, B; Sun, CK; Tseng, PT; Wu, CK; Wu, MK, 2019)	1.55
"Methylphenidate (Ritalin®) is a psychostimulant used chronically to treat attention deficit hyperactivity disorder. "	( Chronic methylphenidate induces increased quinone production and subsequent depletion of the antioxidant glutathione in the striatum. Archibald, KM; Ensley, T; Hall, AN; Ketchem, S; Oakes, HV; Pond, BB, 2019)	2.39
"Methylphenidate (MPH) is a dopamine transporter (DAT) inhibitor used to treat attention-deficit/hyperactivity-disorder (ADHD). "	( Ventral striatum supports Methylphenidate therapeutic effects on impulsive choices expressed in temporal discounting task. Drui, G; Martinez, E; Météreau, É; Pasquereau, B; Saga, Y; Tremblay, L, 2020)	2.3
"Methylphenidate (MPH) is an important drug that modulates the catecholaminergic system."	( Task experience eliminates catecholaminergic effects on inhibitory control - A randomized, double-blind cross-over neurophysiological study. Beste, C; Mückschel, M; Roessner, V, 2020)	1.28
"Methylphenidate (MPH) is a psychostimulant widely misused to increase wakefulness by drivers and students. "	( Stimulants cocktail: Methylphenidate plus caffeine impairs memory and cognition and alters mitochondrial and oxidative status. Barcellos, LJG; de Alcantara Barcellos, HH; Fortuna, M; Freddo, N; Koakoski, G; Maffi, VC; Mozzato, MT; Pompermaier, A; Rossato-Grando, LG; Soares, SM; Varela, ACC, 2021)	2.38
"Methylphenidate (MPH) is a first-line treatment option for attention-deficit hyperactive disorder and narcolepsy. "	( Co-abuse of alprazolam augments the hepato-renal toxic effects of methylphenidate. Chopra, K; Dharavath, RN; Dutt, M; Kaur, N; Kaur, T; Sharma, S, )	1.81
"Methylphenidate (MPH) is a psychostimulant drug used as first-line treatment for ADHD and it inhibits dopamine and norepinephrine reuptake transporters."	( Is contrast sensitivity a physiological marker in attention-deficit hyperactivity disorder? Atas, PBU; Berker, M; Çankaya, C; Ceylan, OM; Dönmez, YE; Güntürkün, PN; Özcan, ÖÖ, 2020)	1.28
"Methylphenidate (MPH) is an efficacious treatment for ADHD but concerns have been raised about potential adverse effects of extended treatment on growth."	( Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis. Balia, C; Banaschewski, T; Buitelaar, JK; Carucci, S; Coghill, D; Danckaerts, M; Dittmann, RW; Gagliano, A; Garas, P; Hollis, C; Inglis, S; Konrad, K; Kovshoff, H; Lampis, A; Liddle, EB; McCarthy, S; Nagy, P; Panei, P; Romaniello, R; Sonuga-Barke, E; Usala, T; Wong, ICK; Zuddas, A, 2021)	2.47
"Methylphenidate is a psychostimulant drug used to treat fatigue in patients with advanced cancer, for which there is no gold standard of treatment."	( Improved cancer-related fatigue in a randomised clinical trial: methylphenidate no better than placebo. Centeno, C; Cuervo, MA; De Santiago, A; Gagnon, B; Gandara, A; Portela, MA; Ramos, D; Rojí, R; Salgado, E; Sanz, A, 2022)	2.4
"Methylphenidate (MPH) is a mild CNS stimulant that has been used in hyperactive children, and patients with neurodegenerative and major depressive disorders. "	( Cannabidiol attenuated the maintenance and reinstatement of extinguished methylphenidate-induced conditioned place preference in rats. Haghparast, A; Jamali, S; Kashefi, A; Rashidy-Pour, A; Tomaz, C; Vafaei, AA, 2021)	2.3
"Methylphenidate (MPH) is a stimulant, FDA-approved for the treatment of ADHD, and often used for ADHD in the setting of pediatric epilepsy."	( Methylphenidate for attention problems in epilepsy patients: Safety and efficacy. Adams, J; Devinsky, O; Leeman-Markowski, BA; Martin, SP; Meador, KJ, 2021)	2.79
"Methylphenidate (MP) is a widely used psychostimulant prescribed for Attention Deficit Hyperactivity Disorder and is also used illicitly by healthy individuals. "	( Abstinence from Chronic Methylphenidate Exposure Modifies Cannabinoid Receptor 1 Levels in the Brain in a Dose-dependent Manner. Connor, C; Hadjiargyrou, M; Hamilton, J; Komatsu, D; Robison, L; Thanos, P, 2022)	2.47
"Methylphenidate (MPH) is an indirect-acting sympathomimetic drug and structurally related to amphetamine. "	( Acute myocardial infarction due to spontaneous coronary artery dissection in a 6-year-old boy with ADHD on the third day of treatment with methylphenidate. Becker, M; Kerst, G; Ostermayer, S; Pitzer, M; Pohlmann, U; Rascher, W; Stammschulte, T, 2022)	2.37
"Methylphenidate (MPH) is a compound commonly used to modulate the catecholaminergic system. "	( Perception-Action Integration Is Modulated by the Catecholaminergic System Depending on Learning Experience. Beste, C; Bluschke, A; Eggert, E; Kleimaker, M; Mückschel, M; Münchau, A; Roessner, V; Takacs, A, 2021)	2.06
"Methylphenidate (MPH) is a medication used to combat attention-deficit/hyperactivity disorder by speeding up brain activity. "	( Short- and Long-Term Stability of Methylphenidate and Its Metabolites in Blood. Smith, CR; Swortwood, MJ, 2021)	2.34
"Methylphenidate is a drug widely prescribed to treat ADHD."	( "Real-world" effectiveness of methylphenidate in improving the academic achievement of Attention-Deficit Hyperactivity Disorder diagnosed students-A systematic review. da Silveira, VT; de Faria, JCM; Duarte, LJR; Ferreira, LA; Menezes de Pádua, C; Perini, E, 2022)	1.73
"Methylphenidate is a stimulant drug commonly prescribed to individuals with attention-deficit/hyperactivity disorder. "	( Effect of Biperiden Treatment in Acute Orofacial and Extremity Dyskinesia With Methylphenidate Therapy. Arslan, E; Arslan, EA; Göksu, Ö; Kilinç, A, 2018)	2.15
"Methylphenidate is a first-line therapeutic option for treating attention-deficit/hyperactivity disorder (ADHD); however, elicited changes on resting-state functional networks (RSFNs) are not well understood. "	( Treatment effect of methylphenidate on intrinsic functional brain network in medication-naïve ADHD children: A multivariate analysis. Choi, J; Jeong, B; Kim, D; Yoo, JH, 2018)	2.25
"Methylphenidate (MPH) is a prescription stimulant used to treat attention-deficit hyperactivity disorder. "	( Methylphenidate disintegration from oral formulations for intravenous use by experienced substance users. Asgrimsson, V; Bjarnadottir, GD; Bragadottir, H; Haraldsson, HM; Johannsson, M; Magnusson, A; Rafnar, BO; Sigurdsson, E; Snorradottir, I; Steingrimsson, S, 2017)	3.34
"Methylphenidate (MPH) is a prescription-stimulant medication which is authorized in France for two indications: attention-deficit hyperactivity disorder in children (aged≥6years) and narcolepsy in cases where modafinil is ineffective (for children and adults). "	( Methylphenidate: Gender trends in adult and pediatric populations over a 7year period. Boucherie, Q; Braunstein, D; Ehrhardt, C; Frauger, E; Micallef, J; Pauly, V; Ronflé, E; Thirion, X, 2017)	3.34
"Methylphenidate (MPH) is a dopamine-reuptake inhibitor approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). "	( Methylphenidate ameliorates hypoxia-induced mitochondrial damage in human neuroblastoma SH-SY5Y cells through inhibition of oxidative stress. Hu, J; Jiao, Y; Ma, X; Shang, B; Tian, Y; Wang, Y; Zhang, H; Zhang, J; Zhang, Y; Zhu, M, 2018)	3.37
"Methylphenidate (MPH) is a widely prescribed drug for the treatment of attention-deficit hyperactivity disorder. "	( Methylphenidate induces state-dependency of social recognition learning: Central components. Bühler, L; Cavalcante, LE; de Carvalho Myskiw, J; Fagundes Ferreira, F; Garrido Zinn, C; Guerino Furini, CR; Izquierdo, I; Schmidt, SD; Zanini, ML, 2018)	3.37
"Methylphenidate (MPH) is a first-line stimulant drug to treat attention deficit hyperactivity disorder (ADHD). "	( Methylphenidate clinically oral doses improved brain and heart glutathione redox status and evoked renal and cardiac tissue injury in rats. Capela, JP; Carvalho, F; Costa, VM; Duarte, JA; Duarte-Araújo, M; Gonçalves-Monteiro, S; Loureiro-Vieira, S; Maria de Lourdes, B, 2018)	3.37
"Methylphenidate is a central nervous system stimulant that is structurally close to amphetamine and acts as a norepinephrine and dopamine reuptake inhibitor."	( [Supervised off-label prescribing of methylphenidate in adult ADHD]. Amad, A; Bordet, R; Brigadeau, F; Carton, L; Cottencin, O; Danel, T; Deheul, S; Devos, D; Dondaine, T; Gautier, S; Marquié, C; Ménard, O, 2019)	1.51
"Methylphenidate (MP) is a commonly prescribed psychostimulant for Attention Deficit Hyperactivity Disorder (ADHD). "	( Weekday-only chronic oral methylphenidate self-administration in male rats: Reversibility of the behavioral and physiological effects. Carias, E; Fricke, D; Hadjiargyrou, M; Kalinowski, L; Komatsu, DE; Martin, C; Popoola, D; Smith, L; Somanesan, R; Thanos, PK; Vijayashanthar, A, 2019)	2.26
"Methylphenidate (MP) is a widely prescribed psychostimulant used to treat attention deficit hyperactivity disorder. "	( Chronic oral methylphenidate treatment increases microglial activation in rats. Carias, E; Delis, F; Eiden, R; Hadjiargyrou, M; Hamilton, J; Komatsu, D; Quattrin, T; Robison, LS; Thanos, PK, 2018)	2.29
"Methylphenidate is a psychostimulant used to treat attention deficit hyperactivity disorder. "	( Neurogenesis within the hippocampus after chronic methylphenidate exposure. Allen, SA; DeVee, CE; Ensley, T; Farmer, B; Hall, AN; Hanley, A; Medlock, K; Oakes, HV; Pond, BB, 2019)	2.21
"Methylphenidate (MPD) is a psychostimulant used to treat attention deficit hyperactivity disorder (ADHD). "	( Methylphenidate and alcohol effects on flash-evoked potentials, body temperature, and behavior in Long-Evans rats. Hetzler, BE; McLester-Davis, LWY; Tenpas, SE, 2019)	3.4
"Methylphenidate (MPD) is a psychostimulant used for the treatment of ADHD and works by increasing the bioavailability of dopamine (DA) in the brain. "	( Acute and chronic methylphenidate administration in intact and VTA-specific and nonspecific lesioned rats. Dafny, N; Ihezie, SA; Thomas, MM, 2019)	2.29
"Methylphenidate (MPH) is a common and effective treatment for attention deficit hyperactivity disorder (ADHD), but little is known about the relationship between early childhood intake of MPH and onset of antidepressant treatment during adolescence. "	( Childhood methylphenidate adherence as a predictor of antidepressants use during adolescence. Akriv, A; Ghilai, A; Hoshen, M; Krivoy, A; Leventer-Roberts, M; Madjar, N; Shlosberg, D; Shoval, G; Zalsman, G, 2019)	2.36
"Methylphenidate is a widely-used drug for the treatment of attention deficit/hyperactivity disorder (ADHD) and other neuropsychiatric disorders. "	( How does methylphenidate affect default mode network? A systematic review. Goncalves, R; Pedroso, S; Santos, PH, 2019)	2.37
"Methylphenidate is a psychostimulant used for the treatment of (ADHD) attention deficit hyperactivity syndrome in children and adults. "	( Methylphenidate increases the urinary excretion of vanillylmandelic acid in rats that is attenuated by buspirone co-administration. Alam, N; Bashir, L; Ikram, R; Kashif, SS; Naeem, S; Naz, S; Siddiqui, T; Wasi, N, 2019)	3.4
"Methylphenidate (MPH) is a first line drug for attention-deficit/hyperactivity disorder (ADHD), yet the neuronal mechanisms underlying the condition and the treatment are still not fully understood. "	( Effects of methylphenidate on the ERP amplitude in youth with ADHD: A double-blind placebo-controlled cross-over EEG study. Gothelf, D; Horowitz, I; Levit-Binnun, N; Moses, E; Naim-Feil, J; Rubinson, M, 2019)	2.35
"Methylphenidate (MPD) is a widely prescribed psychostimulant for the treatment of attention deficit hyperactivity disorder, and is growing in use as a recreational drug and academic enhancer. "	( Glutaminergic signaling in the caudate nucleus is required for behavioral sensitization to methylphenidate. Dafny, N; Floren, S; Kharas, N; King, N; Thomas, M, 2019)	2.18
"Methylphenidate (MPH) is a phenethylamine derivative used in the treatment of attention-deficit hyperactivity disorder (ADHD). "	( Determination of methylphenidate in plasma and saliva by liquid chromatography/tandem mass spectrometry. Bijleveld, YA; Burggraaf, J; Jorjani, S; Mathôt, RA; Schrier, L; Seçilir, A; Toersche, JH; van Gerven, J, 2013)	2.17
"Methylphenidate (MPH) is an effective treatment to improve attentional difficulties in children with attention deficit/hyperactivity disorder (ADHD)."	( Methylphenidate improves some but not all measures of attention, as measured by the TEA-Ch in medication-naïve children with ADHD. Barry, E; Bellgrove, MA; Fitzgerald, M; Gill, M; Hammond, P; Johnson, KA; Kirley, A; McNicholas, F; Paton, K; Robertson, IH, 2014)	2.57
"Methylphenidate (MPH) is a common medication for ADHD."	( Areas of the brain modulated by single-dose methylphenidate treatment in youth with ADHD during task-based fMRI: a systematic review. Czerniak, SM; Frazier, J; Kennedy, DN; King, JA; Mick, E; Moore, CM; Sikoglu, EM, )	1.11
"Methylphenidate is a psychostimulant medication that produces improvements in functions associated with multiple neurocognitive systems. "	( Distributed effects of methylphenidate on the network structure of the resting brain: a connectomic pattern classification analysis. Angstadt, M; Kessler, D; Liberzon, I; Phan, KL; Scott, C; Sripada, CS; Welsh, R, 2013)	2.14
"Methylphenidate is a widely prescribed psychostimulant for treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents, which raises questions regarding its potential interference with the developing brain. "	( Long-term oral methylphenidate treatment in adolescent and adult rats: differential effects on brain morphology and function. Dijkhuizen, RM; Homberg, JR; Klomp, A; Lucassen, PJ; Meerhoff, GF; Reneman, L; Schipper, P; van der Marel, K, 2014)	2.2
"Methylphenidate (MPH) is an effective treatment for ADHD symptoms, but its impact on cognition is less clearly understood."	( Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis. Coghill, DR; Currie, J; Gagliano, A; Pedroso, S; Seth, S; Usala, T, 2014)	1.51
"Methylphenidate is an important element of therapeutic strategies for ADHD."	( [Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate]. Acquaviva, E; Bange, F; Delorme, R; Le Heuzey, MF; Mouren, MC, 2014)	1.34
"Methylphenidate (MPD) is a widely prescribed stimulant used primarily for the treatment for attention-deficit/hyperactivity disorder (ADHD). "	( Fatal oral methylphenidate intoxication with postmortem concentrations. Cantrell, FL; Mallett, P; McIntyre, IM; Ogera, P, 2014)	2.23
"Methylphenidate (MPH) is a dopamine and norepinephrine reuptake inhibitor that is widely used for the treatment of attention-deficit/hyperactivity disorder in children and adults. "	( Object memory impairment at post-drug Day 15 but not at Day 1 after a regimen of repeated treatment with oral methylphenidate. Bigney, EE; Fry, MD; Hooper, C; Taukulis, HK, 2014)	2.06
"Methylphenidate is a psychostimulant that has been used to relieve depressive symptoms in advanced cancer patients. "	( Multicentre, double-blind, randomised placebo-controlled clinical trial on the efficacy of methylphenidate on depressive symptoms in advanced cancer patients. Almaraz, MJ; Centeno, C; Cuervo, MA; Gonzalez, J; Hernansanz, S; Lama, M; Nabal, M; Pascual, A; Ramos, D; Sanz, A; Vara, F, 2012)	2.04
"Methylphenidate (MPH) is an indirect dopaminergic and noradrenergic agonist that is used to treat attention deficit hyperactivity disorder and that has shown therapeutic potential in neuropsychiatric diseases such as depression, dementia, and Parkinson's disease. "	( The effects of methylphenidate on whole brain intrinsic functional connectivity. Berman, A; Coates, U; Costa, A; Ettinger, U; Keeser, D; Meindl, T; Möller, HJ; Mueller, S; Pogarell, O; Reiser, MF; Riedel, M, 2014)	2.2
"Methylphenidate (MPH) is a psychostimulant drug which acts by blocking the dopamine and norepinephrine transporters and is the main drug used to treat attention deficit hyperactivity disorder in children and adolescents. "	( Effects of repeated administration of methylphenidate on reproductive parameters in male rats. Anselmo-Franci, JA; dos Santos, AH; Fernandes, GS; Gerardin, DC; Mesquita, Sde F; Montagnini, BG; Silva, LS, 2014)	2.12
"Methylphenidate is a central nervous system simulant that is used for management of opioid-induced sedation. "	( Evaluation of concomitant methylphenidate and opioid use in patients with pain. Atayee, RS; Best, BM; Jiang, JY; Ma, JD; Morello, CM, 2014)	2.15
"Methylphenidate (MPH) is a stimulant prescribed to treat attention-deficit/ hyperactivity disorder. "	( Chronic methylphenidate treatment during early life is associated with greater ethanol intake in socially isolated rats. Beveridge, TJ; Chappell, AM; Gill, KE; Porrino, LJ; Weiner, JL, 2014)	2.28
"Methylphenidate (MPH) is a commonly used stimulant medication for treating attention-deficit/hyperactivity disorder (ADHD). "	( A preliminary study on methylphenidate-regulated gene expression in lymphoblastoid cells of ADHD patients. Heupel, J; Hilscher, M; Jacob, C; Kittel-Schneider, S; Kopf, J; Lesch, KP; Reichert, S; Reif, A; Schmidt, B; Scholz, CJ; Schwarz, R; Volkert, J; Weber, H; Weissflog, L, 2015)	2.17
"Methylphenidate (MPH) is a common treatment for adult Attention Deficit Hyperactivity Disorder (ADHD). "	( Effects of perinatal methylphenidate (MPH) treatment on postweaning behaviors of male and female Sprague-Dawley rats. Delbert Law, C; Ferguson, SA; Montenegro, SV; Sahin, L, )	1.89
"Methylphenidate (MPH) is a commonly-used medication for the treatment of children with Attention-Deficit/Hyperactivity Disorders (ADHD). "	( Prenatal exposure to methylphenidate affects the dopamine system and the reactivity to natural reward in adulthood in rats. Belzung, C; Castelnau, P; Chalon, S; Cortese, S; Emond, P; Faraone, SV; Galineau, L; Lepelletier, FX; Nicolas, C; Solinas, M; Tauber, C, 2014)	2.16
"Methylphenidate is a non-addictive psychostimulant, although its mode of action resembles that of cocaine, a well-known addictive and abused drug."	( Alterations in brain neurotrophic and glial factors following early age chronic methylphenidate and cocaine administration. Rehavi, M; Simchon-Tenenbaum, Y; Weizman, A, 2015)	1.37
"Methylphenidate (MPH) is a stimulant that is commonly used in the treatment of attention-deficit/hyperactivity disorder in children and adults. "	( Methylphenidate-induced awake bruxism: a case report. Bilgiç, A; Sivri, RÇ, )	3.02
"Methylphenidate (MPH) is a central nervous system stimulant that is widely used to treat attention deficit hyperactivity disorder (ADHD) and has been shown to improve attention, cognitive function and behaviors in both patients and animal models of ADHD. "	( Distinct lncRNA expression profiles in the prefrontal cortex of SD rats after exposure to methylphenidate. Chen, C; Chen, R; Chi, X; Cui, X; Fu, Z; Guo, X; Hong, Q; Ji, C; Jia, J; Tong, M; Wang, J; Wu, T; Yang, L; Zhang, M; Zhang, X, 2015)	2.08
"Methylphenidate (MPH) is a widely prescribed stimulant drug for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents. "	( Effects of long-term methylphenidate treatment in adolescent and adult rats on hippocampal shape, functional connectivity and adult neurogenesis. Bouet, V; Boulouard, M; Dauphin, F; Dijkhuizen, RM; Freret, T; Homberg, JR; Klomp, A; Lucassen, PJ; Meerhoff, GF; Reneman, L; van der Marel, K, 2015)	2.18
"Methylphenidate (MPD) is a dopamine uptake inhibitor and the most commonly prescribed drug for the treatment of attention-deficit/hyperactivity disorder in children. "	( Repeated methylphenidate administration during lactation reduces maternal behavior, induces maternal tolerance, and increases anxiety-like behavior in pups in adulthood. Bernardi, MM; Coelho, CP; Florio, JC; Kirsten, TB; Oshiro, A; Ponchio, RA; Teodorov, E, )	1.99
"Methylphenidate (MPH) is a central stimulant, prescribed for the treatment of attention deficit/hyperactivity disorder. "	( Effects of chronic treatment with methylphenidate on oxidative stress and inflammation in hippocampus of adult rats. Motaghinejad, M; Motevalian, M; Shabab, B, 2016)	2.16
"Methylphenidate (MPH) is a central nervous system stimulant drug that increases concentration and energy level. "	( Investigation of possible teratogenic effects in the offspring of mice exposed to methylphenidate during pregnancy. Bacchi, AD; Costa, Gde A; Galvão, TC; Moreira, EG; Salles, MJ, 2016)	2.1
"Methylphenidate (MPD) is a central nervous system (CNS) stimulant, which belongs to the phenethylamine group and is mainly used in the treatment of attention deficit hyperactive disorder (ADHD). "	( From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate. Busardò, FP; Cipolloni, L; Frati, P; Kyriakou, C; Zaami, S, 2016)	2.11
"Methylphenidate (MPH) is a widely prescribed stimulant compound that may be effective against ADHD symptoms in children and adults."	( A candidate gene investigation of methylphenidate response in adult attention-deficit/hyperactivity disorder patients: results from a naturalistic study. Fredriksen, M; Haavik, J; Hegvik, TA; Jacobsen, KK; Zayats, T, 2016)	1.43
"Methylphenidate is a central nervous system stimulant medicinally used in the treatment of attention-deficit disorder with or without hyperactivity (ADD/ADHD). "	( Methylphenidate in Pregnancy: A Multicenter, Prospective, Comparative, Observational Study. Arnon, J; Beck, E; Borisch, C; Bozzo, P; Diav-Citrin, O; Nulman, I; Ornoy, A; Richardson, JL; Shechtman, S; Wajnberg, R, 2016)	3.32
"Methylphenidate (MPH) is a psychostimulant commonly used for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). "	( MicroPET/CT assessment of FDG uptake in brain after long-term methylphenidate treatment in nonhuman primates. Apana, SM; Berridge, MS; Callicott, R; Liu, S; Newport, GD; Paule, MG; Slikker, W; Thompson, J; Wang, C; Zhang, X, )	1.81
"Methylphenidate (MPH) is a neural stimulant with unclear neurochemical and behavioral effects. "	( The neuroprotective effect of lithium against high dose methylphenidate: Possible role of BDNF. Asadi, M; Motaghinejad, M; Motevalian, M; Seyedjavadein, Z, 2016)	2.12
"Methylphenidate (MPH) is a stimulatory agent in brain with unknown long-term consequences. "	( Effects of acute doses of methylphenidate on inflammation and oxidative stress in isolated hippocampus and cerebral cortex of adult rats. Fatima, S; Motaghinejad, M; Motevalian, M; Shabab, B, 2017)	2.2
"Methylphenidate (MPD) is a widely prescribed psychostimulants used for the treatment of attention deficit hyperactive disorder (ADHD). "	( Methylphenidate modulates dorsal raphe neuronal activity: Behavioral and neuronal recordings from adolescent rats. Dafny, N; Kharas, N; Reyes-Vasquez, C; Whitt, H, 2017)	3.34
"Methylphenidate (MPH) is a stimulant drug and an effective treatment for attention-deficit/hyperactivity disorder (ADHD) in both children and adults. "	( The age-dependent effects of a single-dose methylphenidate challenge on cerebral perfusion in patients with attention-deficit/hyperactivity disorder. Bottelier, MA; Bouziane, C; Mutsaerts, H; Reneman, L; Schrantee, A; Tamminga, H, 2017)	2.16
"Methylphenidate is a noradrenaline and dopamine reuptake inhibitor and commonly used in the pharmacological treatment of individuals with attention deficit/hyperactivity disorder (ADHD)."	( Effects of methylphenidate on attention in Wistar rats treated with the neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4). Hauser, J; Lange, KW; Reissmann, A; Sontag, TA; Tucha, O, 2017)	1.57
"Methylphenidate (MPH) is a central nervous system stimulant derived from an amphetamine and acts as a potent inhibitor of catecholamine reuptake and increases dopamine levels in the brain. "	( Methylphenidate for the treatment of Parkinson disease and other neurological disorders. Auriel, E; Giladi, N; Hausdorff, JM, )	3.02
"Methylphenidate is a psychostimulant that acts blocking the dopamine transporter has been used as an effective treatment for Attention Deficit Hyperactivity Disorder."	( Cerebral DARPP-32 expression after methylphenidate administration in young and adult rats. Gomes, KM; Gomez, MV; Inácio, CG; Martins, MR; Quevedo, J; Réus, GZ; Romano-Silva, MA; Rosa, DV; Soares, EC; Souza, BR; Souza, RP; Valvassori, SS, 2009)	1.35
"Methylphenidate (MPH) is an effective medication to improve these cognitive difficulties."	( Effects of methylphenidate on working memory functioning in children with attention deficit/hyperactivity disorder. Bechtel, N; Klarhöfer, M; Kobel, M; Opwis, K; Penner, IK; Scheffler, K; Specht, K; Weber, P, 2009)	1.46
"Methylphenidate is a potent central nervous system stimulant that exerts its effects by increasing synaptic levels of dopamine and norepinephrine. "	( A case of acute cardiomyopathy and pericarditis associated with methylphenidate. Dadfarmay, S; Dixon, J, 2009)	2.03
"Methylphenidate is a piperidine derivative structurally related to amphetamines and acts as a central nervous system stimulant."	( Methylphenidate has positive hypocholesterolemic and hypotriglyceridemic effects: new data. Charach, G; Grosskopf, I; Kaysar, N; Rabinovich, A; Weintraub, M, 2009)	2.52
"Methylphenidate is a frequently prescribed stimulant for the treatment of attention deficit hyperactivity disorder (ADHD). "	( Plasma and brain concentrations of oral therapeutic doses of methylphenidate and their impact on brain monoamine content in mice. Balcioglu, A; Bhide, PG; Biederman, J; McCarthy, D; Ren, JQ; Spencer, TJ, 2009)	2.04
"Methylphenidate is a central nervous system (CNS)-stimulating agent. "	( [Paradoxical effect of methylphenidate in the treatment of a patient with severe traumatic brain injury]. Grønborg, P; Jansen, J; Liljegren, J, 2009)	2.11
"Methylphenidate is a piperidine derivative and is the drug most often used to treat attention deficit/hyperactivity disorder of children and young adults. "	( Dose-related immunohistochemical and ultrastructural changes after oral methylphenidate administration in cerebrum and cerebellum of the rat. Bahcelioglu, M; Bardakci, Y; Calguner, E; Elmas, C; Erdogan, D; Gozil, R; Kadioglu, D; Oktem, H; Sargon, MF; Senol, S; Take, G; Tas, M; Yazici, AC, 2009)	2.03
"Methylphenidate (Ritalin) is a selective dopamine reuptake inhibitor and an effective treatment for attention deficit hyperactivity disorder (ADHD) however the anatomical foci and neuronal circuits involved in these therapeutic benefits are unclear. "	( Mapping the central effects of methylphenidate in the rat using pharmacological MRI BOLD contrast. Easton, N; Fone, KC; Marsden, CA; Marshall, FH, 2009)	2.08
"Methylphenidate (MPH) is an amphetamine derivative widely prescribed for the treatment of attention deficit-hyperactivity disorder. "	( The effects of chronic methylphenidate administration on operant test battery performance in juvenile rhesus monkeys. Allen, RR; Doerge, DR; Hotchkiss, CE; Mattison, DR; Morris, SM; Paule, MG; Rodriguez, JS, )	1.88
"Methylphenidate is a central nervous system stimulant used for the treatment of attention-deficit hyperactivity disorder. "	( Methylphenidate treatment increases Na(+), K (+)-ATPase activity in the cerebrum of young and adult rats. Comim, CM; Ferreira, AG; Gomes, KM; Matté, C; Mattos, C; Quevedo, J; Scherer, EB; Streck, EL; Wyse, AT, 2009)	3.24
"Dexmethylphenidate is a single-isomer stimulant medication approved for the treatment of attention deficit hyperactivity disorder (ADHD). "	( Dexmethylphenidate for attention deficit hyperactivity disorder. Coury, D, 2009)	1.6
"Dexmethylphenidate is a safe and effective treatment for ADHD. "	( Dexmethylphenidate for attention deficit hyperactivity disorder. Coury, D, 2009)	1.6
"Methylphenidate (MPH) is an effective medication for the treatment of attention deficit hyperactivity disorder (ADHD). "	( Variability of response time as a predictor of methylphenidate treatment response in korean children with attention deficit hyperactivity disorder. Cheon, KA; Ha, EH; Joung, YS; Kim, BN; Lee, SH; Shin, DW; Shin, YJ; Song, DH; Yoo, HJ, 2009)	2.05
"Dexmethylphenidate XR is a stimulant treatment in a single isomer form, and has an efficacy and tolerability similar to two doses of immediate-release (IR) dexmethylphenidate when taken 4 hours apart, but is dosed at half of the usual d,l-methylphenidate dose."	( Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. Kratochvil, CJ; May, DE, 2010)	0.87
"Methylphenidate (MPH) is an efficacious and normally well-tolerated treatment for attention-deficit/hyperactivity disorder (ADHD). "	( Measuring methylphenidate response in attention-deficit/hyperactvity disorder: how are laboratory classroom-based measures related to parent ratings? Coghill, D; DeBacker, M; Sonuga-Barke, EJ; Swanson, J, 2009)	2.2
"Methylphenidate (MPH) is a stimulant medication widely used for treating attention-deficit hyperactivity disorder (ADHD) in children and adolescents. "	( Pharmacokinetics of methylphenidate in oral fluid and sweat of a pediatric subject. Farrè, M; García-Algar, O; Marchei, E; Pacifici, R; Pellegrini, M; Pichini, S; Vall, O, 2010)	2.13
"Methylphenidate (MPH) is a very effective treatment option for children and adolescents with attention-deficit/hyperactivity disorder. "	( Diurnal differences in memory and learning in young and adult rats treated with methylphenidate. Comim, CM; Gomes, KM; Inácio, CG; Martins, MR; Quevedo, J; Réus, GZ; Souza, RP; Valvassori, SS, 2010)	2.03
"Methylphenidate is a psychostimulant widely used in the treatment of attention deficit hyperactivity disorder (ADHD). "	( Methylphenidate attenuates rats' preference for a novel spatial stimulus introduced into a familiar environment: assessment using a force-plate actometer. Fowler, SC; Levant, B; Zarcone, TJ, 2010)	3.25
"Methylphenidate (MPH) is a psychostimulant commonly used to manage ADHD symptoms."	( Manganese in children with attention-deficit/hyperactivity disorder: relationship with methylphenidate exposure. Benko, CR; Cordeiro, ML; Costa, MT; Cunha, A; Farias, AC; Farias, LG; McCracken, JT, 2010)	1.3
"Methylphenidate (MPH) is an immediate-release (IR) or sustained-release (SR) drug used to treat attention-deficit hyperactivity disorder. "	( Pharmacokinetics of methylphenidate following two oral formulations (immediate and sustained release) in the dog. Giorgi, M; Lavy, E; Neri, D; Prise, U; Soldani, G, 2010)	2.13
"Methylphenidate (MPH) is a drug administered either as an immediate- or sustained-release preparation for the treatment of attention deficit hyperactivity disorder in humans. "	( Pharmacokinetics of methylphenidate after oral administration of immediate and sustained-release preparations in Beagle dogs. Bar Chaim, A; Brandriss, N; Giorgi, M; Lavy, E; Neri, D; Prise, U; Soldani, G, 2011)	2.14
"Methylphenidate is a dopamine/norepinephrine reuptake inhibitor that produces altered gene expression in the forebrain; these effects partly mimic gene regulation by cocaine (dopamine/norepinephrine/serotonin reuptake inhibitor)."	( Selective serotonin reuptake inhibitor antidepressants potentiate methylphenidate (Ritalin)-induced gene regulation in the adolescent striatum. Beverley, J; Marinelli, M; Steiner, H; Van Waes, V, 2010)	1.32
"Methylphenidate (MPH) is a stimulant drug that amplifies dopamineric and noradrenergic signaling in the brain, which is believed to underlie its cognition enhancing effects. "	( Methylphenidate enhances brain activation and deactivation responses to visual attention and working memory tasks in healthy controls. Caparelli, EC; Fowler, JS; Jayne, M; Telang, F; Tomasi, D; Volkow, ND; Wang, GJ; Wang, R; Wong, C, 2011)	3.25
"Methylphenidate is a psychostimulant widely used in the treatment of attention deficit hyperactivity disorder. "	( Differences in methylphenidate dose response between periadolescent and adult rats in the familiar arena-novel alcove task. Davis, PF; Fowler, SC; Levant, B; Ozias, MK; Zarcone, TJ, 2011)	2.16
"Methylphenidate (MPD) is a psychostimulant widely used to treat behavioral problems such as attention deficit hyperactivity disorder. "	( Methylphenidate alters basal ganglia neurotensin systems through dopaminergic mechanisms: a comparison with cocaine treatment. Alburges, ME; Fleckenstein, AE; Hanson, GR; Hoonakker, AJ; Horner, KA, 2011)	3.25
"Methylphenidate is a psychostimulant drug indicated for the treatment of attention-deficit hyperactivity disorder (ADHD). "	( Patterns of methylphenidate use and assessment of its abuse and diversion in two French administrative areas using a proxy of deviant behaviour determined from a reimbursement database: main trends from 2005 to 2008. Coudert, H; Frauger, E; Micallef, J; Natali, F; Pauly, V; Pradel, V; Reggio, P; Thirion, X, 2011)	2.19
"Methylphenidate (MPH) is an efficient treatment to reduce behavioral symptoms of attention-deficit/hyperactivity disorder (ADHD); however, its impact on cognitive functioning has not been sufficiently demonstrated so far. "	( Effects of methylphenidate on intelligence and attention components in boys with attention-deficit/hyperactivity disorder. Daseking, M; Goldbeck, L; Hellwig-Brida, S; Keller, F; Petermann, F, 2011)	2.2
"Methylphenidate is an amphetamine psychostimulant used as a symptomatic treatment for attention-deficit hyperactivity disorder. "	( Methylphenidate: growth retardation. , 2011)	3.25
"Methylphenidate is a psychostimulant given for extended periods of time as a treatment of attention-deficit/hyperactivity disorder (ADHD). "	( Methylphenidate treatment in the spontaneously hypertensive rat: influence on methylphenidate self-administration and reinstatement in comparison with Wistar rats. Cheong, JH; dela Peña, I; dela Peña, JB; Lee, JC; Ryu, JH; Shin, CY; Sohn, AR; Yoon, SY, 2012)	3.26
"Methylphenidate is a psychostimulant originally used for the treatment of attention-deficit disorder. "	( Methylphenidate: established and expanding roles in symptom management. Prommer, E, 2012)	3.26
"Methylphenidate (MPH) is a drug that is licensed for treatment of ADHD and also narcolepsy. "	( Determination of methylphenidate and its metabolite ritalinic acid in urine by liquid chromatography/tandem mass spectrometry. Florkowski, CM; George, PM; Moore, GA; Paterson, SM, 2012)	2.16
"Methylphenidate (MPD) is a psychostimulant that enhances dopaminergic neurotransmission in the central nervous system by using mechanisms similar to cocaine and amphetamine. "	( Nucleus accumbens neuronal activity in freely behaving rats is modulated following acute and chronic methylphenidate administration. Chong, SL; Claussen, CM; Dafny, N, 2012)	2.04
"Methylphenidate (MPH) is an indirect dopamine and noradrenalin agonist, commonly used for the treatment of attention-deficit hyperactivity disorder for which it reduces undesirable behavior as evaluated by peers and authority figures, indicative of increased conformity."	( Modulation of social influence by methylphenidate. Campbell-Meiklejohn, DK; Frith, CD; Gjerløff, T; Jensen, M; Møller, A; Roepstorff, A; Scheel-Kruger, J; Simonsen, A; Wohlert, V, 2012)	1.38
"Methylphenidate (MPH) is a commonly abused psychostimulant prescribed for the treatment of attention deficit hyperactivity disorder. "	( Methylphenidate and cocaine self-administration produce distinct dopamine terminal alterations. Bermejo, K; Calipari, ES; Ferris, MJ; Jones, SR; Melchior, JR; Roberts, DC; Salahpour, A, 2014)	3.29
"Methylphenidate (MPD) is a psychostimulant that is prescribed to treat attention-deficit/hyperactivity disorder (ADHD) and has been used as a recreational drug. "	( GABA system changes in methylphenidate sensitized female rats. Barros, HM; Couto-Pereira, NS; Ferigolo, M; Freese, L; Muller, EJ; Souza, MF; Tosca, CF, 2012)	2.13
"Methylphenidate (MP) is a psychostimulant widely prescribed to treat Attention Deficit Hyperactivity Disorder (ADHD). "	( Chronic exposure to methylphenidate impairs appendicular bone quality in young rats. Ananth, M; Hadjiargyrou, M; Janda, HA; John, CM; Komatsu, DE; Mary, MN; Robison, L; Swanson, JM; Thanos, PK; Volkow, ND, 2012)	2.15
"Methylphenidate (MPH) is a psychostimulant that exerts its pharmacological effects via preferential blockade of the dopamine transporter (DAT) and the norepinephrine transporter (NET), resulting in increased monoamine levels in the synapse. "	( Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. Jiao, Y; Pani, AK; Pond, BB; Qu, C; Sadasivan, S; Smeyne, RJ, 2012)	3.26
"Methylphenidate is a medication used routinely in the management of attention deficit hyperactivity disorder. "	( Methylphenidate-induced erections in a prepubertal child. Brady, CM; Kelly, BD; Lundon, DJ; McGuinness, D, 2013)	3.28
"Methylphenidate (MPH) is a catecholamine transporter blocker, with dopamine agonistic effects in the basal ganglia. "	( Methylphenidate effects on neural activity during response inhibition in healthy humans. Costa, A; Ettinger, U; Meindl, T; Menzel-Zelnitschek, F; Möller, HJ; Pogarell, O; Reiser, M; Riedel, M; Rubia, K; Schwarz, M, 2013)	3.28
"Methylphenidate (MPH) is a psychostimulant used in the treatment of attention-deficit/hyperactivity disorder in children and adults. "	( Chronic methylphenidate administration in mice produces depressive-like behaviors and altered responses to fluoxetine. Brookshire, BR; Jones, SR, 2012)	2.26
"Methylphenidate (MPH) is a first line option in the psychopharmacologic treatment of adults with Attention-Deficit/Hyperactivity Disorder (ADHD). "	( Pharmacogenetics of response to methylphenidate in adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD): a systematic review. Bau, CH; Contini, V; Grevet, EH; Rohde, LA; Rovaris, DL; Victor, MM, 2013)	2.12
"Methylphenidate is a short-acting stimulant. "	( Methylphenidate-induced acute orofacial and extremity dyskinesia. Donmez, A; Isik, B; Orun, E; Sonmez, FM; Tas, T; Yilmaz, AE, 2013)	3.28
"Methylphenidate (MPH) is a stimulant that increases extracellular levels of dopamine and noradrenaline. "	( In for a penny, in for a pound: methylphenidate reduces the inhibitory effect of high stakes on persistent risky choice. Campbell-Meiklejohn, D; Frith, CD; Gjerløff, T; Møller, A; Roepstorff, A; Rogers, RD; Scheel-Krüger, J; Simonsen, A; Wohlert, V, 2012)	2.11
"Methylphenidate is a centrally acting sympathomimetic used for the treatment of attention deficit/hyperactivity disorder in children and adolescents and for narcolepsy in adults. "	( First trimester in utero exposure to methylphenidate. Aagaard, L; Damkier, P; Dideriksen, D; Hallas, J; Pottegård, A, 2013)	2.11
"Methylphenidate is a CNS stimulant that blocks the DaT and the noradrenaline (norepinephrine) transporter in the striatum and the prefrontal cortex in particular."	( Methylphenidate : a treatment for Parkinson's disease? Bordet, R; Defebvre, L; Delval, A; Devos, D; Dujardin, K; Moreau, C, 2013)	2.55
"Methylphenidate is a standard pharmaceutical intervention for ADHD."	( An experimental comparison of Pycnogenol and methylphenidate in adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Dodd, DK; Green, L; Paull, JC; Sparrow, EP; Tenenbaum, S, 2002)	1.3
"D-methylphenidate is an enantiomer of D,L-methylphenidate and was developed as an improved treatment for attention deficit hyperactivity disorder (ADHD) in children. "	( The perinatal and postnatal toxicity of D-methylphenidate and D,L-methylphenidate in rats. Christian, MS; Hoberman, AM; Khetani, VD; Stirling, DI; Teo, SK; Thomas, SD, )	1.12
"D-methylphenidate is an enantiomer of D,L-methylphenidate and was developed as an improved treatment for attention deficit hyperactivity disorder in children. "	( A 90-day oral gavage toxicity study of D-methylphenidate and D,L-methylphenidate in Sprague-Dawley rats. Hoberman, A; Khetani, V; Kiorpes, A; Stirling, D; Teo, S; Thomas, S, 2002)	1.3
"Dexmethylphenidate is a schedule II drug."	( Dexmethylphenidate--Novartis/Celgene. Focalin, D-MPH, D-methylphenidate hydrochloride, D-methylphenidate, dexmethylphenidate, dexmethylphenidate hydrochloride. , 2002)	1.45
"Methylphenidate (MPH) is an effective symptomatic treatment of attention deficit hyperactivity disorder (ADHD), but the mechanisms of its therapeutic action have not been fully elucidated. "	( Effects of methylphenidate discontinuation on cerebral blood flow in prepubescent boys with attention deficit hyperactivity disorder. Acton, PD; Austin, G; Elman, I; Krikorian, G; Langleben, DD; Monterosso, JR; Portnoy, O; Ridlehuber, HW; Strauss, HW, 2002)	2.15
"Methylphenidate (Ritalin) is a commonly used central nervous stimulant. "	( Ritalin revisited: does it really help in neurological injury? Kajs-Wyllie, M, 2002)	1.76
"Methylphenidate (Ritalin) is a psychostimulant drug used to treat children with attention deficit hyperactivity disorder. "	( Daily methylphenidate administration attenuates c-fos expression in the striatum of prepubertal rats. Brown, RE; Carrey, N; Chase, TD; Wilkinson, M, 2003)	2.24
"Methylphenidate is a psychostimulant which inhibits the dopamine transporter and produces dopamine overflow in the striatum, similar to the effects of cocaine. "	( Repeated methylphenidate treatment in adolescent rats alters gene regulation in the striatum. Brandon, CL; Steiner, H, 2003)	2.18
"OROS methylphenidate HCL (MPH) is a recently developed long-acting stimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD). "	( A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Black, DO; Conlon, C; Newcorn, JH; Pearl, PL; Robb, AS; Sarampote, CS; Seymour, KE; Stein, MA; Waldman, ID, 2003)	1.12
"Methylphenidate (MPH) is a psychomotor stimulant medication widely used for the treatment of attention-deficit/hyperactivity disorder (ADHD). "	( Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood. Barrot, M; Berton, O; Bolaños, CA; Nestler, EJ; Wallace-Black, D, 2003)	3.2
"Methylphenidate (MPH) is a stimulant prescribed for the treatment of attention-deficit/hyperactivity disorder (ADHD). "	( Enduring behavioral effects of early exposure to methylphenidate in rats. Andersen, SL; Carlezon, WA; Mague, SD, 2003)	2.02
"Methylphenidate is a rapidly absorbed medication that, in its d-isomer form, readily penetrates the CNS, particularly the striatum."	( Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. Doffing, MA; Wolraich, ML, 2004)	1.26
"Methylphenidate is a central nervous system stimulant used for the treatment of attention deficit hyperactivity disorder and narcolepsy and like other psychostimulants has a potential for abuse."	( Lacunar stroke associated with methylphenidate abuse. Sadeghian, H, 2004)	2.05
"Methylphenidate is an important stimulant prescribed to treat attention-deficit hyperactivity disorder. "	( Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. Bosron, WF; Davis, WI; Hurley, TD; Kedishvili, NY; Murry, DJ; Sanghani, SP; Sun, Z; Zou, Q, 2004)	3.21
"Methylphenidate seems to be an effective treatment for ODD, as well as for ADHD itself. "	( The effect of methylphenidate on oppositional defiant disorder comorbid with attention deficit/hyperactivity disorder. Gomes, F; Mattos, P; Pastura, G; Serra-Pinheiro, MA; Souza, I, 2004)	2.13
"Methylphenidate proves to be an effective and well tolerated treatment for symptoms of ADHD in adults in the short term. "	( Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Boonstra, AM; Buitelaar, JK; Burger, H; Kalma, LE; Kooij, JJ; Van der Linden, PD, 2004)	2.08
"Methylphenidate (MPH) is a dopamine and noradrenaline enhancing drug used to treat attentional deficits. "	( Plasma level-dependent effects of methylphenidate on task-related functional magnetic resonance imaging signal changes. Brown, J; Bullmore, ET; Faessel, H; Honey, G; Müller, U; Robbins, TW; Routledge, C; Suckling, J; Williams, SC; Zelaya, F, 2005)	2.05
"Methylphenidate is a first-line therapy for attention deficit hyperactivity disorder, the most prevalent neuropsychiatric disorder of childhood. "	( Methylphenidate HCl: therapy for attention deficit hyperactivity disorder. Capp, PK; Conlon, C; Pearl, PL, 2005)	3.21
"Methylphenidate (MPH) is a prescription stimulant drug with known abuse potential; however, little is known about its patterns of misuse or the characteristics of its abusers."	( Characteristics of methylphenidate misuse in a university student sample. Barrett, SP; Bordy, LE; Darredeau, C; Pihl, RO, 2005)	2.1
"Methylphenidate is a cornerstone of attention-deficit/hyperactivity disorder (ADHD) treatment. "	( Successful desensitization of methylphenidate-induced rash. Confino-Cohen, R; Goldberg, A, 2005)	2.06
"Methylphenidate (MPH) is a psychostimulant effective in treating attention-deficit/hyperactivity disorder (ADHD). "	( Different adaptations in ventral tegmental area dopamine neurons in control and ethanol exposed rats after methylphenidate treatment. Choong, KC; Shen, RY, 2006)	1.99
"OROS-methylphenidate (OROS-MPH) is a once-daily controlled-release formulation of methylphenidate (MPH) developed to overcome some of the limitations associated with IR-MPH and first-generation sustained-release formulations."	( A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Binder, CE; Prinzo, RS; Steele, M; Swanson, J; Wang, J; Weiss, M, 2006)	1.04
"Methylphenidate (MPH) is a potential therapeutic tool for Attention Deficit with Hyperactivity Disorders (ADHD). "	( [Benefit of the extended-release methylphenidate formulations: a comparative study in childhood]. Barthez, MA; Brault, F; Castelnau, P; Deseille-Turlotte, G; Favreau, A; Giraudeau, B; Krier, C, 2006)	2.06
"Methylphenidate is a stimulant used in the treatment of attention deficit hyperactivity disorder in children and is subject to abuse. "	( Methylphenidate abuse in Texas, 1998-2004. Forrester, MB, 2006)	3.22
"Methylphenidate (MPH) is a CNS agent thought to act on dopamine and noradrenaline (norepinephrine) pathways and thereby blocks the reuptake of these neurotransmitters into the presynaptic neuron."	( Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children. Anderson, VR; Scott, LJ, 2006)	2.5
"Methylphenidate (MPH) is a highly effective and commonly used treatment for ADHD but, like cocaine, is a cardiovascular and central nervous system stimulant with the potential to cause toxicity at high doses."	( Methylphenidate and cocaine: a placebo-controlled drug interaction study. Apparaju, S; Chiang, CN; Desai, P; Elkashef, A; Harrer, J; Horn, P; Mezinskis, J; Singal, BM; Somoza, E; Winhusen, T, 2006)	2.5
"Methylphenidate (MPH) is a drug of choice for treating attention-deficit/hyperactivity disorder (ADHD), although its use has been complicated by its short duration of action. "	( Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens. Chang, WW; Foley, M; McGreenery, CE; McKay, G; Midha, KK; Polcari, A; Teicher, MH; Valente, E, 2006)	3.22
"Methylphenidate is a stimulant medication that is sometimes used as an antidepressant in bipolar adults and is frequently used in children with comorbid bipolar and attention-deficit disorder."	( Naturalistic long-term use of methylphenidate in bipolar disorder. El-Mallakh, RS; Lydon, E, 2006)	1.34
"Dexmethylphenidate is a chirally pure d-isomer of the racemic mixture of methylphenidate. "	( Dexmethylphenidate extended-release capsules for the treatment of attention deficit hyperactivity disorder. Kowalik, S; Minami, H; Silva, R, 2006)	1.58
"Methylphenidate (MPH) is a psychostimulant drug used to treat attention deficit hyperactivity disorder in children. "	( Methylphenidate regulates activity regulated cytoskeletal associated but not brain-derived neurotrophic factor gene expression in the developing rat striatum. Carrey, N; Chase, T; Soo, E; Wilkinson, M, 2007)	3.23
"Methylphenidate is a central nervous system stimulant approved by the U.S."	( NTP-CERHR monograph on the potential human reproductive and developmental effects of methylphenidate. , 2005)	1.27
"Methylphenidate is an effective treatment for reducing intravenous drug use in patients with severe amphetamine dependence."	( A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Föhr, J; Haukka, J; Kuikanmäki, O; Kuoppasalmi, K; Meririnne, E; Sokero, P; Tiihonen, J; Tuomola, P; Vorma, H, 2007)	2.07
"g. methylphenidate) proved to be an effective in patients with ADHD."	( [Methylphenidate double-blind trial: indication and performing]. Becker, K; Bliznakova, L; Gerstner, S; Schmidt, MH, )	1.56
"Methylphenidate (MPH) is a DA agonist that blocks the dopamine transporter (DAT)."	( Gender associations with chronic methylphenidate treatment and behavioral performance following experimental traumatic brain injury. Dixon, CE; Kline, AE; Ren, D; Wagner, AK; Wenger, MK; Willard, LA; Zafonte, RD, 2007)	1.34
"Methylphenidate (MPH) is a drug that is widely used in the treatment of children in whom ADHD has been diagnosed."	( Acute effect of methylphenidate on QT interval duration and dispersion in children with attention deficit hyperactivity disorder. Akpinar, O; Congologlu, A; Ilgenli, TF; Kilicaslan, F; Ozturk, C; Turkbay, T, )	1.2
"Methylphenidate (MPH) is a widely prescribed psychostimulant for the treatment of attention-deficit hyperactivity disorder (ADHD). "	( DNA damage in rats after treatment with methylphenidate. Andreazza, AC; Berk, M; Cassini, C; Comim, CM; Frey, BN; Gomes, KM; Gonçalves, CA; Kapczinski, F; Quevedo, J; Ribeiro, LC; Stertz, L; Valvassori, SS; Zanotto, C, 2007)	2.05
"Methylphenidate (MPH) is a phenethylamine derivative used in the treatment of childhood attention-deficit hyperactivity disorder. "	( Development and validation of a liquid chromatography-mass spectrometry assay for hair analysis of methylphenidate. García-Algar, O; Marchei, E; Muñoz, JA; Pellegrini, M; Pichini, S; Vall, O; Zuccaro, P, 2008)	2.01
"Methylphenidate (MPH) is a centrally acting (psycho)stimulant which reversibly blocks the dopamine re-uptake transporter. "	( Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood. Gerlach, M; Herhaus, G; Lange, KW; Melfsen, S; Müller, T; Scheuerpflug, P; Walitza, S; Warnke, A, 2007)	1.78
"Methylphenidate-OROS is a cost-effective treatment for youths with ADHD for whom treatment with IR methylphenidate is suboptimal. "	( Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. Annemans, L; de Jong-van den Berg, LT; Faber, A; Kalverdijk, LJ; Postma, MJ; Tobi, H; van Agthoven, M, 2008)	2.17
"Methylphenidate is a leading first-line treatment for ADHD (AD/HD). "	( Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. Arnold, LE; Bukstein, OG; Faraone, SV; Findling, RL; Glatt, SJ; Lopez, FA, 2009)	2.06
"Methylphenidate is an effective short-term treatment for oppositional behavior in children with comorbid ADHD and chronic multiple tic disorder."	( Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Gadow, KD; Nolan, EE; Schneider, J; Sprafkin, J; Sverd, J, 2008)	2.51
"Methylphenidate is a central nervous system stimulant with a spectrum of action similar to the effects of d-amphetamine. "	( A comparison of the hypothermic effects of methylphenidate and d-amphetamine. Ben-Uriah, Y; Carasso, RL; Yehuda, S, 1981)	1.97
"Methylphenidate appears to be a safe and effective treatment for attention-deficit hyperactivity disorder in the majority of children with comorbid tic disorder."	( Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Ezor, SN; Gadow, KD; Nolan, EE; Sprafkin, J; Sverd, J, 1995)	2.11
"Methylphenidate is a low-cost, potentially efficacious intervention for reducing the duration of comas, for preventing life-threatening and costly complications of prolonged unconsciousness, and for promoting early ambulation and recovery."	( Methylphenidate in the treatment of coma. Comfort, M; Fetters, MD; Worzniak, M, 1997)	2.46
"Methylphenidate is a useful adjunct in the treatment of some children with Williams syndrome."	( Treatment of children with Williams syndrome with methylphenidate. Bawden, HN; MacDonald, GW; Shea, S, 1997)	1.27
"Methylphenidate appears to be an effective, rapidly acting agent in this setting at dosages of 10-20 mg/day, with minimal side effects."	( Methylphenidate in post liver transplant patients. Chodoff, L; Drooker, M; Plutchik, L; Sheiner, P; Snyder, S, )	2.3
"Methylphenidate appears to be a safe and effective intervention in early poststroke rehabilitation that may expedite recovery."	( Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Blackwell, B; Chrostowski, J; Grade, C; Redford, B; Toussaint, L, 1998)	3.19
"Methylphenidate is a short-acting stimulant with a duration of action of 1 to 4 hours and a pharmacokinetic half-life of 2 to 3 hours."	( Pharmacokinetics and clinical effectiveness of methylphenidate. Abernethy, DR; Cross, JT; Kimko, HC, 1999)	1.28
"Methylphenidate (MP, Ritalin) is a psychotropic drug widely prescribed to children for treating the symptoms of attention deficit disorder with and without hyperactivity. "	( Analysis of methylphenidate and its metabolite ritalinic acid in monkey plasma by liquid chromatography/electrospray ionization mass spectrometry. Bajic, S; Doerge, DR; Fogle, CM; McCullagh, M; Paule, MG, 2000)	2.13
"Methylphenidate is a commonly used medication in the United States. "	( Methylphenidate: its pharmacology and uses. Challman, TD; Lipsky, JJ, 2000)	3.19
"Methylphenidate (MPD) is a drug widely used for treating attention-deficit/hyperactivity disorder in children. "	( NMDA receptor antagonist disrupts acute and chronic effects of methylphenidate. Dafny, N; Swann, A; Yang, P, )	1.81
"Methylphenidate is a CNS stimulant that is thought to block the reuptake of dopamine and noradrenaline (norepinephrine) into the presynaptic neuron. "	( Methylphenidate (OROS formulation). Jarvis, B; Keating, GM; McClellan, K, 2001)	3.2
"Methylphenidate is a psychostimulant most commonly used in the treatment of attention deficit hyperactivity disorder."	( Palliative uses of methylphenidate in patients with cancer: a review. Dreisbach, A; Kahn, MJ; Lertora, JJ; Rozans, M, 2002)	1.36
"Methylphenidate (Ritalin) is an effective drug in the treatment of attention deficit hyperactivity disorder. "	( Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Ding, YS; Fowler, JS; Franceschi, D; Gatley, SJ; Gifford, A; Logan, J; Maynard, L; Swanson, JM; Volkow, ND; Wang, GJ; Zhu, W, 2002)	2
"Methylphenidate is a useful, proven method for the effective treatment of minimal brain dysfunction (MBD). "	( Methylphenidate: a review. Majovski, LV; Oettinger, L, 1976)	3.14

Excerpt	Reference	Relevance
"Methylphenidate (MET) has a putative cognitive enhancer effect that has led adolescents and young adults to increase and indiscriminate its use aiming to ameliorate their productivity. "	( The influence of early exposure to methylphenidate on addiction-related behaviors in mice. Cata-Preta, EG; de Brito, ACL; de Oliveira Lima, AJ; Dos Anjos-Santos, A; Dos Santos, TB; Libarino-Santos, M; Marinho, EAV; Oliveira, TS; Oliveira-Campos, D; Patti, CL; Reis, HS, 2021)	2.34
"Methylphenidate has a wide margin of safety and relatively mild adverse effects, most commonly appetite suppression and insomnia."	( Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. Doffing, MA; Wolraich, ML, 2004)	1.26
"Methylphenidate (MPH) has a long history of being an effective medication for attention deficit/hyperactivity disorder (ADHD). "	( Characteristics and motives of college students who engage in nonmedical use of methylphenidate. Bucher, RH; Coleman, JJ; Dupont, RL; Wilford, BB, )	1.8
"Methylphenidate has an abuse potential, and there are increasing reports of recreational use of methylphenidate."	( Characterization of methylphenidate self-administration and reinstatement in the rat. Botly, LC; Burton, CL; Fletcher, PJ; Rizos, Z, 2008)	1.39
"Methylphenidate has a short plasma half-life (1-2 h) and thus needs to be frequently administered for effective therapy."	( Transdermal iontophoretic delivery of methylphenidate HCl in vitro. Boniello, S; Dinh, S; Liu, P; Singh, P, 1999)	1.3
"Methylphenidate also has an adverse event profile that requires consideration."	( How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. King, J; Langford, S; Moher, D; Pham, B; Schachter, HM, 2001)	1.3
"Methylphenidate (MPH) has been widely misused by children and adolescents who do not meet all diagnostic criteria for attention-deficit/hyperactivity disorder without a consensus about the consequences. "	( Evidence That Methylphenidate Treatment Evokes Anxiety-Like Behavior Through Glucose Hypometabolism and Disruption of the Orbitofrontal Cortex Metabolic Networks. Da Costa, JC; Greggio, S; Schmitz, F; Schu, G; Silveira, JS; Venturin, GT; Wyse, ATS; Zimmer, ER, 2021)	2.42
"Methylphenidate has many general side effects including ocular findings."	( Does methylphenidate treatment affect functional and structural ocular parameters in patients with attention deficit hyperactivity disorder? - A prospective, one year follow-up study. Atilla, H; Bingöl-Kızıltunç, P; Yürümez, E, 2022)	1.96
"Methylphenidate (MPH) has been widely misused by children and adolescents who do not meet all diagnostic criteria for attention-deficit/hyperactivity disorder. "	( Effects of methylphenidate after a long period of discontinuation include changes in exploratory behavior and increases brain activities of Na Ferreira, FS; Schmitz, F; Silveira, JS; T S Wyse, A; V R Júnior, O, 2022)	2.55
"Methylphenidate has also been found to reduce temper problems, affective instability, and emotional over-reactivity in adults with ADHD, although with variable effect sizes."	( Revisiting stimulant use for emotional dysregulation in attention-deficit/hyperactivity disorder (ADHD). Acierno, D; Barbuti, M; Brancati, GE; Elefante, C; Gemignani, S; Perugi, G; Raia, A, )	0.85
"Methylphenidate (MPH) has been used for decades to treat attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. "	( Dichotomous effect of methylphenidate on microglia and astrocytes: Insights from in vitro and animal studies. Leitão, RA; Lourenço, T; Muga, M; Novo, JP; Sanches, ES; Silva, AP, 2023)	2.67
"Methylphenidate has been a first line treatment for ADHD, with relatively large numbers of usage."	( Fetal safety of methylphenidate-A scoping review and meta analysis. Barer, Y; Koren, G; Ornoy, A, 2020)	1.63
"Methylphenidate has been shown to facilitate cognitive processing and reduce connectivity between the thalamus and lateral prefrontal cortex."	( Intrinsic connections between thalamic sub-regions and the lateral prefrontal cortex are differentially impacted by acute methylphenidate. Balderston, N; Ernst, M; Fuchs, B; Gorka, AX; Grillon, C; Lago, TR; Torrisi, S, 2020)	1.49
"Methylphenidate has been an established treatment for ADHD, but due to its relatively short half-life, numerous intermediate- and long-acting products have been developed. "	( Update on methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder. Ehret, MJ; Pheils, J, 2021)	2.47
"Methylphenidate (MET) has a putative cognitive enhancer effect that has led adolescents and young adults to increase and indiscriminate its use aiming to ameliorate their productivity. "	( The influence of early exposure to methylphenidate on addiction-related behaviors in mice. Cata-Preta, EG; de Brito, ACL; de Oliveira Lima, AJ; Dos Anjos-Santos, A; Dos Santos, TB; Libarino-Santos, M; Marinho, EAV; Oliveira, TS; Oliveira-Campos, D; Patti, CL; Reis, HS, 2021)	2.34
"Methylphenidate has prominent effects in the dopamine-rich striatum that are absent for the selective norepinephrine transporter inhibitor atomoxetine. "	( Striatal Activation Predicts Differential Therapeutic Responses to Methylphenidate and Atomoxetine. Bédard, AV; Fan, J; Halperin, JM; Hildebrandt, TB; Ivanov, I; Newcorn, JH; Schulz, KP; Stein, MA, 2017)	2.13
"Methylphenidate (MPH) has been shown to modulate the amplitude of the no-go P3 component of the event-related potential (ERP; Øgrim, Aasen, & Brunner, 2016). "	( Methylphenidate selectively modulates one sub-component of the no-go P3 in pediatric ADHD medication responders. Aasen, IE; Brunner, JF; Kropotov, J; Øgrim, G, 2018)	3.37
"Methylphenidate/Ritalin has been used for decades to treat attention deficit disorders and narcolepsy. "	( Use of cognitive enhancers: methylphenidate and analogs. Busardò, FP; Carlier, J; Giorgetti, R; Pirani, F; Ricci, G; Varì, MR, 2019)	2.25
"Methylphenidate (MPH) has been shown to be effective in the treatment of attention deficit hyperactivity disorder (ADHD) in children. "	( An observational study of response heterogeneity in children with attention deficit hyperactivity disorder following treatment switch to modified-release methylphenidate. Döpfner, M; Hautmann, C; Rothenberger, A, 2013)	2.03
"Methylphenidate (MPH) has been the most commonly used intravenous (i.v.) substance in Iceland in recent years. "	( Intravenous Use of Prescription Psychostimulants; A Comparison of the Pattern and Subjective Experience between Different Methylphenidate Preparations, Amphetamine and Cocaine. Bjarnadottir, GD; Bragadottir, H; Haraldsson, HM; Johannsson, M; Magnusson, A; Rafnar, BO; Sigurdsson, E; Steingrimsson, S, 2016)	2.08
"Methylphenidate has been shown to decrease impulsive choice (increase choices of a larger more delayed reinforcer). "	( Effects of methylphenidate on sensitivity to reinforcement delay and to reinforcement amount in pigeons: Implications for impulsive choice. Cummings, C; Cummings, CW; Hughes, CE; Pitts, RC; Woodcock, RL, 2016)	2.27
"Methylphenidate has been used as an effective treatment for attention deficit hyperactivity disorder (ADHD). "	( Methylphenidate alters NCS-1 expression in rat brain. Barichello, T; Gomes, KM; Gomez, MV; Quevedo, J; Réus, GZ; Romano-Silva, MA; Rosa, DV; Soares, EC; Souza, BR; Souza, RP, 2008)	3.23
"Methylphenidate has been studied most and is effective and well tolerated despite common side effects."	( Pharmacologic treatment options for cancer-related fatigue: current state of clinical research. Alici, Y; Breitbart, W, 2008)	1.07
"Methylphenidate has been used to treat these symptoms because of its rapid effect."	( Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. Hardy, SE, 2009)	2.52
"Methylphenidate has short-term symptomatic efficacy but also many adverse effects, including a risk of sudden death."	( Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate. , 2010)	1.32
"Methylphenidate has been shown to be an effective therapy in patients with refractory neurocardiogenic syncope. "	( Use of methylphenidate in the treatment of patients suffering from refractory postural tachycardia syndrome. Grubb, BP; Kanjwal, K; Kanjwal, Y; Karabin, B; Saeed, B, 2012)	2.28
"Methylphenidate (MPH) has been shown to block the norepinephrine transporter (NET), and genetic investigations have demonstrated that the norepinephrine transporter gene (SLC6A2) is associated with ADHD."	( Possible association of norepinephrine transporter -3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder. Cho, SC; Hong, SB; Kim, BN; Kim, JW; Shin, MS; Yoo, HJ, 2010)	1.31
"methylphenidate has rewarding effects, although i.p."	( Oral methylphenidate establishes a conditioned place preference in rats. Bardo, MT; Walton, MT; Wooters, TE, 2011)	1.6
"Methylphenidate (MPH) has long been used to treat attention-deficit/hyperactivity disorder (ADHD); however, its cellular mechanisms of action and potential effects on prefrontal cortical circuitry are not well understood, particularly in the developing brain system. "	( Distinct age-dependent effects of methylphenidate on developing and adult prefrontal neurons. Gao, WJ; Urban, KR; Waterhouse, BD, 2012)	2.1
"Dexmethylphenidate has been found to be effective and well tolerated in clinical trials, involving a total of 684 children with ADHD and in 15 healthy adult volunteers."	( Dexmethylphenidate--Novartis/Celgene. Focalin, D-MPH, D-methylphenidate hydrochloride, D-methylphenidate, dexmethylphenidate, dexmethylphenidate hydrochloride. , 2002)	1.45
"Methylphenidate has been advocated in patients with traumatic brain injury and stroke for a variety of cognitive, attention, and behavioral problems."	( Ritalin revisited: does it really help in neurological injury? Kajs-Wyllie, M, 2002)	1.04
"D-Methylphenidate has been shown to be efficacious in patients at half the dose of D,L-MPH with a potentially improved therapeutic profile."	( D-methylphenidate and D,L-methylphenidate are not developmental toxicants in rats and rabbits. Christian, MS; Hoberman, AM; Khetani, VD; Stirling, DI; Teo, SK; Thomas, SD, 2003)	1.6
"Methylphenidate has a wide margin of safety and relatively mild adverse effects, most commonly appetite suppression and insomnia."	( Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. Doffing, MA; Wolraich, ML, 2004)	1.26
"Methylphenidate has four optical isomers due to two asymmetries (erythro-threo and dextro-levo). "	( Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover labora Cooper, T; Dariani, M; Hirsch, S; Ottolini, Y; Quinn, D; Roffman, M; Swanson, J; Wigal, S; Zeldis, J, 2004)	2
"Methylphenidate has potential for abuse because it produces behavioural effects similar to those observed with other abused stimulants, such as d-amphetamine and cocaine. "	( Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. Fillmore, MT; Glaser, PE; Rush, CR; Stoops, WW, 2004)	2
"Methylphenidate has been suggested to exert its therapeutic effect mainly by blocking the dopamine transporter. "	( Actions of methylphenidate on dopaminergic neurons of the ventral midbrain. Bernardi, G; Federici, M; Geracitano, R; Mercuri, NB, 2005)	2.16
"Methylphenidate has been rigorously studied and found to be a safe and effective drug."	( [Attention deficit hyperactivity disorder: pharmacological options that are not "Ritalin"]. Gross-Tsur, V; Shmueli, D, 2005)	1.05
"Methylphenidate (MPH) has been shown to be effective in the treatment of attention deficits in children with attention deficit hyperactivity disorder (ADHD). "	( Effects of methylphenidate on multiple components of attention in children with attention deficit hyperactivity disorder. Bormann-Kischkel, C; Kübber, S; Lange, KW; Linder, M; Mecklinger, L; Prell, S; Tucha, O; Walitza, S, 2006)	2.17
"dl-Methylphenidate (MPH) has been widely used to treat attention-deficit/hyperactivity disorder (ADHD) for the last half century. "	( A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. DeVane, CL; Markowitz, JS; Muniz, R; Patrick, KS; Pestreich, LK, 2006)	1.2
"Methylphenidate has been shown elsewhere to improve hyperactivity in about half of treated children who have pervasive developmental disorders (PDD) and significant hyperactive-inattentive symptoms. "	( Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Aman, MG; Arnold, LE; Carroll, DH; Chuang, SZ; Cronin, P; Davies, M; McCracken, JT; McDougle, CJ; Posey, DJ; Ramadan, Y; Scahill, L; Shah, B; Swiezy, NB; Tierney, E; Vitiello, B; Wheeler, C; Witwer, AN; Young, C, 2007)	2.11
"Methylphenidate has been shown to have psychostimulus effects similar to methamphetamine."	( Lack of development of behavioral sensitization to methylphenidate in mice: correlation with reversible astrocytic activation. Higashiyama, K; Kurokawa, K; Miyatake, M; Narita, M; Shindo, K; Suzuki, M; Suzuki, T, 2007)	1.31
"Methylphenidate has been studied most and seems to be effective and well tolerated despite common side effects."	( Update on psychotropic medications for cancer-related fatigue. Alici-Evcimen, Y; Breitbart, W, 2007)	1.06
"Methylphenidate (MPH) has shown high response rates and no increase in seizures in small trials."	( Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. Gonzalez-Heydrich, J; Torres, AR; Whitney, J, 2008)	1.07
"Methylphenidate (MPH) has a long history of being an effective medication for attention deficit/hyperactivity disorder (ADHD). "	( Characteristics and motives of college students who engage in nonmedical use of methylphenidate. Bucher, RH; Coleman, JJ; Dupont, RL; Wilford, BB, )	1.8
"Methylphenidate has an abuse potential, and there are increasing reports of recreational use of methylphenidate."	( Characterization of methylphenidate self-administration and reinstatement in the rat. Botly, LC; Burton, CL; Fletcher, PJ; Rizos, Z, 2008)	1.39
"Methylphenidate has been found to be a safe and effective treatment of depression in the medically ill elderly."	( Depression in the medically ill elderly: a focus on methylphenidate. Emptage, RE; Semla, TP, 1996)	1.27
"Methylphenidate has short-term positive effects on children and adolescents with CD. "	( Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Abikoff, H; Ganeles, D; Klass, E; Klein, RG; Pollack, S; Seese, LM, 1997)	2.06
"Methylphenidate (MPH) has been used safely and effectively for many years in children for the treatment of attention deficit disorder with hyperactivity (ADHD). "	( The use of methylphenidate in paediatric traumatic brain injury. Hornyak, JE; Hurvitz, EA; Nelson, VS, )	1.96
"Methylphenidate has a short plasma half-life (1-2 h) and thus needs to be frequently administered for effective therapy."	( Transdermal iontophoretic delivery of methylphenidate HCl in vitro. Boniello, S; Dinh, S; Liu, P; Singh, P, 1999)	1.3
"Methylphenidate has 2 chiral centres, but the drug used in therapy comprises only the threo pair of enantiomers."	( Pharmacokinetics and clinical effectiveness of methylphenidate. Abernethy, DR; Cross, JT; Kimko, HC, 1999)	1.28
"Methylphenidate has been advocated as an effective antidepressant agent in unipolar depression, and depression secondary to medical illness."	( An open study of methylphenidate in bipolar depression. El-Mallakh, RS, 2000)	1.37
"Methylphenidate also has an adverse event profile that requires consideration."	( How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. King, J; Langford, S; Moher, D; Pham, B; Schachter, HM, 2001)	1.3
"Methylphenidate (Ritalin) has been shown to have differential effects on hyperactive children's behavior as a function of dose level. "	( Methylphenidate in hyperactive children: differential effects of dose on academic, learning, and social behavior. Birmingham, BK; DuPaul, GJ; Rapport, MD; Stoner, G; Tucker, S, 1985)	3.15

Excerpt	Reference	Relevance
"Methylphenidate treatment may lower the risk of all-cause fractures from both study designs; however, further evidence is needed about the treatment duration and sex effect. "	( Treatment with methylphenidate and the risk of fractures among children and young people: A systematic review and self-controlled case series study. Cheung, CL; Coghill, D; Fan, M; Gao, L; Ge, GMQ; Ip, P; Lau, WCY; Man, KKC; Wong, ICK; Wong, KHTW, 2023)	2.71
"methylphenidate may cause more adverse events considered non-serious versus placebo or no intervention (RR 1.23, 95% CI 1.11 to 1.37; I² = 72%; 35 trials 5342 participants; very low-certainty evidence). "	( Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Callesen, HE; Darling Rasmussen, P; Gluud, C; Groth, C; Huus, CL; Kirubakaran, R; Pereira Ribeiro, J; Schaug, JP; Simonsen, E; Skoog, M; Storebø, OJ; Storm, MRO; Zwi, M, 2023)	3.8
"Methylphenidate appears to produce dose-dependent benefits to individuals with attention-deficit/hyperactivity disorder, but the evidence for benefit in Parkinson's disease and schizophrenia is inconclusive."	( Is Methylphenidate Beneficial and Safe in Pharmacological Cognitive Enhancement? Kapur, A, 2020)	1.9
"Methylphenidate did not increase 24-h heart rates, whereas omega-3 fatty acid supplementation significantly decreased elevated heart rates and increased HRV in adolescents with IST."	( Diagnosis and management of an inappropriate sinus tachycardia in adolescence based upon a Holter ECG: A retrospective analysis of 479 patients. Baumann, C; Buchhorn, R; Gündogdu, S; Rakowski, U; Willaschek, C, 2020)	1.28
"Does methylphenidate cause liver damage? An analysis of ad hoc reports to the "Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)" Abstract. "	( [Does methylphenidate cause liver damage? An analysis of ad hoc reports to the "Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)"]. Fekete, S; Gerlach, M; Romanos, M, 2018)	1.48
"Methylphenidate is known to produce some addiction-related gene regulation."	( Selective serotonin re-uptake inhibitors potentiate gene blunting induced by repeated methylphenidate treatment: Zif268 versus Homer1a. Beverley, J; Steiner, H; Van Waes, V; Vandrevala, M, 2014)	1.35
"Methylphenidate did not enhance the psychotropic effects of MDMA, although it produced psychostimulant effects on its own."	( Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. Donzelli, M; Grouzmann, E; Hysek, CM; Liechti, ME; Meyer, N; Schillinger, N; Schmid, Y; Simmler, LD, 2014)	1.38
"Methylphenidate (MPH) plays a principal role in the multimodal treatment of attention-deficit/hyperactivity disorder (ADHD). "	( An evaluation of the pharmacokinetics of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder. Banaschewski, T; Döpfner, M; Frölich, J; Görtz-Dorten, A, 2014)	2.11
"Methylphenidate alone can produce gene regulation effects that mimic addiction-related gene regulation by cocaine, consistent with its moderate addiction liability."	( Fluoxetine potentiation of methylphenidate-induced gene regulation in striatal output pathways: potential role for 5-HT1B receptor. Beverley, JA; Ehrlich, S; Steiner, H; Van Waes, V, 2015)	1.44
"Methylphenidate dose and SHSS increase were negatively correlated with baseline SHSS scores."	( Methylphenidate facilitates hypnotizability in adults with ADHD: a naturalistic cohort study. Abramowitz, EG; Bonne, O; Lotan, A, 2015)	2.58
"Methylphenidate caused an increase in the alveolar diameter of rats, which was compatible with human pulmonary emphysema."	( Pulmonary emphysema induced by methylphenidate: experimental study. Antoniolli, A; Facco, G; Pazetti, R; Pêgo-Fernandes, PM; Pereira, DM; Rapello, GV, )	1.86
"Methylphenidate, which inhibit dopamine transporter is effective in the treatment of ADHD (attention deficit hyperactivity disorder), but long term use of this drug is often associated with addiction and dependence. "	( Attenuation of methylphenidate-induced sensitization by co-administration of buspirone. Alam, N; Naeem, S; Najam, R, 2016)	2.23
"Methylphenidate causes an increase in HR as well as increases in both systolic and diastolic BP, but no change in cardiac depolarisation and repolarisation duration or homogeneity."	( The effect of sympathomimetic medication on cardiovascular functioning of children with attention-deficit/hyperactivity disorder. Crafford, D; Negrao, BL; Viljoen, M, )	1.57
"Methylphenidate appears to cause minor increases in BP and HR."	( Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Besag, FM; Stiefel, G, 2010)	1.38
"Methylphenidate can enhance cognitive performance in ADHD patients thus evaluating their IQ scores, although the effect size seems to be relatively small. "	( Effect of methylphenidate on intelligence quotient scores in Chinese children with attention-deficit/hyperactivity disorder. Jin, X; Zhang, L; Zhang, Y, 2011)	2.21
"Methylphenidate displays a high degree of effectiveness and safety in the treatment of adults at doses of around 1 mg/kg/day."	( [Diagnosis and treatment of attention deficit hyperactivity disorder in adults]. Bosch, R; Casas, M; Chalita, PJ; Palomar, G; Prats, L; Ramos-Quiroga, JA; Vidal, R, 2012)	1.1
"Methylphenidate led to an increase in activation in this region but had no effect on task performance."	( The effects of methylphenidate on neural systems of attention in attention deficit hyperactivity disorder. Gore, JC; Marchione, KE; Shafritz, KM; Shaywitz, BA; Shaywitz, SE, 2004)	1.4
"Methylphenidate did not produce any changes in coherence values."	( Effects of methylphenidate on EEG coherence in attention-deficit/hyperactivity disorder. Abbott, I; Barry, RJ; Clarke, AR; Croft, RJ; Hsu, CI; Johnstone, SJ; Lawrence, CA; Magee, CA; McCarthy, R; Selikowitz, M, 2005)	1.44
"dl-Methylphenidate did not inhibit dextrorphan formation in either microsome preparation, and dl-methylphenidate metabolism was unaffected by dextromethorphan or dextrorphan."	( Potential interactions of methylphenidate and atomoxetine with dextromethorphan. Ciccone, PE; Jessen, LM; Ramabadran, K, )	0.95
"Methylphenidate tended to increase the time "on" as measured by tapping (P = .09) but not by walking time or dyskinesia scores (P = .40 and .42, respectively). "	( Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial. Carlson, NE; Carter, JH; Nutt, JG, 2007)	2.17
"Methylphenidate promotes a dose-dependent behavioral profile that is very comparable to that of amphetamine. "	( Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. Kuczenski, R; Segal, DS, 1997)	2.13
"Methylphenidate did not increase cocaine craving nor ratings suggesting abuse potential (i.e., Morphine-Benzedrine Group or drug-liking scores, etc.)."	( Laboratory measures of methylphenidate effects in cocaine-dependent patients receiving treatment. Creson, DL; Grabowski, J; Rhoades, HM; Roache, JD; Schmitz, JM, 2000)	1.34
"Methylphenidate can enhance cognitive performance in adults and children diagnosed with AD/HD (Kempton et al., 1999; Riordan et al., 1999) and also in normal human volunteers on tasks sensitive to frontal lobe damage, including aspects of spatial working memory (SWM) performance (Elliott et al., 1997)."	( Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. Mavaddat, N; Mehta, MA; Owen, AM; Pickard, JD; Robbins, TW; Sahakian, BJ, 2000)	2.47
"Methylphenidate produced an increase in psychopathology reflected by a worsening of both positive and negative symptoms."	( Behavioral response to methylphenidate and treatment outcome in first episode schizophrenia. Alvir, JM; Geisler, S; Jody, D; Lieberman, JA; Szymanski, S, 1990)	1.31

Excerpt	Reference	Relevance
"Methylphenidate (MPH) is the treatment of first choice for developmental ADHD. "	( Moderators and Other Predictors of Methylphenidate Response in Children and Adolescents with ADHD. D'Aiello, B; De Rossi, P; Di Vara, S; Menghini, D; Pretelli, I; Vicari, S, 2022)	2.44
"Methylphenidate treatment was effective in improving daytime sleepiness in NT1 patients with ADHD (PSQ, 16.7 ± 2.1 vs 13.5 ± 1.9, p<0.05) but was ineffective on ADHD symptoms (ADHD-RS, 25.3 ± 9.1 vs 26.4 ± 8.9, p>0.05)."	( A comparison of mood, quality of life and executive function among narcolepsy type 1 patients with or without ADHD symptoms in China. Dong, X; Han, F; Li, C; Qu, S; Wang, M; Wang, P; Xu, L, 2022)	1.44
"Methylphenidate, a first-line treatment for attention-deficit/hyperactivity disorder (ADHD), is thought to influence dopaminergic neurotransmission in the nucleus accumbens (NAc) and its associated brain circuitry, but this hypothesis has yet to be systematically tested."	( Methylphenidate Enhances Spontaneous Fluctuations in Reward and Cognitive Control Networks in Children With Attention-Deficit/Hyperactivity Disorder. Cai, W; Makita, K; Menon, V; Mizuno, Y; Silk, TJ; Supekar, K; Takiguchi, S; Tomoda, A, 2023)	3.8
"Methylphenidate treatment may lower the risk of all-cause fractures from both study designs; however, further evidence is needed about the treatment duration and sex effect. "	( Treatment with methylphenidate and the risk of fractures among children and young people: A systematic review and self-controlled case series study. Cheung, CL; Coghill, D; Fan, M; Gao, L; Ge, GMQ; Ip, P; Lau, WCY; Man, KKC; Wong, ICK; Wong, KHTW, 2023)	2.71
"Methylphenidate treatment duration ranged from 1 to 425 days, with a mean duration of 28.8 days."	( Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Callesen, HE; Darling Rasmussen, P; Gluud, C; Groth, C; Huus, CL; Kirubakaran, R; Pereira Ribeiro, J; Schaug, JP; Simonsen, E; Skoog, M; Storebø, OJ; Storm, MRO; Zwi, M, 2023)	3.07
"Methylphenidate treatment was linked to lower risk for TBI in patients with ADHD and the inverse association was persistent among those with other comorbid mental disorders and epilepsy."	( Methylphenidate and TBI in ADHD and co-occurring epilepsy and mental disorders: a self-controlled case series study. Chen, VC; Chen, YL; Dewey, ME; Gossop, M; Lee, CT; Yang, YH, 2022)	2.89
"Methylphenidate treatment improves the working memory, inhibitory control and mental flexibility of ADHD boys."	( Attention-deficit/hyperactivity disorder: the impact of methylphenidate on working memory, inhibition capacity and mental flexibility. Bolfer, C; Carreira, WS; Casella, BB; Casella, EB; Pacheco, SP; Tsunemi, MH, 2017)	2.14
"Methylphenidate treatment does not have an effect on performance-based measures of delay aversion and executive functioning, but may have significant effects on self-reported delay aversion and executive functioning. "	( Delay Aversion and Executive Functioning in Adults With Attention-Deficit/Hyperactivity Disorder: Before and After Stimulant Treatment. Fagerlund, B; Glenthøj, B; Habekost, T; Jepsen, JRM; le Sommer, J; Low, AM; Sonuga-Barke, E; Vangkilde, S, 2018)	1.92
"15 Methylphenidate (Mph)-treated and 15 Mph-free children of the ADHD-combined type and 17 control children performed a selective attention task with three feedback conditions: no-feedback, gain and loss. "	( Processing of continuously provided punishment and reward in children with ADHD and the modulating effects of stimulant medication: an ERP study. Althaus, M; Groen, Y; Tucha, O; Wijers, AA, 2013)	1.01
"Methylphenidate treatment of apathy in Alzheimer's disease was associated with significant improvement in 2 of 3 efficacy outcomes and a trend toward improved global cognition with minimal adverse events, supporting the safety and efficacy of methylphenidate treatment for apathy in Alzheimer's disease."	( Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. Bachman, DL; Drye, LT; Herrmann, N; Lanctôt, KL; Mintzer, JE; Rosenberg, PB; Scherer, RW, 2013)	2.14
"Methylphenidate treatment is effective for both ADHD and SSD symptoms. "	( Attention-deficit/hyperactivity disorder and comorbid subsyndromal depression: what is the impact of methylphenidate on mood? Golubchik, P; Kodesh, A; Weizman, A, )	1.79
"Methylphenidate treatment reduces attention deficit hyperactivity disorder symptoms and the risk for relapse to substance use in criminal offenders with attention deficit hyperactivity disorder and substance dependence."	( Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. Beck, O; Franck, J; Guterstam, J; Jayaram-Lindström, N; Konstenius, M; Philips, B, 2014)	3.29
"Methylphenidate treatment for ADHD was associated with both symptom alleviation in children with ADHD and improvement in parental depressive mood and quality of life, suggesting that the effects of treatment could go beyond symptom improvement in ADHD."	( Parental quality of life and depressive mood following methylphenidate treatment of children with attention-deficit hyperactivity disorder. Chang, JS; Cho, SC; Hwang, JW; Kim, B; Kim, BN; Kim, Y, 2014)	2.09
"Methylphenidate treatment did not affect patients' worst level of fatigue or other symptoms."	( A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Alvarez, RH; Cleeland, C; Escalante, CP; Gonzalez-Angulo, AM; Holmes, H; Hwang, J; Liu, W; Manzullo, E; Mendoza, T; Meyers, C; Morrow, PK; Overman, M; Pisters, K; Qiao, W; Reuben, JM; Wang, X; Wang, XS, )	1.07
"Methylphenidate treatment and higher cognitive level were associated with improved treatment outcome, while seizure freedom had no clear effect."	( Comparing stimulant effects in youth with ADHD symptoms and epilepsy. Azeem, MW; Biederman, J; Bourgeois, B; Gonzalez-Heydrich, J; Gumlak, S; Hickory, M; Hsin, O; Kimball, K; Mezzacappa, E; Mrakotsky, C; Rober, A; Torres, A, 2014)	1.12
"Methylphenidate-based treatments must therefore be implemented after a specialist has evaluated the patient and be prescribed following the recommendations."	( [Prescription of methylphenidate for children: importance of recommendations to limit misuse]. Amar, M; Bétaud, C; Chéron-Blümel, A; Grall-Bronnec, M; Jolliet, P; Péron, E; Victorri-Vigneau, C, 2014)	1.46
"Methylphenidate treatment did not significantly change any parameter of sleep architecture."	( Sleep in children with attention-deficit/hyperactivity disorder (ADHD) before and after 6-month treatment with methylphenidate: a pilot study. Bagnasco, I; Cortese, S; Delia, G; Galloni, GB; Mana, M; Moletto, A; Vigliano, P, 2016)	1.37
"OROS methylphenidate-treated subjects exhibited a significantly greater mean (SD) AISRS score improvement than placebo subjects (-17.1 [12.44] vs -11.7 [13.30]; P < .001)."	( Randomized, 6-Week, Placebo-Controlled Study of Treatment for Adult Attention-Deficit/Hyperactivity Disorder: Individualized Dosing of Osmotic-Release Oral System (OROS) Methylphenidate With a Goal of Symptom Remission. Armstrong, RB; Ascher, S; Goodman, DW; Ma, YW; Rostain, AL; Starr, HL, 2017)	1.1
"OROS methylphenidate treatment with individualized doses titrated to achieve symptom remission demonstrated greater ADHD symptom reduction than placebo treatment. "	( Randomized, 6-Week, Placebo-Controlled Study of Treatment for Adult Attention-Deficit/Hyperactivity Disorder: Individualized Dosing of Osmotic-Release Oral System (OROS) Methylphenidate With a Goal of Symptom Remission. Armstrong, RB; Ascher, S; Goodman, DW; Ma, YW; Rostain, AL; Starr, HL, 2017)	1.16
"Methylphenidate treatment for ADHD and CD has acute effects on these processes."	( Acute effects of methylphenidate on impulsivity and attentional behavior among adolescents comorbid for ADHD and conduct disorder. Acheson, A; Dougherty, DM; Hill-Kapturczak, N; Mathias, CW; Olvera, RL; Ryan, SR, 2016)	1.5
"Methylphenidate (MPH) treatment in patients with attention-deficit/hyperactivity disorder (ADHD) is reported to reduce the risk for injuries. "	( No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder. Golubchik, P; Kodesh, A; Weizman, A, )	1.8
"Methylphenidate treatment is used for Attention Deficit Hyperactivity Disorder and can improve learning and memory. "	( Methylphenidate amplifies long-term plasticity in the hippocampus via noradrenergic mechanisms. Dommett, EJ; Greenfield, SA; Henderson, EL; Westwell, MS, 2008)	3.23
"Methylphenidate is the treatment of choice in attention-deficit/hyperactivity disorder (ADHD). "	( Desensitization to methylphenidate--the relevance of continued drug intake for a successful outcome. Botelho, C; Cadinha, S; Castel-Branco, MG; Rodrigues, J, )	1.9
"Methylphenidate treatment is equally efficient in children with isolated attention-deficit hyperactivity disorder and in children with attention-deficit hyperactivity disorder and epilepsy (70%-77%)."	( Attention-deficit disorders and epilepsy in childhood: incidence, causative relations and treatment possibilities. Goldberg-Stern, H; Kaufmann, R; Shuper, A, 2009)	1.07
"Methylphenidate treatment however did not cause any differences in the number of labelled cells in any group."	( Effect of postnatal methamphetamine trauma and adolescent methylphenidate treatment on adult hippocampal neurogenesis in gerbils. Bagorda, F; Brummelte, S; Schaefers, AT; Teuchert-Noodt, G, 2009)	1.32
"Methylphenidate (MPH) treatment in boys diagnosed with ADHD is reported to decrease the risk of drug abuse in adulthood. "	( Cocaine responsiveness or anhedonia in rats treated with methylphenidate during adolescence. Boctor, SY; Ferguson, SA, )	1.82
"Methylphenidate treatment did not significantly affect height, weight, or overweight status."	( Body mass index of children with attention-deficit/hyperactivity disorder. Berger, I; Dubnov-Raz, G; Perry, A, 2011)	1.09
"Methylphenidate-treated children with ADHD had more dyskinesia than children in the control group. "	( Methylphenidate treatment and dyskinesia in children with attention-deficit/hyperactivity disorder. Balázs, J; Czobor, P; Dallos, G; Gádoros, J; Keresztény, A, 2011)	3.25
"Methylphenidate pretreatment reduced responding for methylphenidate in SHR but did not affect self-administration behaviors of Wistar rats (PR)."	( Methylphenidate treatment in the spontaneously hypertensive rat: influence on methylphenidate self-administration and reinstatement in comparison with Wistar rats. Cheong, JH; dela Peña, I; dela Peña, JB; Lee, JC; Ryu, JH; Shin, CY; Sohn, AR; Yoon, SY, 2012)	2.54
"Methylphenidate treatment is recommended in cases when ADHD diagnosis was confirmed."	( [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)]. Golubchik, P; Sever, J; Weizman, A, 2011)	1.09
"Methylphenidate treatment, as assessed by teachers' ratings, resulted in a significant improvement in ADHD symptomatology (t = 2.29, df = 27, P < .05); however, a trend for improvement was noted only on the parents' ratings."	( Efficacy of methylphenidate in patients with cerebral palsy and attention-deficit hyperactivity disorder (ADHD). Badihi, N; Gross-Tsur, V; Manor, O; Shalev, RS, 2002)	1.41
"Methylphenidate treatment also resulted in rCBF increase in superior prefrontal and reduction in ventral higher visual areas bilaterally."	( Regional cerebral blood flow in children with attention deficit hyperactivity disorder: comparison before and after methylphenidate treatment. Cho, SC; Chung, JK; Kang, E; Kim, BN; Kim, YK; Lee, DS; Lee, JS; Lee, MC, 2005)	1.26
"Methylphenidate-treated animals and vehicle-treated animals yielded striatal equilibrium ratios (V''3) of 0.24+/-0.26 (mean +/- SD) and 1.09+/-0.42, respectively (t test, two-tailed, p<0.0001). "	( Quantitation of dopamine transporter blockade by methylphenidate: first in vivo investigation using [123I]FP-CIT and a dedicated small animal SPECT. Antke, C; Arkian, S; Larisch, R; Müller, HW; Nikolaus, S; Schramm, N; Wirrwar, A, 2005)	2.03
"Methylphenidate treatment did not significantly affect SDS of height, weight, BMI, IGF-I and IGFBP-3 in the long run."	( Height, weight, IGF-I, IGFBP-3 and thyroid functions in prepubertal children with attention deficit hyperactivity disorder: effect of methylphenidate treatment. Bereket, A; Haklar, G; Karaman, MG; Ozbay, F; Turan, S; Yazgan, MY, 2005)	1.25
"Methylphenidate treatment had no sustained effects on growth parameters, IGF-I and IGFBP-3 during the follow-up period of this study."	( Height, weight, IGF-I, IGFBP-3 and thyroid functions in prepubertal children with attention deficit hyperactivity disorder: effect of methylphenidate treatment. Bereket, A; Haklar, G; Karaman, MG; Ozbay, F; Turan, S; Yazgan, MY, 2005)	1.25
"Methylphenidate is still the treatment of choice for the condition and, although it has been shown that neither methylphenidate nor other psychostimulants provoke seizures, there is still a possibility that seizure frequency may increase in children with active epilepsy."	( Optimizing therapy of seizures in children and adolescents with ADHD. Aldenkamp, AP; Arzimanoglou, A; Reijs, R; Van Mil, S, 2006)	1.06
"Methylphenidate treatment resulted in improved information processing, e.g., better visu-motor coordination under high-stress conditions, improved visual orientation and sustained visual attention compared to baseline and our untreated control group."	( Driving-related risks and impact of methylphenidate treatment on driving in adults with attention-deficit/hyperactivity disorder (ADHD). Alm, B; Kettler, N; Mattern, R; Sabljic, D; Skopp, G; Sobanski, E; Strohbeck-Kühner, P, 2008)	1.34
"In methylphenidate-treated patients, 4.3% discontinued due to adverse event; one serious adverse event was possibly related to study drug."	( A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Buitelaar, JK; Casas, M; Kooij, JJ; Lee, E; Medori, R; Niemelä, A; Ramos-Quiroga, JA; Trott, GE, 2008)	1.08
"Methylphenidate treatment produces an increase in dopamine (DA) signaling through multiple actions, including blockade of the DA reuptake transporter and amplification of DA response duration, disinhibition of DA D2 autoreceptors and amplification of DA tone, and activation of D1 receptors on the postsynaptic neuron."	( Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. Wilens, TE, 2008)	1.46
"The methylphenidate treated rats showed no change in sensitivity to atropine in the conditioned gustatory avoidance paradigm as compared to control rats which indicated that prior exposure to the nonspecific effects of a stimulant without monoaminergic alterations does not alter the sensitivity of atropine's avoidance-inducing properties."	( Effects of methamphetamine on atropine-induced conditioned gustatory avoidance. Preston, KL; Schuster, CR; Seiden, LS; Wagner, GC, 1984)	0.75
"The methylphenidate-treated group consisted of 11 age-matched subjects with narcolepsy."	( REM changes in narcolepsy with selegiline. MacFarlane, JG; Reinish, LW; Sandor, P; Shapiro, CM, 1995)	0.77
"Methylphenidate pretreatment decreased basal ganglia uptake but not cortical or cerebellar binding and reduced DVBG/DVCB by 62% and Bmax/Kd by 91%."	( A new PET ligand for the dopamine transporter: studies in the human brain. Ding, YS; Fowler, JS; Gatley, SJ; Logan, J; Pappas, N; Schlyer, DJ; Volkow, ND; Wang, GJ, 1995)	1.01
"Methylphenidate treatment (3 mg/kg daily for 14 days) did not normalize the decreased electrically-stimulated release of [(3)H]dopamine from SHR caudate-putamen slices nor did it affect postsynaptic D(2) receptor function."	( Methylphenidate affects striatal dopamine differently in an animal model for attention-deficit/hyperactivity disorder--the spontaneously hypertensive rat. de Villiers, AS; Lamm, MC; Russell, VA; Sagvolden, T; Taljaard, JJ, 2000)	2.47
"Methylphenidate-treated children showed significant weight loss but no significant changes in blood pressure or pulse."	( Blood pressure and pulse changes in hyperactive children treated with imipramine and methylphenidate. Greenberg, LM; Yellin, AM, 1975)	1.2
"Methylphenidate treatment did not significantly alter serotonin or 5-hydroxyindoleacetic acid excretion."	( Stimulants, urinary catecholamines, and indoleamines in hyperactivity. A comparison of methylphenidate and dextroamphetamine. Brown, GL; Chuang, LW; Karoum, F; Linnoila, M; Rapoport, JL; Wyatt, RJ; Zametkin, AJ, 1985)	1.21
"With methylphenidate treatment, the mean scores on the ADD-H Comprehensive Teacher Rating Scale displayed an increase in attention span and a decrease in hyperactivity, the Connors' Parent Rating Scale-Revised showed a significant decrease in ADD/H behavior, and the Gordon Diagnostic System mean scores indicated no significant change."	( Parent, teacher, child. A trilateral approach to attention deficit disorder. Atkinson, AW; Cohen, ML; Kelly, PC, 1989)	0.73
"Methylphenidate treatment of illness-related, nonpsychotic depression in the elderly appears to be an effective, quick-acting, and relatively safe therapeutic option."	( Elderly depressed females as a possible subgroup of patients responsive to methylphenidate. Askinazi, C; Karamouz, N; Weintraub, RJ, 1986)	1.22
"Treatment with methylphenidate is associated with clinically significant improvement of ADHD symptoms in 60-75% of patients."	( Attention deficit/hyperactivity disorder and epilepsy. Auvin, S; Rheims, S, 2021)	0.96
"Treatment with methylphenidate and/or atomoxetine increased choice of the large, delayed reward in SHR/NCrl and Wistar rats and changed, in varying degrees, mRNA levels of Nr4a2, Btg2, and Homer2, genes with previously described roles in neuropsychiatric disorders characterized by impulsivity."	( Methylphenidate and Atomoxetine-Responsive Prefrontal Cortical Genetic Overlaps in "Impulsive" SHR/NCrl and Wistar Rats. Cheong, JH; de la Peña, JB; Dela Peña, I; Dela Peña, IJ; Han, DH; Kim, BN; Kim, HJ; Ryu, JH; Shin, CY, 2017)	2.24
"Treatment with methylphenidate medication (mean dose 65.54 mg/d, SD=10.39) was not associated with improvements in performance-based measures of delay aversion and executive functioning compared to controls, although improvements in self-report executive functioning and delay aversion were found."	( Delay Aversion and Executive Functioning in Adults With Attention-Deficit/Hyperactivity Disorder: Before and After Stimulant Treatment. Fagerlund, B; Glenthøj, B; Habekost, T; Jepsen, JRM; le Sommer, J; Low, AM; Sonuga-Barke, E; Vangkilde, S, 2018)	0.82
"Treatment with methylphenidate (5 mg/kg), the most commonly used medication for ADHD, improved attention and normalized expression levels of dopamine-related genes in THRSP OE mice."	( Overexpression of the Thyroid Hormone-Responsive (THRSP) Gene in the Striatum Leads to the Development of Inattentive-like Phenotype in Mice. Abiero, A; Botanas, CJ; Cheong, JH; Custodio, RJP; de la Peña, JB; Dela Peña, IJ; Kim, BN; Kim, HJ; Kim, M; Ryoo, ZY; Sayson, LV, 2018)	0.82
"Treatment with methylphenidate, which blocks dopamine and noradrenaline transporters, is clinically efficacious in reducing the symptoms of ADHD."	( Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD. Ettinger, U; Kambeitz, J; Romanos, M, 2014)	0.96
"Pretreatment with methylphenidate significantly impaired novel object recognition in wild-type mice."	( Methylphenidate restores novel object recognition in DARPP-32 knockout mice. Fienberg, AA; Heyser, CJ; McNaughton, CH; Vishnevetsky, D, 2013)	2.16
"Treatment with methylphenidate (MPD) has improved learning disabilities in ADHD by acting on neurotransmitters."	( The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial. Bréant, V; Combemale, P; Coutinho, V; des Portes, V; Gérard, D; Ginhoux, T; Gueyffier, F; Herbillon, V; Kassaï, B; Kemlin, I; Lion-François, L; Mercier, C; Peyric, E; Pinson, S; Rodriguez, D, 2014)	1.1
"Treatment with methylphenidate resulted in normalisation of the resting state to task activation pattern."	( Normalisation of frontal theta activity following methylphenidate treatment in adult attention-deficit/hyperactivity disorder. Asherson, P; Banaschewski, T; Brandeis, D; Kuntsi, J; McLoughlin, G; Skirrow, C, 2015)	1.01
"Treatment with methylphenidate or atomoxetine based on prescription data."	( Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study. Garbe, E; Horn, J; Langner, I; Lindemann, C; Mikolajczyk, R; Schmedt, N, 2015)	0.77
"Is treatment with methylphenidate associated with benefits or harms for children and adolescents with attention-deficit/hyperactivity disorder (ADHD)?"	( Methylphenidate for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Gluud, C; Simonsen, E; Storebø, OJ, 2016)	2.21
"The treatment with methylphenidate (10mg/kg, ip) increased locomotion in the open field test."	( Lithium and valproate prevent methylphenidate-induced mania-like behaviors in the hole board test. Asth, L; Gavioli, EC; Lobão-Soares, B; Medeiros, IU; Santos, WB; Silva, EF; Soares-Rachetti, VP; Souza, LS, 2016)	1.04
"The treatment with methylphenidate had no beneficial effect on the rats' performance regardless of the DSP4 treatment."	( Effects of methylphenidate on attention in Wistar rats treated with the neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4). Hauser, J; Lange, KW; Reissmann, A; Sontag, TA; Tucha, O, 2017)	1.16
"Treatment with methylphenidate at an early age (P21 to P35) did not alter ethanol consumption in adult SHR or WKY, suggesting that it does not increase susceptibility to ethanol addiction in these rats."	( Methylphenidate does not increase ethanol consumption in a rat model for attention-deficit hyperactivity disorder-the spontaneously hypertensive rat. Howells, FM; Russell, VA; Soeters, HS, 2008)	2.13
"Treatment with methylphenidate, which disrupts social play behavior in adolescent rats, but not social exploratory behavior, prevented the development of socially-induced CPP."	( Conditioned place preference induced by social play behavior: parametrics, extinction, reinstatement and disruption by methylphenidate. Damsteegt, R; Trezza, V; Vanderschuren, LJ, 2009)	0.9
"Treatment with methylphenidate has been shown to induce improvements of various attentional functions."	( [Graphomotor functions in children with attention deficit hyperactivity disorder (ADHD)]. Lange, KW; Stasik, D; Tucha, L; Tucha, O; Walitza, S, )	0.47
"Treatment with methylphenidate has long been considered as a first choice for disabling forms of ADHD, but recent data do not show evidence for superiority of methylphenidate compared to non pharmacological approach at long-term."	( [Attention deficit disorder in childhood]. Van Bogaert, P, 2009)	0.69
"Treatment with methylphenidate normalises this threshold, rendering their pattern of task-related DMN deactivation indistinguishable from that of typically developing children."	( Task-related default mode network modulation and inhibitory control in ADHD: effects of motivation and methylphenidate. Batty, MJ; Groom, MJ; Hollis, C; Liddle, EB; Liddle, PF; Liotti, M; Scerif, G; Totman, JJ, 2011)	0.92
"Pretreatment with methylphenidate (0.56 mg/kg) did not significantly alter methamphetamine self-administration."	( Comparison of the effects of methamphetamine, bupropion, and methylphenidate on the self-administration of methamphetamine by rhesus monkeys. Gilman, JP; Goldberg, SR; McCann, DJ; Panlilio, LV; Schindler, CW, 2011)	0.93
"Treatment with methylphenidate showed a significant change in median scores on the Daytime Sleepiness Scale (-3.0 vs -0.5; P = 0.003) and the Epworth Sleepiness Scale (-3.0 vs -1.5; P = 0.039)."	( Efficacy and tolerability of a 20-mg dose of methylphenidate for the treatment of daytime sleepiness in adult patients with myotonic dystrophy type 1: a 2-center, randomized, double-blind, placebo-controlled, 3-week crossover trial. Bouchard, JP; Mathieu, J; Puymirat, J, 2012)	0.98
"Treatment with methylphenidate or nisoxetine ameliorated CAR impairments in DAT-KO mice."	( Impaired cliff avoidance reaction in dopamine transporter knockout mice. Hall, FS; Kasahara, Y; Kobayashi, H; Numachi, Y; Sakakibara, Y; Sora, I; Uchiumi, O; Uhl, GR; Yamashita, M; Yoshida, S, 2013)	0.73
"Treatment with methylphenidate (MPH) entails a dependency risk as MPH is a psychotropic drug."	( [Methylphenidate prescriptions in the city of Cologne: overrepresentation of privately insured patients. Results of an analysis based on prescription data]. Bessou, H; Puteanus, U; Zeeb, H, 2007)	1.59
"Treatment with methylphenidate (MPH) in the United States has increased to a current prescription rate of > 5 million per year."	( Does methylphenidate cause a cytogenetic effect in children with attention deficit hyperactivity disorder? Gerlach, M; Romanos, M; Stopper, H; Walitza, S; Warnke, A; Werner, B, 2007)	1.19
"Treatment with methylphenidate resulted in increased sleep efficiency as well as a subjective feeling of improved restorative value of sleep."	( Sleep in adults with attention deficit hyperactivity disorder (ADHD) before and during treatment with methylphenidate: a controlled polysomnographic study. Alm, B; Kettler, N; Schredl, M; Sobanski, E, 2008)	0.9
"Treatment with methylphenidate resulted in marked reductions of hyperactive, disruptive, and aggressive behavior, which was evident even for the 0.1 mg/kg dose."	( School observations of children with attention-deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Gadow, KD; Nolan, E; Sprafkin, J; Sverd, J, 1995)	0.84
"Pretreatment with methylphenidate decreased binding only in striatum (40%)."	( Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Ashby, C; Dewey, S; Ding, YS; Fowler, JS; Gatley, JS; Hitzemann, R; Liebermann, J; Logan, J; Volkow, ND; Wang, GJ, 1995)	1.24
"Treatment with methylphenidate resulted in complete resolution of symptoms in two patients and significant improvement in the other two."	( Consideration of narcolepsy in the differential diagnosis of chronic fatigue syndrome. Ambrogetti, A; Olson, LG, 1994)	0.64
"Treatment with methylphenidate may provide neurostimulations by augmenting the activity of injured neuronal tissue within the reticular activating system, and by amplifying the net effect of the reduced number of viable neurons."	( Methylphenidate in the treatment of coma. Comfort, M; Fetters, MD; Worzniak, M, 1997)	2.08
"Pretreatment with methylphenidate reduced the specific binding of [99mTc]TRODAT-1 to DAT sites [(STR-CB)/CB] from 2.45+/-0.13 to 0.32+/-0.04 without any effect on its binding to SERT sites [(MB-CB)/CB], which was confirmed by the co-registration of the [11C](+)McN5652/PET scans."	( In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates. Dresel, SH; Hou, C; Huang, X; Karp, J; Kung, HF; Kung, MP; Plössl, K; Shiue, CY, 1999)	0.63
"Treatment with methylphenidate has been advocated in patients with traumatic brain injury and stroke, cancer patients, and those with human immunodeficiency virus infection."	( Methylphenidate: its pharmacology and uses. Challman, TD; Lipsky, JJ, 2000)	2.09
"Treatment with methylphenidate was more effective and better tolerated than treatment with clonidine."	( [Functioning, comorbidity and treatment of 141 adults with attention deficit hyperactivity disorder (ADHD) at a psychiatric outpatient department]. Aeckerlin, LP; Buitelaar, JK; Kooij, JJ, 2001)	0.65
"Treatment with methylphenidate and clomipramine was effective; methylphenidate (30 mg/day) improved his wakefulness and alertness throughout the day, and clomipramine (20 mg/day) reduced the number of cataplexic episodes."	( [Narcolepsy in a prepubertal boy]. Chang, S; Ishikawa, T; Mizuno, K; Tsukamoto, H, 2001)	0.65
"Treatment with methylphenidate at dosages ranging from 2.5 mg/day to 20 mg/day produced mild to marked improvement in 54% of the patients; the fact that 6 of the 7 responders were female may be indicative of a more responsive subgroup."	( Elderly depressed females as a possible subgroup of patients responsive to methylphenidate. Askinazi, C; Karamouz, N; Weintraub, RJ, 1986)	0.84

Excerpt	Reference	Relevance
"2 years) meeting DSM-III-R criteria for major depression were followed-up during a 3-week efficacy and side effect trial involving methylphenidate."	( Efficacy and side effects of methylphenidate for poststroke depression. Abassian, M; Fawcett, J; Groves, L; Hartman, C; Kartan, U; Lazarus, LW; Lingam, VR; Neyman, I; Winemiller, DR, 1992)	0.78
"Results of this methylphenidate trial for poststroke depression in elderly patients suggest that it is a safe and effective treatment for poststroke depression."	( Efficacy and side effects of methylphenidate for poststroke depression. Abassian, M; Fawcett, J; Groves, L; Hartman, C; Kartan, U; Lazarus, LW; Lingam, VR; Neyman, I; Winemiller, DR, 1992)	0.92
"The adverse side effects of methylphenidate were evaluated in 27 children with attention deficit hyperactivity disorder and IQs of 48 to 74 who participated in a double-blind study of two doses of methylphenidate and placebo."	( Adverse side effects of methylphenidate among mentally retarded children with ADHD. Breaux, AM; Feldman, H; Gosling, A; Handen, BL; McAuliffe, S, 1991)	0.88
" Side effect ratings and EKGs were done weekly."	( Side effects of methylphenidate and desipramine alone and in combination in children. Biancaniello, TM; Carlson, GA; Kelly, KL; Pataki, CS; Rapport, MD, 1993)	0.63
"Methylphenidate is effective in treating children with epilepsy and ADHD and safe in children who are seizure free."	( Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? Gross-Tsur, V; Joseph, A; Manor, O; Shalev, RS; van der Meere, J, 1997)	1.98
" It is both well tolerated and efficacious in the treatment of attention deficit hyperactivity disorder, and is associated with few serious adverse effects."	( Safety issues in the use of methylphenidate. An American perspective. Rappley, MD, 1997)	0.59
"To compare the side effect profiles of methylphenidate (MPH) and dexamphetamine (DEX) in children with attention deficit hyperactivity disorder (ADHD), as well as to determine which symptoms are genuine adverse effects of stimulant medication, as opposed to aspects of the child's underlying behavioral phenotype."	( Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Barker, M; Efron, D; Jarman, F, 1997)	0.91
" Overall, both MPH and DEX were well tolerated by most subjects, with only four subjects discontinuing the trial period because of severe adverse effects (2 -1."	( Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Barker, M; Efron, D; Jarman, F, 1997)	0.64
"Methylphenidate is effective in treating children with epilepsy and ADHD and safe in children who are seizure free."	( Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? Gross-Tsur, V; Joseph, A; Manor, O; Shalev, RS; van der Meere, J, 1997)	1.98
" In general, methylphenidate was tolerated relatively well, with no children withdrawing because of adverse effects."	( Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. Bennett, S; Firestone, P; Mercer, J; Musten, LM; Pisterman, S, 1998)	0.67
" Methylphenidate also has an adverse event profile that requires consideration."	( How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. King, J; Langford, S; Moher, D; Pham, B; Schachter, HM, 2001)	1.49
" Neither compound produced any other significant adverse findings in F0 and F1 generation rats at doses that were at least 25 times the maximum daily human therapeutic dose."	( The perinatal and postnatal toxicity of D-methylphenidate and D,L-methylphenidate in rats. Christian, MS; Hoberman, AM; Khetani, VD; Stirling, DI; Teo, SK; Thomas, SD, )	0.4
" Based on body weight changes, the no observed adverse effect level for D-MPH in rats was 20 mg/kg."	( A 90-day oral gavage toxicity study of D-methylphenidate and D,L-methylphenidate in Sprague-Dawley rats. Hoberman, A; Khetani, V; Kiorpes, A; Stirling, D; Teo, S; Thomas, S, 2002)	0.58
" These initial efficacy and side effect studies in the LSP provided missing information about the basic pharmacokinetic (PK) and pharmacodynamic (PD) properties of MPH and AMP and produced some new discoveries (i."	( The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. Freid, J; Greenhill, L; Lerner, M; Posner, K; Steinhoff, K; Swanson, JM; Wigal, S; Wigal, T, 2002)	0.31
" Adverse events were recorded throughout the study, and Epworth Sleepiness Scale scores were determined at the end of the study."	( Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: an open-label safety study assessing three strategies. Hayduk, R; Kovacevic-Ristanovic, R; Schwartz, JR; Thorpy, MJ, 2003)	0.53
" All three switching strategies were well tolerated, with adverse events mild or moderate in nature."	( Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: an open-label safety study assessing three strategies. Hayduk, R; Kovacevic-Ristanovic, R; Schwartz, JR; Thorpy, MJ, 2003)	0.53
" Adverse events were monitored throughout the study."	( Efficacy and safety of modafinil for improving daytime wakefulness in patients treated previously with psychostimulants. Feldman, NT; Fry, JM; Harsh, J; Schwartz, JR, 2003)	0.32
" The most frequent adverse events were headache, nausea, and insomnia; the majority of adverse events were mild or moderate in nature."	( Efficacy and safety of modafinil for improving daytime wakefulness in patients treated previously with psychostimulants. Feldman, NT; Fry, JM; Harsh, J; Schwartz, JR, 2003)	0.32
" Children with ADHD treated with stimulants for as long as 2 years continue to benefit from the treatment, with improvements observed in ADHD symptoms, comorbid oppositional defiant disorder, and academic and social functioning, with no significant problems of tolerance or adverse effects."	( Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome. Greenfield, B; Hechtman, L, 2003)	0.32
" The adverse events reported were generally mild or moderate, and were similar in both groups."	( Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Biederman, J; Edson, K; Karlsson, G; Markabi, S; Pohlmann, H; Quinn, D; Weidenman, M; Weiss, M; Wigal, S, 2003)	0.54
"To study methylphenidate's adverse effects and impact on vital signs within the adult traumatic brain injury population."	( Effect of methylphenidate on vital signs and adverse effects in adults with traumatic brain injury. Alban, JP; Hopson, MM; Ly, V; Whyte, J, 2004)	1.14
" Participants filled out weekly questionnaires pertaining to the adverse effects."	( Effect of methylphenidate on vital signs and adverse effects in adults with traumatic brain injury. Alban, JP; Hopson, MM; Ly, V; Whyte, J, 2004)	0.73
"Poor appetite was the only adverse effect related to methylphenidate."	( Effect of methylphenidate on vital signs and adverse effects in adults with traumatic brain injury. Alban, JP; Hopson, MM; Ly, V; Whyte, J, 2004)	0.98
"Methylphenidate appears to be safe for the adult population with traumatic brain injury."	( Effect of methylphenidate on vital signs and adverse effects in adults with traumatic brain injury. Alban, JP; Hopson, MM; Ly, V; Whyte, J, 2004)	2.17
"To evaluate the impact of adherence and medication status on effectiveness and adverse effects of stimulant use in children with attention-deficit/hyperactivity disorder (ADHD) over 5 years."	( Stimulant treatment over five years: adherence, effectiveness, and adverse effects. Charach, A; Ickowicz, A; Schachar, R, 2004)	0.32
" Adherence to stimulants, treatment response, and adverse effects were evaluated annually for 5 years."	( Stimulant treatment over five years: adherence, effectiveness, and adverse effects. Charach, A; Ickowicz, A; Schachar, R, 2004)	0.32
" Clinically significant adverse effects were present for 5 years, most commonly loss of appetite."	( Stimulant treatment over five years: adherence, effectiveness, and adverse effects. Charach, A; Ickowicz, A; Schachar, R, 2004)	0.32
"Psychostimulants improve ADHD symptoms for up to 5 years, but adverse effects persist."	( Stimulant treatment over five years: adherence, effectiveness, and adverse effects. Charach, A; Ickowicz, A; Schachar, R, 2004)	0.32
"The aim of this study was to investigate the effects of ongoing methylphenidate (MPH) on ADHD-related and autistic symptoms in Pervasive Developmental Disorders (PDD) in children who did not present any adverse effects to an initial acute dose administered at the clinic."	( Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study. Cianchetti, C; Di Martino, A; Melis, G; Zuddas, A, 2004)	2
" No significant adverse effects were observed in any of the 8 subjects."	( Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study. Cianchetti, C; Di Martino, A; Melis, G; Zuddas, A, 2004)	1.77
" Although the overall percentage of subjects having any side effect on both methylphenidate and placebo was rather high, side effects on methylphenidate over and above those on placebo were few and mild."	( Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Boonstra, AM; Buitelaar, JK; Burger, H; Kalma, LE; Kooij, JJ; Van der Linden, PD, 2004)	0.86
" None of the patients with comorbid epilepsy experienced adverse effects on seizure control or antiepileptic drug use."	( Effectiveness and safety of methylphenidate in adult attention deficit hyperactivity disorder in patients with epilepsy: an open treatment trial. Aldenkamp, AP; van der Feltz-Cornelis, CM, 2006)	0.63
" It was effective against adult ADHD, and there were no adverse effects on seizure severity and frequency."	( Effectiveness and safety of methylphenidate in adult attention deficit hyperactivity disorder in patients with epilepsy: an open treatment trial. Aldenkamp, AP; van der Feltz-Cornelis, CM, 2006)	0.63
" Headache, anorexia, and insomnia were the most frequently reported treatment-related adverse events."	( Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. Bukstein, O; Greenhill, L; Lerner, M; McBurnett, K; McGough, JJ; Stein, M; Wilens, TE, 2006)	0.68
"5%) spontaneously reported adverse events suspected as drug related."	( Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. Ball, RR; Greenhill, LL; Jiang, H; Levine, A; Muniz, R; Pestreich, L, 2006)	0.63
" Pulse, blood pressure, and the presence of treatment emergent adverse events (AEs), parent and teacher AE ratings, and vital signs were recorded in each phase."	( Safety and tolerability of methylphenidate in preschool children with ADHD. Abikoff, H; Chuang, S; Davies, M; Ghuman, J; Greenhill, L; Kollins, S; McCRACKEN, J; McGOUGH, J; Posner, K; Riddle, M; Skrobala, A; Stehli, A; Swanson, J; Thorp, B; Vitiello, B; Wigal, S; Wigal, T, 2006)	0.63
"Once-daily d-MPH-ER at 20 mg, 30 mg, or 40 mg is a safe and effective treatment for adults with ADHD."	( Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Adler, LA; Jiang, H; McGough, JJ; Muniz, R; Pestreich, L; Spencer, TJ, 2007)	0.64
" Groups were compared regarding adverse events and changes from baseline to week 16 in electrocardiograms and vital signs."	( Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. Bukstein, OG; Daviss, WB; Harris, P; McDERMOTT, MP; Palumbo, D; Patel, NC; Pelham, WE; Robb, AS; Sallee, FR, 2008)	0.35
" Moderate or severe adverse events were more common in subjects on clonidine (79."	( Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. Bukstein, OG; Daviss, WB; Harris, P; McDERMOTT, MP; Palumbo, D; Patel, NC; Pelham, WE; Robb, AS; Sallee, FR, 2008)	0.35
"Clonidine, used alone or with methylphenidate, appears safe and well tolerated in childhood ADHD."	( Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. Bukstein, OG; Daviss, WB; Harris, P; McDERMOTT, MP; Palumbo, D; Patel, NC; Pelham, WE; Robb, AS; Sallee, FR, 2008)	0.63
" Similar side effect profile, superior adherence, and improved efficacy were demonstrated in intra-individual comparison of the OROS and IR methylphenidate forms."	( National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. Chang, HL; Chen, SJ; Cheng, H; Chou, MC; Chou, WJ; Gau, SS; Hsu, YC; Huang, YF; Huang, YS; Liang, HY; Lu, HH; Tang, CS; Tzang, RF; Wu, YY, 2008)	0.79
" Adverse events and vital signs were assessed."	( Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. Adler, LA; Michelson, D; Moore, RJ; Spencer, TJ; Williams, DW, 2008)	0.35
" Adverse events consisted primarily of pharmacologically (noradrenergic) expected effects."	( Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. Adler, LA; Michelson, D; Moore, RJ; Spencer, TJ; Williams, DW, 2008)	0.35
" There is little information on the long-term safety of methylphenidate in adults, although the number of serious adverse effects reported to regulatory authorities has, so far, been low."	( Safety of therapeutic methylphenidate in adults: a systematic review of the evidence. Godfrey, J, 2009)	0.91
" Adverse events were monitored throughout the study period."	( Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study. Brams, M; Mao, A; McCague, K; Muniz, R; Pestreich, L; Silva, R, 2008)	0.61
" d-MPH-ER was well tolerated; the most common adverse events (>15%) were headache, insomnia, and decreased appetite."	( Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD. Adler, LA; Jiang, H; McGough, JJ; Muniz, R; Spencer, T, 2009)	0.62
"Once-daily d-MPH-ER 20 to 40 mg is safe and effective for long-term treatment of adult ADHD."	( Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD. Adler, LA; Jiang, H; McGough, JJ; Muniz, R; Spencer, T, 2009)	0.62
" Other assessments included the Clinical Global Impressions-Improvement scale, a post hoc responder analysis, adverse events, and vital signs."	( Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. Adler, LA; Orman, C; Palumbo, J; Silber, S; Spencer, T; Starr, HL; Zimmerman, B, 2009)	0.65
" Adverse events were reported by 93 (84."	( Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. Adler, LA; Orman, C; Palumbo, J; Silber, S; Spencer, T; Starr, HL; Zimmerman, B, 2009)	0.65
" These changes did not, however, appear to be symptomatic, as no participants were withdrawn due to adverse events, and there was no significant self-report of increased heart rate with methylphenidate."	( Safety of methylphenidate following traumatic brain injury: impact on vital signs and side-effects during inpatient rehabilitation. Olver, J; Ponsford, J; Ponsford, M; Willmott, C, 2009)	0.95
"3 mg/kg body weight appears to be safe in the inpatient rehabilitation phase."	( Safety of methylphenidate following traumatic brain injury: impact on vital signs and side-effects during inpatient rehabilitation. Olver, J; Ponsford, J; Ponsford, M; Willmott, C, 2009)	0.76
"Safety concerns about central nervous system stimulants for the treatment of attention-deficit/hyperactivity disorder (ADHD) include adverse cardiac effects."	( Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Gerhard, T; Saidi, A; Shuster, J; Winterstein, AG, 2009)	0.69
"To investigate the frequency and severity of side effects of methylphenidate among childhood survivors of acute lymphoblastic leukemia and brain tumors and identify predictors of higher adverse effect levels."	( Side effects of methylphenidate in childhood cancer survivors: a randomized placebo-controlled trial. Conklin, HM; Howard, SC; Jasper, BW; Khan, RB; Lawford, J; Morris, EB; Ogg, SW; Wu, S; Xiong, X, 2009)	0.94
" Female gender and lower IQ were associated with higher adverse effect levels."	( Side effects of methylphenidate in childhood cancer survivors: a randomized placebo-controlled trial. Conklin, HM; Howard, SC; Jasper, BW; Khan, RB; Lawford, J; Morris, EB; Ogg, SW; Wu, S; Xiong, X, 2009)	0.7
" Adverse events were mild to moderate in severity and similar to previous observations for this class of neurostimulants."	( Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder. Childress, AC; Gerstner, O; Lopez, F; Muniz, R; Post, A; Spencer, T; Thulasiraman, A, 2009)	0.65
" Methylphenidate (MP) appears safe when used in the treatment of depression and fatigue in advanced cancer."	( Methylphenidate side effects in advanced cancer: a retrospective analysis. Davis, MP; Khoshknabi, DS; Lasheen, W; Mahmoud, F; Rivera, N; Walsh, D, 2010)	2.71
" They are generally safe in special populations."	( Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I. Kuchibhatla, A; Merkel, RL, 2009)	0.35
"Safety assessments included adverse events (AEs), vital signs, physical examination, clinical laboratory tests, the Pediatric Daytime Sleepiness Scale, and the Pittsburgh Side Effects Rating Scale."	( Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. Ginsberg, LD; Greenbaum, M; Murphy, WR; Spencer, TJ, 2009)	0.35
"Coadministration of GXR and MPH or AMP was generally safe and associated with statistically significant and clinically meaningful ADHD symptom improvement in children and adolescents."	( Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. Ginsberg, LD; Greenbaum, M; Murphy, WR; Spencer, TJ, 2009)	0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."	( Developing structure-activity relationships for the prediction of hepatotoxicity. Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)	0.36
" Despite their efficacy and long history of use, there is concern about their potential for adverse cardiovascular effects in children and adolescents."	( Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder. Muniz, R; Silva, RR; Skimming, JW, 2010)	0.36
" Intensity and frequency of adverse events were comparable between the two formulations."	( A double-blind, randomized, placebo/active controlled crossover evaluation of the efficacy and safety of Ritalin ® LA in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting. Fleischhaker, C; Haessler, F; Heiser, P; Hennighausen, K; Huss, M; Klatt, J; Linder, M; Oehler, KU; Schmidt, M; Schulte-Markworth, M; Schulz, E; Sieder, C; Tracik, F; Warnke, A, 2010)	0.36
" Physicians were presented with a hypothetical pharmaceutical cognitive enhancer that had been approved by the regulatory authorities for use in healthy adults, and was characterized as being safe, effective, and without significant adverse side effects."	( Physician attitudes towards pharmacological cognitive enhancement: safety concerns are paramount. Banjo, OC; Nadler, R; Reiner, PB, 2010)	0.36
" Dosing began at 36 mg/d, with titration in 18-mg increments every 7 days until a predefined outcome (efficacy threshold, maximum dosage of 108 mg/d, or limiting adverse event)."	( Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study. Adler, LA; Berwaerts, J; Cooper, K; Harrison, DD; Orman, C; Palumbo, J; Silber, S; Starr, HL, 2011)	0.67
" Most common adverse events included decreased appetite (26."	( Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study. Adler, LA; Berwaerts, J; Cooper, K; Harrison, DD; Orman, C; Palumbo, J; Silber, S; Starr, HL, 2011)	0.67
" The adverse events related to the therapy with IR-MPH, OROS-MPH or AHC were mild and the incidence rates of adverse events were not significantly different among the three groups."	( [Effectiveness and safety of methylphenidate and atomoxetine for attention deficit hyperactivity disorder: a systematic review]. Lv, XZ; Shu, Z; Wu, SS; Zhan, SY; Zhang, YW, 2011)	0.66
"16% of patients permanently discontinued treatment due to adverse events."	( An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety. Breuer, D; Döpfner, M; Görtz-Dorten, A; Rothenberger, A, 2011)	0.62
"Psychostimulants are effective treatments for attention-deficit/hyperactivity disorder (ADHD) but may be associated with euphoric effects, misuse/diversion, and adverse effects."	( Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder. Adler, LA; Davies, RD; Lewis, DF; Riggs, PD; Somoza, EC; Sonne, S; Winhusen, TM, 2011)	0.61
" Outcome measures included the Massachusetts General Hospital Liking Scale, self-reported medication compliance, pill counts, and adverse events (AEs)."	( Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder. Adler, LA; Davies, RD; Lewis, DF; Riggs, PD; Somoza, EC; Sonne, S; Winhusen, TM, 2011)	0.61
" Methylphenidate was found to be tolerable and safe in short term treatment when given in its immediate release and long-acting preparations to adults with ADHD."	( [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)]. Golubchik, P; Sever, J; Weizman, A, 2011)	1.28
" Adverse effects were also evaluated."	( Efficacy and adverse effects of venlafaxine in children and adolescents with ADHD: a systematic review of non-controlled and controlled trials. Berk, M; Freeman, RD; Ghanizadeh, A, 2013)	0.39
"Our intensive pharmacosurveillance monitoring program was performed to increase the number of adverse drug reactions (ADRs) recorded in the Italian spontaneous reporting database, and to systematically collect more thorough data about atomoxetine (ATX) and methylphenidate (MPH) safety in the pediatric setting."	( Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Bravaccio, C; Capuano, A; Granato, R; Grimaldi, G; Panei, P; Parretta, E; Pascotto, A; Rafaniello, C; Rinaldi, B; Rossi, F; Ruggiero, S; Sportiello, L, 2012)	0.56
"From September 2007 to October 2010, 1841 youth were enrolled in the Italian Attention- Deficit/Hyperactivity Disorder Register, but we report here on the 76 children from the five Reference Prescription Centers in Campania, an Italian region where we administered our systematic adverse event checklist."	( Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Bravaccio, C; Capuano, A; Granato, R; Grimaldi, G; Panei, P; Parretta, E; Pascotto, A; Rafaniello, C; Rinaldi, B; Rossi, F; Ruggiero, S; Sportiello, L, 2012)	0.38
" While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs."	( Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. Banaschewski, T; Buitelaar, J; Coghill, D; Cortese, S; Danckaerts, M; Dittmann, RW; Graham, J; Holtmann, M; Sergeant, J; Taylor, E, 2013)	0.39
"We explored two different methods of determining adverse events (AEs) among methylphenidate (MPH)-treated adolescents with attention-deficit/hyperactivity disorder (ADHD)."	( Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12-week multicenter, open-label study. Choi, J; Hong, SD; Joung, YS; Kim, JH; Lee, MS; Lee, SI, 2013)	0.84
" We hypothesized that the risk of an emotional side effect to methylphenidate (MPH) treatment may be associated with NTF3 genotypes."	( Neurotrophin 3 genotype and emotional adverse effects of osmotic-release oral system methylphenidate (OROS-MPH) in children with attention-deficit/hyperactivity disorder. Cho, SC; Chung, US; Han, DH; Kim, BN; Kim, JH; Kim, JW; Park, S; Shin, MS; Shin, YM; Son, JW, 2014)	0.87
" ADHD and associated psychiatric symptoms, medication status and dosage frequency, treatment adherence and adverse events were assessed at baseline and after a median treatment length with Medikinet(®) retard of 70 days."	( A non-interventional study of extended-release methylphenidate in the routine treatment of adolescents with ADHD: effectiveness, safety and adherence to treatment. Döpfner, M; Fischer, R; Ose, C; Sobanski, E, 2013)	0.65
"Methylphenidate treatment of apathy in Alzheimer's disease was associated with significant improvement in 2 of 3 efficacy outcomes and a trend toward improved global cognition with minimal adverse events, supporting the safety and efficacy of methylphenidate treatment for apathy in Alzheimer's disease."	( Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. Bachman, DL; Drye, LT; Herrmann, N; Lanctôt, KL; Mintzer, JE; Rosenberg, PB; Scherer, RW, 2013)	2.14
" An association between two CES1 SNP markers and the occurrence of sadness as a side effect of short-acting methylphenidate was found."	( Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene. Barry, E; Bellgrove, MA; Fitzgerald, M; Gill, M; Hawi, Z; Johnson, KA; Kirley, A; Lambert, D; McNicholas, F, 2013)	2.05
"This study found an association between two CES1 SNP markers and the occurrence of sadness as a side effect of short-acting methylphenidate."	( Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene. Barry, E; Bellgrove, MA; Fitzgerald, M; Gill, M; Hawi, Z; Johnson, KA; Kirley, A; Lambert, D; McNicholas, F, 2013)	2.04
" Five participants discontinued, four females due to adverse reactions and one male due to attenuated motivation."	( Evaluation of dosage, safety and effects of methylphenidate on post-traumatic brain injury symptoms with a focus on mental fatigue and pain. Andréll, P; Johansson, B; Mannheimer, C; Odenstedt, J; Rönnbäck, L; Wentzel, AP, 2014)	0.66
"Methylphenidate decreased mental fatigue for subjects suffering a traumatic brain injury, the treatment is considered to be safe and is recommended, starting with a low dose."	( Evaluation of dosage, safety and effects of methylphenidate on post-traumatic brain injury symptoms with a focus on mental fatigue and pain. Andréll, P; Johansson, B; Mannheimer, C; Odenstedt, J; Rönnbäck, L; Wentzel, AP, 2014)	2.11
" Although treatment-emergent adverse events were reported more frequently in the OROS MPH group (81."	( A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan. Kashimoto, Y; Koh, T; Matsumura, T; Saito, Y; Takahashi, N; Tominaga, Y, 2014)	0.6
" Adverse events were numerically less frequent with Omega-3/6 or MPH + Omega-3/6 than MPH alone."	( Efficacy and Safety of Omega-3/6 Fatty Acids, Methylphenidate, and a Combined Treatment in Children With ADHD. Barragán, E; Breuer, D; Döpfner, M, 2017)	0.71
"The purpose of this study was to investigate whether the availability of both dextroamphetamine and methylphenidate provides an opportunity to minimize adverse events in a pediatric attention-deficit/hyperactivity disorder (ADHD) stimulant trial."	( Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate. Aabech, HS; Ramtvedt, BE; Sundet, K, 2014)	0.81
" Barkley's Side-Effect Rating Scale (SERS), rated by parents, was used to assess adverse events."	( Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate. Aabech, HS; Ramtvedt, BE; Sundet, K, 2014)	0.6
"The side-effect profiles of dextroamphetamine and methylphenidate appeared similar at the group level."	( Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate. Aabech, HS; Ramtvedt, BE; Sundet, K, 2014)	0.85
"The availability of both dextroamphetamine and methylphenidate may contribute to minimize adverse events in a subsample of children in pediatric ADHD stimulant trials."	( Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate. Aabech, HS; Ramtvedt, BE; Sundet, K, 2014)	0.85
"A bibliographic search was performed in the MEDLINE, EMBASE and PsycINFO databases for prospective studies evaluating the incidence of adverse events (AEs) in children and adolescents treated for ADHD."	( Safety of medicines used for ADHD in children: a review of published prospective clinical trials. Bonati, M; Clavenna, A, 2014)	0.4
" No occurrences of suicidal ideation or behavior were recorded; the most common open-label treatment-emergent adverse events were typical of stimulant use: decreased appetite, insomnia, and abdominal pain."	( Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD. Belden, HW; Berry, SA; Childress, AC; Findling, RL; Robb, AS; Wigal, SB, 2017)	0.71
" Adverse events (AEs) and serious adverse events (SAEs) were reported at the end of extension study for events monitored from (1) maintenance of effect phase baseline (core study; 12 months) and (2) extension study baseline (6 months)."	( Long-term (1 year) safety and efficacy of methylphenidate modified-release long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity disorder: a 26-week, flexible-dose, open-label extension to a 40-week, double-blind, randomised, pla Arngrim, T; Chen, CW; Gandhi, P; Ginsberg, Y; Huss, M; Kumar, V; Philipsen, A, 2014)	0.67
"7 %) had treatment-related adverse events with one case being serious; 23 patients (8."	( Effectiveness and safety of a long-acting, once-daily, two-phase release formulation of methylphenidate (Ritalin ® LA) in school children under daily practice conditions. Bilke-Hentsch, O; Haertling, F; Mueller, B, 2015)	0.64
"Despite the occurrence of IED, the use of MPH was safe during 2 years follow-up."	( Attention deficit/hyperactivity disorder and interictal epileptiform discharges: it is safe to use methylphenidate? Aurlien, D; Herigstad, A; Larsen, TK; Socanski, D; Thomsen, PH, 2015)	0.63
"We found significant intraclass correlations in family member response to methylphenidate-immediate release and side effect profile, including emotional symptoms and loss of appetite and weight."	( High Familial Correlation in Methylphenidate Response and Side Effect Profile. Brand-Gothelf, A; Dubnov-Raz, G; Gazer-Snitovsky, M; Gothelf, D; Weizman, A, 2019)	1.04
"We present a case of adverse neurological effects of methylphenidate therapy for attention deficit and hyperactivity disorder (ADHD)."	( Neurological adverse effects of methylphenidate may be misdiagnosed as meningoencephalitis. Bakshi, D; Snell, LB, 2015)	0.95
"The aim of this study was to assess the type and frequency of adverse events (AEs) in children with attention-deficit/hyperactivity disorder (ADHD) treated with methylphenidate or atomoxetine over a 5-year period in a large naturalistic study."	( Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry. Arcieri, R; Capuano, A; Chiarotti, F; Cortese, S; Curatolo, P; Germinario, EA; Margari, L; Panei, P, 2015)	1.02
" Methylphenidate is safe in healthy children and has shown to have no cardiac side effects in these patients."	( Psychopharmacology of Attention-Deficit Hyperactivity Disorder: Effects and Side Effects. Golmirzaei, J; Hamzei, E; Kamal, MA; Mahboobi, H; Mushtaq, G; Yazdanparast, M, 2016)	1.34
"Methylphenidate is excreted in breast milk only in small amounts, and to date there have been no reports of breastfed infants demonstrating any adverse effects."	( Is it safe to breastfeed while taking methylphenidate? Bozzo, P; Koren, G; Marchese, M, 2015)	2.13
"The FDA addressed interchangeability problems with generic modified-release alternatives of bupropion and methylphenidate including lack of bioequivalence, reduced efficacy, and increased incidence of adverse events."	( Interchangeability, Safety and Efficacy of Modified-Release Drug Formulations in the USA: The Case of Opioid and Other Nervous System Drugs. Hansen, R; Rodriguez-Monguio, R; Seoane-Vazquez, E, 2016)	0.65
"There is no questionnaire to specifically monitor perceived adverse events of methylphenidate (MPH) on cognition, motivation, and mood."	( Reports of Perceived Adverse Events of Stimulant Medication on Cognition, Motivation, and Mood: Qualitative Investigation and the Generation of Items for the Medication and Cognition Rating Scale. Banaschewski, T; Buitelaar, JK; Carucci, S; Coghill, D; Danckaerts, M; Dittmann, RW; Falissard, B; Grimshaw, DG; Hollis, C; Inglis, S; Konrad, K; Kovshoff, H; Liddle, E; McCarthy, S; Nagy, P; Sonuga-Barke, EJ; Thompson, M; Wong, IC; Zuddas, A, 2016)	0.66
" Purposeful sampling was used to selectively recruit ADHD participants whose histories suggested a degree of vulnerability to MPH adverse events."	( Reports of Perceived Adverse Events of Stimulant Medication on Cognition, Motivation, and Mood: Qualitative Investigation and the Generation of Items for the Medication and Cognition Rating Scale. Banaschewski, T; Buitelaar, JK; Carucci, S; Coghill, D; Danckaerts, M; Dittmann, RW; Falissard, B; Grimshaw, DG; Hollis, C; Inglis, S; Konrad, K; Kovshoff, H; Liddle, E; McCarthy, S; Nagy, P; Sonuga-Barke, EJ; Thompson, M; Wong, IC; Zuddas, A, 2016)	0.43
"While we probed purposefully for cognitive and motivational adverse events, a third domain, related to mood, emerged from the reports."	( Reports of Perceived Adverse Events of Stimulant Medication on Cognition, Motivation, and Mood: Qualitative Investigation and the Generation of Items for the Medication and Cognition Rating Scale. Banaschewski, T; Buitelaar, JK; Carucci, S; Coghill, D; Danckaerts, M; Dittmann, RW; Falissard, B; Grimshaw, DG; Hollis, C; Inglis, S; Konrad, K; Kovshoff, H; Liddle, E; McCarthy, S; Nagy, P; Sonuga-Barke, EJ; Thompson, M; Wong, IC; Zuddas, A, 2016)	0.43
"Items were identified that capture potential/perceived cognitive, motivational, and mood-related adverse events of MPH."	( Reports of Perceived Adverse Events of Stimulant Medication on Cognition, Motivation, and Mood: Qualitative Investigation and the Generation of Items for the Medication and Cognition Rating Scale. Banaschewski, T; Buitelaar, JK; Carucci, S; Coghill, D; Danckaerts, M; Dittmann, RW; Falissard, B; Grimshaw, DG; Hollis, C; Inglis, S; Konrad, K; Kovshoff, H; Liddle, E; McCarthy, S; Nagy, P; Sonuga-Barke, EJ; Thompson, M; Wong, IC; Zuddas, A, 2016)	0.43
" Safety assessments included adverse events (AEs), physical examinations, electrocardiograms (ECGs), and the Columbia Suicide Severity Rating Scale (C-SSRS)."	( Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting. Childress, AC; Cutler, AJ; Kollins, SH; Marraffino, A; Sikes, CR, 2017)	0.68
" A recorded diagnosis (either a primary or secondary cause) of any of the following cardiovascular adverse events: arrhythmias (ICD-10 (international classification of diseases, 10th revision) codes I44, I45, I47, I48, I49), hypertension (codes I10-I15), myocardial infarction (code I21), ischemic stroke (code I63), or heart failure (code I50)."	( Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. Park, BJ; Pratt, NL; Roughead, EE; Shin, JY, 2016)	0.74
" Withdrawals due to all-cause, adverse effects and lack of efficacy were defined as primary outcomes evaluating the safety of such medications."	( An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments. Gao, J; He, S; Li, Y; Wang, Q; Zhang, Y, 2017)	0.46
"To identify and characterize cases of chemical leukoderma, an underrecognized adverse event, associated with the methylphenidate transdermal system (MTS) reported to the US Food and Drug Administration Adverse Event Reporting System (FAERS)."	( Chemical Leukoderma Associated with Methylphenidate Transdermal System: Data From the US Food and Drug Administration Adverse Event Reporting System. Brinker, A; Cheng, C; Diak, IL; La Grenade, L; Levin, RL, 2017)	0.94
"We searched the Food and Drug Administration Adverse Event Reporting System for reports of chemical leukoderma associated with MTS, received by the Food and Drug Administration from April 6, 2006 to December 23, 2014."	( Chemical Leukoderma Associated with Methylphenidate Transdermal System: Data From the US Food and Drug Administration Adverse Event Reporting System. Brinker, A; Cheng, C; Diak, IL; La Grenade, L; Levin, RL, 2017)	0.73
" Outcomes like response rate, ADHD Rating Scale (ADHD-RS) score, and adverse events were compared between ATX and MPH treatments."	( Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials. Fang, Q; Liu, Q; Qin, L; Zhang, H, 2017)	0.73
"01]) and lower risk of adverse events (drowsiness: RR = 0."	( Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials. Fang, Q; Liu, Q; Qin, L; Zhang, H, 2017)	0.73
" Areas covered: Physical adverse effects, psychiatric adverse events and brain development Expert opinion: Some physical adverse events have been described (e."	( An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Dietrich, A; Groenman, AP; Hoekstra, PJ; Schweren, LJ, 2017)	0.46
" Safety assessments included adverse event (AE) monitoring and the Columbia-Suicide Severity Rating Scale (C-SSRS)."	( Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder. Belden, H; Berry, SA; Chappell, P; Childress, A; Orazem, J; Palumbo, D; Sherman, N; Walters, F; Wigal, SB, 2017)	0.73
" MPH ERCT was generally safe and well tolerated, with a safety profile consistent with other MPH ER formulations."	( Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder. Belden, H; Berry, SA; Chappell, P; Childress, A; Orazem, J; Palumbo, D; Sherman, N; Walters, F; Wigal, SB, 2017)	0.73
"To study in more depth the relationship between type, dose, or duration of methylphenidate offered to children and adolescents with attention deficit hyperactivity disorder and their risks of gastrointestinal adverse events based on our Cochrane systematic review."	( Gastrointestinal adverse events during methylphenidate treatment of children and adolescents with attention deficit hyperactivity disorder: A systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials. Gillies, D; Gluud, C; Groth, C; Holmskov, M; Krogh, HB; Magnusson, FL; Moreira-Maia, CR; Ramstad, E; Simonsen, E; Skoog, M; Storebø, OJ; Zwi, M, 2017)	0.95
" Randomised parallel-group trials and cross-over trials reporting gastrointestinal adverse events associated with methylphenidate were included."	( Gastrointestinal adverse events during methylphenidate treatment of children and adolescents with attention deficit hyperactivity disorder: A systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials. Gillies, D; Gluud, C; Groth, C; Holmskov, M; Krogh, HB; Magnusson, FL; Moreira-Maia, CR; Ramstad, E; Simonsen, E; Skoog, M; Storebø, OJ; Zwi, M, 2017)	0.93
" No differences in the risks of gastrointestinal adverse events according to type, dose, or duration of administration were found."	( Gastrointestinal adverse events during methylphenidate treatment of children and adolescents with attention deficit hyperactivity disorder: A systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials. Gillies, D; Gluud, C; Groth, C; Holmskov, M; Krogh, HB; Magnusson, FL; Moreira-Maia, CR; Ramstad, E; Simonsen, E; Skoog, M; Storebø, OJ; Zwi, M, 2017)	0.72
"Our study evaluated adverse events of therapeutic failure (and specifically reduced duration of action) with the use of a branded product, Osmotic Release Oral System (OROS) methylphenidate, which is approved for the treatment of attention deficit/hyperactivity disorder, and a generic product (methylphenidate, methylphenidate ER-C), which was approved for marketing in Canada based on bioequivalence to OROS methylphenidate."	( Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases. Almagor, D; Castillon, G; Park-Wyllie, L; Sherman, SE; van Stralen, J, 2017)	0.86
"Through methodology similar to that used by the US Food and Drug Administration to investigate the issue with the US-marketed generic, reporting rates were calculated from cases of therapeutic failure identified in the Canadian Vigilance Adverse Reaction Online database for a 1-year period beginning 8 months after each product launch."	( Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases. Almagor, D; Castillon, G; Park-Wyllie, L; Sherman, SE; van Stralen, J, 2017)	0.67
" Impacts on social functioning, such as disruption in work or school performance or adverse social behaviors, were found in 51 cases (22."	( Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases. Almagor, D; Castillon, G; Park-Wyllie, L; Sherman, SE; van Stralen, J, 2017)	0.67
" While these results should be interpreted with caution due to the limitations of spontaneous adverse event reporting, which may confound comparisons across products, similar findings nonetheless led the US Food and Drug Administration to declare in 2014 that 2 methylphenidate ER generic products in the United States were neither bioequivalent nor interchangeable with OROS methylphenidate-their reference product."	( Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases. Almagor, D; Castillon, G; Park-Wyllie, L; Sherman, SE; van Stralen, J, 2017)	0.85
" Safety measures included spontaneously reported treatment-emergent adverse events (TEAEs) and two TEAEs of special interest, appetite suppression and insomnia (with direct questioning on sleep disturbance)."	( Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder. Arnold, VK; Bostrom, S; Cutler, AJ; DeSousa, NJ; Incledon, B; López, FA; Marraffino, A; Newcorn, JH; Pliszka, SR; Sallee, FR; Wilens, TE, 2017)	0.69
" Concerning adverse events associated with the treatment, our systematic review of randomised clinical trials (RCTs) demonstrated no increase in serious adverse events, but a high proportion of participants suffered a range of non-serious adverse events."	( Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Aagaard, L; Buch Rasmussen, K; Gauci, D; Gerner, T; Gillies, D; Gluud, C; Groth, C; Håkonsen, SJ; Holmskov, M; Kielsholm, ML; Kirubakaran, R; Krogh, HB; Magnusson, FL; Moreira-Maia, CR; Nielsen, SS; Pedersen, N; Ramstad, E; Rosendal, S; Simonsen, E; Skoog, M; Storebø, OJ; Zwi, M, 2018)	1.92
"To assess the adverse events associated with methylphenidate treatment for children and adolescents with ADHD in non-randomised studies."	( Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Aagaard, L; Buch Rasmussen, K; Gauci, D; Gerner, T; Gillies, D; Gluud, C; Groth, C; Håkonsen, SJ; Holmskov, M; Kielsholm, ML; Kirubakaran, R; Krogh, HB; Magnusson, FL; Moreira-Maia, CR; Nielsen, SS; Pedersen, N; Ramstad, E; Rosendal, S; Simonsen, E; Skoog, M; Storebø, OJ; Zwi, M, 2018)	2.18
" We defined serious adverse events according to the International Committee of Harmonization as any lethal, life-threatening or life-changing event."	( Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Aagaard, L; Buch Rasmussen, K; Gauci, D; Gerner, T; Gillies, D; Gluud, C; Groth, C; Håkonsen, SJ; Holmskov, M; Kielsholm, ML; Kirubakaran, R; Krogh, HB; Magnusson, FL; Moreira-Maia, CR; Nielsen, SS; Pedersen, N; Ramstad, E; Rosendal, S; Simonsen, E; Skoog, M; Storebø, OJ; Zwi, M, 2018)	1.92
"Our findings suggest that methylphenidate may be associated with a number of serious adverse events as well as a large number of non-serious adverse events in children and adolescents, which often lead to withdrawal of methylphenidate."	( Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Aagaard, L; Buch Rasmussen, K; Gauci, D; Gerner, T; Gillies, D; Gluud, C; Groth, C; Håkonsen, SJ; Holmskov, M; Kielsholm, ML; Kirubakaran, R; Krogh, HB; Magnusson, FL; Moreira-Maia, CR; Nielsen, SS; Pedersen, N; Ramstad, E; Rosendal, S; Simonsen, E; Skoog, M; Storebø, OJ; Zwi, M, 2018)	2.22
" The most common adverse effects in subjects still on treatment with MPH were decreased appetite (28%), dry mouth (24%), anxiousness/restlessness and increased pulse frequency (19% each), decreased sexual desire (17%), and perspiration (15%)."	( Long-Term Tolerability and Safety of Pharmacological Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A 6-Year Prospective Naturalistic Study. Edvinsson, D; Ekselius, L, 2018)	0.48
" Those diagnosed with ADHD and on long-term treatment with stimulants experience mild and tolerable adverse effects."	( Long-Term Tolerability and Safety of Pharmacological Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A 6-Year Prospective Naturalistic Study. Edvinsson, D; Ekselius, L, 2018)	0.48
"Sleep disturbances are a feature of attention-deficit/hyperactivity disorder (ADHD) and an adverse event (AE) of methylphenidate treatment."	( Sleep-Associated Adverse Events During Methylphenidate Treatment of Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis. Cortese, S; Faraone, SV; Komolova, M; Po, MD, 2019)	0.99
"To determine the evidence on dose titration and adverse events associated with dose titration of stimulants for ADHD."	( Evaluation of Methylphenidate Safety and Maximum-Dose Titration Rationale in Attention-Deficit/Hyperactivity Disorder: A Meta-analysis. Ching, C; Eslick, GD; Poulton, AS, 2019)	0.87
"The outcomes of interest were (1) the doses used in published clinical trials, (2) the clinical justification given by researchers for their selected dose range, and (3) the adverse effects associated with methylphenidate when the dose is established by titration."	( Evaluation of Methylphenidate Safety and Maximum-Dose Titration Rationale in Attention-Deficit/Hyperactivity Disorder: A Meta-analysis. Ching, C; Eslick, GD; Poulton, AS, 2019)	1.06
" Reports of life-threatening adverse events were absent; further studies of the efficacy, tolerability, and safety of methylphenidate titrated purely on clinical grounds, without reference to any set maximum dose, are needed."	( Evaluation of Methylphenidate Safety and Maximum-Dose Titration Rationale in Attention-Deficit/Hyperactivity Disorder: A Meta-analysis. Ching, C; Eslick, GD; Poulton, AS, 2019)	1.08
" These may also be triggered by drugs and appear as adverse drug reactions (ADRs)."	( Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database. Carnovale, C; Clementi, E; Gentili, M; Mazhar, F; Nobile, M; Peeters, GGAM; Pozzi, M; Radice, S, )	0.13
"We mined data from the US Food and Drug Administration Adverse Event Reporting System pharmacovigilance database, focused on methylphenidate, atomoxetine, amphetamine, lisdexamfetamine, and their derivatives."	( Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database. Carnovale, C; Clementi, E; Gentili, M; Mazhar, F; Nobile, M; Peeters, GGAM; Pozzi, M; Radice, S, )	0.34
"We conclude that real-world data from the US Food and Drug Administration Adverse Event Reporting System are consistent with previous evidence from meta-analyses."	( Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database. Carnovale, C; Clementi, E; Gentili, M; Mazhar, F; Nobile, M; Peeters, GGAM; Pozzi, M; Radice, S, )	0.13
" The frequencies of adverse events were similar between the two groups."	( Efficacy and safety of tipepidine as adjunctive therapy in children with attention-deficit/hyperactivity disorder: Randomized, double-blind, placebo-controlled clinical trial. Akhondzadeh, S; Bagheri, S; Dehbozorghi, S; Mohammadi, MR; Moradi, K; Shokraee, K, 2019)	0.51
" Any long-term psychotropic treatment in childhood raises concerns about possible adverse neurological and psychiatric outcomes."	( Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence. Ansari, MT; Banaschewski, T; Buitelaar, JK; Carucci, S; Coghill, D; Danckaerts, M; Dittmann, RW; Falissard, B; Garas, P; Groom, MJ; Hall, CL; Hollis, C; Inglis, SK; Kochhar, P; Konrad, K; Kovshoff, H; Krinzinger, H; Liddle, EB; McCarthy, S; Nagy, P; Neubert, A; Roberts, S; Sayal, K; Sonuga-Barke, E; Wong, ICK; Xia, J; Zuddas, A, 2019)	0.76
"Sleep problems is the most common side effect of methylphenidate (MPH) treatment in ADHD youth and carry potential to negatively impact long-term self-regulatory functioning."	( Prediction of sleep side effects following methylphenidate treatment in ADHD youth. Hong, SB; Kim, BN; Kim, JW; McMakin, DL; Ryan, ND; Sharma, V; Yoo, JH; Zalesky, A, 2020)	1.08
" Outcomes were the improvement of apathy scales score (primary), mini-mental state examination (MMSE) score, activities of daily living scale score, Zarit burden interview score, all-cause discontinuation, discontinuation due to adverse events, and incidence of at least 1 adverse event."	( Efficacy and Safety of Psychostimulants for Alzheimer's Disease: A Systematic Review and Meta-Analysis. Iwata, N; Kishi, T; Sakuma, K, 2020)	0.56
" Features such as personal noun, nonmedical use terms, medical use terms, side effect terms, sentiment scores, and the presence of a URL were generated for supervised learning."	( Twitter Analysis of the Nonmedical Use and Side Effects of Methylphenidate: Machine Learning Study. Jeong, J; Kim, J; Kim, MG; Kim, SC, 2020)	0.8
"The co-abuse of ALZ has amplified the hepato-renal toxic effects of MPH."	( Co-abuse of alprazolam augments the hepato-renal toxic effects of methylphenidate. Chopra, K; Dharavath, RN; Dutt, M; Kaur, N; Kaur, T; Sharma, S, )	0.37
" Among 433 randomized patients, adverse events (AEs) were documented and analyzed on an "as received" basis during week 0-52."	( Safety Profile of Methylphenidate Under Long-Term Treatment in Adult ADHD Patients - Results of the COMPAS Study. Abdel-Hamid, M; Alm, B; Berger, M; Borel, P; Colla, M; Graf, E; Heßmann, P; Huss, M; Jacob, C; Jans, T; Kis, B; Lücke, C; Matthies, S; Müller, HHO; Philipsen, A; Retz, W; Rösler, M; Sobanski, E; van Elst, LT, 2020)	0.89
"In this so far longest-running clinical trial, methylphenidate treatment was safe and well-tolerated."	( Safety Profile of Methylphenidate Under Long-Term Treatment in Adult ADHD Patients - Results of the COMPAS Study. Abdel-Hamid, M; Alm, B; Berger, M; Borel, P; Colla, M; Graf, E; Heßmann, P; Huss, M; Jacob, C; Jans, T; Kis, B; Lücke, C; Matthies, S; Müller, HHO; Philipsen, A; Retz, W; Rösler, M; Sobanski, E; van Elst, LT, 2020)	1.15
" As compared with placebo (38 [31%] of 124 patients), higher proportions of participants reported adverse events while taking amantadine (49 [39%] of 127 patients), modafinil (50 [40%] of 125 patients), and methylphenidate (51 [40%] of 129 patients)."	( Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021)	1.06
"Amantadine, modafinil, and methylphenidate were not superior to placebo in improving multiple sclerosis fatigue and caused more frequent adverse events."	( Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021)	1.17
"Although attention-deficit/hyperactivity disorder (ADHD) is widely studied, problems regarding the adverse effect risks and non-responder problems still need to be addressed."	( Synergistic efficacy and diminished adverse effect profile of composite treatment of several ADHD medications. Adil, KJ; Cheong, JH; Han, SH; Jeon, SJ; Kim, HJ; Kim, HY; Kim, R; Kwon, KJ; Mabunga, DFN; Park, D; Ryu, O; Shin, CY; Valencia, S, 2021)	0.62
"To evaluate the validity of online information regarding the adverse effects of methylphenidate."	( Can parents believe websites' information about methylphenidate's side effects? Arsac England, T; Tuthill, D, 2021)	1.1
" Three quarters (19 websites; 76%) had at least one side-effect that did not appear in the BNFC; with six websites documenting more than five side-effects not found in the BNFC."	( Can parents believe websites' information about methylphenidate's side effects? Arsac England, T; Tuthill, D, 2021)	0.88
"013), and similar side effect rates."	( Stimulant treatment effectiveness, safety and risk for psychosis in individuals with 22q11.2 deletion syndrome. Basel, D; Eliez, S; Gothelf, D; Maeder, J; Mosheva, M; Schneider, M; Shani, S; Weinberger, R, 2022)	0.72
"Methylphenidate was effective and safe in treating ADHD in 76% of cases in children with DS, with few serious side effects to report."	( Efficacy and safety of methylphenidate on attention deficit hyperactivity disorder in children with Down syndrome. Cieuta-Walti, C; Conte, M; Durand, S; Falquero, S; Labidi, A; Mégarbané, A; Mircher, C; Prioux, E; Ravel, A; Roche, M; Stora, S; Toulas, J, 2021)	2.37
", response, adverse events) and standardized mean differences (SMDs) for continuous outcomes (e."	( Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis. Bahji, A; Mesbah-Oskui, L, 2021)	0.62
" The most frequent adverse events during dose optimization were headache, decreased appetite, and insomnia."	( Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adult Laboratory Classroom Study of the Efficacy and Safety of PRC-063 (Extended-Release Methylphenidate) for the Treatment of ADHD. Bhaskar, S; Childress, A; Cutler, AJ; Donnelly, G; Marraffino, AH, 2022)	0.92
" Trials of amphetamines, atomoxetine, bupropion, clonidine, guanfacine, methylphenidate, and modafinil with a placebo arm and reporting data on headache as an adverse event, were included."	( Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis. Banaschewski, T; Bölte, S; Buitelaar, JK; Coghill, D; Cortese, S; Häge, A; Hohmann, S; Jonsson, U; Nobel Norrman, H; Pan, PY; Şahpazoğlu Çakmak, SS, 2022)	0.95
" Thus, results suggested that prolong co-administration of MPH-buspirone is safe and effective for ADHD patients by preventing adverse effects not only on behavioral but also on biochemical and hematological parameter."	( Effect of Methylphenidate and buspirone-methylphenidate co-administration on biochemical and hematological parameters in rats: Implications for safe and confrontational use. Alam, N; Ikram, R; Kashif, SS; Khan, SS; Khatoon, H; Naeem, S; Siddiqui, T, 2021)	1.02
" Children in the methylphenidate plus educational intervention group had more mild adverse events than the other two groups, and there were no between-group differences for moderate or severe adverse events."	( Efficacy and safety of methylphenidate and behavioural parent training for children aged 3-5 years with attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled, and sham behavioural parent training-controlled trial. Dalmaso, BB; de Morais, EM; de Sousa Gurgel, W; Del Prette, G; Leibenluft, E; Pilatti, CD; Polanczyk, GV; Rohde, LA; Salum, GA; Sugaya, LS, 2022)	1.37
"PRC-063 is an efficacious and safe treatment for ADHD, especially in children and adolescents."	( Efficacy and Safety of PRC-063 for Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis From Randomized Controlled Trials. Chen, G; Gao, H; Wang, J; Wang, T; Yang, S; Yu, Z; Zhu, S, 2023)	0.91
"The concomitant use of MPHs and SSRIs showed generally safe profiles in adolescent ADHD patients with depression."	( Safety outcomes of selective serotonin reuptake inhibitors in adolescent attention-deficit/hyperactivity disorder with comorbid depression: Alhambra, DP; Kim, C; Kim, SJ; Lee, DY; Lee, J; Lee, S; Lee, YH; Park, J; Park, RW; Shin, Y; Tan, EH; Yang, SJ, 2023)	0.91
" After controlling for the effects of these variables using propensity scores, there was little evidence of an effect on growth (24 months height velocity SD score difference -0·07 (95% CI -0·18 to 0·04; p=0·20) or increased risk of psychiatric or neurological adverse events in the methylphenidate group compared with the no-methylphenidate group."	( Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study. Banaschewski, T; Buitelaar, J; Carucci, S; Coghill, D; Danckaerts, M; Dittmann, RW; Falissard, B; Garas, P; Häge, A; Hollis, C; Inglis, SK; Konrad, K; Kovshoff, H; Liddle, E; Man, KKC; McCarthy, S; Nagy, P; Neubert, A; Rosenthal, E; Sonuga-Barke, EJS; Wong, ICK; Zuddas, A, 2023)	1.41
" RRs of adverse events and all-cause discontinuation were secondary and acceptability outcomes, respectively."	( Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations. Birkenhager, TK; Caiazza, C; Cattaneo, CI; de Bartolomeis, A; Fornaro, M; Gillman, K; Iasevoli, F; Rossano, F; Ruhé, HG; Sobrino, A; Solini, N; Stahl, S; Van den Eynde, V; Vellucci, A; Zotti, N, 2023)	0.91
" However, many adverse effects of methylphenidate have been recorded from randomized clinical trials and patient-reported outcomes, but it is difficult to determine abuse from them."	( The Adverse Effects and Nonmedical Use of Methylphenidate Before and After the Outbreak of COVID-19: Machine Learning Analysis. Kim, E; Lee, H; Oh, S; Park, S; Purja, S; Shin, H; Yuniar, CT, 2023)	1.45
"To analyze the effect of the COVID-19 pandemic on the use of methylphenidate, this study analyzed the adverse effects and nonmedical use of methylphenidate and evaluated the change in frequency of nonmedical use based on SNS data before and after the outbreak of COVID-19."	( The Adverse Effects and Nonmedical Use of Methylphenidate Before and After the Outbreak of COVID-19: Machine Learning Analysis. Kim, E; Lee, H; Oh, S; Park, S; Purja, S; Shin, H; Yuniar, CT, 2023)	1.42
" The frequency of adverse effects, nonmedical use, and drug use before and after the COVID-19 pandemic were compared and analyzed."	( The Adverse Effects and Nonmedical Use of Methylphenidate Before and After the Outbreak of COVID-19: Machine Learning Analysis. Kim, E; Lee, H; Oh, S; Park, S; Purja, S; Shin, H; Yuniar, CT, 2023)	1.17
" Psychiatric problems (521/1683, 31%) had the highest frequency among the adverse effects."	( The Adverse Effects and Nonmedical Use of Methylphenidate Before and After the Outbreak of COVID-19: Machine Learning Analysis. Kim, E; Lee, H; Oh, S; Park, S; Purja, S; Shin, H; Yuniar, CT, 2023)	1.17
" Among the machine learning models using SNS data to analyze the adverse effects and nonmedical use of methylphenidate, the random forest model had the highest performance."	( The Adverse Effects and Nonmedical Use of Methylphenidate Before and After the Outbreak of COVID-19: Machine Learning Analysis. Kim, E; Lee, H; Oh, S; Park, S; Purja, S; Shin, H; Yuniar, CT, 2023)	1.39
" The review included patients diagnosed with chorea and NKX2-1-RD genetic diagnosis, drug therapy as intervention, no comparator, and outcomes of chorea improvement and adverse events."	( Systematic review of drug therapy for chorea in NXK2-1-related disorders: Efficacy and safety evidence from case studies and series. Bachoud-Lévi, AC; Blasco-Amaro, JA; Capuano, A; Isabel-Gómez, R; Martín-Gómez, C; Nou-Fontanet, L; Ortigoza-Escobar, JD; Zorzi, G, 2023)	0.91
" No clinical improvements were observed with carbidopa/levodopa, tetrabenazine, or clonazepam, and various adverse effects were reported."	( Systematic review of drug therapy for chorea in NXK2-1-related disorders: Efficacy and safety evidence from case studies and series. Bachoud-Lévi, AC; Blasco-Amaro, JA; Capuano, A; Isabel-Gómez, R; Martín-Gómez, C; Nou-Fontanet, L; Ortigoza-Escobar, JD; Zorzi, G, 2023)	0.91

Excerpt	Reference	Relevance
"1 Pharmacokinetic study has been carried out following oral administration of 10-20 mg of methylphenidate hydrochloride to four behaviorally disorders children."	( Pharmacokinetics of methylphenidate in hyperkinetic children. Hungund, BL; Hurwic, MJ; Perel, JM; Sverd, J; Winsberg, BG, 1979)	0.8
" The two-compartment open pharmacokinetic model fit the data."	( Pharmacokinetics of methylphenidate in the rat using single-ion monitoring GLC-mass spectrometry. Cho, AK; Flamm, BL; Gal, J; Hodshon, BJ; Pintauro, C, 1977)	0.58
" Nine males with ADDH participated in a 1-day pharmacokinetic study following a single morning dose of 20 mg."	( Sustained release methylphenidate: pharmacokinetic studies in ADDH males. Birmaher, B; Cooper, TB; Fried, J; Greenhill, LL; Maminski, B, 1989)	0.61
"The pharmacokinetic behaviour of haloperidol (0."	( Pharmacokinetics and effects of haloperidol in the isolated mouse. Baumann, GH; Zetler, G, 1985)	0.27
" Newborns and premature infants can metabolize and eliminate diazepam, although the parent drug has a longer half-life and decreased rate of biotransformation to its primary metabolites than in older children and adults."	( Pharmacokinetics of benzodiazepines and psychostimulants in children. Coffey, B; Greenblatt, DJ; Shader, RI, 1983)	0.27
"A definitive enantioselective pharmacokinetic evaluation of dl-threo-methylphenidate (MPH) was carried out in 11 healthy volunteers, all of whom received, in a randomized crossover design, three oral administrations of MPH: immediate release (IR), slow release (SR), and SR chewed before swallowing (CH)."	( Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans. Hubbard, JW; Korchinski, ED; Midha, KK; Srinivas, NR, 1993)	0.78
" The clockwise hysteresis between the MPD concentration and the DA level in the dialysate could be explained by the pharmacodynamic model considering Michaelis-Menten type reuptake process of the extracellular DA into the terminal of the dopaminergic nerve and its competitive inhibition by the extracellular MPD."	( Pharmacodynamic modeling for change of locomotor activity by methylphenidate in rats. Aoyama, T; Iga, T; Kotaki, H; Sawada, Y; Yamamoto, K, 1997)	0.54
" Pharmacokinetic parameters were determined by noncompartmental methods, but could not be evaluated for modafinil sulfone due to plasma levels that were close to the assay quantitation limit."	( Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers. Grebow, PE; King, SP; Laughton, WB; McCormick, GC; Wong, YN, 1998)	0.56
" Calculated mean residence time and elimination half-life values for d-p-Br MPH were significantly longer than those for d-MPH and d-p-OCH3 MPH, and clearance of the bromo derivative was substantially lower than the latter two compounds."	( Comparative pharmacokinetics and tissue distribution of the d-enantiomers of para-substituted methylphenidate analogs. Perel, JM; Rudolph, GR; Thai, DL; Yurasits, LN, 1999)	0.52
" A nonlinear regression model was applied to estimate overall population values of MP clearance and elimination half-life (t1/2), assuming a one-component model with first-order absorption and elimination, and further assuming that clearance is linearly related to body weight."	( Population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder. Greenblatt, DJ; Harmatz, JS; Oesterheld, JR; Parmelee, DX; Sallee, FR; Shader, RI, 1999)	0.59
" Although ADHD has been widely studied, the use of methylphenidate in ADHD still poses a number of unresolved questions, including its pharmacodynamic characteristics (drug concentration-effect relationship) and the effect of long term treatment on the patient's psychopathology later in life."	( Pharmacokinetics and clinical effectiveness of methylphenidate. Abernethy, DR; Cross, JT; Kimko, HC, 1999)	0.81
" The terminal half-life of methylphenidate was similar for the three formulations."	( Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. Gupta, SK; Lindemulder, B; Modi, NB, 2000)	0.82
" There was no difference in the plasma elimination half-life of methylphenidate between the fed and fasted state."	( Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects. Gupta, SK; Hu, WT; Modi, NB; Wang, B, 2000)	0.78
"The potential for a pharmacokinetic (PK) drug-drug interaction between modafinil and methylphenidate, each at steady state, was investigated in an open-label, randomized, single-period study in 32 healthy male and female volunteers."	( Steady-state pharmacokinetics and tolerability of modafinil given alone or in combination with methylphenidate in healthy volunteers. Arora, S; Hellriegel, ET; Nelson, M; Robertson, P, 2001)	0.75
"For plasma d-MPH, there were significant differences (ANOVA) between dl-MPH-IR and dl-MPH-SR in tmax, Cmax (peak exposure), and Cmax/AUC (sensitive to rate of absorption)."	( Effects of food on the pharmacokinetics of methylphenidate. Hubbard, JW; Korchinski, ED; McKay, G; Midha, KK; Rawson, MJ, 2001)	0.57
" Although the US FDA approved MPH in the 1960s, the pharmacokinetic (PK) properties of serum concentrations of MPH in children with ADHD were not described until the 1980s, and then in only a few cases."	( Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. Swanson, JM; Volkow, ND, 2002)	0.31
" These values were used to calculate standard noncompartmental pharmacokinetic parameters describing the rate (peak concentration and time to peak concentration) and extent (area under the concentration-time curve, AUC) of absorption of the two formulations."	( Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. DeVane, CL; Lee, J; Markowitz, JS; Muniz, R; Patrick, KS; Pestreich, L; Straughn, AB; Wang, Y, 2003)	0.64
" While pharmacokinetic differences appear to exist between some of these new formulations, there are currently no clinical data available to demonstrate clinical efficacy differences between them."	( Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. Doffing, MA; Wolraich, ML, 2004)	0.54
" MPH plasma concentration-time data were used to calculate the pharmacokinetic parameters for each treatment."	( Dose-proportional pharmacokinetics of a methylphenidate extended-release capsule. Dirksen, SJ; González, MA; Rochdi, M, 2004)	0.59
" This was true for Cmax (maximum observed concentration), AUC(0-last) (area under the plasma concentration curve from time 0 to the last measurable time point) and AUC(0-inf) (area under the plasma concentration curve from time 0 to infinity)."	( Dose-proportional pharmacokinetics of a methylphenidate extended-release capsule. Dirksen, SJ; González, MA; Rochdi, M, 2004)	0.59
"The technique of microdialysis utilizing three simultaneously implanted probes in the anaesthetized rat enables monitoring of pharmacokinetic (PK) profiles of a tested drug both in blood (1st probe) and brain (2nd probe) compartments and the pharmacodynamic (PD) response of neurotransmitters (3rd probe) released into, or accumulating within the brain extracellular fluid (ECF)."	( Application of triple-probe microdialysis for fast pharmacokinetic/pharmacodynamic evaluation of dopamimetic activity of drug candidates in the rat brain. Egestad, B; Kehr, J; Weikop, P, 2004)	0.32
" Dose proportionality was shown for all dose-dependent pharmacokinetic parameters."	( Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. Appel-Dingemanse, S; Maboudian, M; Pommier, F; Sedek, G; Tuerck, D; Wang, Y, 2007)	0.6
" Pharmacokinetic parameters were compared."	( Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. DeVane, CL; Herrin, AE; Janis, GC; Malcolm, R; Markowitz, JS; Minhinnett, RR; Patrick, KS; Straughn, AB; Yeatts, SD, 2007)	0.62
" A nonlinear model was used to derive three pharmacokinetic (PK) values for analysis: Peak plasma concentration (C(max)), half-life (t(1/2)), and clearance (CL)."	( Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder. Greenhill, L; Gupta, S; Kapelinski, A; Lerner, M; Martinez, J; Modi, NB; Posner, K; Stehli, A; Steinhoff, K; Swanson, J; Wigal, SB; Wigal, T, 2007)	0.66
"To use growth mixture modelling (GMM) to identify subgroups of children with attention deficit hyperactive disorder (ADHD) who have different pharmacodynamic profiles in response to extended release methylphenidate as assessed in a laboratory classroom setting."	( Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder. A growth mixture modelling analysis. Coghill, D; Hatch, S; Sonuga-Barke, EJ; Swanson, JM; Van Lier, P; Vandenberghe, M; Wigal, S, 2008)	0.78
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" Although MPH is a racemic compound composed of a 50:50 mixture of dexmethylphenidate (d-MPH) and l-methylphenidate (l-MPH), animal and human studies have confirmed that the d-MPH isomer is responsible for the pharmacodynamic effect of MPH."	( Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder. Quinn, D, 2008)	0.82
"To evaluate the pharmacokinetic properties of the methylphenidate transdermal system (MTS) in pediatric patients diagnosed with ADHD (attention-deficit/hyperactivity disorder) in a laboratory school setting."	( Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study. Dixon, CM; McGough, JJ; Pierce, D; Wigal, SB, 2008)	0.92
" Laboratory school evaluations, including pharmacokinetic blood sampling, occurred at the end of each treatment."	( Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study. Dixon, CM; McGough, JJ; Pierce, D; Wigal, SB, 2008)	0.67
" The clinical relevance of the MTS pharmacokinetic profile is discussed."	( Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study. Dixon, CM; McGough, JJ; Pierce, D; Wigal, SB, 2008)	0.67
" Secondary objectives included assessment of tolerability and determination of further pharmacokinetic parameters."	( A pharmacokinetic study of two modified-release methylphenidate formulations under different food conditions in healthy volunteers. Dietrich, H; Haessler, F; Klatt, J; Stammer, H; Tracik, F, 2008)	0.6
" Pharmacokinetic evaluations included AUC(0-inf), Cmax, tmax, elimination half life (t1/2) and mean residence time MRT(0-inf))."	( A pharmacokinetic study of two modified-release methylphenidate formulations under different food conditions in healthy volunteers. Dietrich, H; Haessler, F; Klatt, J; Stammer, H; Tracik, F, 2008)	0.6
" Under fasted condition Ritalin LA(R) showed a consistent bimodal concentration time profile with two tmax peaks."	( A pharmacokinetic study of two modified-release methylphenidate formulations under different food conditions in healthy volunteers. Dietrich, H; Haessler, F; Klatt, J; Stammer, H; Tracik, F, 2008)	0.6
" Serial blood samples were collected after each MTS application and pharmacokinetic (PK) parameters for d,l-MPH were calculated."	( Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder. Campbell, D; González, MA; Rubin, J, 2009)	0.57
" MPH and RA were both detected in oral fluid with a pharmacokinetic profile similar to that in plasma."	( Pharmacokinetics of methylphenidate in oral fluid and sweat of a pediatric subject. Farrè, M; García-Algar, O; Marchei, E; Pacifici, R; Pellegrini, M; Pichini, S; Vall, O, 2010)	0.68
" The pharmacokinetic evaluation showed that methylphenidate concentrations were not markedly affected by ethanol, but ritalinic acid concentrations were lower, especially if ethanol was ingested first."	( Influence of ethanol on the pharmacokinetics of methylphenidate's metabolites ritalinic acid and ethylphenidate. Kauert, GF; Koehm, M; Toennes, SW, 2010)	0.88
" The pharmacokinetic population consisted of 33 children and 31 adolescents."	( Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. Buckwalter, M; Katic, A; Pierce, D; Webster, K, 2010)	0.62
" Plasma concentrations of d- and l-MPH were determined and pharmacokinetic parameters were calculated."	( The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. Berry, SA; Childress, AC, 2010)	0.6
" The peak plasma concentration, Cmax (ng/mL), was 13."	( The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. Berry, SA; Childress, AC, 2010)	0.6
" NWP06 has a lower peak concentration than IR MPH."	( The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. Berry, SA; Childress, AC, 2010)	0.6
" Coefficients of variance of pharmacokinetic measures can estimate the levels of pharmacokinetic variability based on the measurable variance between different individuals receiving the same dose of stimulant (interindividual variability) and within the same individual over multiple administrations (intraindividual variability)."	( Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder. Adeyi, BA; Ermer, JC; Pucci, ML, 2010)	0.36
" Serial blood samples were obtained before and after drug administration for determination of plasma methylphenidate concentrations and standard pharmacokinetic parameters."	( Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. Berry, SA; Childress, AC; Sallee, FR, 2011)	0.83
" Values for Cmax were observed between 2 and 4 hours after the dose."	( Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. Berry, SA; Childress, AC; Sallee, FR, 2011)	0.61
"There were no age-related pharmacokinetic differences after oral administration of NWP06 to children or adolescents in this small sample."	( Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. Berry, SA; Childress, AC; Sallee, FR, 2011)	0.61
"These results confirm the study hypothesis that central dopamine transporter occupancy parallels peripheral pharmacokinetic findings in orally administered long-acting dexmethylphenidate in later hours after administration."	( Understanding the central pharmacokinetics of spheroidal oral drug absorption system (SODAS) dexmethylphenidate: a positron emission tomography study of dopamine transporter receptor occupancy measured with C-11 altropane. Bonab, AA; Clarke, A; Dougherty, DD; Fischman, AJ; Martin, J; Mirto, T; Spencer, TJ, 2012)	0.79
"Placebo and pharmacodynamic (PD) models were developed which link temporal measures of efficacy in children with attention deficit hyperactivity disorder (ADHD) and methylphenidate (MPH) plasma concentrations from adults."	( Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis. Berwaerts, J; Gibiansky, E; Gibiansky, L; Kimko, H; Massarella, J; Starr, HL; Wiegand, F, 2012)	0.8
" In the case of complex modified-release formulations, these criteria may not address pharmacokinetic differences with potential therapeutic and tolerability implications."	( Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria. Chen, N; Endrenyi, L; Faulknor, J; Luong, D; Quinn, AM; Sellers, EM; Shram, MJ, 2012)	0.6
"This study was performed to characterize in vitro dissolution and in vivo pharmacokinetic profiles of three modified-release formulations of methylphenidate (MPH) marketed in Canada, two of which meet the criteria for assuming bioequivalence as defined by Health Canada: MPH extended-release (ER-C) and osmotic controlled-release oral-delivery-system (OROS-MPH)."	( Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria. Chen, N; Endrenyi, L; Faulknor, J; Luong, D; Quinn, AM; Sellers, EM; Shram, MJ, 2012)	0.8
" Twenty-four subjects completed the pharmacokinetic study and were included in the analyses."	( Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria. Chen, N; Endrenyi, L; Faulknor, J; Luong, D; Quinn, AM; Sellers, EM; Shram, MJ, 2012)	0.6
"The pharmacokinetic data suggest that in vitro and in vivo profiles of OROS-MPH and MPH ER-C are distinct."	( Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria. Chen, N; Endrenyi, L; Faulknor, J; Luong, D; Quinn, AM; Sellers, EM; Shram, MJ, 2012)	0.6
" However, data on the pharmacokinetic profiles and safety of combination treatments in ADHD are needed."	( Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release. Corcoran, M; Ermer, J; Haffey, M; Martin, P; Purkayastha, J; Roesch, B; Stevenson, A; Wang, P, 2013)	0.62
"The primary objective of this study was to evaluate the pharmacokinetic profiles of guanfacine extended release (GXR) and methylphenidate hydrochloride (MPH) extended release, alone and in combination."	( Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release. Corcoran, M; Ermer, J; Haffey, M; Martin, P; Purkayastha, J; Roesch, B; Stevenson, A; Wang, P, 2013)	0.83
" Overall, combining GXR and MPH did not alter the pharmacokinetic parameters of either medication."	( Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release. Corcoran, M; Ermer, J; Haffey, M; Martin, P; Purkayastha, J; Roesch, B; Stevenson, A; Wang, P, 2013)	0.62
"In this short-term, open-label study of healthy adults, coadministration of GXR and MPH did not result in significant pharmacokinetic drug-drug interactions."	( Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release. Corcoran, M; Ermer, J; Haffey, M; Martin, P; Purkayastha, J; Roesch, B; Stevenson, A; Wang, P, 2013)	0.62
" However, their pharmacokinetic profiles differ with respect to peak plasma levels and the rate at which peak levels are attained and decline."	( Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate. Maldonado, R, 2013)	0.61
" Pharmacodynamic interactions of methylphenidate and MDMA are likely."	( Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. Donzelli, M; Grouzmann, E; Hysek, CM; Liechti, ME; Meyer, N; Schillinger, N; Schmid, Y; Simmler, LD, 2014)	0.94
" The method is suitable for the precisely determination of MPH and for pharmacokinetic study of MPH in human plasma."	( [LC-MS/MS assay of methylphenidate: stability and pharmacokinetics in human]. Ding, L; Dong, X; Gu, X; Jiang, LY; Luo, XM, 2014)	0.73
" For the first time a physiologically based pharmacokinetic (PBPK) model has been developed in juvenile and adult humans and nonhuman primates to quantitatively evaluate species- and age-dependent enantiomer specific pharmacokinetics of MPH and its primary metabolite ritalinic acid."	( Development of a physiologically based model to describe the pharmacokinetics of methylphenidate in juvenile and adult humans and nonhuman primates. Doerge, DR; Fisher, JW; Gearhart, JM; Mattison, DR; Morris, SM; Paule, MG; Ruark, CD; Slikker, W; Twaddle, NC; Vitiello, B; Yang, X; Young, JF, 2014)	0.63
"The purpose of this study was to evaluate the relative bioavailability and safety of a multilayer extended-release bead methylphenidate (MPH) hydrochloride 80 mg (MPH-MLR) capsule or sprinkles (37% immediate-release [IR]) versus MPH hydrochloride IR(Ritalin(®)) tablets, and to develop a pharmacokinetic (PK) model simulating MPH concentration-time data for different MPH-MLR dosage strengths."	( Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers. Adjei, A; Chang, WW; Connor, DF; Greenhill, L; Kupper, RJ; Newcorn, JH; Teuscher, NS; Wigal, S, 2014)	0.89
" Based on 90% CIs, total systemic exposure to MPH-MLR 80 mg capsule/sprinkles was similar to that for Ritalin IR 25 mg three times daily, but marked differences in Cmax values indicated that MPH-MLR regimens were not bioequivalent to Ritalin."	( Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers. Adjei, A; Chang, WW; Connor, DF; Greenhill, L; Kupper, RJ; Newcorn, JH; Teuscher, NS; Wigal, S, 2014)	0.69
"Most animal studies using methylphenidate (MP) do not administer it the same way it is administered clinically (orally), but rather by injection, resulting in an altered pharmacokinetic profile (quicker and higher peak concentrations)."	( A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior. Cooper, T; Hadjiargyrou, M; Hwang, YF; Komatsu, DE; Robison, LS; Steier, J; Swanson, JM; Thanos, PK; Volkow, ND, 2015)	1
"A new multilayer-bead formulation of extended-release methylphenidate hydrochloride (MPH-MLR) has been evaluated in pharmacokinetic studies in healthy adults and in Phase III efficacy/safety studies in children and adolescents with attention deficit hyperactivity disorder (ADHD)."	( Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple-layer beads in pediatric subjects with attention deficit hyperactivity disorder. Adjei, A; Findling, RL; Greenhill, LL; Kupper, RJ; Teuscher, NS; Wigal, S, 2015)	0.95
" The validated UFLC-MS/MS method successfully applied to the pharmacokinetic interaction study of oral d-threo-MPH and l-threo-MPH (alone or in combination) in female Sprague Dawley rats."	( Development and validation of an UFLC-MS/MS method for enantioselectivity determination of d,l-thero-methylphenidate, d,l-thero-ethylphenidate and d,l-thero-ritalinic acid in rat plasma and its application to pharmacokinetic study. Lin, G; Luo, H; Wang, H; Wu, Y; Zhang, C; Zhang, F; Zhang, J, 2016)	0.65
"The purpose of this study was to quantify the amounts of the d- and l-threo enantiomers of methylphenidate in maternal plasma, placenta, and maternal and fetal brain tissue following prenatal exposure and to establish a pharmacokinetic profile for MPH during pregnancy."	( The pharmacokinetic profile of methylphenidate use in pregnancy: A study in mice. Brown, SD; Peters, HT; Pond, BB; Strange, LG, )	0.64
" This randomized, open-label, crossover trial compared the pharmacokinetic properties and relative bioavailability of MPH ERCT with an MPH chewable immediate-release tablet (IR MPH) formulation in healthy adults."	( Single-dose Pharmacokinetic Properties and Relative Bioavailability of a Novel Methylphenidate Extended-release Chewable Tablet Compared With Immediate-release Methylphenidate Chewable Tablet. Abbas, R; Belden, H; Berry, SA; Palumbo, D; Walters, F, 2016)	0.66
"A total of 33 participants were enrolled in the study; 31 participants were included in the pharmacokinetic analysis."	( Single-dose Pharmacokinetic Properties and Relative Bioavailability of a Novel Methylphenidate Extended-release Chewable Tablet Compared With Immediate-release Methylphenidate Chewable Tablet. Abbas, R; Belden, H; Berry, SA; Palumbo, D; Walters, F, 2016)	0.66
"To determine the pharmacokinetic (PK) profile of a proprietary formulation of methylphenidate (MPH) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) in a phase 1 study."	( A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Childress, A; McMahen, R; Newcorn, J; Sikes, C; Stark, JG; Tengler, M, 2016)	0.87
" The following plasma PK parameters of MPH were determined for participants grouped by age (6-7, 8-9, 10-12, and 13-17 years old): maximum concentration (Cmax), time to maximum concentration (Tmax), elimination half-life (T½), area under the curve from 0 hours to infinity (AUCinf), oral clearance (CL/F), and volume of distribution in the terminal phase (Vz/F)."	( A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Childress, A; McMahen, R; Newcorn, J; Sikes, C; Stark, JG; Tengler, M, 2016)	0.65
"A previously presented physiologically-based pharmacokinetic model for immediate release (IR) methylphenidate (MPH) was extended to characterize the pharmacokinetic behaviors of oral extended release (ER) MPH formulations in adults for the first time."	( Application of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in Adults. Duan, J; Fisher, J; Yang, X, 2016)	0.86
"We propose a novel semi-automatic approach to design biomarkers for capturing pharmacodynamic effects induced by pharmacological agents on the spectral power of electroencephalography (EEG) recordings."	( Semi-Automated Biomarker Discovery from Pharmacodynamic Effects on EEG in ADHD Rodent Models. Cichocki, A; Hasegawa, M; Hiroyama, S; Horiuchi, M; Jurica, P; Li, J; Nishitomi, K; Ogawa, K; Struzik, ZR; Takahara, Y; Yokota, T, 2018)	0.48
" The objectives of the current study were to describe drug concentrations, develop an analytical method that could be used to regulate its use, and describe the pharmacodynamic effects of ethylphenidate in horses."	( L- and D-threo ethylphenidate concentrations, pharmacokinetics, and pharmacodynamics in horses. Benson, D; Hartmann, P; Hovda, L; Knych, HK; McKemie, DS; Seminoff, K, 2018)	0.48
" This analysis sought to develop a population pharmacokinetic (PK)/pharmacodynamic (PD) model to describe MPH XR-ODT PD-response data in a classroom study and use the model to simulate PD responses for a range of body weights and doses."	( Population Pharmacokinetic-Pharmacodynamic Modeling of a Novel Methylphenidate Extended-Release Orally Disintegrating Tablet in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder. Engelking, D; McMahen, R; Sikes, CR; Teuscher, NS, 2018)	0.72
" CES1 gene variation only partially explains pharmacokinetic (PK) variability."	( Pharmacometabolomics Informs About Pharmacokinetic Profile of Methylphenidate. Baillie, R; Dalhoff, KP; Hankemeier, T; Harms, A; Jűrgens, G; Kaddurah-Daouk, R; Linnet, K; Motsinger-Reif, AA; Nzabonimpa, GS; Rasmussen, HB; Scholl, EH; Stage, C; Taboureau, O; Thomsen, R, 2018)	0.72
" The objectives were to evaluate DR/ER-MPH pharmacokinetic (PK) properties in healthy adults, including dose proportionality, food effect, the potential of accumulation using multiple-dose modeling, and bioavailability compared to an immediate-release MPH (IR MPH)."	( Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults. DeSousa, NJ; Gobburu, JVS; Incledon, B; Liu, T; McLean, A; Po, MD; Sallee, FR, 2019)	0.75
" The pharmacokinetic (PK) profile of DR/ER-MPH is characterized by an 8- to 10-hour delay in initial methylphenidate absorption and a subsequent gradual increase in plasma concentration, followed by a slow decline."	( Effect of Colonic Absorption on the Pharmacokinetic Properties of Delayed-Release and Extended-Release Methylphenidate: In Vivo, In Vitro, and Modeling Evaluations. Gomeni, R; Incledon, B; Incledon, C; Kapuscinski, J; Morris, A; Perry, K; Uchida, CL, 2022)	1.15
"As outlined in changes to the US prescribing information for all methylphenidate and risperidone products, health care professionals should be aware that changes to this combination may be associated with a pharmacodynamic drug-drug interaction resulting in acute hyperkinetic movement disorder."	( Acute Hyperkinetic Movement Disorders as a Multifactorial Pharmacodynamic Drug Interaction Between Methylphenidate and Risperidone in Children and Adolescents. Burkhart, K; Chen, Q; Cheng, C; Croteau, D; Demczar, D; Kortepeter, C; Mohamoud, M; Stone, M; Volpe, DA, )	0.59
" The object of this study is to evaluate CES1 pharmacogenetics as related to MPH metabolism using human liver samples and develop a physiologically-based pharmacokinetic (PBPK) modeling approach to investigate the influence of CES1 genotypes and other factors on MPH PK."	( Physiologically-Based Pharmacokinetic Modeling to Predict Methylphenidate Exposure Affected by Interplay Among Carboxylesterase 1 Pharmacogenetics, Drug-Drug Interactions, and Sex. Shi, J; Smith, DE; Thompson, BR; Xiao, J; Zhang, T; Zhu, HJ, 2022)	0.97
" While each of these medications have their own distinct pharmacokinetic profile, the extent to which pharmacogenetics effects their pharmacokinetic parameters is best described in atomoxetine, followed by methylphenidate."	( The Pharmacogenetic Impact on the Pharmacokinetics of ADHD Medications. Brown, JT, 2022)	0.91

Excerpt	Reference	Relevance
"Sixty-six children received individual reading instruction for 18 weeks, in combination with methylphenidate (mean daily dose 44."	( Children with reading disorders--II. Effects of methylphenidate in combination with reading remediation. Feingold, I; Gittelman, R; Klein, DF, 1983)	0.74
" However, none of the measurements showed a significant difference between the conditions when methylphenidate was given with breakfast and the condition when methylphenidate was given 30 minutes before breakfast."	( Methylphenidate hydrochloride given with or before breakfast: I. Behavioral, cognitive, and electrophysiologic effects. Baren, M; Deutsch, C; Sandman, CA; Swanson, JM, 1983)	1.93
" Often, these agents are used in combination with other medications."	( Drug interactions with psychostimulants. DeVane, CL; Markowitz, JS; Morrison, SD, 1999)	0.3
"The use of methylphenidate (MPH) in combination with antiepileptic drugs is gaining acceptance for children with epilepsy who have the symptoms of attention-deficit hyperactivity disorder (ADHD)."	( Adverse response to methylphenidate in combination with valproic acid. Gara, L; Roberts, W, 2000)	1.02
" The present study extends these results by addressing the issue of clinical significance using drug-placebo and drug-drug response curve analyses of the same data."	( Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug-placebo and drug-drug response curve methodology. Biederman, J; Faraone, SV; Olvera, RL; Pliszka, SR; Skolnik, R, 2001)	0.61
"The potential for a pharmacokinetic (PK) drug-drug interaction between modafinil and methylphenidate, each at steady state, was investigated in an open-label, randomized, single-period study in 32 healthy male and female volunteers."	( Steady-state pharmacokinetics and tolerability of modafinil given alone or in combination with methylphenidate in healthy volunteers. Arora, S; Hellriegel, ET; Nelson, M; Robertson, P, 2001)	0.75
" Thus, oral MPH-SR is safe in combination with repeated cocaine doses and decreases some of the positive and reinforcing effects of cocaine in cocaine abusers with ADHD."	( Response to cocaine, alone and in combination with methylphenidate, in cocaine abusers with ADHD. Collins, SL; Evans, SM; Foltin, RW; Kleber, HD; Levin, FR, 2006)	0.59
" We conducted a randomized crossover trial with MPH and placebo (2 weeks each) combined with aripiprazole in children and adolescents (n = 16; 8-17 years old) with JBPD and ADHD who had a significant response in manic symptoms with aripiprazole but still presented clinically significant symptoms of ADHD."	( Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. Ketzer, CR; Pheula, GF; Rohde, LA; Tramontina, S; Zeni, CP, 2009)	1.8
" The risk of adverse drug-drug interaction(s) is present when metabolic inhibitors are combined with known or suspected substrates of a given enzyme."	( Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions. Appel, DI; Markowitz, JS; Peterson, YK; Wang, Z; Zhu, HJ, 2010)	0.36
" We sought to prospectively study the effects of levodopa (LD) and/or methylphenidate (MPH) in combination with physiotherapy on mood and cognition following stroke in human subjects."	( Effect of methylphenidate and/or levodopa combined with physiotherapy on mood and cognition after stroke: a randomized, double-blind, placebo-controlled trial. Delbari, A; Lokk, J; Salman-Roghani, R, 2011)	1.01
"A 15-day course of daily MPH + LD combined with physiotherapy over a 3-week period was safe and significantly improved mood status in ischemic stroke patients."	( Effect of methylphenidate and/or levodopa combined with physiotherapy on mood and cognition after stroke: a randomized, double-blind, placebo-controlled trial. Delbari, A; Lokk, J; Salman-Roghani, R, 2011)	0.77
"To investigate the effect of parent training combined with methylphenidate treatment on family relationships in children with attention deficit/hyperactivity disorder (ADHD)."	( [Effect of parent training in combination with methylphenidate treatment on family relationships for children with attention deficit/hyperactivity disorder]. Ding, KJ; Kang, CY; Li, XR; Liu, RX; Wan, S; Wang, YJ; Xuan, X; Yang, RX; Zhang, Y; Zhao, XR, 2014)	0.9
" In this study, we characterized the clinical profile of children and adolescents for whom a once-daily lower dose of OROS-MPH combined with a shorter-acting agent was more tolerable than single higher OROS-MPH dose."	( The clinical profile of children with ADHD that require OROS-methylphenidate combined with shorter-acting formulations. Terkel-Dawer, R; Zelnik, N, 2015)	0.66
"  Conclusion: Fluvoxamine combined with MPH-ER is effective in the treatment of refractory obsessive-compulsive disorder."	( [Efficacy of fluvoxamine combined with extended-release methylphenidate on treatment-refractory obsessive-compulsive disorder]. Guo, G; Huang, H; Jia, F; Li, G; Quan, D; Zheng, H, 2018)	0.73
"As outlined in changes to the US prescribing information for all methylphenidate and risperidone products, health care professionals should be aware that changes to this combination may be associated with a pharmacodynamic drug-drug interaction resulting in acute hyperkinetic movement disorder."	( Acute Hyperkinetic Movement Disorders as a Multifactorial Pharmacodynamic Drug Interaction Between Methylphenidate and Risperidone in Children and Adolescents. Burkhart, K; Chen, Q; Cheng, C; Croteau, D; Demczar, D; Kortepeter, C; Mohamoud, M; Stone, M; Volpe, DA, )	0.59
" Carboxylesterase 1 (CES1) is the primary enzyme metabolizing MPH, and its function is affected by genetic variants, drug-drug interaction (DDI), and sex."	( Physiologically-Based Pharmacokinetic Modeling to Predict Methylphenidate Exposure Affected by Interplay Among Carboxylesterase 1 Pharmacogenetics, Drug-Drug Interactions, and Sex. Shi, J; Smith, DE; Thompson, BR; Xiao, J; Zhang, T; Zhu, HJ, 2022)	0.97

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" By measuring the brain function using computer period analysis of cerebral biopotentials, dose-efficacy relations were found (in the range of 25-75 mcg) which suggest the bioavailability of LHM at the CNS level."	( Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram. Akpinar, S; Herrmann, WM; Itil, TM, 1975)	0.25
"The pharmacokinetics and bioavailability of methylphenidate (MPH) and a metabolite, ritalinic acid (RA), were studied in normal adults, children with hyperactivity, monkeys and rats."	( Pharmacokinetics of methylphenidate in man, rat and monkey. Breese, GR; Ellington, K; Gualtieri, CT; Kilts, C; Kraemer, G; Mueller, RA; Patrick, K; Wargin, W, 1983)	0.85
" The bioavailability of methylphenidate and PPA from OROS (methylphenidate HCl) relative to the IR and SR formulations was complete."	( Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. Gupta, SK; Lindemulder, B; Modi, NB, 2000)	0.83
"To determine the relative bioavailability of two marketed, immediate-release methylphenidate tablets."	( Bioequivalence of methylphenidate immediate-release tablets using a replicated study design to characterize intrasubject variability. Chen, ML; Jarvi, EJ; Meyer, MC; Patnaik, R; Patrick, KS; Pelsor, FR; Shah, VP; Straughn, AB; Williams, RL, 2000)	0.87
"Food caused a significant increase in extent of absorption but had no effect on rate of absorption of d-MPH after either dl-MPHIR or dl-MPH-SR."	( Effects of food on the pharmacokinetics of methylphenidate. Hubbard, JW; Korchinski, ED; McKay, G; Midha, KK; Rawson, MJ, 2001)	0.57
"To determine the single-dose bioavailability of 20-mg Metadate CD (methylphenidate HCI, USP) Extended-Release Capsules sprinkled onto 1 level tablespoon (15 mL) of applesauce relative to an intact capsule under fasted conditions in healthy adults."	( Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule. Benedict, MF; Hatch, SJ; Pentikis, HS; Simmons, RD, 2002)	1.99
"The bioavailability of methylphenidate was not altered when Metadate CD capsules were administered by sprinkling their contents onto a small amount of applesauce."	( Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule. Benedict, MF; Hatch, SJ; Pentikis, HS; Simmons, RD, 2002)	2.07
"Open-label, randomised, crossover, bioavailability study."	( Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. DeVane, CL; Lee, J; Markowitz, JS; Muniz, R; Patrick, KS; Pestreich, L; Straughn, AB; Wang, Y, 2003)	0.64
"The Ritalin LA formulation exhibited more rapid initial absorption and reached significantly higher peak plasma concentrations compared with the Concerta formulation, although the oral bioavailability of MPH was similar between the two formulations."	( Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. DeVane, CL; Lee, J; Markowitz, JS; Muniz, R; Patrick, KS; Pestreich, L; Straughn, AB; Wang, Y, 2003)	0.64
" The oral bioavailability of MPH in females may be lower than in males."	( Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Markowitz, JS; Patrick, KS; Straughn, AB, 2003)	0.54
" In summary, food had no substantial effect on the bioavailability of d-MPH, with an equivalent rate and extent of exposure obtained."	( A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects. Khetani, VD; Scheffler, MR; Stirling, DI; Stypinski, D; Teo, SK; Thomas, SD; Wu, A, 2004)	0.56
" Compared with Ritalin IR, the Ritalin LA formulation demonstrated a similar rate of absorption for the first peak, a lower second Cmax and a higher trough concentration between peaks, as well as similar overall plasma AUC."	( In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers. Bakhtiar, R; Hossain, M; Lau, H; Lee, J; Lee, L; Rekhi, GS; Sedek, G; Somma, R; Thompson, G; Wang, Y, 2004)	0.57
" The in vivo biphasic absorption of MPH appeared to be well correlated with the bimodal dissolution characteristics of this new Ritalin LA formulation, and some changes in the dissolution profiles for the DR beads appeared not to affect the overall bioavailability of MPH in humans."	( In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers. Bakhtiar, R; Hossain, M; Lau, H; Lee, J; Lee, L; Rekhi, GS; Sedek, G; Somma, R; Thompson, G; Wang, Y, 2004)	0.57
" It has been speculated that l-threo-MP is poorly absorbed in humans when it is given orally because of rapid presystemic metabolism."	( Brain kinetics of methylphenidate (Ritalin) enantiomers after oral administration. Carter, P; Ding, YS; Fowler, JS; Garza, V; Gatley, SJ; King, P; Park, DJ; Pyatt, B; Shea, C; Taintor, NB; Thanos, PK; Volkow, ND; Warner, D; Xu, Y, 2004)	0.66
"The rate of absorption and elimination of d-MPH was dependent on the pattern of administration, particularly on the initial bolus concentration."	( Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens. Chang, WW; Foley, M; McGreenery, CE; McKay, G; Midha, KK; Polcari, A; Teicher, MH; Valente, E, 2006)	1.78
"This study explores the hypotheses that: (1) ethanol will interact with dl-Methylphenidate (MPH) to enantioselectively elevate plasma d-MPH, and primarily yield l-ethylphenidate as a transesterification metabolite; (2) women will exhibit lower relative bioavailability of MPH than men; and (3) sex-dependent differences in subjective effects will exist."	( Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. DeVane, CL; Herrin, AE; Janis, GC; Malcolm, R; Markowitz, JS; Minhinnett, RR; Patrick, KS; Straughn, AB; Yeatts, SD, 2007)	0.85
" The relative bioavailability of Ritalin LA(R) and Medikinet retard and the food effect were assessed using a 90% confidence interval (CI) based on the lower and upper endpoints of the CI for the ratios of the geometric means being within the 80 - 125% equivalence criterion."	( A pharmacokinetic study of two modified-release methylphenidate formulations under different food conditions in healthy volunteers. Dietrich, H; Haessler, F; Klatt, J; Stammer, H; Tracik, F, 2008)	0.6
" Hip and scapular application resulted in quantifiable levels of d,l-MPH, with approximately 31% higher bioavailability upon hip application."	( Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder. Campbell, D; González, MA; Rubin, J, 2009)	0.57
" Bioavailability of MPH from the same transdermal delivery system appears to differ substantially when applied to two different skin surfaces in young children but with similar overall skin effects assessments."	( Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder. Campbell, D; González, MA; Rubin, J, 2009)	0.57
" An important assumption in the animal models that have been employed to study methylphenidate's effects on the brain and behavior is that bioavailability of methylphenidate in the animal models reflects that in human subjects."	( Plasma and brain concentrations of oral therapeutic doses of methylphenidate and their impact on brain monoamine content in mice. Balcioglu, A; Bhide, PG; Biederman, J; McCarthy, D; Ren, JQ; Spencer, TJ, 2009)	0.82
" Bioequivalence could not be demonstrated for the rate of bioavailability (Cmax); both the lower confidence limit and the point estimate were below 80% of the reference."	( Lack of bioequivalence between two methylphenidate extended modified release formulations in healthy volunteers. Ammer, R; Fischer, R; Grossmann, M; Leis, HJ; Mazur, D; Schütz, H, 2009)	0.63
" The relative bioavailability of the SR formulation was 30."	( Pharmacokinetics of methylphenidate following two oral formulations (immediate and sustained release) in the dog. Giorgi, M; Lavy, E; Neri, D; Prise, U; Soldani, G, 2010)	0.68
" The relative bioavailability of the SR formulation was 30."	( Pharmacokinetics of methylphenidate after oral administration of immediate and sustained-release preparations in Beagle dogs. Bar Chaim, A; Brandriss, N; Giorgi, M; Lavy, E; Neri, D; Prise, U; Soldani, G, 2011)	0.69
" Specifically, we asked: (1) will ethanol increase d-MPH biological concentrations, (2) will MTS facilitate the systemic bioavailability of l-MPH, and (3) will l-MPH enantioselectively interact with ethanol to yield l-ethylphenidate (l-EPH)? Mice were dosed with MTS (¼ of a 12."	( Transdermal and oral dl-methylphenidate-ethanol interactions in C57BL/6J mice: transesterification to ethylphenidate and elevation of d-methylphenidate concentrations. Bell, GH; Griffin, WC; Novak, AJ; Patrick, KS, 2011)	0.68
" Simulations using the fitted parameters determined how changes in fast absorption rate constant (K0Fast) and fraction available (F1) affected curve shape and BE determination using Cmax, AUCINF and PAUC."	( Use of partial AUC (PAUC) to evaluate bioequivalence--a case study with complex absorption: methylphenidate. Fourie Zirkelbach, J; Jackson, AJ; Schuirmann, DJ; Wang, Y, 2013)	0.61
"Enantioselective hydrolysis of oral racemic methylphenidate (dl-MPH) by carboxylesterase 1 (CES1) limits the absolute bioavailability of the pharmacologically active d-MPH isomer to approximately 30% and that of the inactive l-MPH to only 1-2%."	( Differential influences of ethanol on early exposure to racemic methylphenidate compared with dexmethylphenidate in humans. Anderson, ER; Bell, GH; Bernstein, H; Malcolm, RJ; Patrick, KS; Reeves, OT; Straughn, AB, 2013)	0.89
" Simulations using the fitted parameters determined how changes in fast absorption rate constant k0fast, and slow absorption rate constant KAslow affected curve shape and BE determination using Cmax, AUCINF and PAUC."	( Impact of release mechanism on the pharmacokinetic performance of PAUC metrics for three methylphenidate products with complex absorption. Jackson, A, 2014)	0.62
"Current formulations of methylphenidate (MPH) used in treatment of attention-deficit/hyperactivity disorder (ADHD) result in significantly different bioavailability of MPH enantiomers."	( Methylphenidate and impulsivity: a comparison of effects of methylphenidate enantiomers on delay discounting in rats. Katz, JL; Ricaurte, GA; Slezak, JM; Tallarida, RJ, 2014)	2.15
" MPH is characterized by its low bioavailability and short half-life (2-3 hours)."	( Isopropylphenidate: an ester homolog of methylphenidate with sustained and selective dopaminergic activity and reduced drug interaction liability. Markowitz, JS; Patrick, KS; Zhu, HJ, 2013)	0.66
" Metabolism of MPH in the small intestine was assumed to account for the low oral bioavailability of MPH."	( Development of a physiologically based model to describe the pharmacokinetics of methylphenidate in juvenile and adult humans and nonhuman primates. Doerge, DR; Fisher, JW; Gearhart, JM; Mattison, DR; Morris, SM; Paule, MG; Ruark, CD; Slikker, W; Twaddle, NC; Vitiello, B; Yang, X; Young, JF, 2014)	0.63
" Furthermore, it was deduced that the stereoselective cleavage of MPH to produce ritalinic acid (RA) by human carboxylesterase results in a higher oral bioavailability of the d-threo enantiomer."	( Chromatographic and electrophoretic strategies for the chiral separation and quantification of d- and l-threo methylphenidate in biological matrices. Allen, SA; Pond, BB, 2014)	0.61
"The objective of the study was to determine the relative bioavailability of an extended-release multilayer bead formulation of methylphenidate hydrochloride (MPH-MLR) 80 mg vs."	( Steady-state bioavailability of extended-release methylphenidate (MPH-MLR) capsule vs. immediate-release methylphenidate tablets in healthy adult volunteers. Adjei, A; Childress, A; Greenhill, L; Kollins, SH; Kupper, RJ; Sallee, F; Teuscher, NS; Wigal, S, 2014)	0.86
"The purpose of this study was to evaluate the relative bioavailability and safety of a multilayer extended-release bead methylphenidate (MPH) hydrochloride 80 mg (MPH-MLR) capsule or sprinkles (37% immediate-release [IR]) versus MPH hydrochloride IR(Ritalin(®)) tablets, and to develop a pharmacokinetic (PK) model simulating MPH concentration-time data for different MPH-MLR dosage strengths."	( Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers. Adjei, A; Chang, WW; Connor, DF; Greenhill, L; Kupper, RJ; Newcorn, JH; Teuscher, NS; Wigal, S, 2014)	0.89
" Relative bioavailability comparisons included partial area under the plasma concentration-time curves (pAUC0-3 h) for d-MPH."	( Absorption Differences between Immediate-Release Dexmethylphenidate and dl-Methylphenidate. Patrick, KS; Straughn, AB, 2016)	0.68
" This randomized, open-label, crossover trial compared the pharmacokinetic properties and relative bioavailability of MPH ERCT with an MPH chewable immediate-release tablet (IR MPH) formulation in healthy adults."	( Single-dose Pharmacokinetic Properties and Relative Bioavailability of a Novel Methylphenidate Extended-release Chewable Tablet Compared With Immediate-release Methylphenidate Chewable Tablet. Abbas, R; Belden, H; Berry, SA; Palumbo, D; Walters, F, 2016)	0.66
"The relative bioavailability of MPH ERCT 40 mg, based on the exposure (AUC), was comparable to that of IR MPH 40 mg administered in 2 equal doses of 20 mg 6 hours apart."	( Single-dose Pharmacokinetic Properties and Relative Bioavailability of a Novel Methylphenidate Extended-release Chewable Tablet Compared With Immediate-release Methylphenidate Chewable Tablet. Abbas, R; Belden, H; Berry, SA; Palumbo, D; Walters, F, 2016)	0.66
" Deviations from suggested routes of administration such as crushing, chewing, intravenous administration, or snorting stimulant medication may alter the release rate, absorption, and bioavailability of the active drug."	( Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications. Jain, R; Stark, JG, 2016)	0.43
" This was a randomized, open-label, 3-period, 3-treatment study comparing the bioavailability and absorption of 2 MPH XR-ODT formulations with an MPH ER reference medication."	( A Comparison of the Pharmacokinetics of Methylphenidate Extended-Release Orally Disintegrating Tablets With a Reference Extended-Release Formulation of Methylphenidate in Healthy Adults. Childress, A; Engelking, D; McMahen, R; Sikes, C; Stark, JG, 2018)	0.75
" This article evaluates the pharmacokinetic parameters and relative bioavailability of MPH ERCT when chewed versus swallowed whole."	( Relative Bioavailability of Methylphenidate Extended-release Chewable Tablets Chewed Versus Swallowed Whole. Abbas, R; Berry, SA; Childress, AC; Nagraj, P; Palumbo, DR; Rolke, R, 2018)	0.77
" Food and Drug Administration (FDA) partial area under the curve (pAUC) bioavailability metrics have improved discrimination between specific generic MR-MPH products."	( Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations. Koller, L; Nguyen, LV; Patrick, KS; Radke, JL; Raymond, JR; Rodriguez, W; Straughn, AB, 2019)	0.74
"Methylphenidate (MPD) is a psychostimulant used for the treatment of ADHD and works by increasing the bioavailability of dopamine (DA) in the brain."	( Acute and chronic methylphenidate administration in intact and VTA-specific and nonspecific lesioned rats. Dafny, N; Ihezie, SA; Thomas, MM, 2019)	2.29
" The objectives were to evaluate DR/ER-MPH pharmacokinetic (PK) properties in healthy adults, including dose proportionality, food effect, the potential of accumulation using multiple-dose modeling, and bioavailability compared to an immediate-release MPH (IR MPH)."	( Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults. DeSousa, NJ; Gobburu, JVS; Incledon, B; Liu, T; McLean, A; Po, MD; Sallee, FR, 2019)	0.75
" The relative bioavailability for DR/ER-MPH compared to IR MPH was 73."	( Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults. DeSousa, NJ; Gobburu, JVS; Incledon, B; Liu, T; McLean, A; Po, MD; Sallee, FR, 2019)	0.75
"A tenable hypothesis is presented which explains disparities between older oral dl-MPH bioavailability data generated using chiral derivatization-gas chromatography versus more recent findings using chiral liquid chromatography."	( Potential for Underestimation of d-Methylphenidate Bioavailability Using Chiral Derivatization/Gas Chromatography. Patrick, KS; Rodriguez, W, 2019)	0.79
" In general, both stimulants are rapidly absorbed with relatively poor bioavailability and short half-lives."	( The Pharmacokinetics and Pharmacogenomics of Psychostimulants. Markowitz, JS; Melchert, PW, 2022)	0.72
"Adult patients with ADHD, who are not treated with MPH (-MPH), showed varied Arg/NO pathway, but Arg bioavailability seemed to be consistent over the groups."	( l-Arginine/nitric oxide pathway and oxidative stress in adults with ADHD: Effects of methylphenidate treatment. Beckmann, B; Böhme, P; Emons, B; Hanusch, B; Juckel, G; Lücke, T; Sinningen, K; Tsikas, D, 2023)	1.13

Excerpt	Relevance	Reference
" These results had been hypothesized from theoretical dose-response curves which indicate different target behaviors would improve at different doses."	( Methylphenidate in hyperkinetic children: differences in dose effects on learning and social behavior. Sleator, EK; Sprague, RL, 1977)	1.7
" Neither dosage of active medication was found to effect psychomotor or psychological test performance, subjective report, heart rate or blood pressure."	( The effect of methylphenidate on test performance in the cognitively impaired aged. Crook, T; Ferris, S; Gershon, S; Raskin, A; Sathananthan, G, 1977)	0.62
" No clinical predictors of growth deficits were found; growth in height deficits are not related to total dosage or summer drug holidays, but weight deficits may be related to these factors."	( Growth of hyperactive children treated with methylphenidate. Blaschke, T; Cantwell, DP; Satterfield, JH; Schell, A, 1979)	0.52
" This temporary effect on growth is present during the first few years of treatment and seems related to drug dosage and to the presence or absence of drug holidays."	( The effects of stimulant medication on the growth of hyperkinetic children. Hung, W; Lipman, RS; Overall, JE; Roche, AF, 1979)	0.26
"A patient with severe narcolepsy and cataplexy had been treated with a high dosage of methylphenidate hydrochloride, but the drug was not effective."	( Successful treatment of narcolepsy with propranolol: a case report. Cadieux, R; Kales, A; Soldatos, CR; Tan, TL, 1979)	0.48
"A dose-response analysis was performed on D-amphetamine- and methylphenidate-induced changes in neuronal activity in the neostriatum of immobilized, phenidate-induced changes in neuronal activity in the neostriatum of immobilized, locally anesthetized rats."	( Dose-dependent biphasic alterations in the spontaneous activity of neurons in the rat neostriatum produced by d-amphetamine and methylphenidate. Rebec, GV; Segal, DS, 1978)	0.71
"A total of twenty-nine patients have thus far been treated with deanol in various dosage levels for periods ranging from five to thirty days."	( Deanol acetamidobenzoate (Deaner) in tardive dyskinesia. Fann, WE; Stafford, JR, 1977)	0.26
" Dose-response differences were also revealed in "breaking point" comparisons between secobarbital on the one hand, and methylphenidate and cocaine, on the other."	( Behavioral procedures for evaluating the relative abuse potential of CNS drugs in primates. Brady, JV; Griffiths, RR, 1976)	0.46
" No correlations were found between dosage level and changes in weight and height percentiles."	( Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine. Gross, MD, 1976)	0.52
" By repeated dosage a competition is created between receptor-blockade and hypersensitivity, often in favour of the latter."	( [Receptor-blockade and receptor-hypersensitivity following neuroleptic treatment (author's transl)]. Christensen, AV; Hyttel, J; Nielsen, IM, 1976)	0.26
" Methylphenidate dosage was individualized."	( Relative efficacy of methylphenidate and behavior modification in hyperkinetic children: an interim report. Abikoff, H; Gittelman-Klein, R; Gloisten, AC; Kates, W; Katz, S; Klein, DF, 1976)	1.48
"The development of a suitable formulation and a freeze-dry cycle for a pharmaceutical dosage form requires knowledge of some basic properties such as (1) eutectic temperature, if one exists, (2) temperature effect on solubility, (3) degree of supercooling, (4) heat transfer properties of the frozen product and (5) equipment design and equipment capability."	( Research and development of phamaceutical dosage forms. DeLuca, PP, 1976)	0.26
" Patients receiving methylphenidate in a dosage of 20 mg daily improved significantly over a period of six weeks as measured by results of tests for mental status, ward behavior (nursis' rating), target-symptom response, and physician's and nurses' global evaluations."	( Withdrawn, apathetic geriatric patients responsive to methylphenidate. Kaplitz, SE, 1975)	0.82
" A wide range of dosage (0."	( Observations on effects of a central stimulant drug (methylphenidate) in children with hyperactive behavior. Reynard, CL; Schain, RJ, 1975)	0.5
" Methylphenidate is given in 1-3 daily doses; treatment is commenced with small doses, and after 2-4 days the dosage is increased until behaviour changes."	( [Methylphenidat (Ritalin) as a psychotropic drug in children with minimal brain dysfunction and epilepsy]. Kind, CR, 1975)	1.16
"The dose-response relationships for three stimulants have been explored."	( The effects of age and illumination on the dose-response curves for three stimulants. Isaac, W; Kallman, WM, 1975)	0.25
" Both groups were divided into three drug dosage levels (0."	( Methylphenidate effects on avoidance learning at two ages in the rat. Gauron, EF; Rowley, VN, 1975)	1.7
" Dosage should be titrated individually for each patient, and it is best to start with small doses given at least 15 to 30 minutes before meals."	( Methylphenidate: a review. Majovski, LV; Oettinger, L, 1976)	1.7
" Included are the drugs' putative mechanisms of action, pharmacology, toxicology, indications for their use, short-term and long-term actions, adverse effects, specific dosing regimens, therapeutic monitoring techniques, alternative medications, and drug interactions."	( Pharmacologic treatment of attention deficit hyperactivity disorder. Greenhill, LL, 1992)	0.28
" Dose-response functions were determined during 5-min extinction sessions."	( Discriminative stimulus properties of triadimefon: comparison with methylphenidate. Eckerman, DA; MacPhail, RC; Perkins, AN, 1991)	0.52
" The dose-response curve for amphetamine was shifted downward and to the right by reserpine but was flattened by AMPT."	( Depletion of catecholamines in the brain of rats differentially affects stimulation of locomotor activity by caffeine, D-amphetamine, and methylphenidate. Finn, IB; Holtzman, SG; Iuvone, PM, 1990)	0.48
" Generalization testing then followed in which dose-response curves were determined for the following drugs: d-amphetamine (3."	( Discriminative stimulus effects of d-amphetamine, methylphenidate, and diazepam in humans. Heishman, SJ; Henningfield, JE, 1991)	0.53
" The groups were also compared in response to two dosage levels of methylphenidate."	( Auditory stimulus intensity gradients and response to methylphenidate in ADD children. Ackerman, PT; Dykman, RA; Oglesby, DM, )	0.62
" The following were the most significant effects of MDL 19205: a decrease in action potential duration in both ventricular and Purkinje tissues; a cumulative dose-dependent increase in contractile force in ventricular muscle but not in Purkinje strands; no change in aiNa in Purkinje fibers to accompany the positive inotropic effect of this agent; a shift in the dose-response relation by approximately fourfold in the presence of beta-adrenergic blockade with sotalol (10(-7) M); an enhancement of diastolic depolarization in Purkinje fibers resulting in automaticity that is accelerated by overdrive; and a potentiation of the positive inotropic effects of MDL 19205 by 8-bromo-cAMP (1 mM), indicating a potent phosphodiesterase inhibitory action of MDL 19205."	( Effects of MDL 19205 (piroximone), a new cardiotonic agent, on electrophysiological, mechanical, and intracellular ionic characteristics of sheep cardiac tissues. Wasserstrom, JA, )	0.13
"Investigated the effect of methylphenidate (MPH) on the ability of children with Attention Deficit Disorder with Hyperactivity (ADDH) to learn both trained and untrained complex visual relationships and compared these findings to their school performance under identical dosage parameters."	( The effects of methylphenidate on learning in children with ADDH: the stimulus equivalence paradigm. Rapport, MD; Vyse, SA, 1989)	0.93
" Among the issues discussed are (a) differences between peer and adult provocation and (b) the roles of medication dosage and multimodality intervention for promoting socially competent behavior in children with ADHD."	( Anger control in response to verbal provocation: effects of stimulant medication for boys with ADHD. Buhrmester, D; Heller, T; Hinshaw, SP, 1989)	0.28
" Both groups were assessed for dyskinetic symptoms at ten weekly intervals as dosage was phased out in the neuroleptic group."	( Dyskinetic symptoms in profoundly retarded residents following neuroleptic withdrawal and during methylphenidate treatment. Aman, MG; Singh, NN, 1985)	0.49
" The same low dosage of amphetamine which improved the behavior and learning of hyperkinetic and violent dogs disrupted the behavior and produced disorientation in normal dogs with previously stable conditional responses."	( Psychopharmacologic facilitation of psychosocial therapy of violence and hyperkinesis. Corson, EO; Corson, SA, 1988)	0.27
" A dose of 5 mg/kg of AMPH, but not 1 mg/kg of AMPH, caused a 2-fold shift to the right in the dose-response curve for DA in stimulating AC activity when compared with saline controls."	( Desensitization of rat striatal dopamine-stimulated adenylate cyclase after acute amphetamine administration. Barnett, JV; Kuczenski, R, 1986)	0.27
" Significant dose-response relationships were found, indicating enhanced learning from placebo to low to medium to high dose."	( Methylphenidate and memory: dissociated effects in hyperactive children. Amara, I; Evans, RW; Gualtieri, CT, 1986)	1.71
" The dose-response curves for methylphenidate and d-amphetamine appeared to be quantal in nature."	( Effects of chronic amphetamine in BALB/cBy mice, a strain that is not stimulated by acute administration of amphetamine. Cao, W; Carney, JM; Logan, L; Seale, TW, 1988)	0.56
" A multi-step analysis was used to examine the dose-response relationship, contribution of pre-stimulus levels of HR (i."	( Attention deficit disorder and methylphenidate: a multi-step analysis of dose-response effects on children's cardiovascular functioning. DuPaul, GJ; Kelly, KL; Rapport, MD, 1988)	0.56
", complete) so that rats are unresponsive, even to high doses of caffeine, and dose-response curves are displaced downward and flattened; (3) is pharmacologically specific, extending to other methylxanthines but not to nonxanthine psychomotor stimulants."	( Tolerance to behavioral effects of caffeine in rats. Finn, IB; Holtzman, SG, 1988)	0.27
" The medication trials were double-blind, placebo-controlled, dose-response studies."	( Treatment of chronic closed head injury with psychostimulant drugs: a controlled case study and an appropriate evaluation procedure. Evans, RW; Gualtieri, CT; Patterson, D, 1987)	0.27
" Dosage should be directly manipulated in pediatric psychopharmacological studies and the practice of using mg/kg dosage schedules may no longer be necessary."	( Hyperactivity and methylphenidate: rate-dependent effects on attention. DuPaul, GJ; Rapport, MD, 1986)	0.6
" Using signal detection theory methylphenidate significantly increased sensitivity (d) and did not change response bias (beta), independent of the dosage (5 to 20 mg/d)."	( [Attention in hyperkinetic children: a signal detection analysis of the effect of methylphenidate]. Rossel, E, 1987)	0.78
" Dosage effects were assessed on clinic-(PAL--Paired Associates Learning test) and school-(percent on task, teacher ratings, work completion rates, and accuracy) related behaviors."	( Methylphenidate in hyperactive children: differential effects of dose on academic, learning, and social behavior. Birmingham, BK; DuPaul, GJ; Rapport, MD; Stoner, G; Tucker, S, 1985)	1.71
"The short-term, dose-response effects of methylphenidate hydrochloride were evaluated on academic and social classroom measures in 29 children with attention deficit disorder."	( Methylphenidate and children with attention deficit disorder. Dose effects on classroom academic and social behavior. Bender, ME; Booth, S; Caddell, J; Moorer, SH; Pelham, WE, 1985)	1.98
" At a dosage of 2 mg/kg, methylphenidate given intraperitoneally decreased shock frequency during FR 4 periods while FR 1 behavior was not affected; at 4 mg/kg, stimulus control of avoidance responding was impaired during both components."	( Some effects of methylphenidate on stimulus control of ratio avoidance behavior in the rat. Alexander, D; Blackman, D; Stretch, R, 1966)	0.89
" A dose-response analysis of the effect of methylphenidate revealed no differences among the dietary groups."	( Effect of dietary lipid on locomotor activity and response to psychomotor stimulants. Brenneman, DE; Rutledge, CO, 1982)	0.53
"This research tested the hypothesis that a relatively modest dose of stimulant medication would produce optimal effects on cognitive and impulse control performance when compared to three other dosage levels in hyperactive school children."	( How much stimulant medication is appropriate for hyperactive school children? Brown, RT; Slimmer, LW; Wynne, ME, 1984)	0.27
" The clinically titrated methylphenidate dosage levels for the subjects were related both to the augmenter-reducer classification and to pretreatment HR levels; that is, subjects who were ERP reducers and/or had higher HR levels, especially under reward conditions, were blindly titrated at higher levels than those who were augmenters and/or had lower HR levels."	( Effects of reward and methylphenidate on heart rate response morphology of augmenting and reducing children. Ackerman, PT; Dykman, RA; Holcomb, PJ, 1984)	0.89
" The augmenters were blindly titrated at significantly lower dosage levels than the reducers."	( Auditory ERP augmentation-reduction and methylphenidate dosage needs in attention and reading disordered children. Ackerman, PT; Dykman, RA; Holcomb, PJ; McCray, DS, 1983)	0.53
" Amphetamine induces a dose-response partial reversal of the GBL effect."	( gamma-Butyrolactone effects on behavior induced by dopamine agonists. Dougherty, GG; Ellinwood, EH; Gonzalez, AE, 1983)	0.27
" However, there was one notable exception; presenting was dramatically increased following dosing with methylphenidate and diethylpropion."	( The effects of several anorexigenics on monkey social behavior. Bedford, JA; Marquis, DK; Wilson, MC, 1984)	0.48
" The median drug dosage was ."	( Effects of methylphenidate (Ritalin) on information processing in hyperactive children. Borkowski, JG; Reid, MK, 1984)	0.66
" Active compounds exhibited an inverted U-shaped dose-response curve."	( Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam. Butler, DE; L'Italien, YJ; Marriott, JG; Nordin, IC; Poschel, PH; Zweisler, L, 1984)	0.27
" It was concluded that drug effects are likely to be most pronounced in difficult learning situations and that dosage appears to be an important variable for consideration in further studies."	( Effects of methylphenidate on learning a 'beginning reading vocabulary' by normal adults. Gadow, KD; Kupietz, SS; Richardson, E; Winsberg, BG, 1980)	0.65
" Learning took place under placebo and under the child's regular dosage of methylphenidate."	( State-dependent learning in children receiving methylphenidate. Shea, VT, 1982)	0.75
" Dosage was significantly associated with the decrease in height and weight percentile."	( Growth of hyperactive children on maintenance regimen of methylphenidate. Gittelman, R; Mattes, JA, 1983)	0.51
"Four groups of children referred for attention disorders, learning disorders, or both were blindly titrated at statistically equivalent dosage levels of methylphenidate and improved more or less equivalently on several measures of attentiveness (cognitive style tests and reaction time)."	( Methylphenidate effects on cognitive style and reaction time in four groups of children. Ackerman, PT; Dykman, RA; Holcomb, PJ; McCray, DS, 1982)	1.91
" Results indicated that caffeine in low dosage when added to methylphenidate was superior to all other treatment conditions."	( Responses to methylphenidate and varied doses of caffeine in children with attention deficit disorder. Garfinkel, BD; Sloman, L; Webster, CD, 1981)	0.87
" The boys also participated in a blind crossover study contrasting placebo and methylphenidate effects; the prescribing physician, who was not informed of the child's nervous system classification, adjusted the dosage levels so that subjects with weaker nervous systems were titrated at higher dosage levels than those with stronger nervous systems."	( Studies of nervous system sensitivity in children with learning and attention disorders. Ackerman, PT; Dykman, RA; Holcomb, PJ; McCray, DS, )	0.36
" Total milligrams per day dosage, milligrams per kilogram per day dosage and duration of treatment per year were analysed in the medicated hyperactive children and their growth was compared with the other two groups."	( Effect of methylphenidate hydrochloride on stature of hyperactive children. Cohen, MN; Kalachnik, JE; Sleator, EK; Sprague, RL; Ullmann, RK, 1982)	0.67
" For all dosage groups behavior and attention improved with increased dosage, and the best scores were associated with the highest drug levels."	( Optimal dosages of methylphenidate for improving the learning and behavior of hyperactive children. Charles, L; Schain, R; Zelniker, T, 1981)	0.59
" Dose-response relationship of methylphenidate thermal effects exhibits a U-shape curve."	( A comparison of the hypothermic effects of methylphenidate and d-amphetamine. Ben-Uriah, Y; Carasso, RL; Yehuda, S, 1981)	0.81
" All active compounds gave inverted U-shaped dose-response curves."	( Cognition-activating properties of 3-(Aryloxy)pyridines. Butler, DE; Marriott, JG; Poschel, BP, 1981)	0.26
" Teacher rating data showed equivalent effects of therapy and the low dosage of methylphenidate alone but a stronger effect of the high dose alone; only the high dose resulted in improved behavior after 13 weeks of behavioral intervention."	( Behavioral and stimulant treatment of hyperactive children: a therapy study with methylphenidate probes in a within-subject design. Bologna, NC; Contreras, JA; Pelham, WE; Schnedler, RW, 1980)	0.71
" The combination of a clinically useful medication in appropriate dosage schedules with relevant psychological treatments simultaneously directed to each of the child's many disabilities were associated with an unexpectedly good outcome at the end of one and two years."	( Multimodality treatment. A two-year evaluation of 61 hyperactive boys. Cantwell, DP; Satterfield, BT; Satterfield, JH, 1980)	0.26
" Mean dosage levels, individually titrated by the team psychiatrist, were highest for the reading-disabled group, lowest for those with suspected attention disorders."	( Effects of methylphenidate on selective and sustained attention in hyperactive, reading-disabled, and presumably attention-disordered boys. Ackerman, PT; Dykman, RA; McCray, DS, 1980)	0.65
" Therefore, three-times-a-day dosing should be considered for those children exhibiting ADHD symptoms in the evening."	( Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder. Abikoff, H; Blader, JC; Foley, CA; Kent, JD; Koplewicz, HS, 1995)	0.59
" Dissociations of dose effects on cognitive function and behavior were demonstrated: Dose-response functions for changes in behavior were linear, whereas the function for response inhibition was U-shaped."	( Methylphenidate and cognitive flexibility: dissociated dose effects in hyperactive children. Logan, G; Schachar, R; Tannock, R, 1995)	1.73
"A double-blind crossover design was used in an acute dosage trial to assess effects of three dosages (0."	( Do high doses of stimulants impair flexible thinking in attention-deficit hyperactivity disorder? Barr, RG; Desilets, J; Douglas, VI; Sherman, E, 1995)	0.29
" Twelve attention deficit with hyperactivity disorder (ADHD) children performed a Continuous Performance Test involving a button-press response to the letter X (CPT-X) under the influence of MPH in a double-blind placebo controlled acute dosage design."	( Methylphenidate influences on both early and late ERP waves of ADHD children in a continuous performance test. Buitelaar, J; Koelega, HS; Overtoom, CC; Swaab-Barneveld, H; van der Gaag, RJ; van Engeland, H; Verbaten, MN, 1994)	1.73
"Methylphenidate (MPD) increased in rats the incidence of sniffing, rearing and locomotion, and this along dose-response curves that had an inverted U-shape; at 40 mg/kg, MPD exclusively induced stereotyped gnawing, which was inhibited by neuroleptics."	( Inhibition of methylphenidate-induced behaviors in rats: differences among neuroleptics. Colpaert, FC; Koek, W, 1993)	2.09
" Liver injury measured by either method was essentially nonexistent for dosages < or = 50 mg/kg in male mice, and was only minimally evident in female mice at the highest dosage testable."	( Methylphenidate-induced hepatotoxicity in mice and its potentiation by beta-adrenergic agonist drugs. Harbison, RD; James, RC; Roberts, SM; Roth, L, 1994)	1.73
" Transient sedation lasting 2 to 3 days occurred after initial administration or dosage increase; otherwise, clonidine was well tolerated."	( Clonidine therapy for comorbid attention deficit hyperactivity disorder and conduct disorder: preliminary findings in a children's inpatient unit. Mandoki, MW; Schvehla, TJ; Sumner, GS, 1994)	0.29
" Personal or family tic history, medication selection, or dosage was not related to onset of T/D."	( Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. Adesman, AR; Goldstein, IJ; Lipkin, PH, 1994)	0.29
" The P3a and P3b latencies were significantly longer in the ADHD children on baseline testing; there were no latency differences between the groups of children when the normal controls were compared with the ADHD children on their optimal drug dosage (as determined by extensive behavioural and cognitive assessments)."	( Changes in event-related potentials with stimulant medication in children with attention deficit hyperactivity disorder. Logan, WJ; Malone, MA; Taylor, MJ; Voros, JG, 1993)	0.29
" No dose-response relationship was found for either stimulant."	( Classroom academic performance: improvement with both methylphenidate and dextroamphetamine in ADHD boys. Elia, J; Gullotta, CS; Rapoport, JL; Welsh, PA, 1993)	0.53
" Survival was similar in dosed and control groups."	( Experimental studies on the long-term effects of methylphenidate hydrochloride. Dunnick, JK; Hailey, JR, 1995)	0.55
"Using a computerized infrared activity analysis system, the dose-response relationship, timing, and duration for stimulation of motor activity after a single dose of methylphenidate was studied in Sprague-Dawley rats."	( Dose response characteristics of methylphenidate on different indices of rats' locomotor activity at the beginning of the dark cycle. Dafny, N; Gaytan, O; Ghelani, D; Martin, S; Swann, A, 1996)	0.77
" Both interventions proved effective for improving neurocognitive test performance and behavior, although broad-band ratings revealed dose-response curves different from those obtained from the neurocognitive tests."	( Methylphenidate and attentional training. Comparative effects on behavior and neurocognitive performance in twin girls with attention-deficit/hyperactivity disorder. Denney, C; Goya, S; Isaacs, P; Loo, S; Rapport, MD; Scanlan, S, 1996)	1.74
" Although the titration protocol is complex, the study's individual dosing approach and algorithms for openly managing ADHD children's medication over time will be of interest to clinicians in office practice."	( Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. Abikoff, HB; Arnold, LE; Cantwell, DP; Conners, CK; Elliott, G; Greenhill, LL; Hechtman, L; Hinshaw, SP; Hoza, B; Jensen, PS; March, JS; Newcorn, J; Pelham, WE; Severe, JB; Swanson, JM; Vitiello, B; Wells, K, 1996)	0.29
"To evaluate the short-term efficacy and side effects associated with two methylphenidate hydrochloride (MPH) dosing patterns."	( Methylphenidate dosing: twice daily versus three times daily. Blackwell, B; Blondis, TA; Fishkin, J; O'Brien, T; Roizen, NJ; Schnitzler, ER; Stein, MA; Szumowski, E, 1996)	1.97
"All dosing conditions resulted in significant effects on ADHD symptoms when compared with baseline."	( Methylphenidate dosing: twice daily versus three times daily. Blackwell, B; Blondis, TA; Fishkin, J; O'Brien, T; Roizen, NJ; Schnitzler, ER; Stein, MA; Szumowski, E, 1996)	1.74
" dosing may be optimal."	( Methylphenidate dosing: twice daily versus three times daily. Blackwell, B; Blondis, TA; Fishkin, J; O'Brien, T; Roizen, NJ; Schnitzler, ER; Stein, MA; Szumowski, E, 1996)	1.74
" In Study 1, we examined covert visual spatial orienting in ADHD and comparison boys, Study 2 comprised a dose-response study of methylphenidate for the ADHD group, and Study 3 was an investigation of biological and adoptive parents."	( Covert visual spatial attention in boys with attention deficit hyperactivity disorder: lateral effects, methylphenidate response and results for parents. Hinshaw, SP; Nigg, JT; Swanson, JM, 1997)	0.72
"Attention-deficit hyperactivity disorder (ADHD) children participated in a double-blind placebo-controlled study in which the effects of a dosage of 15 mg methylphenidate (MPH) on auditory and visual selective attention tasks was determined by presenting frequent (90%) and infrequent (10%) stimuli in both relevant and irrelevant input channels."	( Effects of methylphenidate on event-related potentials and performance of attention-deficit hyperactivity disorder children in auditory and visual selective attention tasks. Buitelaar, JK; Camfferman, G; Jonkman, LM; Kemner, C; Koelega, HS; van Engeland, H; vd Gaag, RJ; Verbaten, MN, 1997)	0.88
"Dose-response profiles did not differ across children varying incrementally in body mass, nor were systematic variations in dose-response curve parameters observed across discrete groups of children differing in mean body mass."	( Titrating methylphenidate in children with attention-deficit/hyperactivity disorder: is body mass predictive of clinical response? Denney, C; Rapport, MD, 1997)	0.7
"Rapid-release psychostimulants are commonly used to treat attention-deficit hyperactivity disorder (ADHD), but midday dosing requirements and poor compliance rates have prompted the development of sustained-release formulations."	( Optimizing ADHD therapy with sustained-release methylphenidate. Carson, DS; Lawrence, DB; Lawrence, JD, 1997)	0.55
" Data obtained from a screening questionnaire, sleep diaries, and medical records showed that 22 of our 43 treated narcoleptic subjects reduced their dosage of stimulant medications or had not taken any stimulant medications during a 24-hour monitoring period during which they were expected to be on medication."	( Compliance with stimulant medications in patients with narcolepsy. Aldrich, MS; Berrios, AM; Rogers, AE; Rosenberg, RS, 1997)	0.3
" Side effects increased slightly with the high dosage of medication but remained mild."	( Effects of methylphenidate on preschool children with ADHD: cognitive and behavioral functions. Bennett, S; Firestone, P; Mercer, J; Musten, LM; Pisterman, S, 1997)	0.69
" However, the degree of improvement at times varied substantially across dosage and area of functioning."	( Comprehensive school-based behavioral assessment of the effects of methylphenidate. Gulley, V; Northup, J, 1997)	0.53
" Further, to investigate the NIE of methamphetamine, the dose-response relations to isoproterenol, histamine, and calcium were measured with or without methamphetamine (2 x 10(-4) M), after adrenergic neuronal blockade with reserpine."	( Biphasic inotropic effects of methamphetamine and methylphenidate on ferret papillary muscles. Ishiguro, Y; Morgan, JP, 1997)	0.55
"The dose-response relationship and time course of effect on motor activity after a single dose of methylphenidate given at different times of the light/dark cycle was investigated using a computerized infrared activity analysis system."	( Methylphenidate: diurnal effects on locomotor and stereotypic behavior in the rat. Dafny, N; Gaytan, O; Ghelani, D; Martin, S; Swann, A, 1997)	1.96
" Multiple data analytic methods were used with the goal of (a) describing the shape of the dose-response curves across multiple measures of social functioning, (b) determining the percentage of adolescents whose social behavior improved in response to MPH, and (c) assessing the incremental gains that result from increases in dose."	( Dosage effects of methylphenidate on the social behavior of adolescents diagnosed with attention-deficit hyperactivity disorder. Bukstein, O; Evans, S; Gnagy, E; Greiner, A; Molina, B; Myak, C; Pelham, WE; Presnell, M; Smith, BH; Willoughby, M, 1998)	0.63
" Since psychostimulant treatment often requires frequent dosing and may be associated with unacceptable side effects and risks, other classes of medication have been studied as possible treatment alternatives."	( Psychopharmacology of ADHD: children and adolescents. Dogin, JW; Findling, RL, 1998)	0.3
" Side effects were measured after each increase in dosage and weekly."	( Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Blackwell, B; Chrostowski, J; Grade, C; Redford, B; Toussaint, L, 1998)	1.74
" Higher dosage psychostimulants may be indicated in the last weeks of life of the terminally ill."	( Methylphenidate in terminal depression. Macleod, AD, 1998)	1.74
" This article presents a technique for evaluating behavioral and cognitive dose-response relationships at the single-subject level of analysis."	( Evaluating medication response in ADHD: cognitive, behavioral, and single-subject methodology. Coury, DL; DeWitt, MB; Hale, JB; Hoeppner, JA; Ritacco, DG; Trommer, B, )	0.13
" It can assist in optimizing medication dosage for individual children, given its sensitivity to dosage effects."	( Use of the restricted academic task in ADHD dose-response relationships. Fischer, M; Newby, RF, )	0.13
" For such reasons, the development of a transdermal dosage form of methylphenidate may be useful."	( Transdermal iontophoretic delivery of methylphenidate HCl in vitro. Boniello, S; Dinh, S; Liu, P; Singh, P, 1999)	0.81
" Subjective ratings by both teachers and parents were examined for dosage level effects and medication type effects."	( Differential effectiveness of methylphenidate and Adderall in school-age youths with attention-deficit/hyperactivity disorder. Findling, RL; Manos, MJ; Short, EJ, 1999)	0.59
" These results suggest differential dosage effects and a dissociation between dose levels and aspects of processing."	( Effect of methylphenidate on attention in children with attention deficit hyperactivity disorder (ADHD): ERP evidence. Humphries, T; Malone, MA; Roberts, W; Rovet, J; Sunohara, GA; Taylor, MJ, 1999)	0.71
" The model incorporated each patient's dosage size and schedule, body weight, and time of the plasma sample."	( Population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder. Greenblatt, DJ; Harmatz, JS; Oesterheld, JR; Parmelee, DX; Sallee, FR; Shader, RI, 1999)	0.59
" In study I, relative efficacy was determined for three dosing patterns of methylphenidate: a standard twice-daily profile, a flat profile, and an ascending profile."	( Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Agler, D; Flynn, D; Guinta, D; Gupta, S; Lerner, M; Shoulson, I; Swanson, J; Wigal, S; Williams, L, 1999)	0.86
" This should be considered in the design of an optimal dosing regimen for the treatment of children with attention deficit hyperactivity disorder."	( Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Agler, D; Flynn, D; Guinta, D; Gupta, S; Lerner, M; Shoulson, I; Swanson, J; Wigal, S; Williams, L, 1999)	0.63
" Higher dosage was associated with fewer diagnoses of alcoholism or suicide attempts."	( Childhood inattention-overactivity, aggression, and stimulant medication history as predictors of young adult outcomes. Loney, J; Paternite, CE; Salisbury, H; Whaley, MA, 1999)	0.3
"1) To compare standard twice-daily methylphenidate (MPH) dosing with a single morning dose of MPH and of Adderall during a typical school-day time period, and 2) to conduct a dose-response study of the effects of a late-afternoon (3:30 PM) dose of MPH and Adderall on evening behavior and side effects."	( A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Aronoff, HR; Burrows-MacLean, L; Chronis, AM; Fabiano, GA; Gnagy, EM; Meichenbaum, DL; Onyango, AN; Pelham, WE; Steiner, RL; Williams, A, 1999)	0.79
" These results indicate that Adderall may be used as a long-acting stimulant for children for whom midday dosing is a problem."	( A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Aronoff, HR; Burrows-MacLean, L; Chronis, AM; Fabiano, GA; Gnagy, EM; Meichenbaum, DL; Onyango, AN; Pelham, WE; Steiner, RL; Williams, A, 1999)	0.51
" The dosage was increased until behavioral change was achieved, using a decrement in scores of less than or equal to 1 on a commonly used rating scale or until the maximum tolerated dose was achieved."	( Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. Comings, DE; Winsberg, BG, 1999)	0.54
" There is marked individual variability in the dose-response relationship for methylphenidate, and therefore dosage must be titrated for optimal effect and avoidance of toxicity in each child."	( Pharmacokinetics and clinical effectiveness of methylphenidate. Abernethy, DR; Cross, JT; Kimko, HC, 1999)	0.79
" The single high dose of MPTP produced greater losses of [(11)C]dihydrotetrabenazine binding than did the multiple MPTP dosing regimen."	( Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Kilbourn, MR; Kuszpit, K; Sherman, P, 2000)	0.31
" Measures of subjective, behavioural, and physiological responses were evaluated at fixed intervals during 72 h after each dosing occasion."	( An evaluation of the abuse potential of modafinil using methylphenidate as a reference. Jasinski, DR, 2000)	0.55
"In this study we approach problems related to the dosage and specific action of methylphenidate, its effects at cognitive and social levels, possible side-effects and limitations to its usage, and methods for evaluation of the response to treatment in the school environment."	( [The evaluation of the effects of pharmacological treatment of children with attention deficit hyperactivity disorder]. Amado, L; Presentación, MJ; Roselló, B, 1999)	0.53
" An essential component of such studies is the determination of MP plasma levels under chronic and acute dosing conditions."	( Analysis of methylphenidate and its metabolite ritalinic acid in monkey plasma by liquid chromatography/electrospray ionization mass spectrometry. Bajic, S; Doerge, DR; Fogle, CM; McCullagh, M; Paule, MG, 2000)	0.69
" Thirty-two reports (29 studies) evaluated adverse effects of drug therapy; many of the side effects associated with stimulant use appear to be relatively mild and of short duration and to respond to dosing or timing adjustments."	( Treatment of attention-deficit/hyperactivity disorder. Boyle, M; Cunningham, C; Jadad, AR; Kim, M; Schachar, R, 1999)	0.3
" Dosage was adjusted at the end of weeks 1 and 2 via an algorithm based on teacher and parent ratings."	( A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. Browne, RG; Olvera, RL; Pliszka, SR; Wynne, SK, 2000)	0.55
" Adderall produced significantly more improvements on teacher ratings and the CGI than methylphenidate, although the algorithm may have limited dosing in the methylphenidate group."	( A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. Browne, RG; Olvera, RL; Pliszka, SR; Wynne, SK, 2000)	0.77
" It attempts to arrive at a reasonable upper limit of dosage for clinical purposes."	( How high a dose of stimulant medication in adult attention deficit hyperactivity disorder? Sachdev, PS; Trollor, JN, 2000)	0.31
"5 mg each day with twice-a-day dosing in the morning and at noon until the patient responded or showed side effects."	( Treatment of depression with methylphenidate in patients difficult to wean from mechanical ventilation in the intensive care unit. Ehrentraut, S; Kapfhammer, HP; Kilger, E; Rothenhäusler, HB; Schelling, G; Stoll, C; Tichy, M; von Degenfeld, G; Weis, M, 2000)	0.6
"The MTA titration protocol validated the efficacy of weekend MPH dosing and established a total daily dose limit of 35 mg of MPH for children weighing less than 25 kg."	( Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. Abikoff, HB; Arnold, LE; Bukstein, OG; Clevenger, W; Conners, CK; Davies, M; Elliott, GR; Greenhill, LL; Hechtman, L; Hinshaw, SP; Hoza, B; Jensen, PS; Kraemer, HC; March, JS; Newcorn, JH; Severe, JB; Swanson, JM; Vitiello, B; Wells, K; Wigal, T; Wu, M, 2001)	0.57
"To examine the trajectory of methylphenidate (MPH) dosage over time, following a controlled titration, and to ascertain how accurately the titration was able to predict effective long-term treatment in children with attention-deficit/hyperactivity disorder (ADHD)."	( Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. Abikoff, HB; Arnold, LE; Bukstein, OG; Cantwell, DP; Elliott, GR; Greenhill, LL; Hechtman, L; Hinshaw, SP; Jensen, PS; March, JS; Newcorn, JH; Severe, JB; Swanson, JM; Vitiello, B, 2001)	2.04
" Of the 230 children for whom titration identified an optimal treatment, 17% continued both the assigned medication and dosage throughout maintenance."	( Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. Abikoff, HB; Arnold, LE; Bukstein, OG; Cantwell, DP; Elliott, GR; Greenhill, LL; Hechtman, L; Hinshaw, SP; Jensen, PS; March, JS; Newcorn, JH; Severe, JB; Swanson, JM; Vitiello, B, 2001)	1.75
" Results indicated that 3 children were able to accurately report their medication status at levels greater than chance, whereas the accuracy of reports by all children was related to dosage level, differences in behavior, and the presence of adverse effects."	( Testing the ability of children with attention deficit hyperactivity disorder to accurately report the effects of medication on their behavior. Ardoin, SP; Martens, BK, 2000)	0.31
" Recent studies suggest that Adderall, a psychostimulant indicated for the treatment of ADHD, may provide an efficacious, less frequently dosed alternative to methylphenidate."	( Retrospective comparison of Adderall and methylphenidate in the treatment of attention deficit hyperactivity disorder. Grcevich, S; Marcellino, B; Rowane, WA; Sullivan-Hurst, S, 2001)	0.77
" Previous long-acting stimulants and preparations have shown effects equivalent to twice-daily dosing of MPH."	( Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Burrows-Maclean, L; Chronis, AM; Coles, EK; Fabiano, GA; Fielbelkorn, K; Forehand, GL; Gnagy, EM; Hoffman, MT; Lock, TM; Meichenbaum, DL; Morrisey, SM; Morse, GD; Nguyen, CA; Onyango, AN; Panahon, CJ; Pelham, WE; Steiner, RL; Williams, A, 2001)	0.63
" Three dosing levels of medication were used: 5 mg IR MPH tid/18 mg Concerta once a day (qd); 10 mg IR MPH tid/36 mg Concerta qd; and 15 mg IR MPH tid/54 mg Concerta qd."	( Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Burrows-Maclean, L; Chronis, AM; Coles, EK; Fabiano, GA; Fielbelkorn, K; Forehand, GL; Gnagy, EM; Hoffman, MT; Lock, TM; Meichenbaum, DL; Morrisey, SM; Morse, GD; Nguyen, CA; Onyango, AN; Panahon, CJ; Pelham, WE; Steiner, RL; Williams, A, 2001)	0.63
" However, patients may require dosage adjustment for tolerability of this combination."	( Methylphenidate augmentation of citalopram in elderly depressed patients. Kumar, A; Lavretsky, H, 2001)	1.75
"Children with attention-deficit/hyperactivity disorder (ADHD; n = 282), all subtypes, ages 6 to 12 years, were randomized to placebo (n = 90), immediate-release methylphenidate (IR MPH) 3 times a day (tid; dosed every 4 hours; n = 97), or OROS MPH once a day (qd; n = 95) in a double-blind, 28-day trial."	( Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Atkins, M; August, G; Bukstein, O; Greenhill, LL; McBurnett, K; Palumbo, D; Pelham, W; Swanson, J; Wilens, T; Wolraich, ML, 2001)	0.78
"For the treatment of core ADHD symptoms, OROS MPH dosed qd and IR MPH dosed tid were superior to placebo and were not significantly different from each other."	( Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Atkins, M; August, G; Bukstein, O; Greenhill, LL; McBurnett, K; Palumbo, D; Pelham, W; Swanson, J; Wilens, T; Wolraich, ML, 2001)	0.58
" The average daily dosage prescribed differed little among general practitioners, pediatricians and psychiatrists, unlike the mean interval between successive prescriptions: 89."	( Prescription of methylphenidate to children and youth, 1990-1996. Armstrong, RW; Lalonde, CE; McGrail, KM; Miller, AR, 2001)	0.66
" The differences were attributable to differences in drug-acquisition costs and the need for in-school dosing of twice-daily and thrice-daily medications."	( Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Carotenuto, I; Conners, CK; Einarson, TR; Findling, R; Iskedjian, M; Jensen, PS; Lau, H; Magar, R; Marchetti, A; Murphy, EL; Wineburg, E, 2001)	0.31
" Statistical comparisons of specific somatic complaints indicated minimal agreement between parents and children in contrast to the nearly identical parent-child dose-response curves."	( Attention-Deficit/Hyperactivity Disorder and methylphenidate: a dose-response analysis and parent-child comparison of somatic complaints. Moffitt, C; Randall, R; Rapport, MD, 2002)	0.57
" The conservative dosage levels and relatively brief length of treatment may have contributed to the absence of significant differences among treatment conditions."	( An experimental comparison of Pycnogenol and methylphenidate in adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Dodd, DK; Green, L; Paull, JC; Sparrow, EP; Tenenbaum, S, 2002)	0.57
" They were dosed with 2, 6, and 20 mg/kg/day D-methylphenidate and 40 mg/kg/day D,L-methylphenidate from gestation Day 7 to lactation Day 20."	( The perinatal and postnatal toxicity of D-methylphenidate and D,L-methylphenidate in rats. Christian, MS; Hoberman, AM; Khetani, VD; Stirling, DI; Teo, SK; Thomas, SD, )	0.65
" The food effect on early drug exposure and the pharmacokinetic profiles up to 8 h after dosing of the two extended-release stimulants were directly compared using partial area (AUC(p4h), AUC(p6h) and AUC(p8h)) fed/fasted ratios."	( Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study. Auiler, JF; Gelotte, CK; Liu, K; Lynch, JM, 2002)	0.31
" Overall, the toxicity profile observed in rats with 50 mg/kg per day D-MPH was comparable to that of an equimolar dose of D,L-MPH (100 mg/kg per day) when given repeatedly for 90 days using a twice a day dosing regimen."	( A 90-day oral gavage toxicity study of D-methylphenidate and D,L-methylphenidate in Sprague-Dawley rats. Hoberman, A; Khetani, V; Kiorpes, A; Stirling, D; Teo, S; Thomas, S, 2002)	0.58
", blood pressure [BP], heart rate [HR], height/weight) are mostly transient, dose-dependent, easily rectified with dosage adjustments, and considered minor from a clinical perspective considering the breadth and level of improvement in behavior and cognitive functioning observed in most children."	( Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects. Moffitt, C; Rapport, MD, 2002)	0.57
"To test the effects of a standard dosage of the psychostimulant methylphenidate (MPH) - which significantly enhances intracortical inhibition but had no effects on intracortical facilitation in children with attention-deficit hyperactivity disorder (ADHD) - on intracortical excitability in healthy subjects."	( Methylphenidate and intracortical excitability: opposite effects in healthy subjects and attention-deficit hyperactivity disorder. Heinrich, H; Moll, GH; Rothenberger, A, 2003)	2
"Examined the impact of late-afternoon stimulant dosing on parent and parent-child domains."	( The impact of late-afternoon stimulant dosing for children with ADHD on parent and parent-child domains. Aronoff, HR; Chronis, AM; Gnagy, EM; Pelham, WE; Roberts, JE, 2003)	0.32
"The duration of action of the immediate-release formulation of methylphenidate hydrochloride is short (3 to 4 hours), and 3 times daily dosing is thought to maximize effectiveness across a 12-hour day."	( Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Gupta, S; Lam, A; Lerner, M; Lindemulder, E; Modi, N; Shoulson, I; Swanson, J; Wigal, S, 2003)	0.82
" In the pharmacodynamic study, OROS-methylphenidate treatment matched the 3 times daily dosing of methylphenidate for onset and duration of efficacy."	( Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Gupta, S; Lam, A; Lerner, M; Lindemulder, E; Modi, N; Shoulson, I; Swanson, J; Wigal, S, 2003)	0.85
"The current study was aimed at (a) investigating the effect of three doses methylphenidate (MPH) and placebo on inhibition of a prepotent response, inhibition of an ongoing response, and interference control in Attention Deficit/Hyperactivity Disorder (AD/HD), and (b) studying dose-response relations for the three forms of response inhibition."	( The effect of methylphenidate on three forms of response inhibition in boys with AD/HD. Meiran, N; Morein-Zamir, S; Oosterlaan, J; Scheres, A; Schut, H; Sergeant, JA; Swanson, J; Vlasveld, L, 2003)	0.91
" Oral clearance was identical between the two dosage forms."	( Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. DeVane, CL; Lee, J; Markowitz, JS; Muniz, R; Patrick, KS; Pestreich, L; Straughn, AB; Wang, Y, 2003)	0.64
" Measures of regional cerebral blood flow (rCBF) using positron emission tomography (PET) were acquired at rest for ten adult subjects with ADHD during both an unmedicated state and after a 3-week period of chronic dosing with a clinically optimal dose of MPH."	( A positron emission tomography study of methylphenidate in adults with ADHD: alterations in resting blood flow and predicting treatment response. Grafton, ST; Hanford, RB; Hoffman, JM; Kilts, CD; Lee, DO; Schweitzer, JB; Tagamets, MA, 2003)	0.59
"Although attention deficit hyperactivity disorder is thought to be present in preschoolers, there are no clear guidelines for dosing stimulant medications in this population."	( High-dose methylphenidate treatment of attention deficit hyperactivity disorder in a preschooler. Butz, AM; Cozen, MA; Lipkin, PH, 2003)	0.72
" Dogs were orally dosed twice a day in equally divided doses 6 hours apart for total daily doses of 1, 3, and 10 mg/kg/day d-MPH or 20 mg/kg/day d,l-MPH for 90 days, followed by a 30-day recovery period."	( A 90-day oral gavage toxicity study of d-methylphenidate and d,l-methylphenidate in beagle dogs. Evans, MG; Khetani, VD; Stirling, DI; Teo, SK; Thomas, SD, )	0.4
"Groups of pregnant rats were orally dosed twice daily 6 hr apart from Days 7 to 17 of presumed gestation (DG 7-17) for total daily doses of 2, 6 and 20 mg/kg D-MPH and 40 mg/kg D,L-MPH."	( D-methylphenidate and D,L-methylphenidate are not developmental toxicants in rats and rabbits. Christian, MS; Hoberman, AM; Khetani, VD; Stirling, DI; Teo, SK; Thomas, SD, 2003)	1.04
" The number of rats with repetitive pawing, dilated pupil and aggression was significantly greater for the 40 mg/kg D,L-MPH compared to the 20 mg/kg D-MPH dosed rats."	( D-methylphenidate and D,L-methylphenidate are not developmental toxicants in rats and rabbits. Christian, MS; Hoberman, AM; Khetani, VD; Stirling, DI; Teo, SK; Thomas, SD, 2003)	1.04
"Rats and rabbits dosed with D,L-MPH exhibited significantly greater incidence of maternal clinical observations at twice the dose of D-MPH."	( D-methylphenidate and D,L-methylphenidate are not developmental toxicants in rats and rabbits. Christian, MS; Hoberman, AM; Khetani, VD; Stirling, DI; Teo, SK; Thomas, SD, 2003)	1.04
" A total of 28 children with ADHD as defined by DSM IV were randomized to selegiline or methylphenidate dosed on an age and weight-adjusted basis at selegiline 5 mg/day (under 5 years) and 10 mg/day (over 5 years) (Group 1) and methylphenidate 1 mg/kg/day (Group 2) for a 4-week double-blind clinical trial."	( Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. Akhondzadeh, S; Amini, H; Arabgol, F; Davari-Ashtiani, R; Tavakolian, R, 2003)	0.54
" We then increased dosage to 15 mg 3 times daily for 2 weeks and administered a complete reassessment on the final day."	( The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Bouffard, R; Hechtman, L; Iaboni-Kassab, F; Minde, K, 2003)	0.59
" This notwithstanding, a single-isomer d-MPH immediate-release product is now available for dosing recommended at one-half that of dl-MPH."	( Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Markowitz, JS; Patrick, KS; Straughn, AB, 2003)	0.54
" This study was conducted to examine dosage effects on ADHD symptoms and stimulant side effects and to explore potential moderating effects of ADHD subtype."	( A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Black, DO; Conlon, C; Newcorn, JH; Pearl, PL; Robb, AS; Sarampote, CS; Seymour, KE; Stein, MA; Waldman, ID, 2003)	0.61
"Children with ADHD combined type (ADHD-CT) or predominantly inattentive type (ADHD-PI; n = 47), ages 5 to 16 years, underwent a placebo-controlled, crossover trial using forced titration with weekly switches at 3 dosage levels."	( A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Black, DO; Conlon, C; Newcorn, JH; Pearl, PL; Robb, AS; Sarampote, CS; Seymour, KE; Stein, MA; Waldman, ID, 2003)	0.61
" For those with ADHD-CT, there was a clear linear dose-response relationship, with clinically significant reductions in ADHD Rating Scale-IV scores occurring in two thirds to three fourths of the subjects during either 36- or 54-mg dose conditions."	( A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Black, DO; Conlon, C; Newcorn, JH; Pearl, PL; Robb, AS; Sarampote, CS; Seymour, KE; Stein, MA; Waldman, ID, 2003)	0.61
"We used a sequential approach to evaluate the relative and combined effects of different types of behavioral treatments, as well as dosage of methylphenidate (MPH), on the disruptive behavior of 3 students who had been diagnosed with attention deficit hyperactivity disorder."	( Sequential evaluation of behavioral treatments and methylphenidate dosage for children with attention deficit hyperactivity disorder. Gulley, V; Hupp, S; LeVelle, J; Northup, J; Ridgway, A; Spera, S, 2003)	0.77
" There was no clear dose-response relationship."	( Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. Biederman, J; Lerner, M; Wilens, TE, 2004)	0.59
" The behavioral experiment included dose-response (0."	( Dopaminergic ventral tegmental neurons modulated by methylphenidate. Benitez, MT; Dafny, N; Prieto-Gomez, B; Reyes Vazquez, C; Vazquez-Alvarez, AM; Yang, PB, 2004)	0.57
" The behavioural responses of individuals are also highly variable, so that it is necessary to start treatment at a low dosage and increase up to a maximally effective dosage (usually starting at 10-15 mg/day with increases of 10-15mg at weekly intervals to a maximum dosage of 60 mg/day, irrespective of formulation)."	( Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. Doffing, MA; Wolraich, ML, 2004)	0.54
"5% of mild complications being resolved by lowering the drug dosage or by withdrawing it altogether."	( [The diagnostic evaluation and therapeutic basis of immediate release methylphenidate in attention deficit hyperactivity disorder]. Valdizán, JR, )	0.37
" A total of 32 children with ADHD as defined by DSM IV were randomized to theophylline and methylphenidate dosed on an age and weight-adjusted basis at 4 mg/kg/day (under 12 years) and 3 mg/kg/day theophylline (over 12 years) (group 1) and 1 mg/kg/day methylphenidate (group 2) for a 6-week double-blind and randomized clinical trial."	( Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial. Akhondzadeh, S; Izadian, ES; Kashani, L; Mohammadi, MR; Ohadinia, S, 2004)	0.82
" After having received various dosing levels of a stimulant in a placebo-controlled crossover design, best dose was assigned based on the lowest Abbreviated Symptoms Questionnaire T score received in a given week."	( A prospective study of stimulant response in preschool children: insights from ROC analyses. Findling, RL; Manos, MJ; Schubel, EA; Short, EJ, 2004)	0.32
" Methylphenidate and amphetamine-based stimulants are now available in longer-acting, once-daily and shorter-acting divided dosing schedules."	( Pharmacological management of attention-deficit hyperactivity disorder. Reeves, G; Schweitzer, J, 2004)	1.23
" Analysis of dose-response curves revealed significant linear components of trend on measures tapping sustained attention, visual selective attention, auditory selective attention, as well as two tasks tapping inhibition/impulsivity: delay of gratification and match-to-sample."	( Treatment effects of methylphenidate on cognitive functioning in children with mental retardation and ADHD. Casat, CD; Cleveland, LA; Faria, LP; Jerger, SW; Lachar, D; Lane, DM; Loveland, KA; Payne, CD; Pearson, DA; Roache, JD; Santos, CW, 2004)	0.64
" The 20 mg capsule, the first FDA-approved dosage strength, was used as reference treatment."	( Dose-proportional pharmacokinetics of a methylphenidate extended-release capsule. Dirksen, SJ; González, MA; Rochdi, M, 2004)	0.59
"Data collected from this study demonstrate the dose proportionality of the new 10 mg and 30 mg dosage strengths of MPH ER capsules with the 20 mg capsule."	( Dose-proportional pharmacokinetics of a methylphenidate extended-release capsule. Dirksen, SJ; González, MA; Rochdi, M, 2004)	0.59
" The present report describes the determination of plasma concentrations of D-threo- and L-threo-enantiomers of MPH in toxicokinetic (TK) studies in pregnant Wistar Hannover rats and New Zealand white rabbits following repeated daily oral dosing of D,L-MPH (racemate)."	( Toxicokinetic assessment of methylphenidate (Ritalin) enantiomers in pregnant rats and rabbits. Bakhtiar, R; Tse, FL, 2004)	0.62
"Given the dosing limitations of methylphenidate short-acting preparations in treating ADHD, galenics with longer release of the substance were developed mainly to avoid drug intake during school hours."	( Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Banaschewski, T; Breuer, D; Döpfner, M; Freisleder, FJ; Gerber, WD; Gerber-von Müller, G; Günter, M; Hässler, F; Lehmkuhl, G; Ose, C; Rothenberger, A; Schmeck, K; Sinzig, J; Stadler, C; Uebel, H, 2004)	0.86
" The purpose of this study was to examine the acute dose-response characteristics of MPD on three different male rat strains: spontaneously hypertensive/hyperactive rats (SHR), Wistar-Kyoto (WKY) rats, and Sprague-Dawley (SD) rats."	( Differential locomotor responses in male rats from three strains to acute methylphenidate. Amini, B; Dafny, N; Swann, AC; Yang, PB, 2004)	0.55
" Children were assigned on the basis of their pre-trial dosage to either high (Metadate CD 60 mg; Concerta 54 mg), medium (Metadate CD 40 mg; Concerta 36 mg) or low doses (Metadate CD 20 mg; Concerta 18 mg) of MPH, and attended a laboratory school on the 7th day for assessment at 7 sessions across the day."	( Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. Coghill, D; DeCory, HH; Hatch, SJ; Sonuga-Barke, EJ; Swanson, JM, 2004)	0.62
" Future studies are needed to confirm these findings and to evaluate chronic dosing with d-MPH."	( Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder. Cecil, JT; Faleck, H; Khetani, V; Kowalik, S; Patin, J; Silva, R; Tilker, HA, 2004)	0.63
"These data support the use of XR MPH with its simplified dosing regimen for children with ADHD."	( Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. Hwang, P; Lage, M, 2004)	0.73
"The newer treatments for ADHD offer advantages over immediate-release methyphenidate in dosing schedule and duration of action that may be of particular benefit to adolescent and adult patients."	( Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder. Hazell, P, 2004)	0.32
" (total daily MPH IR dosage 45 mg)."	( [Long-acting methylphenidate. An alternative medical therapy for adult patients with attention deficit hyperactivity disorder]. Alm, B; Sobanski, E, 2005)	0.7
"02 years), underwent a 4-week, double-blinded, crossover trial with forced weekly dosage changes."	( Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Conlon, C; Cook, EH; Kim, SJ; Robb, AS; Sarampote, CS; Seymour, KE; Stein, MA; Waldman, ID, 2005)	0.61
" In an attempt to understand these behavioral differences at the neuronal level, the dose-response characteristics of these two psychostimulants on electrophysiologically identified VTA-DA neurons at the glutamatergic synapse were investigated."	( Methylphenidate and amphetamine modulate differently the NMDA and AMPA glutamatergic transmission of dopaminergic neurons in the ventral tegmental area. Dafny, N; Martínez-Peña, JL; Prieto-Gómez, B; Reyes-Vázquez, C; Vázquez-Alvarez, AM; Yang, PB, 2005)	1.77
" This paper draws upon data from a qualitative empirical study to investigate parents' use of the moral ideal of authenticity as part of their narrative justifications for dosing decisions and actions."	( Will the "real boy" please behave: dosing dilemmas for parents of boys with ADHD. Singh, I, 2005)	0.33
" After adjustment of the dosage for body weight, the pharmacokinetic parameters are similar across all age and gender groups."	( [Current evidence about atomoxetine. A therapeutic alternative for the treatment of attention deficit hyperactivity disorder]. Peña, JA; Velásquez-Tirado, JD, )	0.13
" Subjects successfully completing the dose titration phase (n = 177) (ie, tolerated and responded to treatment and adhered to the protocol) were randomized to receive 2 weeks' treatment with their individualized dosage of OROS methylphenidate (18, 36, 54, or 72 mg once daily) or placebo."	( Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Bailey, CE; Bloom, L; Bukstein, O; Casat, C; Conners, CK; Cooper, KM; Coury, D; Denisco, MJ; Duby, J; Greenhill, L; Gu, J; Halstead, P; Kratochvil, CJ; Lerner, M; Lynch, JM; McBurnett, K; McGough, J; Newcorn, J; Stein, MA; Wilens, TE; Zimmerman, BA, 2006)	0.79
" Thirty-seven percent of subjects required the maximum dosage of 72 mg/d."	( Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Bailey, CE; Bloom, L; Bukstein, O; Casat, C; Conners, CK; Cooper, KM; Coury, D; Denisco, MJ; Duby, J; Greenhill, L; Gu, J; Halstead, P; Kratochvil, CJ; Lerner, M; Lynch, JM; McBurnett, K; McGough, J; Newcorn, J; Stein, MA; Wilens, TE; Zimmerman, BA, 2006)	0.61
"The thrice daily dosing regimen of immediate release methylphenidate (IR-MPH) for Attention Deficit/Hyperactivity Disorder (ADHD) requires in-school dosing, leading to issues surrounding dispensing and storage of controlled substances by school personnel and concerns over children?s privacy and the embarrassment associated with taking medication in public at school."	( A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Binder, CE; Prinzo, RS; Steele, M; Swanson, J; Wang, J; Weiss, M, 2006)	0.83
" The objectives of the present study were to investigate the MPD dose-response characteristics on locomotor activity and sensory inputs using acoustic stimuli."	( Sensory-evoked potentials recordings from the ventral tegmental area, nucleus accumbens, prefrontal cortex, and caudate nucleus and locomotor activity are modulated in dose-response characteristics by methylphenidate. Dafny, N; Swann, AC; Yang, PB, 2006)	0.52
" Members of the high-dose group (n = 58) had received at least 1 stimulant at a dosage > or = 120% of the maximum recommended by the American Academy of Sleep Medicine Standards of Practice Committee."	( Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study. Auger, RR; Goodman, SH; Krahn, LE; Pankratz, VS; Silber, MH; Slocumb, NL, 2005)	0.33
"All 12 dosed subjects finished both treatment periods and were included in pharmacokinetic and safety analyses."	( Bioequivalence of a methylphenidate hydrochloride extended-release preparation: comparison of an intact capsule and an opened capsule sprinkled on applesauce. Ammer, R; Fischer, R; Grossmann, M; Leis, HJ; Schütz, H, 2006)	0.66
" Therefore, experiments were carried out in P-gp knockout (KO) mice versus wild-type (WT) mice after intraperitoneal dosing (2."	( The role of the polymorphic efflux transporter P-glycoprotein on the brain accumulation of d-methylphenidate and d-amphetamine. DeVane, CL; Donovan, JL; Gibson, BB; Markowitz, JS; Middaugh, LD; Patrick, KS; Wang, JS; Williard, RL; Zhu, HJ, 2006)	0.55
"Findings indicate that multiple daily dosing of MPH increases the likelihood of poor adherence, particularly in adolescents, and that poor adherence is associated with impaired maternal/family process."	( Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. Chiu, YN; Chou, MC; Gau, CS; Gau, SS; Shen, HY; Tang, CS, 2006)	0.63
" Results showed that repeated administration of MPD increased locomotion in dose-response manner and elicited behavioral sensitization, while the amplitude of the sensory evoked field responses of the VTA and NAc exhibited dose-response attenuation on both recording days (days 1 and 10)."	( Chronic methylphenidate modulates locomotor activity and sensory evoked responses in the VTA and NAc of freely behaving rats. Dafny, N; Swann, AC; Yang, PB, 2006)	0.77
" Flexible d-MPH-ER dosing (30 mg/day) was permitted for 5 weeks, then patients remained on their optimal dose during the last 2 study weeks."	( Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. Ball, RR; Greenhill, LL; Jiang, H; Levine, A; Muniz, R; Pestreich, L, 2006)	0.63
" Since therapeutic MPH in humans is typically administered orally, oral dosing methods that have been verified in the rodent model are of value."	( A novel method for oral stimulant administration in the neonate rat and similar species. Eppolito, AK; Huff, TB; Smith, LN; Smith, RF; Wheeler, TL, 2007)	0.34
" The development of ideal long-acting preparations requires detailed understanding of the pharmacokinetic and pharmacodynamic consequences of complex dosing regimens."	( Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens. Chang, WW; Foley, M; McGreenery, CE; McKay, G; Midha, KK; Polcari, A; Teicher, MH; Valente, E, 2006)	1.78
"This study does not support the expectation that optimally dosed stimulant treated children with ADHD should routinely receive psychosocial treatment to further reduce ADHD- and related symptoms."	( Does brief, clinically based, intensive multimodal behavior therapy enhance the effects of methylphenidate in children with ADHD? Emmelkamp, PM; Oosterlaan, J; Prins, PJ; van der Oord, S, 2007)	0.56
" Clinical trials have shown OROS MPH to have a continued action over a 12-h period, to be superior to placebo and to be as effective as immediate-release MPH dosed three times daily, in reducing symptoms of attention-deficit hyperactivity disorder, with similar incidence of side effects."	( Osmotic, controlled-release methylphenidate for the treatment of ADHD. Coghill, D; Seth, S, 2006)	0.63
" The dosage of Concerta was adjusted by the investigators based on symptoms and safety assessments performed on a weekly basis."	( Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder. Cheong, S; Cho, IH; Choi, JW; Hong, SD; Kim, EJ; Kim, JH; Kim, SY; Lee, SI; Lim, TS; Oh, EY; Park, JH; Park, MK; Park, S, 2007)	0.62
" An automated, computerized, open-field activity monitoring system was used to study the dose-response characteristics of acute and repeated MPD administration throughout the 11-day experimental protocol."	( Acute and chronic methylphenidate dose-response assessment on three adolescent male rat strains. Dafny, N; Swann, AC; Yang, PB, 2006)	0.67
" Trial length, dosing schedule and efficacy assessment differed per physician."	( Use of double-blind placebo-controlled N-of-1 trials among stimulant-treated youths in The Netherlands: a descriptive study. de Jong-van den Berg, LT; Faber, A; Keizer, RJ; Tobi, H; van den Berg, PB, 2007)	0.34
" Overall distribution of CGI-I ratings at final visit was significantly better with each d-MPH-ER dosage than with placebo."	( Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Adler, LA; Jiang, H; McGough, JJ; Muniz, R; Pestreich, L; Spencer, TJ, 2007)	0.64
" The present study was designed to investigate the dose-response effects of MPD on sensory evoked potentials recorded from the PFC and CN in freely behaving rats previously implanted with permanent electrodes, as well as their behavioral (locomotor) activities."	( Chronic administration of methylphenidate produces neurophysiological and behavioral sensitization. Dafny, N; Swann, AC; Yang, PB, 2007)	0.64
"05), with significant linear dose-response relationships evident for both domains."	( Preliminary evidence of beneficial effects of methylphenidate on listening comprehension in children with attention-deficit/hyperactivity disorder. Bedard, AC; Hogg-Johnson, S; McInnes, A; Tannock, R, 2007)	0.6
"To determine if repeated dosing with methylphenidate hydrochloride (MPD) (Ritalin; Novartis Pharmaceuticals, East Hanover, NJ), an inhibitor of the dopamine transporter, would augment the effects of oral levodopa in patients with Parkinson disease."	( Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial. Carlson, NE; Carter, JH; Nutt, JG, 2007)	1
" Oral levodopa dosage was decreased as clinically feasible during the first 4 days in the GCRC during open-label administration of MPD and hourly monitoring of parkinsonism and vital signs between 7 am and 8 pm."	( Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial. Carlson, NE; Carter, JH; Nutt, JG, 2007)	0.73
" These data suggest additional studies should be performed to characterize age-related differences in PK properties of MPH that may inform practitioners about dosing strategies based on the age and size of children being treated."	( Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder. Greenhill, L; Gupta, S; Kapelinski, A; Lerner, M; Martinez, J; Modi, NB; Posner, K; Stehli, A; Steinhoff, K; Swanson, J; Wigal, SB; Wigal, T, 2007)	0.66
" However there are gender specific drug differences in behavioral performance and sensitivity to treatment with MPH that may have implications for treatment efficacy and dosing clinically after TBI."	( Gender associations with chronic methylphenidate treatment and behavioral performance following experimental traumatic brain injury. Dixon, CE; Kline, AE; Ren, D; Wagner, AK; Wenger, MK; Willard, LA; Zafonte, RD, 2007)	0.62
" Patients were treated with a gradually increasing dosage of a psychostimulant over two weeks, followed by a similar two-week period of gradually diminishing dosage."	( Methylphenidate effect on hemispheric attentional imbalance in patients with traumatic brain injury: a psychophysical study. Groswasser, Z; Hochstein, S; Keren, O; Mordvinov, E; Pavlovskaya, M, 2007)	1.78
" These issues include: (1) sequencing and dosage of treatments being combined and compared; (2) difficulty drawing valid conclusions about individual components of treatment when treatment packages are employed; (3) differing results emerging from measurement tools that purportedly measure the same domain; and (4) the resultant difficulty in reaching a summary conclusion when multiple outcome measures yielding conflicting results are used."	( Multimodal treatments for childhood attention-deficit/hyperactivity disorder: interpreting outcomes in the context of study designs. Hoza, B; Hurt, E; Kaiser, NM, 2007)	0.34
" Regarding a minimum requirement of 5 days weekly dosage and drug holidays, cases that took more than 70% of the recommended methylphenidate dose at the end of the first year were described as compliant."	( [Sociodemographic and clinical factors associated with compliance to methylphenidate treatment in children with attention deficit hyperactivity disorder]. Aysev, A; Bilgiç, A; Gürkan, K; Kiliç, BG, 2007)	0.78
" Data available from prescriptions and analyzed were: age, sex and place of residence of the patient, dosage prescribed, date of prescription, place of practice and medical specialization of doctors."	( [Hyperactivity and prescription of Ritalin in the canton of Vaud (Switzerland), 2002]. Dubois-Arber, F; Huissoud, T; Jeannin, A, 2007)	0.34
" Dosage complies with the recommendations of the Swiss Medic Compendium."	( [Hyperactivity and prescription of Ritalin in the canton of Vaud (Switzerland), 2002]. Dubois-Arber, F; Huissoud, T; Jeannin, A, 2007)	0.34
" Subjects were randomly assigned to receive one of six possible dosing orders."	( Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. Calabrese, JR; Demeter, CA; Findling, RL; Gracious, BL; Manos, MJ; McNamara, NK; Short, EJ; Stansbrey, RJ; Whipkey, R, 2007)	1.78
" Increased locomotor activity and cage biting/chewing occurred at > or =5 mpkd (females) and > or =50 mpkd (males) and were absent after dosing ceased."	( Juvenile toxicity assessment of d,l-methylphenidate in rats. Beckman, DA; Schneider, M; Tse, FL; Youreneff, M, 2008)	0.62
"Given that poor adherence to medication may be an important reason for suboptimal outcome in ADHD treatment, physicians should ensure adherence with therapy before adjusting dosage or switching medication."	( National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. Chang, HL; Chen, SJ; Cheng, H; Chou, MC; Chou, WJ; Gau, SS; Hsu, YC; Huang, YF; Huang, YS; Liang, HY; Lu, HH; Tang, CS; Tzang, RF; Wu, YY, 2008)	0.59
"In these healthy young subjects, MLR methylphenidate was associated with a concentration-time profile that resulted in a higher proportion of the administered methylphenidate dose being delivered in the first 4 hours after dosing compared with OROS methylphenidate while maintaining comparable levels of drug in the latter portion of the dosing interval."	( Comparative bioavailability of single-dose methylphenidate from a multilayer-release bead formulation and an osmotic system: a two-way crossover study in healthy young adults. Donnelly, GA; Michalko, K; Reiz, JL, 2008)	0.88
" The methylphenidate transdermal system (MTS) is the first stimulant patch dosage formulation to be approved by the US Food and Drug Administration for the treatment of the symptoms of ADHD in children aged 6 to 12 years."	( Practical management of cutaneous reactions to the methylphenidate transdermal system: recommendations from a dermatology expert panel consensus meeting. Fowler, JF; Paller, AS; Warshaw, EM; Zirwas, MJ, 2008)	1.11
" There was no significant relationship between dosage and severity or frequency of sleep problems."	( Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. Arnold, LE; Bukstein, OG; Faraone, SV; Findling, RL; Glatt, SJ; Lopez, FA, 2009)	0.62
"4 mg/kg, aripiprazole decreased rates of cocaine self-administration without shifting the peak of the dose-response function."	( Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice. Brennum, LT; Fink-Jensen, A; Hee Bengtsen, C; Petersen, JH; Sager, TN; Sørensen, G; Thomsen, M; Thøgersen, P; Woldbye, DP; Wörtwein, G, 2008)	0.35
" Therefore, we dosed subjects with methylphenidate at 1 or 3 mg/kg/day via gastric intubation from postnatal day 22 to 59 and assessed the effects of the drug on performance on the radial arm maze each day."	( Methylphenidate improves performance on the radial arm maze in periadolescent rats. Dow-Edwards, DL; Hellmann, E; Weedon, JC, )	1.85
" The disadvantages of such formulations include the need for multiple daily dosing and a potential for abuse."	( Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review. Findling, RL, 2008)	0.35
"Currently available treatments for ADHD in children are efficacious and well tolerated, but many of them are limited by the requirement for multiple daily dosing and abuse potential."	( Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review. Findling, RL, 2008)	0.35
" The relationship between dosage and effect size was explored by weighted regression analysis."	( Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. Becker, T; Fegert, JM; Kilian, R; Koesters, M; Weinmann, S, 2009)	0.66
" Staggered, double blind dosing was used to examine eating and smoking behavior during the peak effects of varenicline and methylphenidate."	( The influence of acute varenicline administration on smoking and eating behavior in humans. Glaser, PE; Rush, CR; Stoops, WW; Vansickel, AR, 2008)	0.55
" This study compared the cognitive consequences following chronic treatment with two doses (5 and 10 mg/kg) of methylphenidate on recognition and spatial memory in adult male Long-Evans rats using an established oral dosing procedure."	( Chronic oral methylphenidate induces post-treatment impairment in recognition and spatial memory in adult rats. LeBlanc-Duchin, D; Taukulis, HK, 2009)	0.93
"The studies presented in this work were designed to evaluate the genetic toxicity of methylphenidate hydrochloride (MPH) in non-human primates (NHP) using a long-term, chronic dosing regimen."	( The genetic toxicology of methylphenidate hydrochloride in non-human primates. Bishop, ME; Chen, JJ; Dobrovolsky, VN; Doerge, DR; Hotchkiss, CE; Lin, CJ; Manjanatha, MG; Mattison, DR; Mittelstaedt, RA; Morris, SM; Paule, MG; Petibone, D; Shaddock, JG; Shelton, SD; Slikker, W; Tucker, JD; Twaddle, NC, 2009)	0.88
" The dose-response protocol of MPD (0."	( Methylphenidate treated at the test cage--dose-dependent sensitization or tolerance depend on the behavioral assay used. Dafny, N; Swann, AC; Yang, PB, 2007)	1.78
"Following a 5-week, randomized, controlled, fixed-dose study of d-MPH-ER 20 to 40 mg/d, 170 adults entered a 6-month open-label extension (OLE) to assess long-term safety, with flexible dosing of 20 to 40 mg/d."	( Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD. Adler, LA; Jiang, H; McGough, JJ; Muniz, R; Spencer, T, 2009)	0.62
"To evaluate stimulant dosing patterns in the community treatment of children with attention-deficit/hyperactivity disorder (ADHD)."	( Stimulant dosing for children with ADHD: a medical claims analysis. Marcus, S; Olfson, M; Wan, G, 2009)	0.35
"Among children with ADHD who continue stimulants through the first 3 months of treatment, dosing in the community treatment of ADHD tends to be lower than doses used in clinical trials."	( Stimulant dosing for children with ADHD: a medical claims analysis. Marcus, S; Olfson, M; Wan, G, 2009)	0.35
" Medication dosing was flexible, with titration to a maximum of 30 mg/day."	( The open-label treatment of attention-deficit/hyperactivity disorder in 4- and 5-year-old children with beaded methylphenidate. Fried, J; Greenhill, L; Gugga, SS; Maayan, L; Paykina, N; Strauss, T, 2009)	0.56
"To review recent literature on the different stimulant preparations regarding efficacy and safety in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) and describe advantages and disadvantages of the many available dosage formulations."	( An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder. Angstadt, K; Bogart, GT; Chavez, B; Ehret, MJ; Goldberg, KR; Paulino, RE; Sopko, MA, 2009)	0.35
" Daytrana gives patients more control over their dosing by being able to choose when the patch is removed; it is also a feasible alternative for children who cannot swallow pills."	( An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder. Angstadt, K; Bogart, GT; Chavez, B; Ehret, MJ; Goldberg, KR; Paulino, RE; Sopko, MA, 2009)	0.35
" The multiple available dosage forms allow for individualization of treatment."	( An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder. Angstadt, K; Bogart, GT; Chavez, B; Ehret, MJ; Goldberg, KR; Paulino, RE; Sopko, MA, 2009)	0.35
" Additional population-based studies that address manifestation of serious heart disease, especially after long-term use, dosage comparisons, and interactions with preexisting cardiac risk factors are needed to inform psychiatric treatment decisions."	( Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Gerhard, T; Saidi, A; Shuster, J; Winterstein, AG, 2009)	0.69
" All 3 reports had identical dosing schedules and symptom assessments."	( Methylphenidate side effects in advanced cancer: a retrospective analysis. Davis, MP; Khoshknabi, DS; Lasheen, W; Mahmoud, F; Rivera, N; Walsh, D, 2010)	1.8
"Children (ages 6-18 years) with ADHD were recruited for a prospective 12-week, open-labeled, multicenter study to examine optimal dosage of OROS methylphenidate."	( Variability of response time as a predictor of methylphenidate treatment response in korean children with attention deficit hyperactivity disorder. Cheon, KA; Ha, EH; Joung, YS; Kim, BN; Lee, SH; Shin, DW; Shin, YJ; Song, DH; Yoo, HJ, 2009)	0.81
" Children whose aggressive behavior persisted at the conclusion of the lead-in phase were randomly assigned to receive double-blind, flexibly dosed divalproex or a placebo adjunctive to stimulant for 8 weeks."	( Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. Blader, JC; Jensen, PS; Kafantaris, V; Pliszka, SR; Schooler, NR, 2009)	0.35
"All dosed subjects finished both treatment periods and were included in pharmacokinetic and safety analyses."	( Lack of bioequivalence between two methylphenidate extended modified release formulations in healthy volunteers. Ammer, R; Fischer, R; Grossmann, M; Leis, HJ; Mazur, D; Schütz, H, 2009)	0.63
" MPH was administered in a dosage of 1 mg/kg body weight, maximum 60 mg."	( Modulation of motorcortical excitability by methylphenidate in adult voluntary test persons performing a go/nogo task. Buchmann, J; Dueck, A; Gierow, W; Haessler, F; Heinicke, S; Heinrich, H; Hoeppner, J; Klauer, T; Reis, O; Zamorski, H, 2010)	0.62
" Larger studies with higher doses combined with individual dosage and longer follow-up periods are warranted."	( Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Beck, O; Franck, J; Jayaram-Lindström, N; Konstenius, M, 2010)	0.69
" Dexmethylphenidate XR is a stimulant treatment in a single isomer form, and has an efficacy and tolerability similar to two doses of immediate-release (IR) dexmethylphenidate when taken 4 hours apart, but is dosed at half of the usual d,l-methylphenidate dose."	( Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. Kratochvil, CJ; May, DE, 2010)	0.92
"This study compared the methylphenidate (MPH) dose-response profiles of children with the Predominantly Inattentive (PI) and Combined (CB) subtypes of attention-deficit/hyperactivity disorder (ADHD)."	( Stimulant drug response in the predominantly inattentive and combined subtypes of attention-deficit/hyperactivity disorder. Gilbert, S; Ivanov, I; Lara, R; Newcorn, J; Solanto, M; Vail, L, 2009)	0.66
") dosage regimens of immediate-release MPH, administered in random order."	( Stimulant drug response in the predominantly inattentive and combined subtypes of attention-deficit/hyperactivity disorder. Gilbert, S; Ivanov, I; Lara, R; Newcorn, J; Solanto, M; Vail, L, 2009)	0.35
"5 hours after dosing), but not, by and large, immediately after dosing or in the evening."	( Measuring methylphenidate response in attention-deficit/hyperactvity disorder: how are laboratory classroom-based measures related to parent ratings? Coghill, D; DeBacker, M; Sonuga-Barke, EJ; Swanson, J, 2009)	0.76
" Unfortunately, results of current ADHD pharmacogenetic studies have not been entirely consistent, possibly due to differences in study design, medication dosing regimens and outcome measures."	( Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. Froehlich, TE; McGough, JJ; Stein, MA, 2010)	0.36
"Pharmacological treatment for attention deficit hyperactivity disorder, although highly effective, presents a marked variability in clinical response, optimal dosage needed and tolerability."	( A current update on ADHD pharmacogenomics. Genro, JP; Hutz, MH; Kieling, C; Rohde, LA, 2010)	0.36
"Modified-release products are complex dosage forms designed to release drug in a controlled manner to achieve desired efficacy and safety."	( Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified-release products: workshop summary report. Abrahamsson, B; Caro, J; Chen, ML; Conner, D; Davit, B; Fackler, P; Farrell, C; Ganes, D; Gupta, S; Katz, R; Mehta, M; Midha, KK; Nambiar, P; Preskorn, SH; Rocci, ML; Sanderink, G; Shah, VP; Stavchansky, S; Temple, R; Thombre, AG; Wang, Y; Winkle, H; Yu, L, 2010)	0.36
" Plasma level-dependent effects of psychostimulants can be modelled on an inverted U-shaped dose-response relationship, which is highly relevant to predict cognitive enhancing and detrimental effects of psychostimulants in patients with cognitive deficits (e."	( Effects of modafinil and methylphenidate on visual attention capacity: a TVA-based study. Baumann, F; Bublak, P; Dodds, CM; Finke, K; Manly, T; Müller, U; Regenthal, R, 2010)	0.66
" In conclusion, the tested dosage appears to be too low for clinical application in canines, and an increase in dosing is suggested."	( Pharmacokinetics of methylphenidate following two oral formulations (immediate and sustained release) in the dog. Giorgi, M; Lavy, E; Neri, D; Prise, U; Soldani, G, 2010)	0.68
" A total of 34 children with ADHD as defined by DSM-IV-TR were randomized to buspirone or methylphenidate dosed on weight-adjusted basis at buspirone (0."	( Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double-blind and randomized trial. Amini, H; Davari-Ashtiani, R; Mazhabdar, H; Razjouyan, K; Shahrbabaki, ME, 2010)	0.92
" Future studies should address the issue of the optimal therapeutic window and dosage of medications to identify those patients who would benefit most."	( Effect of methylphenidate and/or levodopa coupled with physiotherapy on functional and motor recovery after stroke--a randomized, double-blind, placebo-controlled trial. Delbari, A; Lokk, J; Salman Roghani, R, 2011)	0.77
" Attentional performance increased differentially as a function of MPH dose, with some tasks showing linear improvement with higher dosage whereas more complex tasks in particular showed inverse U-shaped patterns of MPH effects."	( Sex differences in attentional performance and their modulation by methylphenidate in children with attention-deficit/hyperactivity disorder. Günther, T; Herpertz-Dahlmann, B; Konrad, K, 2010)	0.6
"The aim of this study was to evaluate dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder (ADHD) treated with once-daily OROS methylphenidate (OROS MPH) during the 4-week, open-label, escalating dose-titration phase of a larger multisite, placebo-controlled trial."	( Dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder treated with OROS methylphenidate in a 4-week, open-label, dose-titration study. Cooper, KM; Newcorn, JH; Stein, MA, 2010)	0.77
"MLN8054 dosing for up to 14 days of a 28-day cycle was feasible."	( Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Burris, H; Cohen, RB; Danaee, H; Dees, EC; Ecsedy, J; Eton, O; Fingert, H; Galvin, K; Infante, JR; Jones, S; Lee, Y; Liu, H; Manfredi, M; O'Neil, BH; Stringer, B; von Mehren, M, 2011)	0.37
"This was a 1-month, multicenter, open-label, randomized study to determine single- and multiple-dose pharmacokinetics of d,l-methylphenidate (MPH) after MPH transdermal system (MTS) and osmotic-release oral system MPH (OROS MPH) dosing in children (6-12 years) and adolescents (13-17 years) who had a diagnosis of attention deficit hyperactivity disorder."	( Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. Buckwalter, M; Katic, A; Pierce, D; Webster, K, 2010)	0.83
" The mean daily dosage at phase 1 endpoint was 78."	( A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. Biederman, J; Doyle, R; Hammerness, P; Kotarski, M; Mick, E; Spencer, T; Surman, C, 2010)	0.58
"25), diagnosed with ADHD and treated with methylphenidate at a minimal dosage of 10 mg per day."	( Increased dental trauma in children with attention deficit hyperactivity disorder treated with methylphenidate--a pilot study. Brinsky-Rapoport, T; Katz-Sagi, H; Matot, I; Ram, D; Redlich, M, 2010)	0.84
"3%) of 65 children was reduced sufficiently after stimulant dosage adjustment and behavioral therapy to preclude adjunctive medication."	( Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD. Blader, JC; Jensen, PS; Kafantaris, V; Pliszka, SR; Schooler, NR, 2010)	0.36
"MPH and ATM generally produced inverted-U dose-response curves, with improvement occurring at moderate doses, but not at higher doses."	( Methylphenidate and atomoxetine enhance prefrontal function through α2-adrenergic and dopamine D1 receptors. Arnsten, AF; Gamo, NJ; Wang, M, 2010)	1.8
"To determine the single-dose pharmacokinetics of 60 mg NWP06, a novel extended-release (ER) liquid formulation of methylphenidate (MPH) compared with 30 mg immediate-release (IR) liquid MPH, dosed at Hours 0 and 6, in adults."	( The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. Berry, SA; Childress, AC, 2010)	0.81
"Attainment of a stable dosing regimen was defined as no change in type of drug (including a switch from an immediate release (IR) to a long-acting (LA) formulation), strength, and number of pills per day for five consecutive dispensings."	( Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands. Hodgkins, P; Meijer, W; Sasané, R, 2010)	0.36
" The proposed method was successfully applied to the analysis of rat plasma, where the rats were separately dosed with D2PM and MPH (Ritalin)."	( HPLC enantioseparation of α,α-diphenyl-2-pyrrolidinemethanol and methylphenidate using a chiral fluorescent derivatization reagent and its application to the analysis of rat plasma. Goda, Y; Higashi, T; Hirashima, H; Inagaki, S; Kikura-Hanajiri, R; Min, JZ; Taniguchi, S; Toyo'oka, T, 2010)	0.6
" The objective of the present study is to investigate the dose-response effects of repeated MPD administration (0."	( Age and genetic strain differences in response to chronic methylphenidate administration. Cuellar, DO; Dafny, N; Swann, AC; Yang, PB, 2011)	0.61
" Compared with WKY and WIS rats, SHRs with previous methylphenidate treatment acquired cocaine self-administration faster, identified cocaine as a highly efficacious reinforcer by displaying an upward shift in the cocaine dose-response function, and showed the greatest motivation to self-administer cocaine by exhibiting the highest progressive ratio breakpoints."	( Methylphenidate treatment in adolescent rats with an attention deficit/hyperactivity disorder phenotype: cocaine addiction vulnerability and dopamine transporter function. Deaciuc, A; Dwoskin, LP; Harvey, RC; Kantak, KM; Sen, S, 2011)	2.06
"5 mg/kg), and dose-response tests established appropriate reductions in discrimination with declining dose."	( The discriminative stimulus properties of methylphenidate in C57BL/6J mice. Griffin, WC; McGovern, RW; Middaugh, LD; Patrick, KS, 2011)	0.63
" Dosing began at 36 mg/d, with titration in 18-mg increments every 7 days until a predefined outcome (efficacy threshold, maximum dosage of 108 mg/d, or limiting adverse event)."	( Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study. Adler, LA; Berwaerts, J; Cooper, K; Harrison, DD; Orman, C; Palumbo, J; Silber, S; Starr, HL, 2011)	0.67
"OROS methylphenidate, in the flexible dosage range from 36 to 108 mg/d, was well tolerated for up to 1 year in adults with ADHD."	( Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study. Adler, LA; Berwaerts, J; Cooper, K; Harrison, DD; Orman, C; Palumbo, J; Silber, S; Starr, HL, 2011)	1.19
" Specifically, we asked: (1) will ethanol increase d-MPH biological concentrations, (2) will MTS facilitate the systemic bioavailability of l-MPH, and (3) will l-MPH enantioselectively interact with ethanol to yield l-ethylphenidate (l-EPH)? Mice were dosed with MTS (¼ of a 12."	( Transdermal and oral dl-methylphenidate-ethanol interactions in C57BL/6J mice: transesterification to ethylphenidate and elevation of d-methylphenidate concentrations. Bell, GH; Griffin, WC; Novak, AJ; Patrick, KS, 2011)	0.68
" After determining individualized OROS MPH dosing (18-54 mg/day), 71 subjects received blinded treatment (OROS MPH or placebo then vice versa) on each of 2 laboratory school days, separated by 1 week."	( Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder. Armstrong, RB; Brams, M; Schuck, S; Starr, HL; Wigal, SB; Wigal, T; Williamson, D, 2011)	0.62
"OROS MPH dosed to reduce core symptoms of ADHD to within the normal range also improved performance on a variety of academic tasks in school-aged children compared to placebo."	( Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder. Armstrong, RB; Brams, M; Schuck, S; Starr, HL; Wigal, SB; Wigal, T; Williamson, D, 2011)	0.62
" During the treatment period the investigators titrated the OROS-MPH dosage on the basis of symptom severity and side effects."	( Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment. Bellgrove, MA; Cho, SC; Cummins, TD; Kim, BN; Kim, JW, 2012)	0.58
"To examine the pharmacokinetics (PKs) and pharmacodynamics (PDs) of OROS methylphenidate (OROS MPH) dosed once daily (QD) versus an early standard regimen (immediate-release [IR] MPH dosed three times daily [TID]) under various breakfast conditions."	( Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder. Gupta, S; Heverin, E; Starr, HL; Wigal, SB, 2011)	0.86
" Patients were assigned to 1 of 3 dosage levels (OROS MPH 18, 36, and 54 mg QD, and an assumed equivalent regimen of IR MPH 5, 10, and 15 mg given TID) based on their prestudy established clinical dose of IR MPH."	( Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder. Gupta, S; Heverin, E; Starr, HL; Wigal, SB, 2011)	0.62
" Future studies are needed which determine the optimal therapeutic window for and dosage of psychostimulants as well as identify those stroke patients who might benefit the most from treatment."	( Effect of methylphenidate and/or levodopa combined with physiotherapy on mood and cognition after stroke: a randomized, double-blind, placebo-controlled trial. Delbari, A; Lokk, J; Salman-Roghani, R, 2011)	0.77
" Recently a transdermal delivery system has been developed which can allow symptom control all day long but with greater dosing flexibility."	( Methylphenidate delivery mechanisms for the treatment of children with attention deficit hyperactivity disorder: heterogeneity in parent preferences. Dewilde, S; Falconer, S; Hodgkins, P; Lloyd, A; Sasané, R; Sonuga Barke, E, 2011)	1.81
" At each daily visit, signs and symptoms were assessed, and medications and dosing instructions were given for the following 24 hours."	( A nonopioid procedure for outpatient opioid detoxification. Baier, AR; Coons, EE; Fingesten, A; Ockert, DM; Volpicelli, JR, 2011)	0.37
" Further, exploratory analyses on teacher and parent ratings on attention-deficit/hyperactivity disorder and on externalizing symptoms during the day revealed no evidence for the superiority of Concerta over Medikinet retard in an equivalent daily dosage throughout the day."	( Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention-deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet(®) retard and Concerta(®)--a Ammer, R; Döpfner, M; Fischer, R; Ose, C; Scherag, A, 2011)	0.61
" The open field assay was used to assess the dose-response of acute and chronic MPD administration."	( Sex differences in the behavioral response to methylphenidate in three adolescent rat strains (WKY, SHR, SD). Chelaru, MI; Dafny, N; Yang, PB, 2012)	0.64
" Limited observations suggest a potentially different dose-sensitivity of prefrontal cortex (PFC)-dependent function (narrow inverted-U-shaped dose-response curves) versus classroom/overt behavior (broad inverted U) in children with ADHD."	( Differential sensitivity to psychostimulants across prefrontal cognitive tasks: differential involvement of noradrenergic α₁ - and α₂-receptors. Andrzejewski, ME; Berridge, CW; Devilbiss, DM; McGaughy, JA; Shumsky, JS; Spencer, RC; Waterhouse, BD, 2012)	0.38
" Choice of therapy is increasingly influenced by treatment satisfaction and patient preference, with once-daily modified-release methylphenidate (MPH-MR) formulations offering clear benefits compared with immediate-release (IR) dosage forms."	( An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence. Becker, A; Breuer, D; Döpfner, M; Rothenberger, A, 2011)	0.82
"Locomotor activity of C57BL/6J mice was recorded for 3 h following dosing with either oral DL-methylphenidate (7."	( Oral and transdermal DL-methylphenidate-ethanol interactions in C57BL/6J mice: potentiation of locomotor activity with oral delivery. Bell, GH; Griffin, WC; Patrick, KS, 2011)	0.9
" A dose-response study was performed to test for methylphenidate-induced restoration of righting during continuous isoflurane general anesthesia."	( Methylphenidate actively induces emergence from general anesthesia. Brown, EN; Chemali, JJ; Cimenser, A; Cotten, JF; Solt, K; Wong, KF, 2011)	2.07
" Patients were followed for 1 year for dosage change, switch (change to non-MPH treatment), augmentation, persistence (number days on index medication) and adherence (days supplied/days persistent)."	( Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population. Christensen, L; Harley, C; Hodgkins, P; Liu, F; Sasané, R, 2011)	0.68
"4% had a dosing change, 14% switched to a non-MPH agent, and 4% augmented MPH therapy."	( Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population. Christensen, L; Harley, C; Hodgkins, P; Liu, F; Sasané, R, 2011)	0.68
" Parents and teachers assessed each child's response on placebo and three MPH dosage levels using the Vanderbilt ADHD rating scales."	( Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder. Brinkman, WB; Epstein, JN; Froehlich, TE; Graham, AJ; Kahn, RS; Langberg, JM; Melguizo Castro, MS; Nick, TG; Stein, MA, 2011)	0.66
"5 hr before dosing and 1, 2, 4, 10, 11, and 12."	( Time course of treatment effect of OROS® methylphenidate in children with ADHD. Armstrong, RB; Ascher, S; Damaraju, CV; O'Neill, J; Schwarzman, L; Starr, HL, 2012)	0.64
"OROS-MPH treatment at the adequate dosage can achieve higher remission and recovery rates, produce greater functional improvement, and result in better treatment adherence than IR-MPH treatment."	( Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit-hyperactivity disorder. Chang, HL; Cheng, H; Hsu, CD; Hsu, YC; Huang, CF; Huang, YF; Huang, YH; Huang, YS; Liang, HY; Liu, HC; Liu, HJ; Liu, SI; Pan, CH; Tzang, RF; Wang, YC; Wu, YY; Yang, PC; Yeh, CB, 2012)	0.61
" However, repeat dosing has not been examined."	( Importance of pharmacokinetic profile and timing of coadministration of short- and long-acting formulations of methylphenidate on patterns of subjective responses and abuse potential. Batchelder, H; Biederman, J; Clarke, A; Faraone, SV; Martin, JM; Mirto, T; Moorehead, TM; Spencer, TJ, 2012)	0.59
" Such knowledge provides important information for clinicians about the safety and tolerability of the timing of repeat dosing of various permutations of coadministration of MPH formulations."	( Importance of pharmacokinetic profile and timing of coadministration of short- and long-acting formulations of methylphenidate on patterns of subjective responses and abuse potential. Batchelder, H; Biederman, J; Clarke, A; Faraone, SV; Martin, JM; Mirto, T; Moorehead, TM; Spencer, TJ, 2012)	0.59
" Dosage was inversely associated with risk."	( Methylphenidate and risk of serious cardiovascular events in adults. Bilker, WB; Cziraky, MJ; Daniel, GW; Guevara, JP; Hennessy, S; Kimmel, SE; Newcomb, C; Schelleman, H; Strom, BL, 2012)	1.82
"8-fold increase in risk of sudden death or ventricular arrhythmia, the lack of a dose-response relationship suggests that this association may not be a causal one."	( Methylphenidate and risk of serious cardiovascular events in adults. Bilker, WB; Cziraky, MJ; Daniel, GW; Guevara, JP; Hennessy, S; Kimmel, SE; Newcomb, C; Schelleman, H; Strom, BL, 2012)	1.82
" This dosage of MPH also induced a significant increase in the number of activated microglia in the SNpc."	( Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. Jiao, Y; Pani, AK; Pond, BB; Qu, C; Sadasivan, S; Smeyne, RJ, 2012)	1.82
" We have not found examples of ADHD in children who use increased dosage of sustained release of methylphenidate leading to depressive symptomatology."	( Depressive symptoms as a side effect of the sustained release form of methylphenidate in a 7-year-old boy with attention-deficit hyperactivity disorder. Lakić, A, 2012)	0.83
" The two lower dosages showed a good tolerability profile, but the higher dosage of bavisant was less well tolerated, as evidenced by the incidence of total TEAEs (61."	( Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. Cooper, K; Daly, EJ; Gassmann-Mayer, C; Pandina, GJ; Weisler, RH, 2012)	0.38
" Clinicians should carefully follow patients' improvements and titrate the MPH dosage during long-term treatment."	( No beneficial effects of adding parent training to methylphenidate treatment for ADHD + ODD/CD children: a 1-year prospective follow-up study. Ardic, UA; Durak, S; Ercan, ES; Kutlu, A, 2014)	0.65
"The purpose of this study was to identify the optimal dose of osmotic release oral system methylphenidate (OROS-MPH) using a dosage forced-titration scheme to achieve symptomatic remission in children with attention- deficit/hyperactivity disorder (ADHD)."	( Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate. Chan, CH; Chang, HL; Chen, SJ; Chen, YS; Chou, MC; Chou, WJ; Hou, PH; Hsu, JW; Huang, CF; Huang, YF; Huang, YS; Hwang, KL; Liang, HY; Lin, CC; Lin, DY; Liu, HJ; Pan, CH; Tang, CS; Wu, YY; Yeh, CB, 2012)	0.79
" Determinants for remission included less severe ADHD symptoms (SNAP-IV score < 40), no family history of ADHD, and an appropriate dosage of medication according to the patient's weight."	( Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate. Chan, CH; Chang, HL; Chen, SJ; Chen, YS; Chou, MC; Chou, WJ; Hou, PH; Hsu, JW; Huang, CF; Huang, YF; Huang, YS; Hwang, KL; Liang, HY; Lin, CC; Lin, DY; Liu, HJ; Pan, CH; Tang, CS; Wu, YY; Yeh, CB, 2012)	0.57
"The findings suggest remission as a treatment goal for ADHD therapy by providing an optimal dosage of medication for children and adolescents with ADHD through using an effective and tolerable forced-titration scheme."	( Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate. Chan, CH; Chang, HL; Chen, SJ; Chen, YS; Chou, MC; Chou, WJ; Hou, PH; Hsu, JW; Huang, CF; Huang, YF; Huang, YS; Hwang, KL; Liang, HY; Lin, CC; Lin, DY; Liu, HJ; Pan, CH; Tang, CS; Wu, YY; Yeh, CB, 2012)	0.57
" We report a case of a prepubertal child who developed unwanted erections after commencing a response-adjusted dosing regimen of sustained release methylphenidate."	( Methylphenidate-induced erections in a prepubertal child. Brady, CM; Kelly, BD; Lundon, DJ; McGuinness, D, 2013)	2.03
" Previous research has suggested stimulants are less effective than in typically developing children but no studies have titrated medication for individual optimal dosing or tested the effects for longer than 4 weeks."	( Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. Baird, G; Bernard, S; Chadwick, O; Golaszewski, A; Jichi, F; Kelly, J; Kennedy, J; Liang, H; Riemer, K; Rodney, L; Sharma, K; Sharma, SP; Simonoff, E; Taylor, E; Walwyn, R; West, N; Whitwell, S; Wood, N, 2013)	0.64
"Optimal dosing of methylphenidate is practical and effective in some children with hyperkinetic disorder and intellectual disability."	( Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. Baird, G; Bernard, S; Chadwick, O; Golaszewski, A; Jichi, F; Kelly, J; Kennedy, J; Liang, H; Riemer, K; Rodney, L; Sharma, K; Sharma, SP; Simonoff, E; Taylor, E; Walwyn, R; West, N; Whitwell, S; Wood, N, 2013)	0.97
" In seeking to optimize individual response and outcomes to stimulant therapy, important considerations include the selection of stimulant class, the choice of long- or short-acting stimulant formulations, addressing effectively any emergent adverse effects and strategies aimed at enhancing adherence to dosing regimen and persistence on therapy."	( Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Coghill, D; Hechtman, L; Hodgkins, P; Shaw, M, 2012)	0.73
" The LC-MS/MS assay was validated for entomotoxicological use and initially applied to male Sprague-Dawley rats (n=6) that were dosed with MPH (20mg/kg) ante-mortem."	( Determination of methylphenidate in Calliphorid larvae by liquid-liquid extraction and liquid chromatography mass spectrometry--forensic entomotoxicology using an in vivo rat brain model. Bushby, SK; Coulter, CV; Kieser, JA; Priemel, PA; Rades, T; Thomas, N, 2012)	0.72
" This review provides an overview of current understanding of MPH efficacy, safety, and dosage in adult and pediatric ADHD patients, as well as adult animal studies and pioneering studies in juvenile animals treated with MPH."	( Evolution of the Study of Methylphenidate and Its Actions on the Adult Versus Juvenile Brain. Gao, WJ; Urban, KR, 2015)	0.72
" The CEPAC members and clinical experts recommended the increased use of parent behavior training as first-line therapy for preschoolers and emphasized the importance of proper monitoring of and dosing for all children who receive medication for their ADHD symptoms."	( Management strategies for attention-deficit/hyperactivity disorder: a regional deliberation on the evidence. Colby, JA; Emond, SK; Ollendorf, DA; Pearson, SD; Reed, SJ, 2012)	0.38
" Furthermore, since a single dosage resulted in significant changes in NMDA receptors, off-label usage by healthy individuals, especially children and adolescents, may result in altered potential for plastic learning."	( Treatment with a clinically-relevant dose of methylphenidate alters NMDA receptor composition and synaptic plasticity in the juvenile rat prefrontal cortex. Gao, WJ; Li, YC; Urban, KR, 2013)	0.65
" Additional studies are needed to further investigate these findings and examine short-versus long-acting stimulant medications and dosage effects."	( Caregiver survey of pharmacotherapy to treat attention deficit/hyperactivity disorder in individuals with Williams syndrome. Andridge, RR; Coury, DL; Foster, JE; Martens, MA; McClure, KE; Seyfer, DL, 2013)	0.39
" The doses identified as best doses from two nicotine dose-response curve determinations were unrelated, and the improvement associated with the best dose observed during the first dose-response curve determination was not reliable when the dose was administered repeatedly."	( A critical examination of best dose analysis for determining cognitive-enhancing potential of drugs: studies with rhesus monkeys and computer simulations. Ator, NA; Dallery, J; Katz, BR; Soto, PL, 2013)	0.39
") dose-response curves were determined, self-administration sessions were suspended and MPD (0."	( Effects of chronic methylphenidate on cocaine self-administration under a progressive-ratio schedule of reinforcement in rhesus monkeys. Czoty, PW; Gould, RW; Martelle, SE; Nader, MA, 2013)	0.72
"In the author's opinion, Concerta, Equasym XL/Metadate CD, Medikinet Retard and Ritalin LA offer the convenience of once-daily administration with absorption characteristics resembling two or three times daily dosing with IR MPH preparations."	( Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate. Maldonado, R, 2013)	0.61
"To psychometrically assess cognitive domains in adolescents with ADHD during long-term open treatment with robust dosing of extended-release methylphenidate (OROS MPH)."	( Assessment of cognitive domains during treatment with OROS methylphenidate in adolescents with ADHD. Biederman, J; Fried, R; Hammerness, P; Meller, B; Petty, C, 2014)	0.85
" The former, on sale without prescription, presents a varied symptomatology, dosage and dependent metabolic action, ranging from euphoria to hallucinations."	( [Emergent drugs (II): the Pharming phenomenon]. Aldea-Perona, A; Burillo-Putze, G; Climent, B; Dueñas, A; García-Sáiz, MM; Hoffman, RS; Munné, P; Nogué, S; Rodríguez-Jiménez, C, )	0.13
" To evaluate the efficacy of LDX throughout the day, symptoms and behaviors of ADHD were evaluated using an abbreviated version of the Conners' Parent Rating Scale-Revised (CPRS-R) at 1000, 1400 and 1800 hours following early morning dosing (0700 hours)."	( Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial. Banaschewski, T; Bloomfield, R; Civil, R; Coghill, DR; Dittmann, RW; Lecendreux, M; Otero, IH; Squires, LA; Zuddas, A, 2014)	0.4
" ADHD and associated psychiatric symptoms, medication status and dosage frequency, treatment adherence and adverse events were assessed at baseline and after a median treatment length with Medikinet(®) retard of 70 days."	( A non-interventional study of extended-release methylphenidate in the routine treatment of adolescents with ADHD: effectiveness, safety and adherence to treatment. Döpfner, M; Fischer, R; Ose, C; Sobanski, E, 2013)	0.65
"Clinical pharmacology as an interdisciplinary science is unique in its capacity and the diversity of the methods and approaches it can provide to derive dosing recommendations in various subpopulations."	( An integrated clinical pharmacology approach for deriving dosing recommendations in a regulatory setting: review of recent cases in psychiatry drugs. Mehta, MU; Rogers, H; Uppoor, RS; Younis, IR; Zhang, H; Zhu, H, 2013)	0.39
" The objective of this study was to investigate the repetitive dose-response effects of MPD on circadian rhythm of locomotor activity pattern of female WKY rats."	( Adult female rats' altered diurnal locomotor activity pattern following chronic methylphenidate treatment. Burau, KD; Dafny, N; Kohllepel, SR; Trinh, TN; Yang, PB, 2013)	0.62
" Because of its short duration of effect, MPH-IR had to be dosed multiple times daily."	( The use of methylphenidate hydrochloride extended-release oral suspension for the treatment of ADHD. Childress, A; Sallee, FR, 2013)	0.78
" Owing to the short half-life and the issues associated with multiple daily dosing of immediate-release MPH formulations, a new generation of long-acting MPH formulations has emerged."	( Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. Banaschewski, T; Coghill, D; Doepfner, M; Gagliano, A; Pelaz, A; Zuddas, A, 2013)	0.77
" Recent studies have suggested that early life exposure of healthy rodent models to methylphenidate resulted in altered sleep/wake cycle, heightened stress reactivity, and, in fact, a dosage previously thought of as therapeutic depressed neuronal function in juvenile rats."	( Methylphenidate and the juvenile brain: enhancement of attention at the expense of cortical plasticity? Gao, WJ; Urban, KR, 2013)	2.06
"At baseline and at weeks 4 and 8, the parents evaluated their children, who were receiving treatment with osmotic-release oral system methylphenidate (mean dosage 36."	( Parental quality of life and depressive mood following methylphenidate treatment of children with attention-deficit hyperactivity disorder. Chang, JS; Cho, SC; Hwang, JW; Kim, B; Kim, BN; Kim, Y, 2014)	0.85
" To evaluate whether the dose-response relationship follows an inverted-U-shaped curve, MPH effects on cognition are also quantified for low, medium and high doses, respectively."	( Cognitive effects of methylphenidate in healthy volunteers: a review of single dose studies. Linssen, AM; Riedel, WJ; Sambeth, A; Vuurman, EF, 2014)	0.72
" Whereas there was a linear dose-response curve for medication in NBM, the dose-response curves flattened considerably in LBM and HBM."	( A dose-ranging study of behavioral and pharmacological treatment in social settings for children with ADHD. Burrows-MacLean, L; Chacko, A; Coles, EK; Fabiano, GA; Garefino, A; Gnagy, EM; Hoffman, MT; Pelham, WE; Walker, KS; Waschbusch, DA; Waxmonsky, JG; Wymbs, BT; Wymbs, F, 2014)	0.4
"5, 5 or 10mg/kg for its physical dependence potential in a repeated dose non-precipitated withdrawal test, for its drug profiling in a drug discrimination learning procedure (single escalating doses), and for its reinforcing properties in a conditioned place preference test (alternate dosing days) and an intravenous self-administration procedure (0."	( Abuse liability assessment in preclinical drug development: predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models. Geuens, SM; Geys, HM; Meert, TF; Stinissen, P; Teuns, GB, )	0.33
"Cessation of subchronic dosing up to 10mg/kg methylphenidate led to sustained or even exacerbated effects on locomotion and behavior, body temperature, body weight, food consumption, and alteration of the diurnal rhythm during withdrawal."	( Abuse liability assessment in preclinical drug development: predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models. Geuens, SM; Geys, HM; Meert, TF; Stinissen, P; Teuns, GB, )	0.59
"These findings may help clinicians assess factors upon initiation of ADHD treatment to improve course prediction, proper dosing and treatment adherence and persistence."	( Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates. Altin, M; Desaiah, D; El-Shafei, A; Faries, D; Feng, Q; Gado, M; Serebryakova, E; Treuer, T; Wu, S, 2014)	0.64
" After changing the dosage of methylphenidate and additionally using dog appeasing pheromone, the behavior of the bitch became normal after 8 days."	( [Methylphenidate use in dogs with attention deficit hyperactivity disorder (ADHD). A case report of a Weimaraner bitch]. Piturru, P, 2014)	1.6
" Specifically, while methylphenidate at this dosage enhances connectivity to the motor cortex and memory circuits, it dampens prefrontal cortical connectivity perhaps by increasing catecholaminergic signalling past the 'optimal' level."	( The effects of methylphenidate on resting-state striatal, thalamic and global functional connectivity in healthy adults. Abdelghany, O; Farr, OM; Hu, S; Li, CS; Malison, RT; Matuskey, D; Zhang, S, 2014)	1.07
" Considerable clinical expertise is required to identify an individually well-adapted dosage which will produce the optimal clinical effects with potential side effects minimized."	( An evaluation of the pharmacokinetics of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder. Banaschewski, T; Döpfner, M; Frölich, J; Görtz-Dorten, A, 2014)	0.67
" Comparing the acute MPD effect to the repetitive MPD effect revealed that the acute response to MPD exhibited dose-response characteristics: an increase in behavioral activity correlated with increasing MPD doses."	( Behavioral and neuronal recording of the nucleus accumbens in adolescent rats following acute and repetitive exposure to methylphenidate. Dafny, N; Frolov, A; Reyes-Vasquez, C, 2015)	0.62
" In the present study, we used a regimen of MPH (8 mg/kg daily×14 days) in C57BL/6J mice to determine whether establishing locomotor sensitization to MPH influenced the acquisition and the dose-response function of MPH in a classic drug discrimination procedure."	( Influence of sensitization on the discriminative stimulus effects of methylphenidate in mice. Griffin, WC; Knecht, K; Luderman, L; McGovern, R, 2014)	0.64
" Patterns of medication selection and dosing were compared with CMAP guidelines."	( Treatment receipt and outcomes from a clinic employing the attention-deficit/hyperactivity disorder treatment guideline of the children's medication algorithm project. McLennan, JD; Vallerand, IA; Wagner, DJ, 2014)	0.4
" Eligibility and dosing were determined by the physician based on the drug label."	( Effectiveness and safety of a long-acting, once-daily, two-phase release formulation of methylphenidate (Ritalin ® LA) in school children under daily practice conditions. Bilke-Hentsch, O; Haertling, F; Mueller, B, 2015)	0.64
" The ideal dosing regimen of methylphenidate is debatable with daily use being considered harmful by many."	( Drug holiday utilisation in ADHD-diagnosed children and adolescents in South Africa. McCartney, J; Regnart, J; Truter, I, 2014)	0.69
"The purpose of this study was to evaluate the relative bioavailability and safety of a multilayer extended-release bead methylphenidate (MPH) hydrochloride 80 mg (MPH-MLR) capsule or sprinkles (37% immediate-release [IR]) versus MPH hydrochloride IR(Ritalin(®)) tablets, and to develop a pharmacokinetic (PK) model simulating MPH concentration-time data for different MPH-MLR dosage strengths."	( Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers. Adjei, A; Chang, WW; Connor, DF; Greenhill, L; Kupper, RJ; Newcorn, JH; Teuscher, NS; Wigal, S, 2014)	0.89
" The PK modeling in adults suggested that differences in MPH pharmacokinetics between MPH-MLR and Ritalin are the result of dosage form design attributes and the associated absorption profiles of MPH."	( Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers. Adjei, A; Chang, WW; Connor, DF; Greenhill, L; Kupper, RJ; Newcorn, JH; Teuscher, NS; Wigal, S, 2014)	0.69
" A dose-response study was performed to monitor caloric intake, liquid intake and growth rate in rats following repeated administration of human oral therapeutic doses 2 mg/kg/day, 5mg/kg/day and 8mg/kg/day of methylphenidate."	( Effect of repeated oral therapeutic doses of methylphenidate on food intake and growth rate in rats. Alam, N; Najam, R, 2015)	0.86
" The acquisition of cocaine self-administration was faster, and cocaine dose-response functions were shifted upward under fixed-ratio and progressive ratio schedules compared to adult SHR that received adolescent vehicle treatment or to control strains that received adolescent methylphenidate treatment."	( Methylphenidate treatment beyond adolescence maintains increased cocaine self-administration in the spontaneously hypertensive rat model of attention deficit/hyperactivity disorder. Baskin, BM; Dwoskin, LP; Kantak, KM, 2015)	2.04
"The age, sex, leading diagnosis, prescribed medication, and dosage of each patient were recorded anonymously twice a year."	( [Hyperkinetic disorders in childhood and adolescence- an analysis of KinderAGATE 2009-2012]. Haen, E; Rexroth, CA; Stegmann, B; Wenzel-Seifert, K, 2015)	0.42
" Knowledge of the relationship between dose, body weight, and clinical response following the administration of MPH-MLR in children and adolescents may be useful for clinicians selecting initial dosing of MPH-MLR."	( Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple-layer beads in pediatric subjects with attention deficit hyperactivity disorder. Adjei, A; Findling, RL; Greenhill, LL; Kupper, RJ; Teuscher, NS; Wigal, S, 2015)	0.7
"For psychostimulants, a marked individual variability in the dose-response relationship and large differences in plasma concentrations after similar doses are known."	( Quantification of Methylphenidate, Dexamphetamine, and Atomoxetine in Human Serum and Oral Fluid by HPLC With Fluorescence Detection. Dörfelt, A; Haen, E; Stegmann, B, 2016)	0.77
" The entire sample (N = 14) demonstrated a reduction in the mean score on the Inattention Scale from clinically significant (T-score > 65) to not clinically significant (T-score < 65) when patients were changed from non-OROS to OROS at the same dosage (mean T-score reduction = 23, p < ."	( Not All Generic Concerta Is Created Equal: Comparison of OROS Versus Non-OROS for the Treatment of ADHD. Boan, AD; Kral, MC; Lally, MD, 2016)	0.43
" The AUC0-3 h difference reported here points to the potential limitations of using bioequivalence for sound predictions of dose-response relationships."	( Absorption Differences between Immediate-Release Dexmethylphenidate and dl-Methylphenidate. Patrick, KS; Straughn, AB, 2016)	0.68
" Recent products offer convenience in terms of dosing and timing of drug administration to improve symptom control, but efficacy is similar among all MPH-ER products."	( Methylphenidate HCL for the treatment of ADHD in children and adolescents. Childress, AC, 2016)	1.88
" Methylphenidate extended-release orally disintegrating tablets (MPH XR-ODTs) combine two technologies in a single-tablet formulation-an extended-release profile that was designed for once-daily dosing in an ODT that does not require water or chewing for ingestion."	( A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Childress, A; McMahen, R; Newcorn, J; Sikes, C; Stark, JG; Tengler, M, 2016)	1.56
" To minimize the acute effects of MPH on FDG uptake, microPET/CT scans were scheduled on Mondays before their first daily dosing of the week (approximately 68h since their last treatment)."	( MicroPET/CT assessment of FDG uptake in brain after long-term methylphenidate treatment in nonhuman primates. Apana, SM; Berridge, MS; Callicott, R; Liu, S; Newport, GD; Paule, MG; Slikker, W; Thompson, J; Wang, C; Zhang, X, )	0.37
" This dose-response pattern is commonly observed with psychostimulant cognitive modulation."	( Methylphenidate has nonlinear dose effects on cued response inhibition in adults but not adolescents. Moghaddam, B; Simon, NW, 2017)	1.9
" A marked individual variability in the dose-response has been observed, and therefore dosage must be titrated for optimal therapeutic effect with minimal toxicity."	( Metabolomics of Methylphenidate and Ethylphenidate: Implications in Pharmacological and Toxicological Effects. Dinis-Oliveira, RJ, 2017)	0.8
" For patients with pre-existing tic disorders, the usual recommended dosing of stimulants should be used because supratherapeutic doses of this class of medications, specifically dextroamphetamine, have shown to exacerbate tic disorders."	( Attention Deficit Hyperactive Disorder and Occurrence of Tic Disorders in Children and Adolescents-What is the Verdict. Cooke, T; So, TY, 2016)	0.43
"To evaluate the efficacy and safety of individualized dosing within the approved dose range for osmotic-release oral system (OROS) methylphenidate hydrochloride in adults with attention-deficit/hyperactivity disorder (ADHD)."	( Randomized, 6-Week, Placebo-Controlled Study of Treatment for Adult Attention-Deficit/Hyperactivity Disorder: Individualized Dosing of Osmotic-Release Oral System (OROS) Methylphenidate With a Goal of Symptom Remission. Armstrong, RB; Ascher, S; Goodman, DW; Ma, YW; Rostain, AL; Starr, HL, 2017)	0.85
" The model provides a quantitative tool to predict the biphasic plasma time course data for ER MPH, helping elucidate factors responsible for the diverse plasma MPH concentration profiles following oral dosing of different ER formulations."	( Application of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in Adults. Duan, J; Fisher, J; Yang, X, 2016)	0.64
" The goal of this study is to investigate the effects of acute and chronic dose-response characteristics following MPD exposure on both the PFC neuronal population and behavioral activity in freely behaving animals implanted previously with permanent electrodes within the PFC."	( Concomitant behavioral and PFC neuronal activity recorded following dose-response protocol of MPD in adult male rats. Claussen, C; Dafny, N; Joseph, M; Venkataraman, SS, 2017)	0.46
" Given that immediate-release and/or tablet/capsule formulations may decrease adherence to methylphenidate treatment, several drug companies have been developing novel long-acting and/or liquid/chewable formulations that may improve adherence as well as (for long-acting formulations) reduce abuse potential, decrease stigma associated with multiple administrations per day, and decrease the potential for adverse effects related to dosage peak."	( New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability. Cortese, S; D'Acunto, G; Konofal, E; Masi, G; Vitiello, B, 2017)	1
"In this article, accounting for day-to-day children's activities and using up-to-date pharmacokinetic knowledge of methylphenidate, we propose a computational approach for the identification of the most suitable dosing regimens of immediate-release formulations of methylphenidate based on constraints on drug concentration and time frame of activities, defined through therapeutic boxes."	( An Evaluation Approach for the Performance of Dosing Regimens in Attention-Deficit/Hyperactivity Disorder Treatment. Barrière, O; Bonnefois, G; Li, J; Nekka, F; Robaey, P, 2017)	0.67
"A web-based interface that can serve as an educational tool for clinicians and patients has been developed based on the proposed approach for the evaluation of dosing regimens."	( An Evaluation Approach for the Performance of Dosing Regimens in Attention-Deficit/Hyperactivity Disorder Treatment. Barrière, O; Bonnefois, G; Li, J; Nekka, F; Robaey, P, 2017)	0.46
" After 3 months 2/8 (25%, CI 95%: 8-65%) showed improvements, remaining 75% has been increased dosage of methylphenidate."	( Attention-deficit/hyperactivity disorder and enuresis: a study about effectiveness of treatment with methylphenidate or desmopressin in a pediatric population. Ferrara, P; Ianniello, F; Mariotti, P; Petitti, T; Quattrocchi, E; Sannicandro, V; Sbordone, A, 2019)	0.94
" The anorexigenic effect of methylphenidate has been demonstrated in preclinical studies although the dosage and the administration routes differ in animals from those used for human beings."	( [The effect of methylphenidate on appetite and weight]. Bou Khalil, R; Fares, N; Richa, S; Saliba, Y; Tamraz, J, 2017)	1.1
" We explored differences in test scores between current methylphenidate users versus never users and methylphenidate users who stopped treatment at least 6 months before the test, early versus late starters, different dosage of methylphenidate, and concurrent antipsychotic or asthma treatment."	( Methylphenidate use and school performance among primary school children: a descriptive study. Bos, JH; Çiçek, R; de Vries, TW; Hak, E; Hoekstra, PJ; van der Schans, J; Vardar, S, 2017)	2.14
" Unfortunately, there is little information regarding changes in drug absorption after bariatric surgeries, limiting the ability of medical professionals to produce clear recommendations on what changes should be made to the formulations and dosing regimens of drugs after bariatric surgery."	( Impaired oral absorption of methylphenidate after Roux-en-Y gastric bypass. Azran, C; Dahan, A; Langguth, P, 2017)	0.75
"6 g/kg), dosed 4 hours later."	( Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers. Bernstein, H; Johnson, HJ; Knight, JM; Malcolm, RJ; Markowitz, JS; Patrick, KS; Reeves, OT; Shi, J; Smith, AT; Straughn, AB; Zhu, HJ, 2017)	0.75
" Lack of longitudinal follow-up studies of dosing and adverse effects has resulted in conflicting treatment guidelines."	( Methylphenidate doses in Attention Deficit/Hyperactivity Disorder and comorbid substance use disorders. Brandt, L; D'Onofrio, B; Franck, J; Larsson, H; Skoglund, C, 2017)	1.9
"6 mg/kg of immediate-release MPH dosed TID)."	( How do stimulant treatments for ADHD work? Evidence for mediation by improved cognition. Colder, CR; Fosco, WD; Hawk, LW; Pelham, WE; Rosch, KS; Waxmonsky, JG, 2018)	0.48
" The dose-response (0."	( How do stimulant treatments for ADHD work? Evidence for mediation by improved cognition. Colder, CR; Fosco, WD; Hawk, LW; Pelham, WE; Rosch, KS; Waxmonsky, JG, 2018)	0.48
" These comprised comparative and non-comparative cohort studies, patient-control studies, patient reports/series and cross-sectional studies of methylphenidate administered at any dosage or formulation."	( Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Aagaard, L; Buch Rasmussen, K; Gauci, D; Gerner, T; Gillies, D; Gluud, C; Groth, C; Håkonsen, SJ; Holmskov, M; Kielsholm, ML; Kirubakaran, R; Krogh, HB; Magnusson, FL; Moreira-Maia, CR; Nielsen, SS; Pedersen, N; Ramstad, E; Rosendal, S; Simonsen, E; Skoog, M; Storebø, OJ; Zwi, M, 2018)	2.12
" Therefore, the aim of this retrospective observational study is to evaluate the influence of psychostimulants on BMI-sds and height-sds in a pediatric cohort with ADHD from an outpatient clinic, and to study the correlation between psychostimulant dosage and BMI-sds and height-sds change."	( Psychostimulants: Influence on Body Mass Index and Height in a Pediatric Population with Attention-Deficit/Hyperactivity Disorder? Knibbe, CAJ; Lentferink, YE; van de Garde, EMW; van der Vorst, MMJ, 2018)	0.48
" However, the correlation with psychostimulant dosage was weak, and the decline was not observed in all subgroups."	( Psychostimulants: Influence on Body Mass Index and Height in a Pediatric Population with Attention-Deficit/Hyperactivity Disorder? Knibbe, CAJ; Lentferink, YE; van de Garde, EMW; van der Vorst, MMJ, 2018)	0.48
" Neither acute nor chronic dosing produced a change in locomotion during the EPM, indicating that the anxiolytic effects of MPH are independent of changes in locomotor behavior."	( A recreational dose of methylphenidate, but not methamphetamine, decreases anxiety-like behavior in female rats. Boyette-Davis, JA; Gonzalez, CMF; Guarraci, FA; Kunkel, MN; Lucero, DA; Rice, HR; Shoubaki, RI; Womble, PD, 2018)	0.79
" In one study, tics limited further dosage increases of methylphenidate."	( Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Osland, ST; Pringsheim, T; Steeves, TD, 2018)	0.73
" If the decision is made to initiate treatment, it is started at the lowest dosage and followed by a titration phase."	( [Supervised off-label prescribing of methylphenidate in adult ADHD]. Amad, A; Bordet, R; Brigadeau, F; Carton, L; Cottencin, O; Danel, T; Deheul, S; Devos, D; Dondaine, T; Gautier, S; Marquié, C; Ménard, O, 2019)	0.79
" Multivariate regression analysis confirmed an inverse dose-response association between MP and fractures in men (p < 0."	( Lower risk of fractures under methylphenidate treatment for ADHD: A dose-response effect. Ankory, R; Gurel, R; Kadar, A; Karakis, I; Schermann, H; Snir, N; Sternheim, A; Yoffe, V, 2018)	0.77
" The adverse effects may limit optimal dosing and patients' compliance with treatment leading to the discontinuation of treatment."	( Preventive effect of cyproheptadine on sleep and appetite disorders induced by methylphenidate: an exploratory randomised, double-blinded, placebo-controlled clinical trial. Elyasi, S; Kadkhoda Mezerji, F; Mohammadpour, AH; Moharreri, F, 2019)	0.74
" Further, transdermal, suspension, and orally disintegrating tablet products are now available to overcome any solid dosage form swallowing difficulties."	( Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations. Koller, L; Nguyen, LV; Patrick, KS; Radke, JL; Raymond, JR; Rodriguez, W; Straughn, AB, 2019)	0.74
"Whether long-term methylphenidate (MPH) results in any changes in cardiovascular function or structure can only be properly addressed through a randomized trial using an animal model which permits elevated dosing over an extended period of time."	( A randomized controlled laboratory study on the long-term effects of methylphenidate on cardiovascular function and structure in rhesus monkeys. Bodien, A; Callicott, R; Czachor, J; Dauphin, DD; Davis, K; Greenhaw, J; Jones, Y; Lipshultz, SE; Paredes, A; Paule, MG; Rusconi, PG; Salminen, WF; Sandhu, SK; Slikker, W; Westphal, JA; Wilkinson, JD, 2019)	1.08
" Dosage groups were compared on serum cardiovascular and inflammatory biomarkers, electrocardiograms (ECGs), echocardiograms, myocardial biopsies, and clinical pathology parameters following 5 years of uninterrupted dosing."	( A randomized controlled laboratory study on the long-term effects of methylphenidate on cardiovascular function and structure in rhesus monkeys. Bodien, A; Callicott, R; Czachor, J; Dauphin, DD; Davis, K; Greenhaw, J; Jones, Y; Lipshultz, SE; Paredes, A; Paule, MG; Rusconi, PG; Salminen, WF; Sandhu, SK; Slikker, W; Westphal, JA; Wilkinson, JD, 2019)	0.75
"With the exception of serum myoglobin, there were no statistical differences or apparent dose-response trends in clinical pathology, cardiac inflammatory biomarkers, ECGs, echocardiograms, or myocardial biopsies."	( A randomized controlled laboratory study on the long-term effects of methylphenidate on cardiovascular function and structure in rhesus monkeys. Bodien, A; Callicott, R; Czachor, J; Dauphin, DD; Davis, K; Greenhaw, J; Jones, Y; Lipshultz, SE; Paredes, A; Paule, MG; Rusconi, PG; Salminen, WF; Sandhu, SK; Slikker, W; Westphal, JA; Wilkinson, JD, 2019)	0.75
" The optimization of the benefit-risk ratio can be achieved by identifying the most adequate dose (and/or dosage regimen) jointly with the best-performing in vivo release properties of a drug."	( A General Framework for Assessing In vitro/In vivo Correlation as a Tool for Maximizing the Benefit-Risk Ratio of a Treatment Using a Convolution-Based Modeling Approach. Babiskin, A; Bressolle-Gomeni, F; Fang, LL; Faraone, SV; Gomeni, R; Spencer, TJ, 2019)	0.51
" Importantly, the dose-response curve for this action was right-shifted relative to working memory, as seen with systemic administration."	( Receptor and circuit mechanisms underlying differential procognitive actions of psychostimulants. Berridge, CW; Spencer, RC, 2019)	0.51
" A high-fat meal immediately preceding evening dosing did not affect total MPH exposure but lowered peak MPH exposure by 14% and 11% versus fasted and sprinkled states, and time to peak exposure was delayed by ∼2."	( Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults. DeSousa, NJ; Gobburu, JVS; Incledon, B; Liu, T; McLean, A; Po, MD; Sallee, FR, 2019)	0.75
" We investigated the effect of OT, delivered intraperitoneally, on the methylphenidate (MP) dose-response function for self-administration in rats."	( Effect of systemically administered oxytocin on dose response for methylphenidate self-administration and mesolimbic dopamine levels. Coggiano, MA; Lee, MR; Leggio, L; Rohn, MCH; Tanda, G; Zanettini, C, 2019)	0.98
" However, further studies are needed to provide more robust evidence on efficacy, dosage and safety for this population."	( Amphetamine Use in the Elderly: A Systematic Review of the Literature. Colpo, GD; John, V; Rocha, NP; Sassi, KLM; Teixeira, AL, 2020)	0.56
" This study is unique in that it investigated acute and chronic, dose-response MPD exposure on animals' behavior activity concomitantly with PFC and CN neuronal circuitry in freely behaving adult animals without the interference of anesthesia."	( The prefrontal cortex and the caudate nucleus respond conjointly to methylphenidate (Ritalin). Concomitant behavioral and neuronal recording study. Claussen, CM; Dafny, N; Kharas, N; Venkataraman, SS, 2020)	0.79
" We used mixed-effects logistic regression models to personalize the dosage of Methylphenidate (MPH) in ADHD."	( Individualizing the dosage of Methylphenidate in children with attention deficit hyperactivity disorder. Fotouhi, A; Hoseini, M; Mahmoudi-Gharaei, J; Mozaffarpur, SA; Shirafkan, H; Yaseri, M, 2020)	1.07
" In multivariable mixed logit model, three variables (severity of ADHD, time duration receiving MPH, and dosage of MPH) had a significant relationship with improvement."	( Individualizing the dosage of Methylphenidate in children with attention deficit hyperactivity disorder. Fotouhi, A; Hoseini, M; Mahmoudi-Gharaei, J; Mozaffarpur, SA; Shirafkan, H; Yaseri, M, 2020)	0.85
"To determine the dosage of MPH for a new patient, the more the severity of baseline is, the more of an initial dose is required."	( Individualizing the dosage of Methylphenidate in children with attention deficit hyperactivity disorder. Fotouhi, A; Hoseini, M; Mahmoudi-Gharaei, J; Mozaffarpur, SA; Shirafkan, H; Yaseri, M, 2020)	0.85
" Studies using standardized dosing schemes for longer durations and evaluating sleep with objective measurements may clarify the differential effects of treatments on sleep among children with ADHD."	( Sleep habits of children diagnosed with attention/ deficit/ hyperactivity disorder and effects of treatment on sleep related parameters. Sarıgedik, E; Tufan, AE; Yektaş, Ç, 2020)	0.56
" An important consequence of this study finding is that it may be important to adjust MPH dosage depending on learning effects in a specific setting to constantly increase cognitive control functions in that setting."	( Task experience eliminates catecholaminergic effects on inhibitory control - A randomized, double-blind cross-over neurophysiological study. Beste, C; Mückschel, M; Roessner, V, 2020)	0.56
" Further investigations containing larger sample sizes, longer supplementation periods, and dose-response evaluations are required to replicate these findings in ADHD children more confidently."	( Resveratrol adjunct to methylphenidate improves symptoms of attention-deficit/hyperactivity disorder: a randomized, double-blinded, placebo-controlled clinical trial. Akhondzadeh, S; Ashraf-Ganjouei, A; Bagheri, S; Mohammadi, MR; Moradi, K; Rafeiy-Torghabeh, M, 2021)	0.93
" Participants (N = 12; 33% female) completed a within-subject, outpatient, acute dosing study."	( Acute methylphenidate administration reduces cocaine-cue attentional bias. Alcorn, JL; Lile, JA; Rush, CR; Stoops, WW; Strickland, JC, 2020)	1.04
" The results from the literature underline the necessity of caution and patient monitoring when risperidone dosing is modified during methylphenidate therapy."	( Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance. Burden, AM; Stämpfli, D; Weiler, S, 2021)	1.08
" Secondary endpoints comprise patient evaluation (Wender-Reimherr self-report, WR-SR), safety, tolerability, and dosage of MPH."	( Methylphenidate treatment of adult ADHD patients improves the degree of ADHD severity under routine conditions. Ammer, R; Fischer, R; Ose, C; Retz, W; Rösler, M, 2020)	2
" PRC-063 (100 mg/d) was compared with immediate-release methylphenidate (20 mg, 3 times daily) when administered on a single day under fasted and fed conditions and at steady state (day 5 of repeat dosing under fasted conditions)."	( Randomized Controlled Crossover Trials of the Pharmacokinetics of PRC-063, a Novel Multilayer Extended-Release Formulation of Methylphenidate, in Healthy Adults. Cataldo, MJ; Donnelly, GAE; Katzman, MA; Klassen, LJ; Mattingly, G, )	0.58
"Although the relationship between attention-deficit/hyperactivity disorder (ADHD) and transport accidents has been shown, there is limited information on the relationship between medication and dose-response effects and transport accident risk."	( Association of psychiatric comorbidities with the risk of transport accidents in ADHD and MPH. Chen, VC; Chen, YL; Gossop, M; Liu, YC; Yang, YH, 2021)	0.62
" MPH treatment lowered the accident risk with a dose-response relationship."	( Association of psychiatric comorbidities with the risk of transport accidents in ADHD and MPH. Chen, VC; Chen, YL; Gossop, M; Liu, YC; Yang, YH, 2021)	0.62
" The participants had drug dosage adjustment based on body weight/dose (mg/kg)."	( Methylphenidate decreases the EEG mu power in the right primary motor cortex in healthy adults during motor imagery and execution. Aprigio, D; Basile, LF; Bastos, VH; Bittencourt, J; Budde, H; Cagy, M; Gongora, M; Marinho, V; Ribeiro, P; Teixeira, S; Velasques, B, 2021)	2.06
" The effectiveness of MP for cognitive enhancement is well documented along a dose-response curve."	( The Use of Methylphenidate for Cognitive Enhancement in Young Healthy Adults: The Clinical and Ethical Debates. Koren, G; Korn, L, )	0.52
"Accurate estimation of daily dosage and duration of medication use is essential to pharmacoepidemiological studies using electronic healthcare databases."	( Prediction of treatment dosage and duration from free-text prescriptions: an application to ADHD medications in the Swedish prescribed drug register. Chang, Z; Chen, Q; D'Onofrio, BM; Ghirardi, L; Lagerberg, T; Larsson, H; Viktorin, A; Zhang, L, 2021)	0.62
"To develop and validate an algorithm for predicting prescribed daily dosage and treatment duration from free-text prescriptions, and apply the algorithm to ADHD medication prescriptions."	( Prediction of treatment dosage and duration from free-text prescriptions: an application to ADHD medications in the Swedish prescribed drug register. Chang, Z; Chen, Q; D'Onofrio, BM; Ghirardi, L; Lagerberg, T; Larsson, H; Viktorin, A; Zhang, L, 2021)	0.62
"We developed an algorithm to predict daily dosage from free-text prescriptions using 8000 ADHD medication prescriptions as the training sample, and estimated treatment periods while taking into account several features including titration, stockpiling and non-perfect adherence."	( Prediction of treatment dosage and duration from free-text prescriptions: an application to ADHD medications in the Swedish prescribed drug register. Chang, Z; Chen, Q; D'Onofrio, BM; Ghirardi, L; Lagerberg, T; Larsson, H; Viktorin, A; Zhang, L, 2021)	0.62
"In the validation sample, the overall accuracy for predicting daily dosage was 96."	( Prediction of treatment dosage and duration from free-text prescriptions: an application to ADHD medications in the Swedish prescribed drug register. Chang, Z; Chen, Q; D'Onofrio, BM; Ghirardi, L; Lagerberg, T; Larsson, H; Viktorin, A; Zhang, L, 2021)	0.62
"The algorithm provides a flexible approach to estimate prescribed daily dosage and treatment duration from free-text prescriptions using register data."	( Prediction of treatment dosage and duration from free-text prescriptions: an application to ADHD medications in the Swedish prescribed drug register. Chang, Z; Chen, Q; D'Onofrio, BM; Ghirardi, L; Lagerberg, T; Larsson, H; Viktorin, A; Zhang, L, 2021)	0.62
" Study durations ranged from 8 to 16 weeks and MPH dosing ranged from 5 to 90 mg per day."	( Methylphenidate use in geriatric depression: A systematic review. Britt, RB; Brown, JN; Kahlon, CH; Smith, KR, 2021)	2.06
"The findings suggest that the IN-DA treatment has potential for use in the treatment of ADHD; however, caution must be exercised when determining the dosage to be administered, because too much dopamine may have negative effects."	( Acute intranasal dopamine application counteracts the reversal learning deficit of spontaneously hypertensive rats in an attentional set-shifting task. Chao, OY; Huston, JP; Li, JS; Mattern, C; Yang, SS; Yang, YM, 2021)	0.62
" Determining the dosing effects of methylphenidate (MPH) on a broad range of neurocognitive functions and investigating possible impairing effects of high doses is therefore important."	( Meta-analysis: Dose-Dependent Effects of Methylphenidate on Neurocognitive Functioning in Children With Attention-Deficit/Hyperactivity Disorder. Bet, P; de Vries, R; Luman, M; Oosterlaan, J; Staff, A; Twisk, J; Vertessen, K, 2022)	1.26
"Placebo-controlled trials were included that investigated MPH dosing effects on neurocognitive functions in children and adolescents (aged 5-18 years) diagnosed with ADHD."	( Meta-analysis: Dose-Dependent Effects of Methylphenidate on Neurocognitive Functioning in Children With Attention-Deficit/Hyperactivity Disorder. Bet, P; de Vries, R; Luman, M; Oosterlaan, J; Staff, A; Twisk, J; Vertessen, K, 2022)	0.99
" Significant linear dosing effects were found for ADHD symptoms and lower-order neurocognitive functions (baseline speed, variability in responding, nonexecutive memory), with greater enhancement of functioning with increasing dose."	( Meta-analysis: Dose-Dependent Effects of Methylphenidate on Neurocognitive Functioning in Children With Attention-Deficit/Hyperactivity Disorder. Bet, P; de Vries, R; Luman, M; Oosterlaan, J; Staff, A; Twisk, J; Vertessen, K, 2022)	0.99
" A physiologically-based pharmacokinetic modeling simulation revealed that the CES1-based individualized dosing strategy might significantly reduce d-methylphenidate exposure variability in pediatric patients relative to conventional trial and error fixed dosing regimens."	( Plasma Carboxylesterase 1 Predicts Methylphenidate Exposure: A Proof-of-Concept Study Using Plasma Protein Biomarker for Hepatic Drug Metabolism. Bleske, BE; Jung, SM; Markowitz, JS; Patrick, KS; Shi, J; Wang, X; Xiao, J; Zhu, HJ, 2022)	1.2
" However, robust evidence-base regarding the effects of doses and dosing strategies of stimulants on clinical outcomes in the treatment of children/adolescents with ADHD is currently lacking and stimulants are often underdosed in clinical practice."	( The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis. Avila-Quintero, VJ; Behling, E; Bloch, MH; Cortese, S; Farhat, LC; Flores, JM; Lombroso, A; Polanczyk, GV, 2022)	0.72
" Heart rate and blood pressure were measured at dosing and 1, 2, and 3 hours afterwards."	( Acute Tolerability of Methylphenidate in Treatment-Naïve Children with ADHD: An Analysis of Naturalistically Collected Data from Clinical Practice. Amianto, F; D'Acunto, G; Davico, C; Falcone, F; Fantozzi, P; Favole, I; Lenzi, F; Levantini, V; Liboni, F; Masi, G; Muratori, P; Pfanner, C; Simonelli, V; Villafranca, A; Vitiello, B, 2022)	1.04
"A simple, robust stability indicating RP-HPLC method was developed for simultaneous quantification of serdexmethyl phenidate and dexmethyl phenidate in a fixed capsule dosage form."	( A Novel Stability Indicating RP-HPLC Method for Simultaneous Quantification of Serdexmethylphenidate and Dexmethylphenidate in Fixed Dosage Form. Gollu, G; Gummadi, S, 2023)	1.13
" Nonetheless, patients' growth and the appropriateness of drug dosage should be closely monitored."	( Growth Hormone and Thyroid Function in Children With Attention Deficit Hyperactivity Disorder Undergoing Drug Therapy. Chou, WJ; Huang, YH; Lee, SY; Wang, LJ, 2022)	0.72
" The syrup dosage is 5cc every 8 h, and MP will have a stabilized dose for 8 weeks during the study."	( The effect of Rosa canina L. and a polyherbal formulation syrup in patients with attention-deficit/hyperactivity disorder: a study protocol for a multicenter randomized controlled trial. Abniki, E; Bahrami, M; Dadmehr, M; Golsorkhi, H; Kamalinejad, M; Montazerlotfelahi, H; Qorbani, M; Sabbaghzadegan, S; Vafaee-Shahi, M, 2022)	0.72
" Further research is needed to evaluate effects of higher average dosing and adherence to treatment, multi-modal treatments and preventative interventions in the community."	( Randomised controlled trial of the short-term effects of osmotic-release oral system methylphenidate on symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder: CIAO-II study. Asherson, PJ; Bedding, M; Forrester, A; Giannulli, L; Ginsberg, Y; Holland, R; Howitt, S; Johansson, L; Kelly, C; Khan, K; Kretzschmar, I; Landau, S; Lawrie, SM; Mansfield, M; Marsh, C; McCafferty, C; Müller-Sedgwick, U; Strang, J; Thomson, LDG; Williamson, G; Wilson, L; Young, S, 2023)	1.13
" At present, pharmacogenomic testing as an aid to guide dosing and personalized treatment cannot be recommended for either agent."	( The Pharmacokinetics and Pharmacogenomics of Psychostimulants. Markowitz, JS; Melchert, PW, 2022)	0.72
" A high dosage of methylphenidate diminished both behavioral inflexibility and improved learning abilities in adult rats."	( Former Training Relieves the Later Development of Behavioral Inflexibility in an Animal Model Overexpressing the Dopamine Transporter. Akinola, EO; Bernhardt, N; Edemann-Callesen, H; Glienke, M; Habelt, B; Hadar, R; Lieser, MK; Winter, C, 2022)	1.06
" Human mesenchymal stem cells (hMSCs) were incubated with a therapeutic plasma dosage of modafinil, atomoxetine and guanfacine."	( Psychostimulants Modafinil, Atomoxetine and Guanfacine Impair Bone Cell Differentiation and MSC Migration. Böker, KO; Di Fazio, P; Jäckle, K; Lehmann, W; Schilling, AF; Wagener, N; Weiser, L, 2022)	0.72
" It is important that future research addresses the current weaknesses in this area, which include small sample sizes, variability of selection criteria, variability of the type and dosage of supplementation, and short follow-up times."	( Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Gillies, D; Leach, MJ; Perez Algorta, G, 2023)	0.91
" HC received 30 mg methylphenidate (MPH) and ADHD patients received either MPH or lisdexamphetamine (LDX) as selected by their clinician, with dosage individually determined for optimal effect."	( Salience and hedonic experience as predictors of central stimulant treatment response in ADHD - A resting state fMRI study. Msghina, M; Rode, J; Runnamo, R; Thunberg, P, 2023)	1.24
"The aim of this study is to characterize children with GI and evaluate their response to methylphenidate, as well as describe treatment duration, dosage of methylphenidate, relapse rates after discontinuation of medication, and side effects."	( The effect of methylphenidate for giggle incontinence in children. Arvad, M; Borch, L; Hagstroem, S; Kamperis, K; Svendsen, AM; Thorsteinsson, KN, 2023)	1.49
" Results underscore the need to consider dosing as well as parent preference when utilizing combined treatment approaches."	( Single and Combined Effects of Multiple Intensities of Behavioral Modification and Methylphenidate for Children with ADHD in the Home Setting. Burrows-MacLean, L; Chacko, A; Coles, EK; Fabiano, GA; Garefino, A; Gnagy, EM; Macphee, FL; Massetti, GM; Merrill, BM; Pelham, WE; Robb Mazzant, J; Walker, K; Waschbusch, DA; Waxmonsky, JG; Wymbs, BT; Wymbs, F, 2023)	1.14

Class	Description
piperidines
methyl ester	Any carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
beta-amino acid ester	An amino acid ester resulting from the formal condensation of the carboxy group of a beta-amino acid with the hydroxy group of an alcohol or phenol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	37.9083	0.0123	7.9835	43.2770	AID1645841
G	Vesicular stomatitis virus	Potency	10.6840	0.0123	8.9648	39.8107	AID1645842
Interferon beta	Homo sapiens (human)	Potency	10.6840	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	10.6840	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	10.6840	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	10.6840	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Fatty-acid amide hydrolase 1	Homo sapiens (human)	IC50 (µMol)	0.4630	0.0002	0.5982	7.0000	AID1363884; AID1363885; AID1798724; AID1798725; AID1798726; AID1798727; AID430491
Fatty-acid amide hydrolase 1	Rattus norvegicus (Norway rat)	Ki	0.0330	0.0006	0.1619	2.0000	AID412539
Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0002	0.6060	10.0000	AID470070
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	IC50 (µMol)	0.0610	0.0008	1.5416	20.0000	AID275446
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	Ki	0.5000	0.0003	1.4656	10.0000	AID1184915; AID275445
Sodium-dependent dopamine transporter	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0830	0.0007	0.9774	9.7000	AID65807
Sodium-dependent serotonin transporter	Homo sapiens (human)	IC50 (µMol)	5.1000	0.0001	0.8645	8.7096	AID275444
Sodium-dependent serotonin transporter	Homo sapiens (human)	Ki	37.5000	0.0000	0.7048	8.1930	AID1184913; AID275443
Sodium-dependent dopamine transporter	Homo sapiens (human)	IC50 (µMol)	0.0790	0.0007	1.8419	46.0000	AID275442
Sodium-dependent dopamine transporter	Homo sapiens (human)	Ki	0.0720	0.0002	1.1115	8.0280	AID1184914; AID275441
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)	EC50 (µMol)	25.0000	0.0003	3.1662	10.0000	AID470071
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
fatty acid catabolic process	Fatty-acid amide hydrolase 1	Homo sapiens (human)
arachidonic acid metabolic process	Fatty-acid amide hydrolase 1	Homo sapiens (human)
positive regulation of vasoconstriction	Fatty-acid amide hydrolase 1	Homo sapiens (human)
monoacylglycerol catabolic process	Fatty-acid amide hydrolase 1	Homo sapiens (human)
monoatomic ion transport	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
intracellular calcium ion homeostasis	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
cell surface receptor signaling pathway	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
response to cold	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
response to xenobiotic stimulus	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
response to organic substance	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
response to organic cyclic compound	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
sensory perception of pain	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
calcium-mediated signaling	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
response to pain	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
thermoception	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of pain	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
protein homotetramerization	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
cellular response to hydrogen peroxide	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
calcium ion transmembrane transport	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
cellular response to organic substance	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
thermoception	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
fever generation	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
microglial cell activation	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
diet induced thermogenesis	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
peptide secretion	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
negative regulation of systemic arterial blood pressure	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
lipid metabolic process	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cell surface receptor signaling pathway	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
chemosensory behavior	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
negative regulation of heart rate	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
negative regulation of mitochondrial membrane potential	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
glutamate secretion	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
calcium-mediated signaling	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to heat	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
positive regulation of apoptotic process	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
response to peptide hormone	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
behavioral response to pain	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
sensory perception of mechanical stimulus	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
detection of temperature stimulus involved in thermoception	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of pain	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
protein homotetramerization	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
excitatory postsynaptic potential	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
smooth muscle contraction involved in micturition	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
calcium ion transmembrane transport	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to alkaloid	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to ATP	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to tumor necrosis factor	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to acidic pH	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to temperature stimulus	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
negative regulation of establishment of blood-brain barrier	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
calcium ion import across plasma membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
response to capsazepine	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to nerve growth factor stimulus	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
monoamine transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
chemical synaptic transmission	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
response to pain	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine uptake	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuron cellular homeostasis	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
monoamine transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to hypoxia	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to nutrient	Sodium-dependent serotonin transporter	Homo sapiens (human)
memory	Sodium-dependent serotonin transporter	Homo sapiens (human)
circadian rhythm	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to toxic substance	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of gene expression	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of serotonin secretion	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferation	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergic	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to estradiol	Sodium-dependent serotonin transporter	Homo sapiens (human)
social behavior	Sodium-dependent serotonin transporter	Homo sapiens (human)
vasoconstriction	Sodium-dependent serotonin transporter	Homo sapiens (human)
sperm ejaculation	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of neuron differentiation	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of cell cycle	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of organ growth	Sodium-dependent serotonin transporter	Homo sapiens (human)
behavioral response to cocaine	Sodium-dependent serotonin transporter	Homo sapiens (human)
enteric nervous system development	Sodium-dependent serotonin transporter	Homo sapiens (human)
brain morphogenesis	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin uptake	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane depolarization	Sodium-dependent serotonin transporter	Homo sapiens (human)
platelet aggregation	Sodium-dependent serotonin transporter	Homo sapiens (human)
cellular response to retinoic acid	Sodium-dependent serotonin transporter	Homo sapiens (human)
cellular response to cGMP	Sodium-dependent serotonin transporter	Homo sapiens (human)
regulation of thalamus size	Sodium-dependent serotonin transporter	Homo sapiens (human)
conditioned place preference	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoamine transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
lactation	Sodium-dependent dopamine transporter	Homo sapiens (human)
sensory perception of smell	Sodium-dependent dopamine transporter	Homo sapiens (human)
locomotory behavior	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to iron ion	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
adenohypophysis development	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to nicotine	Sodium-dependent dopamine transporter	Homo sapiens (human)
positive regulation of multicellular organism growth	Sodium-dependent dopamine transporter	Homo sapiens (human)
regulation of dopamine metabolic process	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to cocaine	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine biosynthetic process	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine catabolic process	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to ethanol	Sodium-dependent dopamine transporter	Homo sapiens (human)
cognition	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to cAMP	Sodium-dependent dopamine transporter	Homo sapiens (human)
norepinephrine uptake	Sodium-dependent dopamine transporter	Homo sapiens (human)
prepulse inhibition	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine uptake	Sodium-dependent dopamine transporter	Homo sapiens (human)
hyaloid vascular plexus regression	Sodium-dependent dopamine transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
norepinephrine transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Fatty-acid amide hydrolase 1	Homo sapiens (human)
phospholipid binding	Fatty-acid amide hydrolase 1	Homo sapiens (human)
fatty acid amide hydrolase activity	Fatty-acid amide hydrolase 1	Homo sapiens (human)
identical protein binding	Fatty-acid amide hydrolase 1	Homo sapiens (human)
acylglycerol lipase activity	Fatty-acid amide hydrolase 1	Homo sapiens (human)
amidase activity	Fatty-acid amide hydrolase 1	Homo sapiens (human)
calcium channel activity	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
channel activity	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
intracellularly gated calcium channel activity	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
identical protein binding	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
temperature-gated cation channel activity	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
transmembrane signaling receptor activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
extracellular ligand-gated monoatomic ion channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
voltage-gated calcium channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
calcium channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
protein binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
calmodulin binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
ATP binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
intracellularly gated calcium channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
chloride channel regulator activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
phosphatidylinositol binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
identical protein binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
metal ion binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
phosphoprotein binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
temperature-gated ion channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
actin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
protein binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
alpha-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
metal ion binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
beta-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
integrin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoatomic cation channel activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin:sodium:chloride symporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
antiporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
syntaxin-1 binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
cocaine binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
identical protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
nitric-oxide synthase binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
actin filament binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
protease binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
signaling receptor binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine:sodium symporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
amine binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein-containing complex binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
metal ion binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein phosphatase 2A binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
heterocyclic compound binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
norepinephrine:sodium symporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
endoplasmic reticulum membrane	Fatty-acid amide hydrolase 1	Homo sapiens (human)
cytoskeleton	Fatty-acid amide hydrolase 1	Homo sapiens (human)
organelle membrane	Fatty-acid amide hydrolase 1	Homo sapiens (human)
plasma membrane	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
stereocilium bundle	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
external side of plasma membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
dendritic spine membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
neuronal cell body	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
postsynaptic membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
plasma membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
cell surface	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuronal cell body membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
axon	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
focal adhesion	Sodium-dependent serotonin transporter	Homo sapiens (human)
endosome membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
endomembrane system	Sodium-dependent serotonin transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane raft	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonergic synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
neuron projection	Sodium-dependent serotonin transporter	Homo sapiens (human)
cytoplasm	Sodium-dependent dopamine transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
cell surface	Sodium-dependent dopamine transporter	Homo sapiens (human)
membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuron projection	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuronal cell body	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon terminus	Sodium-dependent dopamine transporter	Homo sapiens (human)
membrane raft	Sodium-dependent dopamine transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopaminergic synapse	Sodium-dependent dopamine transporter	Homo sapiens (human)
flotillin complex	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon	Sodium-dependent dopamine transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuronal cell body membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1798726	FAAH Inhibition Assay (30 min Preincubation) from Article 10.1021/bi701378g: \\Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.\\	2007	Biochemistry, Nov-13, Volume: 46, Issue:45	Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.
AID1798724	FAAH Inhibition Assay (5 min Preincubation) from Article 10.1021/bi701378g: \\Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.\\	2007	Biochemistry, Nov-13, Volume: 46, Issue:45	Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.
AID1798725	FAAH Inhibition Assay (15 min Preincubation) from Article 10.1021/bi701378g: \\Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.\\	2007	Biochemistry, Nov-13, Volume: 46, Issue:45	Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.
AID1798727	FAAH Inhibition Assay (60 min Preincubation) from Article 10.1021/bi701378g: \\Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.\\	2007	Biochemistry, Nov-13, Volume: 46, Issue:45	Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.
AID470070	Antagonist activity at human TRPV1 expressed in HEK293 cells assessed as decrease in intracellular calcium level	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands.
AID470069	Inhibition of FAAH-mediated hydrolysis of [3H]AEA in rat brain membrane at 50 uM	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands.
AID470071	Antagonist activity at human TRPA1 expressed in HEK293 cells assessed as decrease in intracellular calcium level	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands.
AID470068	Inhibition of FAAH-mediated hydrolysis of [3H]AEA in rat brain membrane	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands.
AID1363885	Inhibition of recombinant human N-terminal -His6 tagged FAAH (32 to 579 residues) expressed in Escherichia coli BL21-AI preincubated for 5 mins followed by olamide substrate addition measured every 10 sec intervals for 30 mins by spectrophotometry	2017	Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1	Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.
AID412539	Inhibition of rat cortex FAAH by [3H]anandamide carbon filtration assay	2009	Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1	Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors.
AID430491	Inhibition of FAAH	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas.
AID1363884	Inhibition of recombinant human N-terminal -His6 tagged FAAH (32 to 579 residues) expressed in Escherichia coli BL21 preincubated for 60 mins followed by olamide substrate addition measured every 10 sec intervals for 30 mins by spectrophotometry	2017	Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1	Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.
AID496828	Antimicrobial activity against Leishmania donovani	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID275447	Selectivity for human DAT over human NET in radio ligand binding assay	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.
AID120997	Compound was tested at subtoxic dose of 25 mg/kg in mice; Symptoms are hyperactivity, irritability, stereotypy.	2003	Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1	New benzo[h][1,6]naphthyridine and azepino[3,2-c]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1184914	Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting	2014	ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7	Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID195887	Ability to inhibit the uptake of dopamine [3H]DA in to rat brain synaptosomes	1998	Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4	Asymmetric synthesis and pharmacology of methylphenidate and its para-substituted derivatives.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID65807	Tested for the ability to bind stereoselectively and enantioselectively to the dopamine transporter (DAT); Value ranges from 34 - 83 nM	2003	Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8	Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID64208	Inhibition of [3H]WIN-35428 Binding to the Dopamine Transporter in Rhesus (Macaca mulatta) orCynomolgus Monkey (Macaca fascicularis) Caudate-Putamen	2003	Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8	Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.
AID111826	Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 1.25 mg/kg	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID275448	Selectivity for human DAT over human NET in radio ligand uptake assay	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.
AID275444	Inhibition of [3H]5-HT uptake into human SERT expressing HEK293 cells	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID603953	In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat	2008	European journal of medicinal chemistry, Mar, Volume: 43, Issue:3	Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID275443	Displacement of [125I]RTI-55 from human SERT expressing HEK293 cells	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.
AID1597737	Half life in human at 20 mg	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Sleep modulating agents.
AID395325	Lipophilicity, log P by microemulsion electrokinetic chromatography	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID497005	Antimicrobial activity against Pneumocystis carinii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID118787	Retention for passive avoidance learning in mice at dose 1.25 mg/kg	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Cognition-activating properties of 3-(Aryloxy)pyridines.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID118790	Retention for passive avoidance learning in mice at dose 20 mg/kg	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Cognition-activating properties of 3-(Aryloxy)pyridines.
AID496826	Antimicrobial activity against Entamoeba histolytica	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID111828	Ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 10.0 mg/kg	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID496827	Antimicrobial activity against Leishmania amazonensis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496832	Antimicrobial activity against Trypanosoma brucei rhodesiense	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID496820	Antimicrobial activity against Trypanosoma brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID118789	Retention for passive avoidance learning in mice at dose 2.5 mg/kg	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Cognition-activating properties of 3-(Aryloxy)pyridines.
AID111834	Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 20.0 mg/kg	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID275445	Displacement of [125I]RTI-55 from human NET expressing HEK293 cells	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496817	Antimicrobial activity against Trypanosoma cruzi	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496818	Antimicrobial activity against Trypanosoma brucei brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID496830	Antimicrobial activity against Leishmania major	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID539464	Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID111830	Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 2.5 mg/kg	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID395327	Dissociation constant, pKa by capillary electrophoresis	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID395324	Lipophilicity, log D at pH 7.4 by liquid chromatography	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID496831	Antimicrobial activity against Cryptosporidium parvum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID409956	Inhibition of mouse brain MAOB	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID420090	Ratio of Ki for [3H]dopamine uptake at rat dopamine transporter expressed in CHO cells to Ki for displacement of [3H]WIN-35428 from rat dopamine transporter expressed in CHO cells	2009	Bioorganic & medicinal chemistry, Jun-01, Volume: 17, Issue:11	A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID275446	Inhibition of [3H]NE uptake into human NET expressing HEK293 cells	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID496825	Antimicrobial activity against Leishmania mexicana	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID298031	Lipophilicity, log D at pH7.4	2007	Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19	High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID275441	Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.
AID1184915	Displacement of [3H]Nisoxetine from human NET expressed in HEK293E cells after 1 hr by liquid scintillation counting	2014	ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7	Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors.
AID111841	Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 5 mg/kg	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID496829	Antimicrobial activity against Leishmania infantum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496824	Antimicrobial activity against Toxoplasma gondii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID203945	Inhibition of [3H]citalopram Binding to the Serotonin Transporter in Rhesus (Macaca mulatta) or Cynomolgus Monkey (Macaca fascicularis) Caudate-Putamen	2003	Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8	Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID118793	Retention for passive avoidance learning in mice at dose 5 mg/kg	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Cognition-activating properties of 3-(Aryloxy)pyridines.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID275442	Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.
AID416532	Acute toxicity in NMRI mouse assessed as behavioral changes at 25 mg/kg, ip by CNS activity test	2009	Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6	Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines.
AID496823	Antimicrobial activity against Trichomonas vaginalis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID118788	Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 10 mg/kg	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Cognition-activating properties of 3-(Aryloxy)pyridines.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID298032	Acid dissociation constant, pKa of the compound	2007	Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19	High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID195888	Ability to inhibit the uptake of norepinephrine [3H]-NE in to rat brain synaptosomes	1998	Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4	Asymmetric synthesis and pharmacology of methylphenidate and its para-substituted derivatives.
AID1184913	Displacement of [3H]Citolapram from human SERT expressed in HEK293E cells after 1 hr by liquid scintillation counting	2014	ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7	Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors.
AID640615	Clearance in human liver microsomes at 1 uM measured after 60 mins by HPLC analysis	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
AID409954	Inhibition of mouse brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID496821	Antimicrobial activity against Leishmania	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1346963	Human DAT (Monoamine transporter subfamily)	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.
AID493017	Wombat Data for BeliefDocking	2004	Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7	Synthesis of methylphenidate analogues and their binding affinities at dopamine and serotonin transport sites.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1804 (24.53)	18.7374
1990's	732 (9.95)	18.2507
2000's	1882 (25.59)	29.6817
2010's	2334 (31.74)	24.3611
2020's	602 (8.19)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Trials	1,698 (21.82%)	5.53%
Reviews	1 (11.11%)	6.00%
Reviews	932 (11.97%)	6.00%
Case Studies	0 (0.00%)	4.05%
Case Studies	721 (9.26%)	4.05%
Observational	0 (0.00%)	0.25%
Observational	51 (0.66%)	0.25%
Other	8 (88.89%)	84.16%
Other	4,381 (56.29%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (408)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Open-label, Single-dose, Three-way Crossover Study to Determine the Relative Pharmacokinetic Profile of Oral Doses of CONCERTA Tablets, Ritalin-SR Tablets and Novo-Methylphenidate ER-CTablets Under Fasted Condition in Healthy Subjects [NCT01118702]	Phase 1	30 participants (Actual)	Interventional	2010-05-31	Completed
COST-EFFECTIVENESS STUDY OF THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER IN BRAZIL [NCT01228604]	Phase 4	23 participants (Actual)	Interventional	2010-12-31	Completed
ADHD Treatment: Comparative and Combined Dosage Effects [NCT00050622]		154 participants (Actual)	Interventional	2001-09-30	Completed
Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD) [NCT00264797]	Phase 3	303 participants (Actual)	Interventional	2006-02-28	Completed
Phase 1, Single-dose, Double-blind, Rand., Placebo- and Active-controlled, 4-period, 4-sequence Crossover, Proof-of-Concept Study to Evaluate Effect of Naltrexone on Abuse Potential of Methylphenidate in Healthy Recreational Stimulant Users [NCT03769064]	Phase 1	94 participants (Actual)	Interventional	2018-03-27	Completed
Effect of Central Nervous System Stimulants on Physical Function in Children With Cerebral Palsy: A Pilot Randomized Controlled Trial [NCT05675098]	Early Phase 1	30 participants (Anticipated)	Interventional	2023-05-01	Not yet recruiting
Bariatric Surgery and Pharmacokinetics Methylphenidate: BAR-MEDS Methylphenidate [NCT03440190]		12 participants (Anticipated)	Observational	2018-01-02	Recruiting
Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD and Substance Use Disorder [NCT02477280]	Phase 4	39 participants (Actual)	Interventional	2016-09-30	Completed
A Novel Drug Combination for Alcohol-Use Disorders: A Human Laboratory Study [NCT03575403]	Phase 1	19 participants (Actual)	Interventional	2018-09-01	Completed
Phase Ia/Ib Study of Normal Healthy Volunteer Clinical Trial of a Novel Ondansetron Formulation [NCT01290276]	Phase 1	6 participants (Actual)	Interventional	2010-12-31	Completed
Amantadine VS Ritalin in the Treatment of ADHD: a Double Blind Randomized Trial [NCT01099059]	Phase 2	40 participants (Anticipated)	Interventional	2010-04-30	Recruiting
Efficacy and Learning Skill After OROS Methylphenidate Treatment in Adolescents With Attention-Deficit/Hyperactivity Disorder: A 12-week, Multi-center, Open-label Study [NCT01060150]	Phase 4	115 participants (Actual)	Interventional	2008-07-31	Completed
Electroencephalogram Study of Intravenous Methylphenidate-Induced Emergence From Propofol Sedation [NCT03610282]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2019-11-30	Withdrawn(stopped due to We have decided to withdraw the study prior to enrollment of the first participant in order to pursue other research studies.)
Genetic Modulation of Functional Brain Activity of Attention-deficit/Hyperactivity Disorder-related Working Memory Processes [NCT01351272]	Phase 3	41 participants (Actual)	Interventional	2011-05-31	Completed
Adaptive Response to Intervention (RTI) for Students With ADHD [NCT03511976]	Phase 4	300 participants (Anticipated)	Interventional	2018-05-14	Recruiting
Multimodal Therapy for the Treatment of Sleep Disturbance in Patients With Cancer [NCT01628029]	Phase 2	68 participants (Actual)	Interventional	2014-01-15	Active, not recruiting
Stimulant Effects on Brain Activity During the Stop Signal Task [NCT02453698]	Phase 1	19 participants (Actual)	Interventional	2011-01-31	Completed
Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness - A Phase 1 Study [NCT03814356]	Phase 1	22 participants (Anticipated)	Interventional	2020-08-24	Recruiting
TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease: A Single Center, Randomized Pilot Study [NCT02879136]	Early Phase 1	42 participants (Anticipated)	Interventional	2016-12-31	Recruiting
Patient Controlled Administration of Methylphenidate for Cancer Related Fatigue [NCT02361125]	Phase 1	31 participants (Actual)	Interventional	2002-08-01	Completed
A Study to Identify the Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in Attention Deficit Hyperactivity Disorder [NCT02074228]	Phase 4	120 participants (Anticipated)	Interventional	2012-08-31	Recruiting
Effects of Modulation of the Dopaminergic System Using Methylphenidate on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome [NCT04647500]		45 participants (Actual)	Interventional	2016-08-26	Completed
Methylphenidate for Depressed Cancer Patients in Hospice [NCT00129467]		47 participants (Actual)	Interventional	2005-02-28	Completed
A Phase 4, Open-label, Safety, Tolerability And Pharmacokinetic Study Of Methylphenidate Hydrochloride (Hcl) Extended Release Chewable Tablet (Erct) In 4-5 Year Old Children With Attention Deficit Hyperactivity Disorder (Adhd) [NCT03546400]	Phase 4	0 participants (Actual)	Interventional	2018-09-25	Withdrawn(stopped due to The study was cancelled prior to the enrollment of any participants.)
Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder [NCT02247986]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2014-09-04	Withdrawn
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD [NCT01338818]	Phase 3	299 participants (Actual)	Interventional	2011-04-30	Completed
Efficacy of Careful Medication and Tailored Case Management Follow up Treatment for Children With Attention Deficit Hyperactivity Disorder [NCT02142140]		326 participants (Anticipated)	Interventional	2012-12-31	Active, not recruiting
An Open-label, Single-Ascending-Dose Study to Investigate the Pharmacokinetics and Safety of CONCERTA in Healthy Japanese Adult Male Subjects [NCT01202734]	Phase 1	10 participants (Actual)	Interventional	2010-09-30	Completed
Evaluating Safety and Potential Benefit of Methylphenidate as a Symptomatic Treatment for Apathy in Veterans With Parkinson's Disease. [NCT05669170]	Phase 2	60 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Oxytocin and Social Cognition in Children With Attention Deficit Hyperactivity Disorder: Impact of Methylphenidate [NCT03788902]		90 participants (Actual)	Interventional	2014-02-01	Completed
Assessing the Efficacy of Immediate Release Methylphenidate, Sustained Release Methylphenidate and Modafinil for Patients With Brain Tumors [NCT00418691]	Phase 3	34 participants (Actual)	Interventional	2004-02-29	Terminated(stopped due to Closed early due to slow accrual.)
Étude Pilote de Phase II Sur l'Effet du méthylphénidate Sur la Fonction Cognitive Des Patientes en rémission d'un Cancer du Sein [NCT02970500]	Phase 2	20 participants (Actual)	Interventional	2017-10-09	Terminated(stopped due to We decided to close recruitment in December 2022 as we were having trouble recruiting participants who met our inclusion criteria and the study funding was coming to an end.)
A Six-month, Open-label, Multi-center Study of the Safety and Efficacy of PRC-063 in Adults and Adolescents With ADHD [NCT02168127]	Phase 3	360 participants (Actual)	Interventional	2014-05-31	Completed
The Effects of Long-acting Methylphenidate on Academic Activity and Related Constructs in Children With ADHD: A Randomised Placebo Controlled Trial [NCT02501798]	Phase 4	61 participants (Anticipated)	Interventional	2013-01-31	Completed
The Effects of Methylphenidate on the Cognitive Function of Older People With Mild Cognitive Impairment: a Randomized, Placebo Controlled, Double-blind Trial. [NCT02180529]		16 participants (Actual)	Interventional	2015-11-30	Terminated(stopped due to recruiting difficulties)
Brain Connectivity in Attention Deficit Hyperactivity Disorder (ADHD): a Biomarker to Predict Treatment Response [NCT03709940]		60 participants (Actual)	Interventional	2013-05-03	Completed
Precision Functional Brain Mapping to Understand the Mechanisms of Psilocybin [NCT04501653]	Early Phase 1	25 participants (Anticipated)	Interventional	2021-06-01	Active, not recruiting
Repetitive Transcranial Magnetic Stimulation for Apathy Clinical Trial (REACT) [NCT05561205]		8 participants (Anticipated)	Interventional	2023-02-09	Recruiting
Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of Attention-Deficit/Hyperactivity Disorder (ADHD) [NCT02430896]		600 participants (Anticipated)	Observational	2015-02-28	Recruiting
Ph 3 Multicenter DBRCT Parallel Group Study to Evaluate Safety & Efficacy of Evening-dosed HLD200, a Novel Delayed & Extended Release Formulation (DELEXIS) of MPH HCl, on Post-waking, Early Morning Function in Children Aged 6-12 With ADHD [NCT02520388]	Phase 3	163 participants (Actual)	Interventional	2015-08-31	Completed
Diagnostic Utility of ADHD by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials [NCT01063153]	Phase 4	71 participants (Actual)	Interventional	2009-09-30	Completed
The Characteristics of Prepulse Inhibition in Children and Adolescents Suffering From Attention Deficit Disorder: With and Without Medication. [NCT02344784]		46 participants (Actual)	Observational	2015-01-31	Active, not recruiting
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants [NCT03511118]		1,600 participants (Anticipated)	Observational	2018-10-04	Recruiting
A Phase 4, Double-blind, Randomized, Parallel Group, Placebo-controlled Study Of The Efficacy And Safety Of Methylphenidate Hydrochloride (Hcl) Extended Release Chewable Tablet (Erct) In 4-5 Year Old Children With Attention Deficit Hyperactivity Disorder [NCT03536390]	Phase 4	0 participants (Actual)	Interventional	2018-09-19	Withdrawn(stopped due to The study was cancelled prior to the enrollment of any participants.)
PHASE IIA: Randomized, Double Blind, Placebo Controlled, Single Center Clinical Trial of a Combination of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®) [NCT01377662]	Phase 2	30 participants (Actual)	Interventional	2011-08-31	Completed
A Novel Drug Combination as a Pharmacotherapeutic for Methamphetamine-Use Disorder [NCT04178993]	Phase 1	8 participants (Actual)	Interventional	2019-09-01	Completed
Symptomatic Treatment of Vascular Cognitive Impairment [NCT02098824]	Phase 2/Phase 3	30 participants (Anticipated)	Interventional	2014-02-28	Recruiting
A Randomized Controlled Trial of Methylphenidate and a Nursing Telephone Intervention (NTI) for Fatigue in Advanced Cancer Patients [NCT00424099]	Phase 2/Phase 3	197 participants (Actual)	Interventional	2007-01-09	Completed
Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans [NCT06081179]	Phase 1	120 participants (Anticipated)	Interventional	2023-10-24	Recruiting
A Phase 4, Double-blind, Randomized, Parallel Group, Placebo-controlled Study Of The Efficacy And Safety Of Quillichew (Methylphenidate Hydrochloride (Hcl)) Extended Release Chewable Tablets (Erct) In 4-5 Year Old Children With Attention Deficit Hyperacti [NCT03580005]	Phase 4	0 participants (Actual)	Interventional	2018-10-31	Withdrawn(stopped due to The study was cancelled prior to the enrollment of any participants.)
Effect of Methylphenidate on Ecologic Function in Paediatric Acquired Brain Injury Population [NCT02227056]	Phase 2	34 participants (Actual)	Interventional	2014-01-31	Completed
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk [NCT03781765]	Phase 4	44 participants (Anticipated)	Interventional	2019-06-04	Recruiting
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD [NCT03781752]	Phase 4	500 participants (Anticipated)	Interventional	2018-03-04	Enrolling by invitation
Added Value of the Oculomotor and Cognitive Examination in the Management of Patients With Attention Deficit Disorder With or Without Hyperactivity. Interventional Study to Evaluate Current Care [NCT03411434]		90 participants (Anticipated)	Interventional	2014-02-17	Recruiting
A Phase I/II, Single Center, Single-Treatment, Open-Label, Adaptive Clinical Trial Design Examining the Pharmacokinetic Effects of up to Two Separate HLD200 Modified Release Formulations of Methylphenidate in Adolescent and Pediatric Subjects With ADHD [NCT01907360]	Phase 1/Phase 2	29 participants (Actual)	Interventional	2013-08-31	Completed
Impact of CES1 Genotype on Metabolism of Methylphenidate [NCT02147535]	Phase 4	78 participants (Actual)	Interventional	2014-03-31	Completed
Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI [NCT02148783]	Phase 2	11 participants (Actual)	Interventional	2014-09-30	Terminated(stopped due to Recruitment was slower than anticipated. Incomplete neuropsychological outcome measures obtained.)
Efficacy and Safety of Transdermal Methylphenidate for Cancer-Related Fatigue [NCT01124500]		0 participants (Actual)	Interventional	2010-05-31	Withdrawn
Comparing the Efficacy of Methylphenidate, Dextroamphetamine and Placebo in Children Diagnosed With ADHD [NCT01220440]	Phase 4	36 participants (Actual)	Interventional	2006-01-31	Completed
[NCT01124032]		30 participants (Anticipated)	Interventional	2010-05-31	Not yet recruiting
Efficacy of Cognitive Behavioral Therapy in Treatment of Adults With Attention Deficit Hyperactivity Disorder [NCT02210728]		200 participants (Anticipated)	Interventional	2006-04-30	Active, not recruiting
A Randomized, Double Blind, Placebo Controlled Trial To Study Difference In Cognitive Learning Associated With Repeated Self-administration Of Remote Computer Tablet-based Application Assessing Dual-task Performance Based On Amyloid Status In Healthy Elde [NCT02265718]		97 participants (Actual)	Observational	2014-09-30	Completed
A Phase II, Open-Label Co-Administration Study of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD) [NCT00151996]	Phase 2	75 participants (Actual)	Interventional	2004-08-16	Completed
Randomized Placebo-Controlled Trial of Methylphenidate for the Treatment of Post-Traumatic Stress Disorder With Associated Neurocognitive Complaints [NCT05776056]	Phase 4	70 participants (Anticipated)	Interventional	2023-12-04	Not yet recruiting
[NCT01130467]		150 participants (Anticipated)	Observational	2009-09-30	Recruiting
Influence of Methylphenidate and Duloxetine Maintenance on Pharmacodynamic Effects of Cocaine [NCT03519022]	Early Phase 1	9 participants (Actual)	Interventional	2018-06-01	Completed
The Influence of Dopamine Activity on Neuromuscular Function During Passive Heat Stress [NCT03515668]		6 participants (Actual)	Interventional	2018-04-20	Active, not recruiting
Train Your Brain? Exercise and Neurofeedback Intervention for ADHD [NCT01363544]	Phase 2/Phase 3	112 participants (Actual)	Interventional	2010-06-30	Completed
The Neuroprotective Effects of Methylphenidate and Atomoxetine in Children With Attention Deficit Hyperactivity Disorder: A Lipidomic Study [NCT03936491]		105 participants (Anticipated)	Interventional	2019-08-01	Not yet recruiting
Dopaminergic Modulation of Cognition and Psychomotor Function [NCT01218425]		20 participants (Actual)	Interventional	2010-11-30	Completed
Large-scale Brain Organization During Cognitive Control in ADHD [NCT04349917]	Phase 4	37 participants (Actual)	Interventional	2016-12-16	Completed
Quality Assurance of Administering Methylphenidate in Adults With ADHD [NCT00730249]	Phase 3	150 participants (Anticipated)	Interventional	2008-09-30	Completed
Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease [NCT00393562]		0 participants (Actual)	Interventional	2006-03-31	Withdrawn(stopped due to Unable to recruit any subjects for this study)
Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between Intravenous Methamphetamine and Osmotic-Release Methylphenidate (OROS-MPH) [NCT00603434]	Phase 1	16 participants (Anticipated)	Interventional	2008-01-31	Completed
A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS Methylphenidate (54 and 72 mg/Day) in Adults With Attention Deficit/Hyperactivity Disorder [NCT00714688]	Phase 3	279 participants (Actual)	Interventional	2008-02-29	Completed
Placebo Controlled Double Blind Study With Methylphenidate in Treatment of Adults With Cancer-Related Fatigue [NCT00758407]	Phase 2/Phase 3	66 participants (Anticipated)	Interventional	2006-08-31	Completed
EEG-MRI Study of the Effect of Methylphenidate on Neural Mechanisms in Adult Patients With ADHD With or Without Mood Disorders: a Randomized Controlled Trial Versus Placebo [NCT05832489]	Phase 3	80 participants (Anticipated)	Interventional	2023-10-01	Not yet recruiting
Differences by Sex and Genotype in the Effects of Stress on Executive Functions [NCT04273880]	Phase 1	146 participants (Anticipated)	Interventional	2018-04-28	Recruiting
Studying the Role of Brain Molecules for Decision Making [NCT04384562]		160 participants (Anticipated)	Interventional	2020-12-17	Recruiting
NWP06 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)- A Laboratory Classroom Study [NCT00904670]	Phase 3	45 participants (Actual)	Interventional	2009-04-30	Completed
Stimulant Drug Treatment of AD/HD, Inattentive Type [NCT00824317]		25 participants (Actual)	Interventional	2001-10-31	Completed
The Reinforcing Mechanisms of Smoking in Adult ADHD [NCT00573859]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2006-09-30	Completed
Targeting Neural, Behavioral and Pharmacological Mechanisms of Drug Memories in Drug Addiction With Methylphenidate [NCT05978167]	Early Phase 1	50 participants (Anticipated)	Interventional	2023-07-05	Recruiting
Irritability in Children With ADHD and Emotion Dysregulation: Clinical Profiles, Neuropsychological Characteristics , and Pharmacological Treatment: A Cross-over Study [NCT05974241]	Phase 4	36 participants (Actual)	Interventional	2017-04-21	Completed
Methylphenidate Effect on Performing Humphrey Visual Fields [NCT02162381]		32 participants (Actual)	Interventional	2014-06-30	Completed
Effectiveness of a Personalized Neurofeedback Training Device (ADHD@Home) as Compared With Methylphenidate in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Multicentre Randomized Clinical Study [NCT02778360]	Phase 1/Phase 2	179 participants (Anticipated)	Interventional	2016-08-31	Recruiting
Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD [NCT02473185]	Phase 4	40 participants (Actual)	Interventional	2015-09-30	Completed
Assessing Cognitive Performance Among Adults With Attention Disorders Working on Treadmill [NCT05243186]	Phase 2/Phase 3	30 participants (Anticipated)	Interventional	2021-10-01	Recruiting
Effects of Modafinil, Caffeine and Methylphenidate on Functional Brain Activity and Cognitive Performance in Healthy Volunteers: a Randomized, Placebo-controlled, Double-blind fMRI Study [NCT02071615]		48 participants (Actual)	Interventional	2013-08-31	Completed
Metabolism of Methylphenidate and Enalapril Based on CES1 Genotype [NCT02135263]	Phase 4	44 participants (Actual)	Interventional	2012-04-30	Completed
The Assessment of Efficacy and Tolerability of Methylphenidate vs. Risperidone in the Treatment of Children and Adolescents With ADHD and Disruptive Disorders [NCT02063945]	Phase 4	5 participants (Actual)	Interventional	2017-02-01	Terminated(stopped due to Major difficulties recruiting participants)
Exploration of the Metabolic Mechanisms of the Electrophysiological Biomarkers for Response to Methylphenidate Treatment in Children With Attention-Deficit/Hyperactivity Disorder [NCT06073470]		160 participants (Anticipated)	Observational	2024-01-01	Not yet recruiting
Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI [NCT03326245]	Phase 1	40 participants (Anticipated)	Interventional	2018-01-29	Enrolling by invitation
A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder [NCT00181571]	Phase 4	297 participants (Actual)	Interventional	2003-06-30	Completed
[NCT02194075]	Phase 4	60 participants (Actual)	Interventional	2013-10-31	Completed
Biomarkers of ADHD Treatment Response [NCT05650775]	Phase 1	30 participants (Anticipated)	Interventional	2023-02-17	Recruiting
Measuring and Predicting Response to Atomoxetine and Methylphenidate [NCT00183391]	Phase 4	232 participants (Actual)	Interventional	2005-07-31	Completed
Applied Physiology of Oxygen Toxicity: Mechanisms in Humans [NCT05761756]		62 participants (Anticipated)	Interventional	2024-02-29	Not yet recruiting
Concerta in the Treatment of Adult ADHD and a Comparison of Four Adult ADHD Scales and Effects on Personality [NCT02215538]	Phase 2/Phase 3	47 participants (Actual)	Interventional	2004-11-30	Completed
A Phase IIIb, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Efficacy and Safety of MTS in Adolescents Aged 13-17 Years With ADHD [NCT00499863]	Phase 3	217 participants (Actual)	Interventional	2007-07-31	Completed
Phase III Study of Autism Co-Morbid for Attention Deficit Hyperactivity Disorder [NCT00541346]	Phase 3	16 participants (Actual)	Interventional	2007-09-30	Completed
An Open-label, Behavioral-treatment-controlled Evaluation of the Effects of Extended Release Methylphenidate on the Frequency of Cytogenetic Abnormalities in Children 6 - 12 Years of Age With Attention Deficit Hyperactivity Disorder (ADHD) [NCT00409708]	Phase 2	142 participants (Actual)	Interventional	2006-11-30	Completed
Sustained-Release Methylphenidate for Management of Methamphetamine Dependence [NCT01044238]	Phase 2	90 participants (Anticipated)	Interventional	2010-10-31	Active, not recruiting
Methylphenidate (Ritalin) and Memory/Attention in Traumatic Brain Injury (TBI) [NCT00453921]		76 participants (Actual)	Interventional	2007-02-28	Completed
Evaluating Assessment and Medication Treatment of ADHD in Children With Down Syndrome [NCT04219280]	Phase 4	100 participants (Anticipated)	Interventional	2020-10-02	Recruiting
A Phase IV, Multi-center, Open-label Study of DAYTRANA (Methylphenidate Transdermal System [MTS]) to Characterize the Dermal Reactions in Pediatric Patients Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD). [NCT00434213]	Phase 4	309 participants (Actual)	Interventional	2007-01-31	Completed
Carnitine as an Adjunct to Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder Children and Adolescents in the Placebo Control Double -Blind Randomized Clinical Trail [NCT01099072]	Phase 2	40 participants (Anticipated)	Interventional	2010-04-30	Enrolling by invitation
The Effects of Methylphenidate on the Reduction of Food Energy Intake and on the Augmentation of Energy Expenditure [NCT02754258]	Phase 3	40 participants (Anticipated)	Interventional	2017-01-31	Recruiting
Early Interventions in Children With Attention Deficit/Hyperactivity Disorder: Randomized Controlled Trial Comparing Methylphenidate Parental Training in Treating Preschool Children With Attention Deficit / Hyperactivity Disorder [NCT02807870]	Phase 4	153 participants (Actual)	Interventional	2016-06-30	Completed
Comparison of the Effects of Cognitive-Motor Rehabilitation, Stimulant Drugs, and Active Control on Executive Functions and Clinical Symptoms of Attention Deficit/ Hyperactivity Disorder [NCT02780102]		48 participants (Actual)	Interventional	2015-09-30	Completed
Concerta-to-Generic Switch Study [NCT02730572]		1,464 participants (Actual)	Observational	2015-09-30	Completed
Imaging of Dopamine Systems in Anorexia Nervosa [NCT00670293]		50 participants (Actual)	Observational	2008-07-31	Completed
Does Methylphenidate, Prescribed for Attention Deficit Disorder, Influence Primary Enuresis in These Children? [NCT02699528]		50 participants (Anticipated)	Observational	2016-05-31	Recruiting
Treatments for Fathers With Attention Deficit/Hyperactivity Disorder (ADHD) and Their At-Risk Children (Fathers Too) [NCT02675400]	Phase 4	19 participants (Actual)	Interventional	2015-12-31	Completed
Fatigue in Sarcoidosis - A Feasibility Study Investigating the Treatment of Fatigue in Stable Sarcoidosis Patients Using Methylphenidate [NCT02643732]		30 participants (Anticipated)	Interventional	2016-11-30	Recruiting
Acute Effect of Three Neuroactive Drugs on Brain Activity Measured by MEG, EEG and the Synchronous Neural Interaction Test [NCT00972985]		15 participants (Anticipated)	Interventional	2009-09-30	Completed
Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine, a Post-authorization Safety Study [NCT04132557]		430,000 participants (Actual)	Observational	2019-10-09	Completed
Pediatric Attention Deficit Hyperactivity Disorder: Predicting Clinical Response to Stimulant Medication From Single-dose Changes in Event Related Potentials [NCT02695355]	Phase 2	87 participants (Actual)	Interventional	2006-10-31	Completed
Effect of Methylphenidate Formulation on ADHD-patients' Adherence to Medical Treatment. A Comparison of Medikinet Retard® (ER) Once Daily and Medikinet® (IR) Twice Daily in Children and Adolescents Diagnosed With ADHD [NCT00852059]	Phase 4	32 participants (Actual)	Interventional	2009-03-31	Terminated(stopped due to Diffculties to recruit anticipated study size, now analysis)
Investigating Fundamental Mechanisms of Mental and Physical Fatigue Using Neurotransmitter Reuptake Inhibitors and Electroencephalography: a Randomized Counterbalanced Crossover Trial [NCT05880342]	Phase 3	62 participants (Anticipated)	Interventional	2023-05-03	Recruiting
An Eight-Week, Randomized, Double-Blind Comparison of Guanfacine, Focalin XR, and the Combination, With a Twelve Month Open-Label Extension for the Treatment of ADHD in Pediatric Subjects Aged 7 to 14 Years [NCT00429273]	Phase 4	212 participants (Actual)	Interventional	2007-01-31	Completed
An Open International Multicentre Long-Term Follow Up Study to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder [NCT00307684]	Phase 3	155 participants (Actual)	Interventional	2006-01-31	Completed
Medications Development for Drug Abuse Disorders [NCT00499746]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2007-11-30	Completed
A Double-blind, Randomized, Placebo-controlled, Crossover Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults [NCT00302458]	Phase 4	44 participants (Actual)	Interventional	2006-01-31	Completed
Randomized, Observer-blind, Placebo-controlled, Four-way Cross-over Study to Study the Ability of Functional Magnetic Resonance Imaging (fMRI) of the Brain to Detect and Characterize the Effects of Single Doses of a Selective Serotonin Reuptake Inhibitor [NCT01045083]	Phase 1	25 participants (Actual)	Interventional	2010-01-31	Completed
A Controlled Trial of Citalopram Added to Methylphenidate in Youth With Severe Mood Dysregulation [NCT00794040]	Phase 2	103 participants (Actual)	Interventional	2008-11-17	Completed
Further Studies of Attention Deficit Disorder - Residual Type [NCT00693212]	Phase 3	116 participants (Actual)	Interventional	1986-02-28	Completed
A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity [NCT00763971]	Phase 3	336 participants (Actual)	Interventional	2008-11-17	Completed
From Immediate-release MPH to OROS MPH: The Impact Upon Family of Children and Adolescents With ADHD [NCT00758160]	Phase 4	296 participants (Actual)	Interventional	2008-03-31	Completed
A Double-Blind, Double-Dummy, Placebo-Controlled, Dose Ranging Study of 7.5, 15, and 30 mg of Sublingual Lobeline in Adult ADHD Patients [NCT00664703]	Phase 2	13 participants (Actual)	Interventional	2008-07-31	Completed
A Phase IV, Real World, Open-label, Multi-centre Study on the Use of FOQUEST® (Methylphenidate Hydrochloride Controlled-release Capsules) for the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Pediatric and Adult Patients [NCT04152629]	Phase 4	257 participants (Actual)	Interventional	2019-09-19	Completed
Comparative Crossover Study of OROS (Methylphenidate HCl), Ritalin, and Placebo in Children With ADHD [NCT00269789]	Phase 3	0 participants	Interventional	1998-03-31	Completed
Learning Impairments Among Survivors of Childhood Cancer [NCT00576472]	Phase 4	469 participants (Actual)	Interventional	2000-01-31	Completed
A Randomized, Multi-center, Double-blind, Placebo-controlled, Cross-over Study Evaluating the Safety and Efficacy of Dex-Methylphenidate Extended Release 30 mg vs. 20 mg as Measured by SKAMP-Combined Scores in Children With Attention-Deficit/Hyperactivity [NCT00776009]	Phase 4	165 participants (Actual)	Interventional	2008-10-31	Completed
Effects of Methylphenidate on Postural Stability of Old Adults Under Single and Dual Task Conditions. [NCT00817960]		30 participants (Actual)	Interventional	2011-07-31	Completed
Neurobiological Principles Applied to the Rehabilitation of Stroke Patients [NCT00715520]		33 participants (Actual)	Interventional	2007-04-30	Completed
Association Between Norepinephrine Transporter Polymorphism and Response of Methylphenidate [NCT00757029]	Phase 4	150 participants (Anticipated)	Interventional	2005-10-31	Completed
A Single-Center, Single-Blind, Randomized, Oral Dose Cross-Over Study in Prepuberal Boys With ADHD to Investigate Efficacy and Bioequivalence of 20 mg Ritalin LA Compared to 20 mg Medikinet Retard After Treatment With o.d. Doses Over 7 Days Each. [NCT00772161]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2008-10-31	Completed
A 12-Month Open Label Safety Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR®) in Children Ages 4-5 Years Diagnosed With Attention-Deficit/Hyperactivity Disorder (ADHD) [NCT02677519]	Phase 4	120 participants (Anticipated)	Interventional	2016-09-30	Not yet recruiting
Double-Blind Randomized Trial of Methylphenidate for Alleviation of Fatigue and Lethargy Associated With Interferon Alpha 2b [NCT00003266]	Phase 3	200 participants (Anticipated)	Interventional	1999-10-12	Completed
Assessing the Effect of Missing Doses (Off-Days) of Daily Medication in Patients Stable on Pharmacotherapy for ADHD Receiving Atomoxetine or OROS Methylphenidate: A Parallel Matched Group Clinical Study (On/Off Study) [NCT01127646]	Phase 4	23 participants (Actual)	Interventional	2010-06-30	Terminated(stopped due to Due to lack of availability of study participants to accommodate the study design)
The Role of Methylphenidate on Performance in the Cold [NCT04283877]	Phase 4	24 participants (Anticipated)	Interventional	2019-12-15	Active, not recruiting
Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy [NCT01410942]	Phase 2	175 participants (Anticipated)	Interventional	2012-02-29	Active, not recruiting
Methylphenidate and Response to Alcohol Cues (MARA) Pilot Study [NCT06063200]	Early Phase 1	30 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
Functional Brain Markers and Predictors of Treatment Response Associated With Norepinephrine System Genes in ADHD [NCT00862108]	Phase 4	50 participants (Anticipated)	Interventional	2008-09-30	Recruiting
Near-infrared Spectroscopy Neurofeedback as a Treatment for Children With Attention Deficit Hyperactivity Disorder [NCT04065906]		90 participants (Anticipated)	Interventional	2019-01-15	Recruiting
Orexin's Role in The Neurobiology of Substance Use Disorder [NCT05630781]		140 participants (Anticipated)	Interventional	2023-02-15	Recruiting
[NCT00815841]	Phase 4	50 participants (Anticipated)	Interventional	2009-01-31	Not yet recruiting
A Cognitive Behavioral Therapy Group Intervention for Adolescents With Attention-Deficit / Hyperactivity Disorder [NCT02566824]	Phase 4	216 participants (Anticipated)	Interventional	2010-10-31	Recruiting
Title: Eye Tracking as a Predictor of Methylphenidate Response in Autism With Co-morbid Attention Deficit Hyperactivity Disorder [NCT02874690]	Early Phase 1	40 participants (Actual)	Interventional	2016-02-19	Completed
Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth [NCT01109849]	Phase 3	230 participants (Actual)	Interventional	2010-11-30	Completed
Apathy in Dementia Methylphenidate Trial (ADMET) [NCT01117181]	Phase 2	60 participants (Actual)	Interventional	2010-06-30	Completed
The Effect of the Drug Methylphenidate on Physiological Stress and Function During Exposure to Exercise and Heat Stress in ADD/ADHD Treated Patients [NCT02704546]		20 participants (Anticipated)	Interventional	2016-04-30	Not yet recruiting
Genetic Polymorphism of Drug Transporters in OROS-Methylphenidate Treatment in Children and Adolescents With Attention Deficit Hyperactivity Disorder(ADHD) [NCT00842127]	Phase 4	150 participants (Actual)	Interventional	2006-03-31	Completed
Phase 1,Randomized,Open-Label,Two Period Single Dose Crossover Bioequivalence Study of Two Capsule Strengths of SPD544 In Healthy Volunteers. [NCT01183234]	Phase 1	28 participants (Actual)	Interventional	2010-08-27	Completed
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder. [NCT00863499]	Phase 4	1,344 participants (Anticipated)	Interventional	2009-10-31	Active, not recruiting
Efficacy of Methylphenidate for Treating Tobacco Dependence [NCT00549640]	Phase 2	80 participants (Actual)	Interventional	2008-01-31	Completed
The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors [NCT00768820]	Phase 4	400 participants (Anticipated)	Interventional	2001-05-31	Recruiting
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study [NCT00376675]	Phase 3	148 participants (Actual)	Interventional	2008-02-29	Completed
Comprehensive Pathophysiological Study Based on the Core Neurocognitive Deficits and Development of Biological Markers of Treatment Response in Attention Deficit Hyperactivity Disorder [NCT02623114]	Phase 4	400 participants (Anticipated)	Interventional	2012-05-31	Recruiting
[NCT00773916]	Phase 4	130 participants (Anticipated)	Interventional	2006-03-31	Completed
A Multicenter Open Trial to Evaluate the Effectiveness and Quality of Life in Adults With Attention Deficit /Hyperactivity Disorder (ADHD) Treated With Long Acting Methylphenidate (CONCERTA) [NCT00783835]	Phase 4	60 participants (Actual)	Interventional	2008-02-29	Completed
A Study to Assess the Sensitivity of Project: EVO Monitor Cognitive Function Measurements to Methylphenidate and Triazolam in Adults 40-55 Years Old [NCT02822937]		18 participants (Actual)	Interventional	2016-07-31	Completed
The Effects of ADHD Medication (TEAM) Study: Neurobehavioral Effects of Abrupt Methylphenidate Discontinuation [NCT02293655]	Phase 4	204 participants (Actual)	Interventional	2015-01-12	Completed
A Randomized Placebo-controlled Trial of Methylphenidate in Veterans With a Diagnosis of Post Traumatic Stress Disorder and Recent Cerebral Stroke. [NCT04885257]	Phase 2	60 participants (Anticipated)	Interventional	2022-01-14	Recruiting
Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity [NCT03481959]	Phase 3	3 participants (Actual)	Interventional	2019-05-07	Terminated(stopped due to insufficient recrutement in the study)
An Open-label Prospective Trial to Evaluate Functional Outcomes of OROS Methylphenidate in Children With ADHD (FOSCO) [NCT01012622]	Phase 4	142 participants (Actual)	Interventional	2008-09-30	Completed
Randomized Clinical Trial: 03 (Methylphenidate and Duloxetine) [NCT02700711]	Phase 1	13 participants (Actual)	Interventional	2016-02-29	Completed
Methylphenidate for the Treatment of Gain Impairment in Parkinson's Disease: a Randomized Double-Blind, Placebo-Controlled, Cross-over Study [NCT00526630]	Phase 4	23 participants (Actual)	Interventional	2007-12-31	Completed
The Relation Between Attentional, Sensory and Emotional Dysregulation in Adults With Posttraumatic Stress Disorder: a Double-blind, Placebo-controlled Randomized Controlled Trial of the Combined Treatment With Reboxetine and Methylphenidate [NCT05133804]	Phase 2	53 participants (Anticipated)	Interventional	2022-06-01	Recruiting
A 7 Week Multicenter, Double-Blind, Randomized, Placebo-Controlled Cross-Over Evaluation of the Efficacy and Safety of Two Different Brands of Modified-Release Oral Dosage Forms of Methylphenidate-HCl (20 mg, q.d.) in Children With Attention Deficit Hyper [NCT00254878]	Phase 3	130 participants	Interventional	2005-10-31	Completed
Cocaine-Methylphendidate Interaction Study [NCT00015067]	Phase 1	8 participants	Interventional	1997-12-31	Completed
Methyphendidate in the Treatment of Cocaine Dependent Patients With Adult ADHD [NCT00015223]	Phase 2	0 participants	Interventional	1997-06-30	Completed
Methylphenidate Raclopride PET Test [NCT00015301]	Phase 4	0 participants	Interventional	2003-12-31	Completed
Methylphenidate Study in Young Children With Developmental Disorders [NCT00517504]	Phase 4	48 participants (Actual)	Interventional	2001-05-31	Completed
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product. [NCT00151983]	Phase 3	175 participants (Actual)	Interventional	2005-06-30	Completed
Efficacy and Safety/Tolerability of Methylphenidate Transdermal System (MTS) for Before-School Dysfunction in Children With Attention Deficit Hyperactivity Disorder (ADHD) [NCT00586157]	Phase 4	36 participants (Actual)	Interventional	2006-09-30	Completed
Long-Duration Stimulant Treatment of ADHD in Young Children-Feasibility Study [NCT00257725]	Phase 4	11 participants (Actual)	Interventional	2005-03-31	Completed
Comportemental and Neuropsychologic Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate. A Double-blind Randomised Study Methylphenidate Versus Placebo [NCT00169611]	Phase 4	80 participants (Anticipated)	Interventional	2004-01-31	Completed
A Phase IIB, Randomized, Double-blind, Multi-Center, Placebo-Controlled, Dose-Optimization, 3-way Cross-Over, Analog Classroom Study to Assess the Efficacy, Duration of Effect, Tolerability and Safety of 4- and 6- Hour Wear Times of Methylphenidate Transd [NCT00151970]	Phase 2	128 participants (Actual)	Interventional	2005-06-30	Completed
A Pilot Study of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers With ADHD [NCT00253747]	Phase 3	255 participants (Actual)	Interventional	2005-11-30	Completed
Treatment of College Students With ADHD Using OROS Methylphenidate [NCT00931398]	Phase 4	0 participants (Actual)	Interventional	2010-04-30	Withdrawn(stopped due to Study was not initiated due to lack of funding by the sponsor)
An Open-label, Randomized, Rater-blinded, Cross-over, Multicenter Study Comparing the Clinical Efficacy of Methylphenidate (Immediate Release/Extended Release) Treatment (20 or 40 mg Orally od) in Children With Attention-Deficit Hyperactivity Disorder (AD [NCT00428792]	Phase 3	150 participants (Actual)	Interventional	2007-04-30	Completed
The Effect of Methylphenidate on Decision-making Ability of ADHD Adults [NCT01040702]	Phase 1	58 participants (Actual)	Interventional	2008-01-31	Completed
A Randomized, Double Blind, Two Period, Placebo-Controlled Crossover Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients [NCT00516269]	Phase 3	42 participants (Actual)	Interventional	2004-08-31	Terminated(stopped due to Slow Accrual)
Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD [NCT00506285]	Phase 3	92 participants (Actual)	Interventional	2007-06-30	Completed
A Phase IIIb, Long-Term, Open-Label, Multi-Center, Extension Study Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) [NCT00501293]	Phase 3	163 participants (Actual)	Interventional	2007-08-31	Completed
Methylphenidate Modified-release as Treatment of MS-associated Fatigue. A Single-center Randomized Double-blind Placebo-controlled Study. [NCT01879202]	Phase 2	96 participants (Anticipated)	Interventional	2012-12-31	Recruiting
The Effect of Ritalin (Methylphenidate Hydrochloride) on Pain and Auditory Sensitivity: an Exploratory Double-blind Randomized Controlled Trial on Healthy Subjects [NCT01914822]	Phase 2	41 participants (Actual)	Interventional	2013-07-31	Completed
A Double-Blind Placebo-Controlled Study of Combination Therapy in Children With ADHD [NCT01940978]	Phase 4	99 participants (Actual)	Interventional	2014-03-31	Completed
Efficacy and Safety of Generic Methylphenidate Prolong-released Comparison With Original in Child With Attention-deficit-hyperactive Disorders [NCT05410626]		78 participants (Anticipated)	Interventional	2022-06-01	Not yet recruiting
Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study [NCT01951508]	Early Phase 1	24 participants (Actual)	Interventional	2013-10-31	Completed
Clinical Study Protocol: Evaluation of the Efficiency of Ritalin in Multiple Sclerosis Patients [NCT00220493]	Phase 1	80 participants	Interventional	2003-06-30	Recruiting
Identifying Characteristic Signature of Brain Activity of Electroencephalogram Records in Attention Deficit / Hyperactivity Disorder (ADHD) and Ritalin Treatment [NCT01962181]		40 participants (Anticipated)	Interventional	2013-10-31	Not yet recruiting
Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Methylphenidate Hydrochloride as a Treatment for Chronic Fatigue Syndrome in Patients Taking a CFS-Specific Nutrient Formula [NCT01966276]	Phase 2	134 participants (Actual)	Interventional	2013-11-30	Active, not recruiting
The Effects of a Single Dose of Methylphenidate on Motor Performance [NCT04283604]	Phase 4	200 participants (Anticipated)	Interventional	2021-05-27	Recruiting
Preschool Supplement to Clonidine in ADHD (Kiddie-CAT) [NCT00414921]	Phase 2	30 participants (Actual)	Interventional	2003-09-30	Completed
Evaluation and Treatment of Autonomic Failure. [NCT00223691]	Phase 1	389 participants (Actual)	Interventional	2002-03-31	Completed
The Control of Brain Networks After Traumatic Brain Injury: a Neuroimaging and Neuropsychological Study of Dopamine and Cognition [NCT02015949]	Phase 4	40 participants (Actual)	Interventional	2014-02-28	Completed
A Crossover Study on the Effect of Methylphenidate (MPH) on Cognitive Abilities of Adults With Bipolar Disorder (BD), During Remission or Depressed State, Compared With Healthy Adults and Adults With Attention Deficit Hyperactivity Disorder (ADHD). [NCT02020200]		40 participants (Anticipated)	Interventional	2014-01-31	Not yet recruiting
Effects of Methylphenidate (Ritalin®) on the Neural Basis of Anxiety: a Placebo-controlled fMRI Study in Healthy Male Subjects [NCT02021214]	Early Phase 1	24 participants (Actual)	Interventional	2014-03-31	Completed
The Role of Dopamine in the Central Neural Signature of Chronic Pain [NCT05285683]	Phase 2	10 participants (Anticipated)	Interventional	2023-01-01	Recruiting
Brain Dopamine Function in Adults With ADHD [NCT00580814]		24 participants (Actual)	Interventional	2006-02-28	Completed
[NCT01683032]		38 participants (Actual)	Interventional	2012-10-31	Completed
A Phase II, Randomized, Double-blind, Placebo Controlled Trial of Methylphenidate Hydrochloride for Reduction of Fatigue in Prostate Cancer Patients Receiving LHRH-Agonist Therapy [NCT00593853]	Phase 2	33 participants (Actual)	Interventional	2008-01-31	Terminated(stopped due to Slow Accrual)
A Randomized Open-label Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate (20 mg, 30 mg, and 40 mg) as Measured With C-11 Altropane in Healthy Adult Volunteers [NCT00593138]	Phase 1/Phase 2	23 participants (Actual)	Interventional	2006-12-31	Completed
Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral and Cognitive Effects of CONCERTA on Older Children With ADHD (The ABC Study) [NCT00799487]	Phase 4	89 participants (Actual)	Interventional	2009-01-02	Completed
The ABC Study: A Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral, and Cognitive Effects of CONCERTA on Older Children With ADHD [NCT00799409]	Phase 4	78 participants (Actual)	Interventional	2008-12-31	Completed
Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan: A Retrospective Cohort Study of Label Compliance [NCT04113551]		17,418 participants (Actual)	Observational	2019-10-01	Completed
Effect of OROS-Methylphenidate (Concerta) on Different Domains of Attention and Working Memory in Children With Attention-Deficit/Hyperactivity Disorder [NCT00530257]	Phase 4	30 participants (Actual)	Interventional	2004-06-30	Completed
A Pilot Study of Proton Magnetic Spectroscopy in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) Before and After Treatment With Osmotic-controlled Release Oral Delivery System (OROS) Methylphenidate [NCT00593112]	Phase 4	39 participants (Actual)	Interventional	2006-11-30	Completed
Benefits of In-prison OROS-methylphenidate vs. Placebo Treatment in Detained People With Attention-deficit/Hyperactivity Disorder: A Randomized Controlled Trial [NCT05842330]	Phase 3	150 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
Effect of a Polyphenol-rich Plant Extract on Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Double Blind, Placebo and Active Product Controlled Multicenter Trial. [NCT02700685]	Phase 3	88 participants (Actual)	Interventional	2017-09-01	Completed
A 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate HCl Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD [NCT01259492]	Phase 3	725 participants (Actual)	Interventional	2010-11-30	Completed
A Fixed-Dose, Randomized, Double-Blind, Placebo-Controlled Study of LY2216684 in Pediatric Patients With Attention Deficit/Hyperactivity Disorder [NCT00922636]	Phase 2/Phase 3	340 participants (Actual)	Interventional	2009-06-30	Completed
A Phase 1, Open-label, Randomized, Three-period Crossover Drug Interaction Study Evaluating the Pharmacokinetic Profiles of SPD503 and CONCERTA, Administered Alone and in Combination in Healthy Adult Volunteers [NCT00901576]	Phase 1	38 participants (Actual)	Interventional	2009-05-18	Completed
Evaluation of the Ability for Monitoring Dynamics in ADD/ADHD With an Easy to Use EEG [NCT02625805]		30 participants (Actual)	Interventional	2016-04-30	Completed
Effects of Methylphenidate on Neuropsychological Functioning in Children With Attention Deficits Secondary to Childhood Cancer [NCT01100658]		1 participants (Actual)	Interventional	2010-05-31	Terminated(stopped due to Due to slow accrual)
Placebo-Controlled Multi-Centre Double-Blind Trial for Adults With Extended-Release Methylphenidate for ADHD [NCT00619840]	Phase 3	363 participants (Actual)	Interventional	2004-11-30	Completed
Methylphenidate for Cancer-Related Fatigue: A Pilot N-of-1 Study [NCT01164956]	Phase 1	3 participants (Actual)	Interventional	2011-07-31	Terminated(stopped due to Insufficient Resources)
Intervention for Teens With ADHD and Substance Use [NCT02502799]	Phase 3	158 participants (Actual)	Interventional	2015-07-31	Terminated
Dose Response Pharmacogenetic Study of ADHD [NCT00663442]	Phase 4	48 participants (Actual)	Interventional	1999-12-31	Completed
Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentric Trial [NCT00914095]	Phase 4	69 participants (Actual)	Interventional	2009-10-31	Completed
Response Variability in Children With ADHD [NCT01238822]	Phase 4	96 participants (Actual)	Interventional	2006-06-30	Completed
Comparing Treatment With Melatonin to Treatment With Stimulants (Methylphenidate) in Children With Attention Deficit Hyperactivity Disorder and Sleep Difficulties [NCT01393574]	Phase 4	46 participants (Anticipated)	Interventional	2011-06-30	Recruiting
Ameliorating Attention Problems in Children With SCD [NCT01411280]	Phase 3	34 participants (Actual)	Interventional	2006-06-30	Completed
Randomized Controlled Trial of Galantamine, Methylphenidate, and Placebo for the Treatment of Cognitive Symptoms in Patients With Traumatic Brain Injury (TBI) and/or Posttraumatic Stress Disorder (PTSD) [NCT01416948]	Phase 2	32 participants (Actual)	Interventional	2011-08-31	Terminated(stopped due to The funding agency, DoD, determined that the study could not meet its enrollment numbers by the end of the grant.)
Phase 2/3 Study of Efficacy and Tolerability of Methylphenidate in the Treatment of Excessive Daytime Sleepiness in Myotonic Dystrophy Type 1 [NCT01421992]	Phase 2/Phase 3	28 participants (Actual)	Interventional	2008-06-30	Completed
A Double Blind Crossover Study on the Effect of Methylphenidate on Decision-making Ability of Adults With Borderline Personality Disorder (BPD) Compared to Adults With Attention Deficit Hyperactivity Disorder (ADHD) and Healthy Adults [NCT01426984]		20 participants (Anticipated)	Interventional	2012-05-31	Recruiting
Cognitive vs. Emotional Psycho-Pharmacological Manipulations of Fear vs. Anxiety [NCT02153944]	Phase 4	142 participants (Actual)	Interventional	2014-06-16	Completed
A Multi-center Randomized Parallel Group Study Evaluating Treatment Outcomes of Concerta (Extended Release Methylphenidate) and Strattera (Atomoxetine) in Children With Attention-deficit/Hyperactivity Disorder [NCT00866996]	Phase 4	1,323 participants (Actual)	Interventional		Completed
Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study [NCT00495820]	Phase 4	60 participants (Actual)	Interventional	2007-08-31	Completed
The Relative Efficacy of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD) Versus Medication Only and the Combination of the Two: A Pilot Study [NCT02788851]		70 participants (Anticipated)	Interventional	2016-04-30	Active, not recruiting
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Incomplete Block, Two-period, Crossover Clinical Trial to Study the Safety and Efficacy of MK0249, 10 mg, for Adult Patients, Ages 18 to 55, With Attention Deficit Hyperactivity Disorder (ADHD) [NCT00475735]	Phase 2	72 participants (Actual)	Interventional	2007-07-31	Completed
Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD [NCT04781972]	Phase 4	30 participants (Anticipated)	Interventional	2021-07-27	Recruiting
Naturalistic Study of ADHD Medication and Predictors of Treatment Outcome [NCT02136147]		632 participants (Actual)	Observational [Patient Registry]	2015-06-30	Completed
An Assessment of the Drug Interaction Potential Between Oral Cannabidiol (Epidiolex®) and the CES1 Substrate Methylphenidate in Healthy Volunteers [NCT04603391]	Phase 4	12 participants (Actual)	Interventional	2021-02-25	Completed
A Single Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy of PR OROS Methylphenidate Followed by Open-Label Extension, in Swedish Male Prison Inmates With ADHD [NCT00482313]	Phase 3	30 participants (Actual)	Interventional	2007-05-31	Completed
Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients: a Randomized, Mono-blind Pilot Trial [NCT00599287]	Phase 3	80 participants (Anticipated)	Interventional	2008-02-29	Terminated(stopped due to Inclusion rate too low due to a lack of eligible patients and difficulties obtaining informed consent.)
A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride Augmented With Either Extended-Release Methylphenidate Hydrochloride (Concerta-TM) or Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Who Have Not Responded to Sti [NCT00485550]	Phase 3	14 participants (Actual)	Interventional	2004-01-31	Completed
Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer [NCT05474846]	Phase 2/Phase 3	188 participants (Anticipated)	Interventional	2022-11-21	Recruiting
Single and Combined Effects of Positive Behavior Support, Medication and Academic Accommodation for Children With ADHD [NCT05469386]	Phase 4	288 participants (Anticipated)	Interventional	2022-06-13	Recruiting
Methylphenidate Treatment of Children and Adolescents Diagnosed With ADHD and Its Influence on Comorbid Trichotillomania [NCT00552266]	Phase 4	30 participants (Anticipated)	Interventional	2007-10-31	Recruiting
Adjunctive Methylphenidate Extended Release in Patients With Schizophrenia: a Single-centre Fixed Dose Cross-over Open-label Trial to Improve Functional and Cognitive Outcomes [NCT05414058]	Phase 2	24 participants (Anticipated)	Interventional	2022-09-09	Recruiting
[NCT00446537]	Early Phase 1	0 participants	Interventional		Not yet recruiting
Acoustic and Vestibular Noise as Possible Non-pharmacological Treatments of ADHD in School Children [NCT03425669]		70 participants (Anticipated)	Interventional	2019-05-01	Recruiting
[NCT01821170]		51 participants (Actual)	Interventional	2013-04-01	Completed
Double-Blind, Placebo-Controlled Trial of Flexible Dose Divalproex Sodium Adjunctive to Stimulant Treatment for Aggressive Children With Attention-Deficit Hyperactivity Disorder [NCT00228046]	Phase 4	40 participants (Anticipated)	Interventional	2004-01-31	Completed
A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study To Evaluate the Safety And Efficacy Of Prolonged Release OROS Methylphenidate Hydrochloride (18, 36 and 72 mg/Day), With Open-Label Extension, In Adults With [NCT00246220]	Phase 3	402 participants (Actual)	Interventional	2005-03-31	Completed
Screening, Efficacy, and Safety Study Evaluating OROS (Methylphenidate HCl), Ritalin and Placebo in Children With ADHD [NCT00269776]	Phase 3	0 participants	Interventional	1998-11-30	Completed
Long-term Safety and Effectiveness of OROS (Methylphenidate HCl) in Children With ADHD [NCT00269815]	Phase 3	0 participants	Interventional		Completed
A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults [NCT00301639]	Phase 3	40 participants	Interventional	2005-03-31	Completed
The Effectiveness of CONCERTA® vs. Usual Clinical Care With Immediate Release Methylphenidate (IR MPH) in Children (6-12 Years) With Attention Deficit Hyperactivity Disorder (ADHD): A Randomized, Open-Label Trial [NCT00304681]	Phase 3	147 participants (Actual)	Interventional		Completed
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits: a Randomized, Double-blind, Placebo-controlled Trial [NCT04419272]	Phase 4	226 participants (Anticipated)	Interventional	2023-08-14	Recruiting
Double Blind, Placebo Controlled, Crossover Study of Extended Release Methylphenidate for Treatment of ADHD in Children With Epilepsy [NCT00323947]	Phase 4	33 participants (Actual)	Interventional	2003-05-31	Completed
Methylphenidate Treatment for Cocaine Abuse and ADHD [NCT00136734]	Phase 1	124 participants (Actual)	Interventional	1998-04-30	Completed
Psychostimulants for Fatigue in Advanced Prostate Cancer [NCT00138138]	Phase 2	120 participants	Interventional	2002-10-31	Completed
Methylphenidate Treatment of ADHD in Children With Tourette Syndrome [NCT00441649]		71 participants	Interventional	2000-02-29	Completed
A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) vs. CONCERTA® in Pediatric Patients Aged 6-12 With A [NCT00444574]	Phase 3	282 participants (Actual)	Interventional	2004-09-30	Completed
Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD) [NCT00483106]	Phase 4	885 participants (Actual)	Interventional	1999-11-30	Completed
Effects of Methylphenidate on Postural Stability of Children Suffer From Attention Deficit Hyperactivity Disorder (ADHD) Under Single and Dual Task Conditions. [NCT00485797]		30 participants (Actual)	Interventional	2007-10-31	Completed
Two-phase Randomized Controlled Trial of Low and Moderate Dose Methylphenidate for Non-motor and Postural Symptoms in Parkinson's Disease. [NCT01244269]	Phase 4	6 participants (Actual)	Interventional	2010-12-31	Terminated(stopped due to Inadequate enrolment, protocol too challenging for participants, lack of observable benefit after analysis of 6 patients.)
Effects of Methylphenidate on Resting State Connectivity in Healthy Controls and in Adults With Attention Deficit Hyperactivity Disorder. [NCT01764672]	Phase 4	0 participants (Actual)	Interventional	2013-04-30	Withdrawn
Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Children and Adolescents With ADHD [NCT06077669]	Phase 4	80 participants (Anticipated)	Interventional	2024-01-20	Not yet recruiting
Efficacy of Concerta in Treating ADHD in Mothers of Children With ADHD [NCT00318981]	Phase 4	40 participants	Interventional	2004-12-31	Completed
A Randomized, Multi-center, Double-blind, Cross-over Study Comparing the Efficacy and Safety of Focalin® XR 20 mg Versus Placebo at the 0.5 Hour Timepoint (Post-dose) in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Labor [NCT00564954]	Phase 4	86 participants (Actual)	Interventional	2007-10-31	Completed
Stimulant and Risperidone in Children With Severe Physical Aggression [NCT00796302]	Phase 4	168 participants (Actual)	Interventional	2008-08-31	Completed
Enhancing Attention in Adults With Compulsive Hoarding: A Pilot Study [NCT01100268]	Phase 2	4 participants (Actual)	Interventional	2010-04-30	Completed
Association Between Motorcycle Accidents, Attention Deficit/Hyperactivity Disorder and Substance Use Disorder and Motorcycle Accidents [NCT00536419]	Phase 4	53 participants (Anticipated)	Interventional	2007-09-30	Recruiting
An Open-label Study Evaluating the Safety and Effectiveness of OROS Methylphenidate Hydrochloride (CONCERTA) in Adults With Attention Deficit Hyperactivity Disorder [NCT00246207]	Phase 3	32 participants (Actual)	Interventional	2005-03-31	Completed
Enhancing ADHD Driving Performance With Stimulant Medication [NCT00572026]		14 participants (Anticipated)	Interventional	2007-07-31	Recruiting
Reading ICARD: Interventions for Children With Attention and Reading Disorders [NCT01133847]	Phase 4	222 participants (Actual)	Interventional	2010-11-30	Completed
A Phase II, Randomized, Double-blind, Multi-center, Placebo-controlled, Dose Optimization, Analog Classroom, Crossover Study Designed to Assess the Time Course of Treatment Effect, Tolerability and Safety of Methylphenidate Transdermal System (MTS) in Ped [NCT00466791]	Phase 2	93 participants (Actual)	Interventional	2004-08-31	Completed
A Randomized, Double-Blind Comparison, Safety and Efficacy Trial of Atomoxetine Hydrochloride and Methylphenidate Hydrochloride in Pediatric Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder [NCT00486083]	Phase 3	330 participants (Actual)	Interventional	2003-12-31	Completed
Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder [NCT02951754]	Phase 4	600 participants (Anticipated)	Interventional	2002-02-28	Recruiting
The Effective and Tolerable Titration Scheme and Dosage in Children With Attention-deficit Hyperactivity Disorder Treated With OROS-Methylphenidate [NCT00518232]	Phase 4	520 participants (Actual)	Interventional	2006-09-30	Completed
A Combination Therapy to Treat Cancer-Related Fatigue - NCI R01 [NCT03772834]	Phase 2/Phase 3	200 participants (Anticipated)	Interventional	2019-03-25	Recruiting
The Role of Apathy in Glycemic Control [NCT00844090]		106 participants (Actual)	Interventional	2009-07-31	Completed
International Randomised Double-blind Placebo-controlled Study on the Initial Treatment of Acute Mania With Methylphenidate [NCT01541605]	Phase 3	42 participants (Actual)	Interventional	2012-03-31	Completed
A Randomized, Double-Blind Comparison of the Time Course of Response to Two Extended-Release Oral Delivery Systems for Methylphenidate in Pediatric Patients With Attention Deficit Hyperactivity Disorder in an Analog Classroom Setting: The CoMACS Study [NCT00381758]	Phase 4	184 participants	Interventional	2002-05-31	Completed
Methylphenidats Betydning for motoriskindlæring Hos Patienter Med Apopleksi [NCT00396058]	Phase 4	13 participants (Anticipated)	Interventional	2006-11-30	Terminated(stopped due to Recruitment of patients proved much too difficult based on the chosen criteria.)
A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy [NCT00031798]	Phase 3	0 participants	Interventional	2002-04-01	Terminated(stopped due to low accrual; loss of funding)
MPD04961-Methylphendidate Treatment of Cocaine Dependent ADHD Patients [NCT00015054]	Phase 2	20 participants	Interventional	1998-09-30	Completed
Treatment of Adult ADHD in Methadone Patients [NCT00061087]	Phase 2/Phase 3	115 participants (Actual)	Interventional	1998-02-28	Completed
A Treatment Study of Youth With Comorbid Attention Deficit Hyperactivity Disorder (ADHD) and Anxiety Disorders [NCT00012584]		120 participants	Interventional	2000-11-30	Completed
Methylphenidate for Hyperactivity and Impulsiveness in Children and Adolescents With Pervasive Developmental Disorders [NCT00025779]		60 participants	Interventional	2001-10-31	Completed
Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) Treatment (CAT) [NCT00031395]	Phase 3	122 participants (Actual)	Interventional	1999-09-30	Completed
Pediatric Traumatic Brain Injury: Methylphenidate Effects on Early Recovery [NCT00035139]	Phase 4	0 participants	Interventional		Completed
Emotional Effects of Methylphenidate and MDMA in Healthy Subjects [NCT01465685]	Phase 1	16 participants (Actual)	Interventional	2011-12-31	Completed
A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy [NCT03525873]	Phase 3	212 participants (Actual)	Interventional	2018-08-02	Active, not recruiting
Methylphenidate Efficacy and Safety in ADHD Preschoolers [NCT00018863]	Phase 3	165 participants	Interventional	2001-04-01	Completed
Adderall-XR Versus Concerta For Cancer Treatment-Related Neurocognitive Sequelae And Depression In Pediatric Patients: A Randomized Phase II Study [NCT00069927]	Phase 2	12 participants (Actual)	Interventional	2003-08-31	Terminated(stopped due to Only 12 subjects enrolled. DSMB recommended closing due to lack of feasibility)
A Phase III, Multi-center, Open-label Study of Methylphenidate Transdermal System (MTS) in Pediatric Patients Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) [NCT00151957]	Phase 3	450 participants (Actual)	Interventional	2004-10-31	Completed
Open-Label Study of Concerta in the Treatment of ADHD in Youth and Adults With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder [NCT00181987]	Phase 4	29 participants (Actual)	Interventional	2002-08-31	Completed
A Double Blind, Placebo-Controlled Crossover Study to Determine the Effects of Methylphenidate on Driving Ability in Adult Patients With Attention-Deficit Hyperactivity Disorder [NCT00223561]	Phase 4	18 participants	Interventional	2003-02-28	Completed
Long Acting Stimulant Treatment of ADHD in Young Children [NCT00754208]	Phase 4	7 participants (Actual)	Interventional	2008-09-18	Completed
A Double Blind Randomized Crossover Study of the Effect of Methylphenidate Versus Placebo on State Anxiety in Children With Attention Deficit Hyperactivity Disorder. [NCT01798459]		30 participants (Anticipated)	Interventional	2013-02-28	Recruiting
Virtual Reality a Novel Screening and Treatment Aid in Attention Deficit Disorder [NCT00364702]	Phase 2	40 participants (Anticipated)	Interventional	2006-08-31	Completed
Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With Attention Deficit Hyperactivity Disorder: A Randomized Placebo-controlled Pilot Study [NCT02638168]	Phase 4	3 participants (Actual)	Interventional	2016-01-31	Terminated(stopped due to challenge in recruitment)
The Effects of Methylphenidate (MPH) and Non-invasive Brain Stimulation (tDCS) on Inhibitory Control Children With Attention-Deficit/Hyperactivity Disorder (ADHD) [NCT04964427]		26 participants (Actual)	Interventional	2021-02-08	Completed
A Randomized Controlled Trial of Methylphenidate Transdermal System (Daytrana), Lisdexamfetamine Dimesylate (Vyvanse), OROS MPH (Concerta), and Mixed Amphetamine Salts Extended Release (Adderall XR) in Children and Adolescents With ADHD [NCT00889915]	Phase 4	228 participants (Actual)	Interventional	2009-04-30	Completed
Behavioral Differences in Effortful Control [NCT01852344]		108 participants (Actual)	Interventional	2012-06-30	Completed
A Randomized, Parallel, Double-Blind Efficacy and Safety Study of Biphentin Methylphenidate HCl Extended Release Capsules Compared to Placebo in Children and Adolescents 6 to 18 Years With Attention Deficit Hyperactivity Disorder (ADHD) [NCT01239030]	Phase 3	230 participants (Actual)	Interventional	2010-11-30	Completed
Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI [NCT02225106]	Phase 2	11 participants (Actual)	Interventional	2014-08-06	Completed
Multicenter Study Comparing the Efficacy and Safety of OROS (Methylphenidate HCl), Ritalin, and Placebo in Children With ADHD [NCT00269802]	Phase 3	0 participants	Interventional		Completed
Randomized Study Evaluating the Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients [NCT00273741]	Phase 3	39 participants (Actual)	Interventional	2007-01-31	Terminated(stopped due to difficulty of recrutement)
A Double-blind, Placebo-controlled, Randomized Trial to Evaluate the Safety, Tolerability and Efficacy of CONCERTA® (Methylphenidate Hydrochloride) Augmentation of SSRI/SNRI Monotherapy in Adult Patients With Major Depressive Disorder. [NCT00246233]	Phase 3	145 participants (Actual)	Interventional	2005-06-30	Completed
An Evaluation of the Safety and Effectiveness of CONCERTA® (Methylphenidate Hydrochloride), up to 72 mg Daily, in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) [NCT00249353]	Phase 3	220 participants (Actual)	Interventional	2002-03-31	Completed
The Role of the Dopaminergic Brain Reward System in Apathy Associated With Alzheimer's Disease [NCT00254033]	Phase 4	40 participants	Interventional	2003-10-31	Completed
Treatment of Patients With Alcoholism and Attention Deficit Disorder [NCT00261872]	Phase 4	100 participants	Interventional	2005-12-01	Completed
An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects [NCT00302367]	Phase 4	20 participants	Interventional	2004-01-31	Completed
Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate [NCT00302406]	Phase 4	50 participants (Anticipated)	Interventional	2003-07-31	Completed
A Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Titration Study to Evaluate the Efficacy and Safety of CONCERTA (Methylphenidate HCl) Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder at Doses of 36 mg, 54 mg, 72 mg [NCT00326391]	Phase 3	229 participants (Actual)	Interventional	2006-04-30	Completed
A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults [NCT00302354]	Phase 4	50 participants	Interventional	2004-12-31	Completed
A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy of Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults [NCT00302393]	Phase 3	20 participants (Actual)	Interventional	2006-06-30	Completed
A Parallel-group, Double-blind, Placebo-controlled Study of Methylphenidate as an Add on Therapy for Mirtazapine in the Treatment of Major Depressive Disorder in Cancer Patients Under Palliative Care [NCT01497548]	Phase 3	120 participants (Anticipated)	Interventional	2011-03-31	Recruiting
Prospective Follow-Up Observational Study to Examine the Progression of ADHD Drug Treatment and to Analyze Associated Factors [NCT01624649]		289 participants (Actual)	Observational	2012-02-29	Completed
Evaluating the Effect of Methylphenidate on Intracortical Inhibition in Methamphetamine Abusers Comorbid With Attention Deficit Disorder With Hyperactivity(ADHD) in TMS Unit, Neurcognitive Lab, Iranian National Center for Addiction Studies (INCAS), in 201 [NCT01651169]		30 participants (Anticipated)	Interventional	2012-09-30	Enrolling by invitation
A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity [NCT03785223]	Phase 4	60 participants (Actual)	Interventional	2019-04-20	Completed
Double-blind, Placebo-controlled, Multicenter Randomized Clinical Trial to Evaluate Short-term Efficacy of Palliative Treatment With Methylphenidate in Asthenia in Advanced Cancer Patients [NCT01773837]	Phase 3	100 participants (Actual)	Interventional	2012-01-31	Terminated(stopped due to Slow accrual. 100 patients included)
A Phase III Clinical Endpoint Evaluation Study Examining the Safety and Efficacy of HLD200 in Pediatric Subjects With Attention-Deficit Hyperactivity Disorder. [NCT02255513]	Phase 3	43 participants (Actual)	Interventional	2014-05-31	Completed
Psychopharmacology of Novel Medications for Cocaine Dependence - Buspirone [NCT01267292]	Phase 2	50 participants (Actual)	Interventional	2011-03-31	Completed
Impulsivity and Stimulant Administration [NCT01978431]	Phase 1	29 participants (Actual)	Interventional	2012-11-30	Completed
A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Aptensio XR® in Children Ages 4 to Under 6 Years Diagnosed With Attention Deficit-Hyperactivity Disorder (ADHD) [NCT02683265]	Phase 4	158 participants (Actual)	Interventional	2016-04-25	Completed
[NCT01740206]		50 participants (Actual)	Interventional	2012-11-30	Completed
Medication Response in Children With Predominately Inattentive Type ADHD [NCT01727414]	Phase 4	171 participants (Actual)	Interventional	2006-06-30	Completed
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years Wit [NCT01552902]	Phase 4	549 participants (Actual)	Interventional	2012-04-03	Completed
The Effect of Methylphenidate (Ritalin IR) Treatment in Familial Attention Deficit/Hyperactivity Disorder (ADHD) [NCT01554046]		40 participants (Actual)	Interventional	2011-10-31	Completed
Subacute Trial of Methylphenidate in Parkinson's Disease [NCT00359723]	Phase 2	13 participants (Actual)	Interventional	2004-07-31	Completed
Gene-environment Interactions and Brain Functional Connectivity Associated With Norepinephrine System Genes in Attention Deficit Hyperactivity Disorder [NCT01912352]		83 participants (Actual)	Interventional	2010-05-31	Completed
Real-world Evidence of Duration of Adhansia XR for Treatment of ADHD (RE-DAX): An Open-label Pragmatic Study to Assess the Real-world Effectiveness of Adhansia XR in Treatment of Adult and Adolescent Patients With ADHD in the United States [NCT04507204]	Phase 4	267 participants (Actual)	Interventional	2020-07-30	Terminated(stopped due to (due to administrative reasons not related to efficacy or safety.))
A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study of 3 Dosages of JNJ-31001074 in the Treatment of Adult Subjects With Attention-Deficit/Hyperactivity Disorder [NCT00880217]	Phase 2	430 participants (Actual)	Interventional	2009-05-31	Completed
Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach [NCT01678209]	Phase 4	127 participants (Actual)	Interventional	2012-10-31	Completed
Anomalous Motor System Physiology in Attention Deficit Hyperactivity Disorder: Biomarker Validation and Modeling Domains of Function [NCT04421248]	Phase 4	214 participants (Anticipated)	Interventional	2020-09-01	Recruiting
Understanding the Mechanism of Action of Methylphenidate in ADHD: A Computational Psychiatry Approach [NCT05600881]		35 participants (Anticipated)	Observational	2023-06-30	Not yet recruiting
Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With DESR Traits: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial [NCT01399827]	Phase 2	2 participants (Actual)	Interventional	2012-02-29	Completed
The Evaluation of the Safety and Efficacy of the Methylphenidate Patch in Former Stimulant Users With ADHD [NCT00780208]		14 participants (Actual)	Interventional	2007-04-30	Completed
LAMAinDiab - Lisdexamphetamine vs Methylphenidate for Pediatric Patients With ADHD and Type 1 Diabetes - a Randomized Cross-over Clinical Trial [NCT05957055]	Phase 2	150 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
Electroencephalogram Studies of Intravenous Methylphenidate-Induced Emergence From General Anesthesia [NCT02429076]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2017-06-30	Withdrawn(stopped due to We are not going to complete this study with healthy volunteers at this time.)
A Pharmacokinetic Study of Aptensio XR® (Methylphenidate Hydrochloride (HCl) Extended-release) Capsules in Male or Female Pre-School Children 4 to Under 6 Years of Age With Attention Deficit Hyperactivity Disorder (ADHD) in Fed Condition [NCT02470234]	Phase 4	10 participants (Actual)	Interventional	2016-07-30	Completed
Ph 3 Multicenter OL Treatment-optimized RDBPC Forced-withdrawal, Parallel Grp Study to Evaluate Safety & Efficacy of Evening Dosed HLD200, a Novel DR/ER Formulation (DELEXIS) of MPH HCl in Children Aged 6-12 With ADHD in Classroom Setting [NCT02493777]	Phase 3	125 participants (Actual)	Interventional	2015-07-31	Completed
Phase I Study About Effects of Caffeine, Methylphenidate, Modafinil and Placebo on Cognitive Performance of Chess Players. [NCT01834547]	Phase 1	40 participants (Actual)	Interventional	2011-05-31	Completed
The Relationship Between CES1 Genotype and Methylphenidate Response in Children With ADHD - INDICES Work Package 6 [NCT04366609]		207 participants (Actual)	Observational	2012-05-01	Completed
Novel Cross-Species Neurophysiological Assays of Reward and Cognitive Domains [NCT02855229]		222 participants (Actual)	Observational	2020-08-15	Completed
Phase III, Placebo-Controlled, Double-Blind Crossover Study of Slow-Release Methylphenidate (Concerta ™) for Treatment of HIV Associated Neurocognitive Disorder [NCT01599975]	Phase 3	40 participants (Anticipated)	Interventional	2012-05-31	Recruiting
Effects of MDMA (Ecstasy) and Methylphenidate (Ritalin) on Social Cognition [NCT01616407]	Early Phase 1	30 participants (Actual)	Interventional	2012-08-31	Completed
An Open-Label, Dose-Titration, Long-Term Safety Study to Evaluate CONCERTA (Methylphenidate HCL) Extended-release Tablets at Doses of 36 mg, 54 mg, 72 mg, 90 mg, and 108 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder [NCT00326300]	Phase 3	560 participants (Actual)	Interventional	2006-04-30	Completed
Quillivant XR in Children With Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study [NCT02255565]	Phase 4	36 participants (Actual)	Interventional	2014-09-30	Completed
Open-Label Treatment Trial to Assess the Short-Term Tolerability, Safety, and Efficacy of Methylphenidate Hydrochloride Extended-Release Liquid Formulation in High-Functioning Autism Spectrum Disorder Adults With Attention-Deficit/Hyperactivity Disorder [NCT02096952]	Phase 4	15 participants (Actual)	Interventional	2014-05-31	Completed
Methylphenidate to Improve Balance and Walking in MS [NCT01896700]	Phase 2/Phase 3	24 participants (Actual)	Interventional	2013-07-31	Completed
An Open-Label Study of Quetiapine Added to Oros Methylphenidate in the Treatment of ADHD and Aggressive Behavior [NCT00550147]	Phase 2	30 participants (Actual)	Interventional	2004-02-29	Completed
Active Emergence of From Isoflurane General Anesthesia Induced by Methylphenidate [NCT02327195]	Phase 1	54 participants (Actual)	Interventional	2014-05-31	Completed
A Phase II Proof-of-concept Trial of Methylphenidate in Children With Apraxia of Speech: a Double-blind, Randomised, Placebo-controlled, Cross-over Trial [NCT05185583]	Phase 2	24 participants (Anticipated)	Interventional	2022-03-14	Recruiting
Sensitivity of the NIH Toolbox Cognition Battery to Stimulant Treatment in Intellectual Disabilities [NCT05301361]	Phase 1	68 participants (Anticipated)	Interventional	2023-02-01	Enrolling by invitation
Improving Function, Quality of Life, Glycemia in Diabetics With Dementia [NCT00792662]	Phase 4	0 participants (Actual)	Interventional	2008-11-18	Withdrawn(stopped due to No Subjects enrolled)
Attention Management Trial for Children With FASD - a N-of-1 Control Trial of Prescribed Stimulants for ADHD in FASD [NCT04968522]	Phase 4	20 participants (Anticipated)	Interventional	2022-02-14	Recruiting
Randomized, Double-Blind, Placebo-Controlled Study of Dexmethylphenidate Hydrochloride, (d-MPH) in the Treatment of Fatigue in Sarcoidosis Subjects. [NCT00361387]	Phase 4	12 participants (Anticipated)	Interventional	2006-06-30	Completed
Pharmacokinetic Pharmacodynamic Studies of Methylphenidate Extended Release Products in Pediatric Attention Deficit Hyperactivity Disorder [NCT02536105]		88 participants (Actual)	Interventional	2016-05-31	Completed
Motivated Behavior in Adults With and Without ADHD [NCT02630017]	Phase 2	51 participants (Actual)	Interventional	2016-03-07	Completed
[NCT02152670]		1 participants (Actual)	Interventional	2014-05-31	Terminated(stopped due to Study drug became unaffordable for the purposes of the research.)
Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis [NCT03185065]	Phase 3	141 participants (Actual)	Interventional	2017-10-04	Completed
Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study [NCT01533493]		33 participants (Actual)	Interventional	2012-05-31	Completed
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Dose-optimization Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Att [NCT01552915]	Phase 4	464 participants (Actual)	Interventional	2012-04-17	Completed
Can Methylphenidate (Ritalin) Improve Memory and Attention in Mild Cognitive Impairment? A Combined Behaviour-EEG Study [NCT02326038]	Phase 4	40 participants (Anticipated)	Interventional	2014-11-30	Recruiting
Equine-Assisted Activities and Therapy for Treating Children With Attention-Deficit/Hyperactivity Disorder [NCT02482649]		46 participants (Anticipated)	Interventional	2013-01-31	Recruiting
WAKIX® (Pitolisant) Pregnancy Registry: An Observational Study of the Safety of Pitolisant Exposure in Pregnant Women and Their Offspring [NCT05536011]		1,329 participants (Anticipated)	Observational [Patient Registry]	2021-08-24	Recruiting
Examining Tolerance to CNS Stimulants in ADHD [NCT02039908]	Phase 4	267 participants (Actual)	Interventional	2013-04-30	Completed
Multi Neuro-functional Biomarkers for Monitoring the Effects of Treatments in ADHD Children [NCT04272021]	Phase 4	20 participants (Anticipated)	Interventional	2018-04-13	Recruiting
Relationship Between the Neuroendocrine Substrates, Candidate Genes and Endophenotypes in Patients With Attention-deficit/Hyperactivity Disorder [NCT02392169]		300 participants (Anticipated)	Observational	2013-08-31	Recruiting
Etude Comparative Monocentrique, randomisée, en Cross-over, en Double Aveugle, Contre Placebo, de l'Action du méthylphénidate Sur Les paramètres Cognitifs de la Motivation [NCT03190681]	Early Phase 1	24 participants (Anticipated)	Interventional	2017-07-01	Not yet recruiting
Pilot Study to Evaluate the Benefits and the Risks of Methylphenidate for the Treatment of Cocaine Dependence [NCT03090269]	Phase 2	0 participants (Actual)	Interventional	2018-06-01	Withdrawn(stopped due to feasibility reasons.)
Efficacy of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder [NCT05916339]	Phase 4	500 participants (Anticipated)	Interventional	2023-10-01	Not yet recruiting
The Interaction of Cognitive Control Mechanisms and Language Processing: An Investigation With Methylphenidate [NCT05272397]		36 participants (Actual)	Interventional	2019-11-26	Completed
Influence of Stimulant Medication on Brain Processes for Decision Making in Attention Deficit Hyperactivity Disorder [NCT01831622]	Phase 4	131 participants (Actual)	Interventional	2013-06-30	Completed
The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making [NCT04371146]		120 participants (Actual)	Interventional	2019-07-03	Completed
An Extension Study to Evaluate the Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD [NCT02704390]	Phase 3	64 participants (Actual)	Interventional	2016-01-31	Completed
A Randomized Clinical Trial Comparing Computer-assisted Cognitive Rehabilitation (CACR), Psycho-stimulants, and Placebo CACR in the Treatment of Attention Deficit/ Hyperactivity Disorder [NCT01675804]	Phase 3	34 participants (Actual)	Interventional	2011-11-30	Completed
The Impact of Genetic Variation In Nicotinic Cholinergic Receptors on Functional Brain Networks Underlying Addiction Susceptibility [NCT01924468]	Phase 1	76 participants (Actual)	Interventional	2013-08-14	Completed
Open Label Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children 6-12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD) [NCT00989950]		26 participants (Actual)	Interventional	2009-12-31	Completed
A Randomized Comparison of Osmotic Release Oral System Methylphenidate and Cognitive Behavioural Therapy for the Treatment of Obese Patients With Binge Eating Disorder [NCT01921582]	Phase 2	51 participants (Actual)	Interventional	2013-08-31	Completed
Prevention of Cigarette Smoking in ADHD Youth With Concerta [NCT00181714]	Phase 4	203 participants (Actual)	Interventional	2003-11-30	Completed
Efficacy and Safety/Tolerability of OROS MPH (Concerta) Plus Atomoxetine (ATMX) in Children and Adolescents (Age 6-17) With Attention Deficit Hyperactivity Disorder (ADHD) [NCT00585910]	Phase 4	94 participants (Actual)	Interventional	2004-01-31	Completed
The Use of Methylphenidate to Improve Clinical Outcomes in Geriatric Depression: A Double-blind Placebo-Controlled Trial of Methylphenidate (Ritalin) Augmentation of Citalopram (Celexa) in Depressed Elderly Patients [NCT00602290]	Phase 4	181 participants (Actual)	Interventional	2008-02-29	Completed
Efficacy of Methylphenidate for Management of Long-Term Attention Problems After Pediatric Traumatic Brain Injury (TBI) [NCT01933217]	Phase 4	26 participants (Actual)	Interventional	2013-11-30	Completed
MethylphenIdate for Fatigue in Haematological Cancer. A Randomized, Double-blind, Placebo-controlled, CROssover Trial - the MICRO Trial [NCT03218254]	Phase 3	150 participants (Anticipated)	Interventional	2018-06-08	Recruiting
Potentiation of Cognitive Functions in Healthy Elderly by Association of Methylphenidate and Cognitive Training: Proof of Concept Study in Order to Develop a Synergic Symptomatic Treatment for the Cognitive Disorders Before Dementia [NCT03280251]	Phase 2	120 participants (Anticipated)	Interventional	2018-09-19	Recruiting
The Roles of Endocrine Disrupting Chemicals, Growth Hormone and Thyroid Function in Attention-deficit/Hyperactivity Disorder [NCT04970303]		240 participants (Anticipated)	Observational	2019-07-12	Enrolling by invitation
L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial [NCT01853280]	Phase 2/Phase 3	47 participants (Actual)	Interventional	2014-05-31	Completed
Apathy in Dementia Methylphenidate Trial 2 [NCT02346201]	Phase 3	200 participants (Actual)	Interventional	2016-01-31	Completed
Patient Controlled Methylphenidate for Cancer Related Fatigue: A Double Blind, Randomized, Placebo Controlled Trial [NCT05041946]	Phase 3	112 participants (Actual)	Interventional	2003-07-16	Completed
Functional Neuroimaging of Acute Concerta Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD): Differences Across Development [NCT00778310]	Phase 4	76 participants (Actual)	Interventional	2008-11-30	Completed
A Randomized, Phase II Placebo-controlled Study of the Use of Extended-release Methylphenidate or Modafinil for the Treatment of Excessive Daytime Sleepiness in Children Following Cancer Therapy [NCT01348607]	Phase 2	1 participants (Actual)	Interventional	2010-07-31	Terminated(stopped due to Study only randomized 1 subject and was determined not feasible by DSMB)
An Open, Self-Controlled, Prospective Study of Concerta on Cognitive Functions, Efficacy and Tolerance in the Pediatric Patients With Attention Deficit Hyperactivity Disorder (ADHD) [NCT01933880]	Phase 4	194 participants (Actual)	Interventional	2009-12-31	Completed
Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia. [NCT01825577]	Phase 4	14 participants (Actual)	Interventional	2012-11-30	Terminated(stopped due to Administrative Reasons)
Control of Cognition: Naltrexone, Methylphenidate, and ADHD Study [NCT01993108]	Phase 4	23 participants (Actual)	Interventional	2013-10-31	Completed
Effects of Atomoxetine and Oros-mph on Executive Functions in Patients With Combined Type Attention Deficit Hyperactivity Disorder [NCT02352051]	Phase 4	43 participants (Actual)	Interventional	2014-02-28	Completed
An Electroencephalography Study of the Effects of Psychostimulants on Dynamic Patterns of Cognitive Task-based Functional Connectivity in Youths With Attention Deficit Hyperactivity Disorder [NCT02318017]		75 participants (Anticipated)	Interventional	2014-12-31	Not yet recruiting
A Pilot Study of Omega-3 Fatty Acid Supplementation to ADHD Medication in Children With ADHD and Deficits in Emotional Self-Regulation [NCT02204410]	Phase 4	21 participants (Actual)	Interventional	2014-07-31	Completed
Multimodal Magnetic Resonance Imaging Study on the Neural Mechanisms of Remission in Children With ADHD Treated With Methylphenidate or Atomoxetine [NCT05229627]		250 participants (Anticipated)	Observational	2016-01-31	Enrolling by invitation
The Neural Correlates of and Effects of Methylphenidate on Acute Pain Dynamics [NCT05669924]	Phase 2	30 participants (Anticipated)	Interventional	2022-09-19	Recruiting
Methylphenidate Treatment of Attentional and Cognitive Deficits in Epilepsy [NCT02178995]	Phase 4	55 participants (Actual)	Interventional	2014-08-31	Completed
A Pilot, Multiple Crossover, Randomized Block Sequence, Double-Blind, Placebo-Controlled Trial for Use of Methylphenidate for Cognitive and Behavioral Symptoms in Mild Cognitive Impairment and Dementia [NCT03811847]	Phase 4	11 participants (Actual)	Interventional	2019-11-01	Completed
Use of Methylphenidate in Children and Adolescents in France [NCT03371069]		1 participants (Actual)	Observational	2015-09-30	Completed
Aripiprazole Added on Methylphenidate in the Treatment of Youths With Comorbid ADHD and DMDD [NCT03358277]		58 participants (Actual)	Interventional	2014-11-19	Completed
A Randomized, Double-Blind Study of the Time Course of Response to Biphentin® Methylphenidate Hydrochloride ER Capsules Compared to Placebo in Children 6 to 12 Years With Attention Deficit Hyperactivity Disorder in Analog Classroom Setting [NCT01269463]	Phase 3	26 participants (Actual)	Interventional	2011-01-19	Completed
ADHD Symptoms in Autism: Cognition, Behavior, Treatment [NCT00178503]	Phase 2/Phase 3	24 participants (Actual)	Interventional	2005-09-30	Completed
Reversal of General Anesthesia With Intravenous Methylphenidate [NCT02051452]	Phase 1/Phase 2	32 participants (Actual)	Interventional	2014-11-30	Completed
Stimulant Medication Effects on Auditory Sensitivity and Acoustic Reflex in Adolescents With ADHD [NCT04577417]		70 participants (Actual)	Observational	2020-09-13	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00050622 (3) [back to overview]	Classroom Behavior
NCT00050622 (3) [back to overview]	Social Behavior-Negative Verbalizations
NCT00050622 (3) [back to overview]	Treatment Satisfaction
NCT00129467 (1) [back to overview]	Days to Remission of Depression
NCT00151996 (5) [back to overview]	Change From Baseline in Child Health Questionnaire-Parent Form (CHQ-PF50) Scores at 6 Weeks
NCT00151996 (5) [back to overview]	Number of Participants With Improvement on Parent Global Assessment (PGA) Scores
NCT00151996 (5) [back to overview]	Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores
NCT00151996 (5) [back to overview]	Change From Baseline in the Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Total Score at 6 Weeks
NCT00151996 (5) [back to overview]	Change From Baseline in Conner's Parent Rating Scale-revised Short Version (CPRS-R) Total Score at 6 Weeks
NCT00178503 (3) [back to overview]	Mean Conners' Parent ADHD Index T Score by Week
NCT00178503 (3) [back to overview]	Mean Conners' Teacher ADHD Index T Score by Dose
NCT00178503 (3) [back to overview]	Mean Continuous Performance Test (CPT)-Commission Errors by Dose
NCT00181714 (1) [back to overview]	Cigarette Smoking
NCT00183391 (16) [back to overview]	Assessment of Affective Range (AAR)
NCT00183391 (16) [back to overview]	Child Conflict Index (CCI)
NCT00183391 (16) [back to overview]	Children's Sleep Questionnaire
NCT00183391 (16) [back to overview]	Clinical Global Impressions (CGI)- Severity
NCT00183391 (16) [back to overview]	Continuous Performance Test (CPT)
NCT00183391 (16) [back to overview]	Social Skills Rating Scale (SSRS)- Parent Version
NCT00183391 (16) [back to overview]	Tics: Total Impairment
NCT00183391 (16) [back to overview]	Tics: Total Motor
NCT00183391 (16) [back to overview]	Tics: Total Phonic
NCT00183391 (16) [back to overview]	Vital Signs - Diastolic Blood Pressure
NCT00183391 (16) [back to overview]	Vital Signs - Pulse
NCT00183391 (16) [back to overview]	Vital Signs - Systolic Blood Pressure
NCT00183391 (16) [back to overview]	ADHD - H/I
NCT00183391 (16) [back to overview]	ADHD-RS Inattention
NCT00183391 (16) [back to overview]	ADHD-RS Total Score
NCT00183391 (16) [back to overview]	Treatment Preference Survey
NCT00253747 (3) [back to overview]	Prolonged Abstinence
NCT00253747 (3) [back to overview]	Diagnostic and Statistical Manual-IV(DSM-IV) ADHD Rating Scale
NCT00253747 (3) [back to overview]	Point-prevalence Abstinence
NCT00257725 (3) [back to overview]	Swanson, Nolan, and Pelham Questionnaire (SNAP-IV)
NCT00257725 (3) [back to overview]	Children's Global Assessment Scale (C-GAS)
NCT00257725 (3) [back to overview]	Clinical Global Impressions-Severity (CGI-S)
NCT00264797 (4) [back to overview]	ADHD Severity
NCT00264797 (4) [back to overview]	OROS-MPH Abuse Liability
NCT00264797 (4) [back to overview]	Substance Use
NCT00264797 (4) [back to overview]	Substance Use Outcomes
NCT00302458 (1) [back to overview]	Peak Plasma Concentration of d-Methylphenidate
NCT00307684 (7) [back to overview]	Change From OL Baseline in Clinical Global Impression Scale (CGI-S) Score at OL Endpoint
NCT00307684 (7) [back to overview]	Change From OL Baseline in Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Score at OL Endpoint
NCT00307684 (7) [back to overview]	Change From OL Baseline to OL Endpoint in Conners' Adult ADHD Rating Scale (CAARS) Total and Subscale Scores
NCT00307684 (7) [back to overview]	Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00307684 (7) [back to overview]	Change From DB Baseline to DB Endpoint in CGI-S Score
NCT00307684 (7) [back to overview]	Change From DB Baseline to DB Endpoint in CAARS Self Rated Scale (CAARS-S:S) Total Score
NCT00307684 (7) [back to overview]	Change From DB Baseline in Conners' Adult ADHD Rating Scale (CAARS) Total Score at DB Endpoint
NCT00376675 (9) [back to overview]	AUC of Sleep Quality as Measured by the Pittsburgh Sleep Quality Index at Baseline and at Weeks 1-4
NCT00376675 (9) [back to overview]	AUC of Vitality as Measured by the Short Form-36 Vitality Subscale at Baseline and at Weeks 1-4
NCT00376675 (9) [back to overview]	Prorated AUC of Total Fatigue as Measured by the Brief Fatigue Inventory (BFI) at Baseline and at Weeks 1-4
NCT00376675 (9) [back to overview]	AUC of Other Fatigue Scores as Measured by Items of the Brief Fatigue Inventory (BFI) at Baseline and at Weeks 1-4
NCT00376675 (9) [back to overview]	AUC of Overall Quality of Life (QOL) and QOL Domains as Measured by the Linear Analogue Self Assessment at Baseline and at Weeks 1-4
NCT00376675 (9) [back to overview]	Severity of Adverse Events as Measured by the Symptom Experience Diary Based on Mean Changes From Baseline to Week 4
NCT00376675 (9) [back to overview]	Anchor-based Minimally Important Difference in SGIC Overall Quality of Life Based on Mean Changes From Baseline to Week 4 on BFI Usual Fatigue
NCT00376675 (9) [back to overview]	Anchor-based Minimally Important Difference in SGIC Physical Condition Based on Mean Changes From Baseline to Week 4 on BFI Usual Fatigue
NCT00376675 (9) [back to overview]	Anchor-based Minimally Important Difference in SGIC Emotional State Based on Mean Changes From Baseline to Week 4 on BFI Usual Fatigue
NCT00409708 (6) [back to overview]	Number of Sister Chromatoid Exchanges Per Cell
NCT00409708 (6) [back to overview]	The Number of Chromosomal Aberrations Per 100 Cells Excluding Gaps at Baseline and at the End of Treatment i.e Day 84 (Week 12)
NCT00409708 (6) [back to overview]	The Number of Micronuclei Per 1000 Binucleated Cells Endpoints at Baseline and at the End of Treatment i.e Day 84 (Week 12)
NCT00409708 (6) [back to overview]	Change From Baseline to End of Treatment (Week 12) on the Conners' ADHD/DSM-IV Scale for Parents (CADS-P)
NCT00409708 (6) [back to overview]	Change From Baseline to the End of Treatment (Week 12) on the Global Improvement Rating of the Clinical Global Impression Scale (CGI-I)
NCT00409708 (6) [back to overview]	Change From Baseline to the End of Treatment (Week 12) on the Severity of Illness Rating of the Clinical Global Impression Scale (CGI-S)
NCT00418691 (1) [back to overview]	Mean Processing Speed Change From Baseline in the Trail-making Test Part A Score
NCT00424099 (2) [back to overview]	Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Fatigue Subscale Score
NCT00424099 (2) [back to overview]	Change in Edmonton Symptom Assessment System (ESAS) Fatigue Score
NCT00428792 (10) [back to overview]	Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Parent Rating
NCT00428792 (10) [back to overview]	Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Hyperactivity Subscale Teacher Rating
NCT00428792 (10) [back to overview]	Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Impulsiveness Subscale Teacher Rating
NCT00428792 (10) [back to overview]	Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Teacher Rating in the Intent-to-Treat (ITT) Population
NCT00428792 (10) [back to overview]	Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Teacher Rating in the Per Protocol (PP) Population
NCT00428792 (10) [back to overview]	Clinical Global Impression (CGI-I) Scale Score - Physician Rating of Improvement (Change in State)
NCT00428792 (10) [back to overview]	Clinical Global Impression Severity (CGI-S) Scale Score - Physician Rating of Severity
NCT00428792 (10) [back to overview]	Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Attention Deficit Subscale Teacher Rating
NCT00428792 (10) [back to overview]	10-Minute Math Test - Problems Attempted
NCT00428792 (10) [back to overview]	10-Minute Math Test - Problems Solved
NCT00429273 (1) [back to overview]	ADHD IV Rating Scale (Attention Deficit Hyperactivity Disorder Rating Scale)
NCT00434213 (2) [back to overview]	Contact Sensitization to Methylphenidate
NCT00434213 (2) [back to overview]	Dermal Reactions
NCT00453921 (7) [back to overview]	Self Report Questionnaire - MASQ
NCT00453921 (7) [back to overview]	Neuropsychological Assessment, CVLT-II
NCT00453921 (7) [back to overview]	Neuropsychological Assessment - CPT, Distractibility Condition (Reaction Time)
NCT00453921 (7) [back to overview]	Functional MRI Task Performance and Brain Activation (Change From Baseline to Post-treatment)
NCT00453921 (7) [back to overview]	Change in Right Inferior Frontal Activation During Working Memory Processing (3-back > 0-back Condition) From Baseline to Post-intervention
NCT00453921 (7) [back to overview]	Change in Left Middle/Inferior Frontal Activation During Working Memory Processing (3-back > 0-back Condition) From Baseline to Post-intervention
NCT00453921 (7) [back to overview]	Change in Anterior Cingulate Gyrus Activation During Working Memory Processing (3-back > 0-back Condition) From Baseline to Post-intervention
NCT00475735 (2) [back to overview]	Baseline AISRS
NCT00475735 (2) [back to overview]	Mean Change From Baseline in the Adult Attention Deficit Hyperactivity Disorder Investigator Symptom Rating Scale (AISRS) Total Score After 4 Weeks of Treatment
NCT00495820 (3) [back to overview]	Apathy Evaluation Scale Score at 12 Weeks
NCT00495820 (3) [back to overview]	Clinical Global Impression
NCT00495820 (3) [back to overview]	Mini-mental State Examination (MMSE) at 12 Weeks
NCT00499746 (8) [back to overview]	Physiologic Effects Assessed by the Pharmacological Class Questionnaire
NCT00499746 (8) [back to overview]	Discrimination Effects Assessed by Point Distribution
NCT00499746 (8) [back to overview]	Discrimination Effects Assessed by Operant Responses
NCT00499746 (8) [back to overview]	Discrimination Effects Assessed by Discrete Choice
NCT00499746 (8) [back to overview]	Physiological Effects Assessed by Peak Change From Baseline Pupil Diameter
NCT00499746 (8) [back to overview]	Peak Change From Baseline Stimulant Effects Assessed by the Visual Analog Scale (VAS)
NCT00499746 (8) [back to overview]	Peak Change From Baseline Opioid Agonist Effects Assessed by the Visual Analog Scale (VAS)
NCT00499746 (8) [back to overview]	Acquisition of Discrimination Assessed by Accuracy of the Discrimination Test
NCT00499863 (12) [back to overview]	Change From Baseline in the Conner's Parent Rating Scale-Revised (CPRS-R) Total Score at Endpoint
NCT00499863 (12) [back to overview]	Change From Baseline in Weight at Endpoint
NCT00499863 (12) [back to overview]	Change From Baseline in Youth Quality of Life-research Version (YQOL-R) Total Score at Endpoint
NCT00499863 (12) [back to overview]	Dermal Response Scale (DRS) Scores
NCT00499863 (12) [back to overview]	Improvement in Clinical Global Impressions-Improvement (CGI-I) Score
NCT00499863 (12) [back to overview]	Improvement in Parent Global Assessment (PGA) Score
NCT00499863 (12) [back to overview]	Post Sleep Questionnaire (PSQ) Quality of Sleep
NCT00499863 (12) [back to overview]	Change From Baseline in Diastolic Blood Pressure at Endpoint
NCT00499863 (12) [back to overview]	Change From Baseline in Electrocardiogram Results(QTcF Interval) at Endpoint
NCT00499863 (12) [back to overview]	Change From Baseline in Pulse Rate at Endpoint
NCT00499863 (12) [back to overview]	Change From Baseline in Systolic Blood Pressure at Endpoint
NCT00499863 (12) [back to overview]	Change From Baseline in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Endpoint
NCT00501293 (12) [back to overview]	Electrocardiogram Results (QTcF Interval)
NCT00501293 (12) [back to overview]	Diastolic Blood Pressure
NCT00501293 (12) [back to overview]	Change From Baseline in Youth Quality of Life-research Version (YQOL-R) Total Score at 6 Months
NCT00501293 (12) [back to overview]	Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores
NCT00501293 (12) [back to overview]	Number of Participants With Improvement on Parent Global Assessment (PGA) Scores.
NCT00501293 (12) [back to overview]	Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Scores at 6 Months
NCT00501293 (12) [back to overview]	Dermal Reactions
NCT00501293 (12) [back to overview]	Weight
NCT00501293 (12) [back to overview]	Pulse Rate
NCT00501293 (12) [back to overview]	Post Sleep Questionnaire (PSQ) Quality of Sleep
NCT00501293 (12) [back to overview]	Change From Baseline in Conner's Parent Rating Scale-revised Short Version (CPRS-R) at 6 Months
NCT00501293 (12) [back to overview]	Systolic Blood Pressure
NCT00506285 (2) [back to overview]	Conners' Adult ADHD Rating Scales (CAARS)
NCT00506285 (2) [back to overview]	Wender Reimherr Adult Attention Deficit Disorder Scale
NCT00516269 (1) [back to overview]	Mean Difference Between Post-Methylphenidate and Post-Placebo Measurement
NCT00526630 (8) [back to overview]	Duration of Freezing and Shuffling Episodes Between Groups at 12 and 27 Weeks.
NCT00526630 (8) [back to overview]	Montgomery-Åsberg Depression Rating Scale (MADRS) Between Groups at 12 and 27 Weeks.
NCT00526630 (8) [back to overview]	The 5-item EuroQoL (EQ-5D) Quality of Life Generic Instrument Between Groups at 12 and 27 Weeks.
NCT00526630 (8) [back to overview]	The Epworth Sleepiness Scale (ESS) Between Groups at 12 and 27 Weeks
NCT00526630 (8) [back to overview]	The Primary Outcome Measure Was Change in a Gait Stride Length Between Groups at 12 and 27 Weeks.
NCT00526630 (8) [back to overview]	The Primary Outcome Measure Was Change in Gait Velocity Between Groups at 12 and 27 Weeks.
NCT00526630 (8) [back to overview]	The Unified Parkinson Disease Rating Scale (UPDRS) Between Groups at 12 and 27 Weeks
NCT00526630 (8) [back to overview]	Freezing of Gait Questionnaire (FOGQ) Scores Between Groups at 12 and 27 Weeks.
NCT00530257 (11) [back to overview]	Test of Everyday Attention for Children: Sky Search
NCT00530257 (11) [back to overview]	Test of Everyday Attention for Children: Walk, Don't Walk
NCT00530257 (11) [back to overview]	Wechsler Intelligence Scale for Children-IV, Digit Span Subtest
NCT00530257 (11) [back to overview]	ADHD Rating Scale-IV, Parent and Teacher Version
NCT00530257 (11) [back to overview]	Gordon Diagnostic System Continuous Performance Test
NCT00530257 (11) [back to overview]	Test of Everyday Attention for Children: Map Mission
NCT00530257 (11) [back to overview]	Test of Everyday Attention for Children: Creature Counting
NCT00530257 (11) [back to overview]	Test of Everyday Attention for Children-Sky Search Dual Task
NCT00530257 (11) [back to overview]	Stimulant Side Effect Rating Scale
NCT00530257 (11) [back to overview]	Test of Everyday Attention for Children: Opposite Worlds
NCT00530257 (11) [back to overview]	Test of Everyday Attention for Children: Score Dual Task (DT)
NCT00541346 (11) [back to overview]	Change in Aberrant Behavior Checklist (ABC) Irritability Scores From Baseline to 8-week Follow-up Visit
NCT00541346 (11) [back to overview]	Change in Pediatric Evaluation Disability Inventory (PEDI) Social Function From Baseline to 8-week Follow-up Visit
NCT00541346 (11) [back to overview]	Change in Pediatric Evaluation Disability Inventory (PEDI) Caregiver Assistance: Self-Care From Baseline to 8-week Follow-up Visit
NCT00541346 (11) [back to overview]	Change in Lifetime Participation Scale (LPS) Total Scores From Baseline to 8-week Follow-up Visit
NCT00541346 (11) [back to overview]	Change in Family III General Scale Summed Score From Baseline to 8-week Follow-up Visit
NCT00541346 (11) [back to overview]	Change in Attention Deficit Hyperactivity Disorder Rating Scale - IV (ADHD-RS-IV) Total Score From Baseline to 8-week Follow-up Visit
NCT00541346 (11) [back to overview]	Change in Aberrant Behavior Checklist (ABC) Stereotypy Scores From Baseline to 8-week Follow-up Visit
NCT00541346 (11) [back to overview]	Change in Aberrant Behavior Checklist (ABC) Hyperactivity Scores From Baseline to 8-week Follow-up Visit
NCT00541346 (11) [back to overview]	Change in Attention Deficit Hyperactivity Disorder Rating Scale IV: Teacher Assessment Total Scores From Baseline to 8-week Follow-up Visit
NCT00541346 (11) [back to overview]	Change in Aberrant Behavior Checklist (ABC) Lethargy Scores From Baseline to 8-week Follow-up Visit
NCT00541346 (11) [back to overview]	Change in Aberrant Behavior Checklist (ABC) Inappropriate Speech Scores From Baseline to 8-week Follow-up Visit
NCT00549640 (3) [back to overview]	Number of Subjects Biochemically Confirmed to be Abstinent From Smoking at End of Study
NCT00549640 (3) [back to overview]	Number of Subjects Biochemically Confirmed to be Abstinent From Smoking at End of Treatment.
NCT00549640 (3) [back to overview]	The Change in the Average Nicotine Withdrawal Symptom Score From Baseline to 14 Days Post Target Quit Date.
NCT00550147 (5) [back to overview]	Attention Deficit/Hyperactivity Disorder Rating Scale -IV- Parent Version (ADHDRS-IV-Parent Version)
NCT00550147 (5) [back to overview]	CGI-S: Clinical Global Improvement Scale
NCT00550147 (5) [back to overview]	Modified Overt Aggression Scale (MOAS)
NCT00550147 (5) [back to overview]	RAAPP: Rating of Aggression Against People and/or Property Scale
NCT00550147 (5) [back to overview]	Swanson, Nolan and Pelham IV (SNAP-IV) Oppositional-Defiant Disorder Subscale
NCT00564954 (6) [back to overview]	Change From Pre-dose in SKAMP Deportment Score
NCT00564954 (6) [back to overview]	Change From Pre-dose (0 hr) in SKAMP Combined Score at All Times Excluding the 0.5 Hour Timepoint (Hours 1, 2, 4, 6, 8)
NCT00564954 (6) [back to overview]	Change From Pre-dose (0 hr.) in Permanent Product Measure of Performance (PERMP) Math Test-Attempted Scores at All Timepoints (0.5, 1, 2, 4, 6, 8)
NCT00564954 (6) [back to overview]	Change From Pre-dose (0 hr [Hour]) on the Swanson, Kotkin, Agler, M-Flynn & Pelham (SKAMP) Rating Scale Combined Score at 0.5 Hour During the 8- Hour Laboratory Classroom Day
NCT00564954 (6) [back to overview]	Change From Pre-dose in SKAMP Attention Score at All Timepoints (0.5, 1, 2, 4, 6, 8)
NCT00564954 (6) [back to overview]	Change From Pre-dose in Number of Math Questions Answered Correctly on the Permanent Product Measure of Performance (PERMP) Math Test
NCT00573859 (3) [back to overview]	The Interacting Effects of Smoking and Overnight Abstinence With ADHD Medication and Placebo on Continuous Performance Task (CPT) Errors of Omission.
NCT00573859 (3) [back to overview]	The Interacting Effects of Smoking and Abstinence With ADHD Medication and Placebo on Nicotine Withdrawal Measured by the Shiffman-Jarvik Withdrawal Questionnaire.
NCT00573859 (3) [back to overview]	The Effects of ADHD Medication Versus Placebo on Cotinine Levels
NCT00576472 (34) [back to overview]	Change From Maintenance Phase Baseline to Completion of Phase as Measured by Conner's Parent Rating Scale (CPRS: Cognitive Problem T Score)
NCT00576472 (34) [back to overview]	Change From Maintenance Phase Baseline to Completion of Phase as Measured by Conners' Parent Rating Scale (CPRS: ADHD T Score)
NCT00576472 (34) [back to overview]	Change From Maintenance Phase Baseline to Completion of Phase as Measured by Conners' Teacher Rating Scale (CTRS: Cognitive Problem T Score)
NCT00576472 (34) [back to overview]	Change From Maintenance Phase Baseline to Completion of Phase as Measured by Social Skill Rating System (SSRS-P)
NCT00576472 (34) [back to overview]	Change From Maintenance Phase Baseline to Completion of Phase as Measured by Wechsler Individual Achievement Test (WIAT) Math: Composite Standard Score
NCT00576472 (34) [back to overview]	Change From Maintenance Phase Baseline to Completion of Phase as Measured by Wechsler Individual Achievement Test (WIAT) Reading: Composite Standard Score
NCT00576472 (34) [back to overview]	Change From Maintenance Phase Baseline to Completion of Phase as Measured by Wechsler Individual Achievement Test (WIAT) Spelling: Standard Score
NCT00576472 (34) [back to overview]	Change From Methylphenidate (MPH) Home Maintenance Phase Baseline to Completion of Phase as Measured by Conners' Teacher Rating Scale (CTRS: ADHD T Score)
NCT00576472 (34) [back to overview]	Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by Social Skills Rating System - Parent (SSRS-P) - Problem Behavior.
NCT00576472 (34) [back to overview]	Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by Social Skills Rating System - Teacher (SSRS-T) - Problem Behavior.
NCT00576472 (34) [back to overview]	Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by Social Skills Rating System - Teacher (SSRS-T) - Social Skill.
NCT00576472 (34) [back to overview]	Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by The Conners' Parent Rating Scale (CPRS) ADHD Index.
NCT00576472 (34) [back to overview]	Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by The Conners' Parent Rating Scale (CPRS) Cognitive Problem/Inattention Scale.
NCT00576472 (34) [back to overview]	Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by The Conners' Parent Rating Scale (CPRS) Hyperactivity Scale.
NCT00576472 (34) [back to overview]	Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by The Conners' Teacher Rating Scale (CTRS) ADHD Index.
NCT00576472 (34) [back to overview]	Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by The Conners' Teacher Rating Scale (CTRS) Cognitive Problem/Inattention Scale.
NCT00576472 (34) [back to overview]	Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by The Conners' Teacher Rating Scale (CTRS) Hyperactivity Scale.
NCT00576472 (34) [back to overview]	Establish the Effectiveness of MPH on Laboratory Measures of Interference, Impulsivity, Cognitive Flexibility, and Selective Attention Using the Stroop Word-Color Association Test (Stroop) for Color Naming Time.
NCT00576472 (34) [back to overview]	Establish the Effectiveness of MPH on Laboratory Measures of Interference, Impulsivity, Cognitive Flexibility, and Selective Attention Using the Stroop Word-Color Association Test (Stroop) for Ink Color Naming Time.
NCT00576472 (34) [back to overview]	Establish the Effectiveness of MPH on Laboratory Measures of Interference, Impulsivity, Cognitive Flexibility, and Selective Attention Using the Stroop Word-Color Association Test (Stroop) for Interference Score.
NCT00576472 (34) [back to overview]	Establish the Effectiveness of MPH on Laboratory Measures of Interference, Impulsivity, Cognitive Flexibility, and Selective Attention Using the Stroop Word-Color Association Test (Stroop) for Word Naming Time.
NCT00576472 (34) [back to overview]	Establish the Effectiveness of MPH on Laboratory Measures of Learning and Recall Using California Verbal Learning Test (CVLT) for Long Delay Free Recall.
NCT00576472 (34) [back to overview]	Establish the Effectiveness of MPH on Laboratory Measures of Learning and Recall Using California Verbal Learning Test (CVLT) for Short Delay Free Recall.
NCT00576472 (34) [back to overview]	Establish the Effectiveness of MPH on Laboratory Measures of Learning and Recall Using California Verbal Learning Test (CVLT) Over Five Learning Trials.
NCT00576472 (34) [back to overview]	Establish the Effectiveness of MPH on Laboratory Measures of Sustained Attention, Reaction Time, and, Impulsivity Using Conner's Continuous Performance Test (CPT) for Commission Errors.
NCT00576472 (34) [back to overview]	Establish the Effectiveness of MPH on Laboratory Measures of Sustained Attention, Reaction Time, and, Impulsivity Using Conner's Continuous Performance Test (CPT) for d' (Sensitivity).
NCT00576472 (34) [back to overview]	Establish the Effectiveness of MPH on Laboratory Measures of Sustained Attention, Reaction Time, and, Impulsivity Using Conner's Continuous Performance Test (CPT) for Hit Reaction Time.
NCT00576472 (34) [back to overview]	Establish the Effectiveness of MPH on Laboratory Measures of Sustained Attention, Reaction Time, and, Impulsivity Using Conner's Continuous Performance Test (CPT) for Omission Errors.
NCT00576472 (34) [back to overview]	Best Weekly Score Measured by Conners' Parent Rating Scale (CPRS: ADHD T Score) During the 3-week Home Crossover Phase.
NCT00576472 (34) [back to overview]	Establish the Effectiveness of MPH on Laboratory Measures of Sustained Attention, Reaction Time, and, Impulsivity Using Conner's Continuous Performance Test (CPT) for Beta (Risk Taking).
NCT00576472 (34) [back to overview]	Brain White Matter Volume for Patients Versus Sibling Controls
NCT00576472 (34) [back to overview]	Brain White Matter Volume for Patients With Acute Lymphoblastic Leukemia Versus Brain Tumors
NCT00576472 (34) [back to overview]	Brain White Matter Volume for Treatment Intensity Groups and Sibling Controls
NCT00576472 (34) [back to overview]	Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by Social Skills Rating System - Parent (SSRS-P) - Social Skill.
NCT00585910 (2) [back to overview]	Attention Deficit Hyperactivity Disorder Rating Scale (ADHD RS)
NCT00585910 (2) [back to overview]	Clinical Global Impressions - Level of Severity (CGIs) for ADHD and Other Psychiatric Disorders
NCT00586157 (3) [back to overview]	Efficacy Defined as Change From Baseline on Investigator and Parental/Self-report Based Rating Scales and Questionnaires
NCT00586157 (3) [back to overview]	Efficacy Defined as Change From Baseline on the Investigator Rated DSM-IV Based ADHD Rating Scale, During the AM.
NCT00586157 (3) [back to overview]	Efficacy Defined as Change From Baseline on the Investigator Rated DSM-IV Based ADHD Rating Scale, Over the Course of the Day.
NCT00593112 (3) [back to overview]	H MRS Scan Results - Glutamate & Glutamine (Glx)/Ino
NCT00593112 (3) [back to overview]	H MRS Scan Results - Glutamine (Gln)/Ino
NCT00593112 (3) [back to overview]	Proton Magnetic Resonance Spectroscopy (H MRS) Scan Results - Glutamate(Glu)/Myo-inositol-containing Compounds (Ino)
NCT00602290 (2) [back to overview]	Hamilton Depression Rating Scale (HDRS) Maintained Scores at Week 16
NCT00602290 (2) [back to overview]	Quality of Life Assessment
NCT00714688 (4) [back to overview]	Attention Deficit/Hyperactivity Disorder (ADHD) Symptoms Total Score of the Conners Adult ADHD Rating Scale (CAARS)
NCT00714688 (4) [back to overview]	Change in Clinical Global Impression-Severity (CGI-S) From Baseline to End of Treatment
NCT00714688 (4) [back to overview]	Clinical Global Impression-Change (CGI-C)
NCT00714688 (4) [back to overview]	Change in Conners Adult ADHD Rating Scale Self Report Short Version (CAARS-S:S) Total Score
NCT00715520 (6) [back to overview]	Aim 1: Mean Parameter Estimate for Maximal Motor Evoked Potential (MEPmax) Derived From Stimulus Response Curves (SRC)
NCT00715520 (6) [back to overview]	Aim 1: Mean Peak Acceleration of Wrist Extension Movements
NCT00715520 (6) [back to overview]	Aim 2: Mean Peak Acceleration for rTMS Treatment With Respect to Frequency
NCT00715520 (6) [back to overview]	Aim 2: Mean Peak Acceleration of Wrist Extension Movements With Respect to Pulse
NCT00715520 (6) [back to overview]	Aim 2: Mean Sum of Normalized Motor Evoked Potentials (MEPs) for rTMS Treatment With Respect to Frequency
NCT00715520 (6) [back to overview]	Aim 2: Mean Sum of Normalized Motor Evoked Potentials (MEPs) With Respect to Pulse
NCT00754208 (3) [back to overview]	Change in Children's Global Assessment Scale (CGAS) Score
NCT00754208 (3) [back to overview]	Change in Clinical Global Impression-Severity
NCT00754208 (3) [back to overview]	Change in Attention Deficit Hyperactivity Disorder Rating Scale-IV Parent Version Investigator-Scored (ADHD-IV-Parent: Inv) Total Score.
NCT00758160 (12) [back to overview]	Mean Change From Baseline in Chinese Health Questionnaire (CHQ) at Week 4
NCT00758160 (12) [back to overview]	Chinese Version of the Family Adaptation, Partnership, Growth, Affection, and Resolve (Family APGAR-C) Score
NCT00758160 (12) [back to overview]	Clinical Global Impression-Severity (CGI-S) Score
NCT00758160 (12) [back to overview]	Global Assessment of Satisfaction by Parents/Caregivers
NCT00758160 (12) [back to overview]	Global Assessment of Satisfaction by Participant
NCT00758160 (12) [back to overview]	Social Adjustment Scale Score for Children and Adolescents (SAICA)
NCT00758160 (12) [back to overview]	Mean Change From Baseline in Chinese Health Questionnaire (CHQ) at Week 8
NCT00758160 (12) [back to overview]	Mean Change From Baseline in Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Parents) Score at Week 4
NCT00758160 (12) [back to overview]	Mean Change From Baseline in Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Parents) Score at Week 8
NCT00758160 (12) [back to overview]	Number of Participants With Clinical Global Impression-Improvement (CGI-I) Score
NCT00758160 (12) [back to overview]	Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Teachers) Score
NCT00758160 (12) [back to overview]	Mean Change From Baseline in Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Parents) Score at Week 2
NCT00763971 (8) [back to overview]	Health Utilities Index-2 (HUI-2) Scores at up to 7 Weeks
NCT00763971 (8) [back to overview]	Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT00763971 (8) [back to overview]	Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 7 Weeks
NCT00763971 (8) [back to overview]	Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at up to 7 Weeks
NCT00763971 (8) [back to overview]	Change From Baseline in Conner's Parent Rating Scale - Revised (CPRS-R) Total Score at up to 7 Weeks
NCT00763971 (8) [back to overview]	Change From Baseline in the Child Health and Illness Profile, Child Edition: Parent Report Form (CHIP-CE:PRF) Global T-score at up to 7 Weeks
NCT00763971 (8) [back to overview]	Change From Baseline in Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at up to 7 Weeks
NCT00763971 (8) [back to overview]	Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores
NCT00776009 (5) [back to overview]	Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Attention Score at 10, 11, and 12 Hour (Averaged) Post-dose
NCT00776009 (5) [back to overview]	Change From Pre-dose in the Permanent Product Measure of Performance of Measurement (PERMP) Math Test-Correctly Answered Score at 10, 11, and 12 Hours (Averaged) Post-dose
NCT00776009 (5) [back to overview]	Change From Pre-dose in the Permanent Product Measure of Performance of Measurement (PERMP) Math Test-Attempted Score at 10, 11, and 12 Hours (Averaged) Post-dose
NCT00776009 (5) [back to overview]	Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Combined Attention and Deportment Scores at 10, 11, and 12 Hour (Averaged) Post-dose
NCT00776009 (5) [back to overview]	Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Deportment Score at 10, 11, and 12 Hour (Averaged) Post-dose
NCT00778310 (1) [back to overview]	Brain Oxygenation Level Dependent Signal in the Fusiform Gyrus and the Amygdala on Concerta vs. Placebo
NCT00780208 (2) [back to overview]	Number of Participants With Positive Drug Screen
NCT00780208 (2) [back to overview]	ADHD Symptom Severity
NCT00783835 (9) [back to overview]	Change From Baseline in the State-Trait Anxiety Inventory (STAI) Scale
NCT00783835 (9) [back to overview]	Change From Baseline in Adult Attention Deficit Hyperactivity Disorder (ADHD) Self-Report Scale (ASRS) Total Score at Week 12
NCT00783835 (9) [back to overview]	Change From Baseline in Adult ADHD Quality of Life (AAQoL) Scale Score at Week 4
NCT00783835 (9) [back to overview]	Change From Baseline in Adult Attention Deficit Hyperactivity Disorder (ADHD) Self-Report Scale (ASRS) Total Score at Week 8
NCT00783835 (9) [back to overview]	Change From Baseline in Adult ADHD Quality of Life (AAQoL) Scale Score at Week 12
NCT00783835 (9) [back to overview]	Clinical Global Impression-Improvement (CGI-I) Score
NCT00783835 (9) [back to overview]	Change From Screening in the Hamilton Depression Rating (HAM-D) Scale Score at Week 4 and 12
NCT00783835 (9) [back to overview]	Change From Screening in Clinical Global Impression-Severity of Illness (CGI-S) Score at Weeks 4, 8 and 12
NCT00783835 (9) [back to overview]	Change From Baseline in Adult Attention Deficit Hyperactivity Disorder (ADHD) Self-Report Scale (ASRS) Total Score at Week 4
NCT00794040 (5) [back to overview]	"Percentage of Participants That Much Improved (Score of 2) in, or Completely Recovered (Score of 1) From Their Irritability Severity, as Measured With the Clinical Global Impression-Improvement (CGI-I)."
NCT00794040 (5) [back to overview]	Functional Impairment at 8th Week of Trial
NCT00794040 (5) [back to overview]	Depressive Symptoms at 8th Week of Trial
NCT00794040 (5) [back to overview]	Irritability Severity at 8th Week of Trial.
NCT00794040 (5) [back to overview]	Anxiety Symptoms at 8th Week of Trial
NCT00796302 (4) [back to overview]	NCBRF-TIQ D-Total Score
NCT00796302 (4) [back to overview]	Clinical Global Impressions Scale for Severity of Illness
NCT00796302 (4) [back to overview]	Antisocial Behavior Scale - Reactive Aggression Subscale
NCT00796302 (4) [back to overview]	Clinical Global Impressions Scale for Improvement
NCT00799409 (25) [back to overview]	Hour 7.5 Test of Handwriting Skills (Revised) (THS-R) Standard Score
NCT00799409 (25) [back to overview]	Hour 8.75 Gray Silent Reading Test (GSRT) Reading Quotient
NCT00799409 (25) [back to overview]	Hour 8.75 Packet Activity Alphabetize List of Words
NCT00799409 (25) [back to overview]	Hour 8.75 Packet Activity Complete Sentences Using Words Provided
NCT00799409 (25) [back to overview]	Hour 8.75 Packet Activity Decode the Mystery Sentence
NCT00799409 (25) [back to overview]	Hour 8.75 Packet Activity Identify Multiple Meanings for Words
NCT00799409 (25) [back to overview]	Hour 8.75 Packet Activity Identify Root Word
NCT00799409 (25) [back to overview]	Hour 8.75 Packet Activity Short Story With Questions for Comprehension
NCT00799409 (25) [back to overview]	Hour 8.75 Packet Activity Word Search
NCT00799409 (25) [back to overview]	Hour 3.0 Grammar Task
NCT00799409 (25) [back to overview]	Hour 3.5 Dynamic Indicators of Basic Early Literacy Skills (DIBELS)
NCT00799409 (25) [back to overview]	Hour 4 Permanent Product Math Test Attempted Score (PERMP-Attempted)
NCT00799409 (25) [back to overview]	Hour 4 Permanent Product Math Test Correct Score (PERMP-Correct)
NCT00799409 (25) [back to overview]	Hour 4 Swanson, Kotkin, Alger, M-Flynn and Pelham Scale for Attention (SKAMP-Attention)
NCT00799409 (25) [back to overview]	Hour 4 Swanson, Kotkin, Alger, M-Flynn and Pelham Scale for Composite (SKAMP-Composite)
NCT00799409 (25) [back to overview]	Hour 4 Swanson, Kotkin, Alger, M-Flynn and Pelham Scale for Deportment (SKAMP-Deportment)
NCT00799409 (25) [back to overview]	Hour 5.5 Test of Variables of Attention (TOVA) ADHD Composite Cutoff Score
NCT00799409 (25) [back to overview]	Hour 5.5 Test of Variables of Attention (TOVA) Commissions Standard Score
NCT00799409 (25) [back to overview]	Hour 5.5 Test of Variables of Attention (TOVA) Omissions Standard Score
NCT00799409 (25) [back to overview]	Hour 5.5 Test of Variables of Attention (TOVA) Reaction Time Standard Score
NCT00799409 (25) [back to overview]	Hour 5.5 Test of Variables of Attention (TOVA) Reaction Time Variability Standard Score
NCT00799409 (25) [back to overview]	Hour 5.5 Wechsler Intelligence Scale for Children - 3rd ed. (WISC-III-PI) Digit Span Backwards
NCT00799409 (25) [back to overview]	Hour 5.5 Wechsler Intelligence Scale for Children - 3rd ed. (WISC-III-PI) Digit Span Forwards
NCT00799409 (25) [back to overview]	Hour 5.5 Wide Range Assessment of Memory and Learning (WRAML-2) Finger Windows Backwards
NCT00799409 (25) [back to overview]	Hour 5.5 Wide Range Assessment of Memory and Learning (WRAML-2) Finger Windows Forwards
NCT00799487 (25) [back to overview]	Hour 5.5 Wide Range Assessment of Memory and Learning (WRAML-2) Finger Windows Forwards
NCT00799487 (25) [back to overview]	Hour 8.75 Packet Activity - Decode the Mystery Sentence
NCT00799487 (25) [back to overview]	Hour 8.75 Packet Activity - Complete Sentences Using Words Provided
NCT00799487 (25) [back to overview]	Hour 8.75 Packet Activity - Alphabetize List of Words
NCT00799487 (25) [back to overview]	Hour 8.75 Gray Silent Reading Test (GSRT)
NCT00799487 (25) [back to overview]	Hour 7.5 Test of Handwriting Skills (Revised) (THS-R)
NCT00799487 (25) [back to overview]	Hour 4 Permanent Product Math Test Attempted Score (PERMP-Attempted)
NCT00799487 (25) [back to overview]	Hour 5.5 Wide Range Assessment of Memory and Learning (WRAML-2) Finger Windows Backwards
NCT00799487 (25) [back to overview]	Hour 5.5 Wechsler Intelligence Scale for Children - 3rd ed. (WISC-III-PI) Digit Span Forwards
NCT00799487 (25) [back to overview]	Hour 5.5 Wechsler Intelligence Scale for Children - 3rd ed. (WISC-III-PI) Digit Span Backwards
NCT00799487 (25) [back to overview]	Hour 5.5 Test of Variables of Attention(TOVA) Reaction Time Variability (Standard Deviation in Milliseconds (Msecs))
NCT00799487 (25) [back to overview]	Hour 3.5 Dynamic Indicators of Basic Early Literacy Skills (DIBELS)
NCT00799487 (25) [back to overview]	Hour 5.5 Test of Variables of Attention (TOVA) Omissions
NCT00799487 (25) [back to overview]	Hour 4 Swanson, Kotkin, Alger, M-Flynn and Pelham Scale for Deportment (SKAMP-Deportment)
NCT00799487 (25) [back to overview]	Hour 8.75 Packet Activity - Identify Multiple Meanings for Words
NCT00799487 (25) [back to overview]	Hour 8.75 Packet Activity - Identiy Root Word
NCT00799487 (25) [back to overview]	Hour 8.75 Packet Activity - Short Story With Questions for Comprehension
NCT00799487 (25) [back to overview]	Hour 8.75 Packet Activity - Word Search
NCT00799487 (25) [back to overview]	Hour 5.5 Test of Variables of Attention (TOVA) ADHD Score
NCT00799487 (25) [back to overview]	Hour 5.5 Test of Variables of Attention (TOVA) Commissions
NCT00799487 (25) [back to overview]	Hour 5.5 Test of Variables of Attention (TOVA) Reaction Time (Msec)
NCT00799487 (25) [back to overview]	Hour 4 Swanson, Kotkin, Alger, M-Flynn and Pelham Scale for Composite (SKAMP-Composite)
NCT00799487 (25) [back to overview]	Hour 3.0 Grammar Task
NCT00799487 (25) [back to overview]	Hour 4 Swanson, Kotkin, Alger, M-Flynn and Pelham Scale for Attention (SKAMP-Attention)
NCT00799487 (25) [back to overview]	Hour 4 Permanent Product Math Test Correct Score (PERMP-Correct)
NCT00844090 (1) [back to overview]	Change in HbA1c Over Baseline
NCT00889915 (3) [back to overview]	Clinical Global Improvements-Acceptability (CGI-A) Scale
NCT00889915 (3) [back to overview]	Clinical Global Impressions-Improvement (CGI-I) Scale
NCT00889915 (3) [back to overview]	Dichotomized Clinical Global Impression-Effectiveness (CGI-E) Scale
NCT00901576 (8) [back to overview]	Time of Plasma Half-Life(T 1/2) of Guanfacine
NCT00901576 (8) [back to overview]	Time of Maximum Plasma Concentration (Tmax) of Guanfacine
NCT00901576 (8) [back to overview]	T 1/2 of d-Methylphenidate
NCT00901576 (8) [back to overview]	Maximum Plasma Concentration (Cmax) of Guanfacine
NCT00901576 (8) [back to overview]	Cmax of d-Methylphenidate
NCT00901576 (8) [back to overview]	AUC of d-Methylphenidate
NCT00901576 (8) [back to overview]	Tmax of d-Methylphenidate
NCT00901576 (8) [back to overview]	Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Guanfacine
NCT00904670 (7) [back to overview]	Permanent Product Measure of Performance (PERMP) Score Over 12 Hours
NCT00904670 (7) [back to overview]	SKAMP Quality of Work Subscale Score Over 12 Hours
NCT00904670 (7) [back to overview]	SKAMP Deportment Subscale Score Over 12 Hours
NCT00904670 (7) [back to overview]	Onset and Duration of Clinical Effect Based on SKAMP-Combined Scale
NCT00904670 (7) [back to overview]	SKAMP Compliance Subscale Score Over 12 Hours
NCT00904670 (7) [back to overview]	SKAMP Attention Subscale Score Over 12 Hours
NCT00904670 (7) [back to overview]	Swanson, Kotin, Agler, M-Flynn, and Pelham Rating Scale (SKAMP)-Combined Scores at Hour 4 Post-Dose
NCT00922636 (52) [back to overview]	Change From Baseline in the Conners' Comprehensive Behavior Rating Scale (CP-CBRS DSM-IV-TR) Symptom Subscale for Oppositional Defiant Disorder (ODD) Total Score at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) Total Score at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) Total Score at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Conners' Comprehensive Behavior Rating Scale (CP-CBRS DSM-IV-TR) Conduct Disorder Symptom Subscale Score at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Conners' Comprehensive Behavior Rating Scale (CP-CBRS DSM-IV-TR) Conduct Disorder Symptom Subscale Score at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Conners' Comprehensive Behavior Rating Scale (CP-CBRS DSM-IV-TR) Major Depressive Episode Score at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Conners' Comprehensive Behavior Rating Scale (CP-CBRS DSM-IV-TR) Major Depressive Episode Score at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Conners' Comprehensive Behavior Rating Scale (CP-CBRS DSM-IV-TR) Symptom Subscale for Manic Episode - Total Score at 8 Weeks in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Conners' Comprehensive Behavior Rating Scale (CP-CBRS DSM-IV-TR) Symptom Subscale for Manic Episode - Total Score at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Conners' Comprehensive Behavior Rating Scale (CP-CBRS DSM-IV-TR) Symptom Subscale for Oppositional Defiant Disorder (ODD) Total Score at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Swanson, Nolan and Pelham (SNAP-IV) Oppositional Defiant Disorder (ODD) Total Score at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Swanson, Nolan and Pelham (SNAP-IV) Oppositional Defiant Disorder (ODD) Total Score at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Swanson, Nolan and Pelham Questionnaire: Attention-Deficit/Hyperactivity Disorder Subscale (SNAP-IV: ADHD) Total Score at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Swanson, Nolan and Pelham Questionnaire: Attention-Deficit/Hyperactivity Disorder Subscale (SNAP-IV: ADHD) Total Score at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Wechsler Intelligence Scale for Children - Fourth Edition (WISC-IV) Digit Span Total Score at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Wechsler Intelligence Scale for Children - Fourth Edition (WISC-IV) Digit Span Total Score at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Child Health and Illness Profile - Child Edition (CHIP-CE) at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Child Health and Illness Profile-Adolescent Edition (CHIP-AE) Domain Scores at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Conners' Comprehensive Behavior Rating Scale (CP-CBRS) Content Subscales - Total Score at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Child Health and Illness Profile-Adolescent Edition (CHIP-AE) Domain Scores at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Conners' Comprehensive Behavior Rating Scale (CP-CBRS DSM-IV-TR) Generalized Anxiety Disorder (GAD) and Separation Anxiety Disorder Symptom Subscales at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Conners' Comprehensive Behavior Rating Scale (CP-CBRS DSM-IV-TR) Generalized Anxiety Disorder (GAD) and Separation Anxiety Disorder Symptom Subscales at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Conners' Comprehensive Behavior Rating Scale (CP-CBRS) Academic Difficulties Total Score and the Language and Math Subscales at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Conners' Comprehensive Behavior Rating Scale (CP-CBRS) Academic Difficulties Total Score and the Language and Math Subscales at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Hyperactivity-Impulsivity and Inattention Subtotal Scores at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Conners' Comprehensive Behavior Rating Scale (CP-CBRS) Content Subscales - Total Score at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Child Health and Illness Profile - Child Edition (CHIP-CE) at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Conners' Comprehensive Behavior Rating Scale (CP-CBRS DSM-IV-TR ADHD) Predominantly Hyperactive-Impulsive Type and Predominantly Inattentive Type Total Score and Symptom Scores at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Conners' Comprehensive Behavior Rating Scale (CP-CBRS) Impairment Items Subscales-Total Score at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Conners' Comprehensive Behavior Rating Scale (CP-CBRS) Impairment Items Subscales-Total Score at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the CP-CBRS DSM-IV-TR ADHD Predominantly Hyperactive-Impulsive Type and Predominantly Inattentive Type Total Score and Symptom Scores at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Rapid Automatized Naming/Rapid Alternating Stimulus Test (RAN/RAS) Subtotal Scores at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Rapid Automatized Naming/Rapid Alternating Stimulus Test (RAN/RAS) Subtotal Scores at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Wechsler Intelligence Scale for Children - Fourth Edition (WISC-IV) Digit Span Subtotal Scores at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Wechsler Intelligence Scale for Children - Fourth Edition (WISC-IV) Digit Span Subtotal Scores at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Number of Participants With Suicidal Behaviors, Ideations, and Acts Based on The Columbia Suicide Severity Rating Scale (C-SSRS) at Week 8
NCT00922636 (52) [back to overview]	Number of Participants With Suicidal Behaviors, Ideations, and Acts Based on The Columbia Suicide Severity Rating Scale (C-SSRS) at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the ADHDRS-IV-Parent:Inv Hyperactivity-Impulsivity and Inattention Subtotal Scores at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator-Administered and Scored (ADHD-RS-IV-PV:IR) Total Score at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator-Administered and Scored (ADHD-RS-IV-PV:IR) Total Score at Week 8
NCT00922636 (52) [back to overview]	Number of Participants With a Response (Response Rate) up to Week 8
NCT00922636 (52) [back to overview]	Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Improvement Scale (CGI-ADHD-I) Endpoint Score During the Treatment Phase (Weeks 1-8) in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Improvement Scale (CGI-ADHD-I) Endpoint Score During the Treatment Phase (Weeks 1-8)
NCT00922636 (52) [back to overview]	Change From Baseline in the Weekly Parent Ratings of Evening and Morning Behavior-Revised (WPREMB-R) Total Score at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Weekly Parent Ratings of Evening and Morning Behavior-Revised (WPREMB-R) Total Score at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Wechsler Intelligence Scale for Children - Fourth Edition (WISC-IV) Letter-Number Sequencing Score at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Weekly Parent Ratings of Evening and Morning Behavior-Revised (WPREMB-R) Morning Summary Score at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Weekly Parent Ratings of Evening and Morning Behavior-Revised (WPREMB-R) Morning Summary Score at Week 8
NCT00922636 (52) [back to overview]	Number of Participants With a Response (Response Rate) up to Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Weekly Parent Ratings of Evening and Morning Behavior-Revised (WPREMB-R ) Evening Summary Score at Week 8 in Stimulant Naive Methylphenidate Group
NCT00922636 (52) [back to overview]	Change From Baseline in the Weekly Parent Ratings of Evening and Morning Behavior-Revised (WPREMB-R ) Evening Summary Score at Week 8
NCT00922636 (52) [back to overview]	Change From Baseline in the Wechsler Intelligence Scale for Children - Fourth Edition (WISC-IV) Letter-Number Sequencing Score at Week 8 in Stimulant Naive Methylphenidate Group
NCT00989950 (1) [back to overview]	Sleep Latency
NCT01012622 (16) [back to overview]	Change From Baseline in Parenting Stress Index (PSI) Total Score at Week 12
NCT01012622 (16) [back to overview]	Change From Baseline in Korean Version of the Attention-Deficit Hyperactivity Disorder (K-ADHD) Rating Scale (K-ARS) Total Score at Week 12
NCT01012622 (16) [back to overview]	Change From Baseline in Interference-Selective Attention Subtest of Comprehensive Attention Test (CAT) Total Score at Week 12
NCT01012622 (16) [back to overview]	Change From Baseline in Inhibition-Sustained Attention Subtest of Comprehensive Attention Test (CAT) Total Score at Week 12
NCT01012622 (16) [back to overview]	Clinical Global Impression - Improvement (CGI-I) Scale Score at Week 12
NCT01012622 (16) [back to overview]	Number of Participants With Remission Based on K-ARS Total Score and Clinical Global Impression - Improvement (CGI-I) Scale Score at Week 12
NCT01012622 (16) [back to overview]	Change From Baseline in Working Memory Forward Subtest of Comprehensive Attention Test (CAT) at Week 12
NCT01012622 (16) [back to overview]	Change From Baseline in Academic Performance Rating Scale (APRS) Score at Week 12
NCT01012622 (16) [back to overview]	Change From Baseline in Auditory Selective Attention Subtest of Comprehensive Attention Test (CAT) Total Score at Week 12
NCT01012622 (16) [back to overview]	Change From Baseline in Beck Depression Inventory (BDI) Score at Week 12
NCT01012622 (16) [back to overview]	Change From Baseline in Child Health and Illness Profile-Child Edition (CHIP) Total Score and 5 Sub-domains Score at Week 12
NCT01012622 (16) [back to overview]	Change From Baseline in Clinical Global Impression-severity (CGI-S) Score at Week 12
NCT01012622 (16) [back to overview]	Change From Baseline in Divided Attention Subtest of Comprehensive Attention Test (CAT) at Week 12
NCT01012622 (16) [back to overview]	Change From Baseline in Working Memory Backward Subtest of Comprehensive Attention Test (CAT) at Week 12
NCT01012622 (16) [back to overview]	Change From Baseline in Visual Selective Attention Subtest of Comprehensive Attention Test (CAT) Total Score at Week 12
NCT01012622 (16) [back to overview]	Number of Participants With Response Based on K-ARS Total Score at Week 12
NCT01060150 (12) [back to overview]	Clinical Global Impression - Severity (CGI-S) Score
NCT01060150 (12) [back to overview]	Korean Version of the Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (K-ARS) Score
NCT01060150 (12) [back to overview]	Learning Skill Test (LST) Total Score
NCT01060150 (12) [back to overview]	Attention-Deficit/Hyperactivity Disorder (ADHD) Diagnostic System (ADS) Test Result for Omission Errors and Commission Errors
NCT01060150 (12) [back to overview]	Attention-Deficit/Hyperactivity Disorder (ADHD) Diagnostic System (ADS) Test Score for Reaction Time and Response Variability
NCT01060150 (12) [back to overview]	Controlled Oral Words Association Test (COWAT) Score
NCT01060150 (12) [back to overview]	Digit Span Test Score
NCT01060150 (12) [back to overview]	Finger Window (FW) Test Score
NCT01060150 (12) [back to overview]	Stroop Test Result for False Reaction
NCT01060150 (12) [back to overview]	Stroop Test Result for Reaction Time
NCT01060150 (12) [back to overview]	Stroop Test Score for Ratio Interference
NCT01060150 (12) [back to overview]	Clinical Global Impression - Improvement (CGI-I) Score
NCT01063153 (2) [back to overview]	Adult ADHD Investigator Symptom Rating Scale (AISRS)
NCT01063153 (2) [back to overview]	Percent Errors in Visual Go/NoGo Task
NCT01100268 (2) [back to overview]	Number of Patients Who Met and Exceeded Response Criteria of Attention Deficit Hyperactivity Disorder Symptom Scale
NCT01100268 (2) [back to overview]	Number of Patients Who Met Response Criteria for the Saving Inventory-Revised.
NCT01109849 (18) [back to overview]	Change Score for z Weight
NCT01109849 (18) [back to overview]	Change Score for Z-height Baseline to Endpoint
NCT01109849 (18) [back to overview]	Change in Weight z Score During Weight Recovery Phase (Second Randomization) Based on Actual Usage
NCT01109849 (18) [back to overview]	Number of Behavior Therapy Sessions
NCT01109849 (18) [back to overview]	Change in zBody Mass Index (BMI)
NCT01109849 (18) [back to overview]	Change in Zscore for BMI During Weight Recovery Phase (Second Randomization)
NCT01109849 (18) [back to overview]	Change in BMI z Score by Actual Medication Usage
NCT01109849 (18) [back to overview]	Change Score for Zheight Months 0 to 6
NCT01109849 (18) [back to overview]	Treatment Adherence for Caloric Supplement
NCT01109849 (18) [back to overview]	Medication Adherence
NCT01109849 (18) [back to overview]	ADHD Symptoms- Parent Rated
NCT01109849 (18) [back to overview]	ADHD Symptoms- Teacher Rated
NCT01109849 (18) [back to overview]	Change in BMI z Score During Weight Recovery Period (Second Randomization) Based on Actual Usage
NCT01109849 (18) [back to overview]	Change in Height z Score by Actual Medication Usage
NCT01109849 (18) [back to overview]	Change in Height z Score During Weight Recovery Phase (Second Randomization)
NCT01109849 (18) [back to overview]	Change in Weight z Score by Actual Medication Usage
NCT01109849 (18) [back to overview]	Difference in Height z Score During Weight Recovery Phase (Second Randomization) by Actual Usage
NCT01109849 (18) [back to overview]	Change in Weight z Score During Weight Recovery Phase (Second Randomization)
NCT01117181 (8) [back to overview]	Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change
NCT01117181 (8) [back to overview]	Apathy Evaluation Scale (AES)
NCT01117181 (8) [back to overview]	Digit Span
NCT01117181 (8) [back to overview]	Electrocardiogram (ECG)
NCT01117181 (8) [back to overview]	Mini-Mental State Exam (MMSE)
NCT01117181 (8) [back to overview]	Neuropsychiatric Inventory (NPI): Apathy Subscale
NCT01117181 (8) [back to overview]	Electrolytes
NCT01117181 (8) [back to overview]	Vital Status
NCT01127646 (2) [back to overview]	Change From Baseline in Heart Rate up to 5 Weeks
NCT01127646 (2) [back to overview]	Change From Baseline in Systolic and Diastolic Blood Pressure up to 5 Weeks
NCT01133847 (11) [back to overview]	Test of Silent Reading Fluency and Comprehension (TOSREC)
NCT01133847 (11) [back to overview]	Wechsler Individual Achievement Test-III (WIAT-III) Reading Comprehension Subtest
NCT01133847 (11) [back to overview]	Dynamic Indicators of Basic Early Literacy Skills Oral Reading Fluency Subtest (DIBELS ORF)
NCT01133847 (11) [back to overview]	Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Parent Rating of Hyperactivity-impulsivity
NCT01133847 (11) [back to overview]	Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Parent Rating of Inattention
NCT01133847 (11) [back to overview]	Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Teacher Rating of Hyperactivity-impulsivity
NCT01133847 (11) [back to overview]	Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Teacher Rating of Inattention
NCT01133847 (11) [back to overview]	Test of Word Reading Efficiency (TOWRE) - Phonemic Decoding Efficiency
NCT01133847 (11) [back to overview]	Test of Word Reading Efficiency (TOWRE) - Sight Word Efficiency
NCT01133847 (11) [back to overview]	Wechsler Individual Achievement Test-III (WIAT-III) Pseudoword Decoding Subtest
NCT01133847 (11) [back to overview]	Wechsler Individual Achievement Test-III (WIAT-III) Word Reading Subtest
NCT01164956 (3) [back to overview]	Rate of Receiving Clinically Definite Answer Regarding the Ability of Experimental Treatment to Reduce Fatigue Using the N-1-T Design
NCT01164956 (3) [back to overview]	Completion Rate of Two Treatment Pairs Using the N-1-T Design
NCT01164956 (3) [back to overview]	Change Over Treatment Pairs in pedsFACIT-F Score
NCT01183234 (3) [back to overview]	Maximum Plasma Concentration (Cmax) for MPH Using Two Different Formulations (Equasym XL and Metadate CD)
NCT01183234 (3) [back to overview]	Area Under the Steady-state Plasma Concentration-time Curve (AUC 0-t) for Methylphenidate Hydrochloride (MPH) Using Two Different Formulations (Equasym XL and Metadate CD)
NCT01183234 (3) [back to overview]	Time of Maximum Plasma Concentration (Tmax) for MPH Using Two Different Formulations (Equasym XL and Metadate CD)
NCT01238822 (1) [back to overview]	Attention Deficit / Hyperactivity Disorder Total Sum Score of All 18 ADHD Symptom Items
NCT01239030 (1) [back to overview]	Change in ADHD-RS-IV Total Score From Baseline (Visit 2) to the End of the Double-Blind Phase (Visit 3)
NCT01259492 (13) [back to overview]	Change From Baseline Period 1 (Baseline 1) to End of Period 1 on Sheehan Disability Scale (SDS) Total Score by Treatment
NCT01259492 (13) [back to overview]	Change From Baseline of Period 1 (Baseline 1) to End of Period 1 on Attention-Deficit/Hyperactivity Disorder Rating Scale (DSM-IV ADHD RS) Total Score by Treatment
NCT01259492 (13) [back to overview]	Change From Baseline Period 3 (Baseline 2) to End of Period 3 in ASRS Total Score by Treatment
NCT01259492 (13) [back to overview]	Number of Participants With Clinical Global Impression - Improvement Scale Severity of Illness (CGI-S) Rating at the End of Period 2 (Visit 13/ Week 14)
NCT01259492 (13) [back to overview]	Percentage of Participants With Treatment Failures During Period 3
NCT01259492 (13) [back to overview]	Number of Participants With Clinical Global Impression - Improvement Scale (CGI-I) Rating at the End of Period 2 (Visit 13/ Week 14)
NCT01259492 (13) [back to overview]	Change From Baseline 1 in DSM-IVADHD RS Total Score, SDS Total Score, The Conners' Adult ADHD Rating Scale Observer Short Version (CAARS-O:S) Total Score and Adult Self-Report Scale (ASRS) Total Score at the End of Period 2 (Visit 13/ Week 14)
NCT01259492 (13) [back to overview]	Percentage of Patients With Improvement on Clinical Global Impression - Improvement Scale (CGI-I) From Baseline Period 1 (Baseline 1) to End of Period 1
NCT01259492 (13) [back to overview]	Number of Patients With Worsening on CGI-S Scale From Baseline Period 3 (Baseline 2) to End of Period 3 by Treatment
NCT01259492 (13) [back to overview]	Number of Patients With Worsening on CGI-I Scale From Baseline Period 3 (Baseline 2) to End of Period 3 by Treatment
NCT01259492 (13) [back to overview]	Change From Baseline Period 3 (Baseline 2) to End of Period 3 on SDS Total Score by Treatment
NCT01259492 (13) [back to overview]	Change From Baseline Period 3 (Baseline 2) to End of Period 3 on DSM-IV Attention-Deficit/Hyperactivity Disorder Rating Scale ADHD RS Total Score by Treatment
NCT01259492 (13) [back to overview]	Change From Baseline Period 3 (Baseline 2) to End of Period 3 in Conners Adult ADHD Rating Scales Observer: Short Version (CAARS-O:S:) Total Score by Treatment
NCT01267292 (14) [back to overview]	Reversal Learning as Assessed by Number of Perseverative Errors on the Reversal Learning Task
NCT01267292 (14) [back to overview]	Reversal Learning as Assessed by Number of Perseverative Errors on the Reversal Learning Task
NCT01267292 (14) [back to overview]	Rapid Response Inhibition as Assessed by the Immediate Memory Task (IMT)
NCT01267292 (14) [back to overview]	Rapid Response Inhibition as Assessed by the Immediate Memory Task (IMT)
NCT01267292 (14) [back to overview]	Reversal Learning as Assessed by Number of Perseverative Errors on the Reversal Learning Task
NCT01267292 (14) [back to overview]	Rapid Response Inhibition as Assessed by the Immediate Memory Task (IMT)
NCT01267292 (14) [back to overview]	Diastolic Blood Pressure
NCT01267292 (14) [back to overview]	Systolic Blood Pressure
NCT01267292 (14) [back to overview]	Subjective Effects as Assessed by Score on the Vigor Subscale of the Profile of Mood States (POMS)
NCT01267292 (14) [back to overview]	Risky Decision Making as Assessed by Score on the Risky Decision Making Task
NCT01267292 (14) [back to overview]	Heart Rate
NCT01267292 (14) [back to overview]	Attentional Bias as Assessed by Score on the Stroop Task
NCT01267292 (14) [back to overview]	"Subjective Effects as Assessed by the Elated Subscale of the Visual Analogue Scale (VAS)"
NCT01267292 (14) [back to overview]	"Subjective Effects as Assessed by Score on the Feel High Subscale of the Drug Effects Questionnaire (DEQ)"
NCT01269463 (2) [back to overview]	Comparison Following Treatment Between Drug and Placebo Using Evaluation by SKAMP Combined, Attention, and Deportment Scales
NCT01269463 (2) [back to overview]	Comparison Following Treatment With Drug or Placebo Using PERMP (Permanent Product of Arithmetic) Evaluations
NCT01338818 (3) [back to overview]	Change From Extension Baseline (Week 40) to End of Study (Week 66) on Sheehan Disability Scale (SDS) Total Score
NCT01338818 (3) [back to overview]	Number of Participants With Adverse Events, Serious Adverse Events and Deaths.
NCT01338818 (3) [back to overview]	Change From Extension Baseline (Week 40) to End of Study (Week 66) in on DSM-IV Attention-Deficit/Hyperactivity Disorder Rating Scale (DSM-IV ADHD RS) Total Score.
NCT01348607 (2) [back to overview]	Average Daytime Napping Minutes in a Week
NCT01348607 (2) [back to overview]	Adverse Events
NCT01399827 (5) [back to overview]	Efficacy Measured by Mean Change From Baseline to Endpoint on Clinical Global Impression (CGI) Scale
NCT01399827 (5) [back to overview]	Efficacy Measured by Mean Change From Baseline to Endpoint on the Global Assessment of Functioning (GAF) Scale
NCT01399827 (5) [back to overview]	Efficacy Measured by Mean Change From Baseline to Endpoint on Adult ADHD Investigator Rating Scale (AISRS) Total Score
NCT01399827 (5) [back to overview]	Mean Change From Baseline to Endpoint on the BRIEF-A Emotional Control Scale
NCT01399827 (5) [back to overview]	Efficacy Measured by Mean Change From Baseline to Endpoint on BRIEF-A Subscales
NCT01533493 (1) [back to overview]	Percent Change in Global Executive Composite T-Score on the Behavior Rating Inventory of Executive Function-Adult (BRIEF-A)
NCT01552902 (5) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
NCT01552902 (5) [back to overview]	Change From Baseline in Blood Pressure at Week 6
NCT01552902 (5) [back to overview]	Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at Week 6
NCT01552902 (5) [back to overview]	Change From Baseline in Pulse Rate at Week 6
NCT01552902 (5) [back to overview]	Percentage of Participants With an Improvement on Clinical Global Impression - Global Improvement (CGI-I) at Week 6
NCT01552915 (5) [back to overview]	Change From Baseline in Systolic Blood Pressure at up to 8 Weeks - Last on Treatment Assessment
NCT01552915 (5) [back to overview]	Change From Baseline in Diastolic Blood Pressure at up to 8 Weeks - Last on Treatment Assessment
NCT01552915 (5) [back to overview]	Percentage of Participants With Improvement on Clinical Global Impression - Global Improvement (CGI-I) at Week 8 - Last Observation Carried Forward (LOCF)
NCT01552915 (5) [back to overview]	Change From Baseline in Pulse Rate at up to 8 Weeks - Last on Treatment Assessment
NCT01552915 (5) [back to overview]	Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at Week 8
NCT01678209 (7) [back to overview]	Finger Windows
NCT01678209 (7) [back to overview]	Digit Span
NCT01678209 (7) [back to overview]	Adult Attention Deficit Hyperactivity Disorder Investigator Symptom Rating Scale (ADHD-RS)
NCT01678209 (7) [back to overview]	Clinical Global Impressions-Severity (CGI-S)
NCT01678209 (7) [back to overview]	Continuous Performance Test (CPT)
NCT01678209 (7) [back to overview]	Response Time in Attention Networks Test (ANT)
NCT01678209 (7) [back to overview]	Percentage of Correct Inhibition in Participants Assessed With the Go-No go Task
NCT01727414 (1) [back to overview]	Attention Deficit Hyperactivity Disorder Total Symptom Score
NCT01740206 (6) [back to overview]	mYPAS Measurement in Patients Not Receiving Midazolam
NCT01740206 (6) [back to overview]	Heart Rate
NCT01740206 (6) [back to overview]	Diastolic Blood Pressure
NCT01740206 (6) [back to overview]	mYPAS Measurement in Patients Receiving Midazolam
NCT01740206 (6) [back to overview]	Mean Blood Pressure
NCT01740206 (6) [back to overview]	Systolic Blood Pressure
NCT01825577 (2) [back to overview]	Timed Get Up and Go Test - Measure of Mobility
NCT01825577 (2) [back to overview]	POMA -Performance Oriented Mobility Assessment - Measure of Gait and Balance.
NCT01852344 (3) [back to overview]	Accuracy on the Multi-Source Interference Task.
NCT01852344 (3) [back to overview]	Reaction Time on the Multi-Source Interference Task
NCT01852344 (3) [back to overview]	Reaction Time Variability on the Multi-Source Interference Task.
NCT01853280 (1) [back to overview]	Adult ADHD Investigator Symptom Rating Scale (AISRS)
NCT01896700 (8) [back to overview]	Change From Baseline in Timed 25 Foot Walk (T25FW) at 6 Weeks
NCT01896700 (8) [back to overview]	Change From Baseline in Pittsburgh Sleep Quality Assessment Questionnaire Score at 6 Weeks
NCT01896700 (8) [back to overview]	Change From Baseline in Modified Fatigue Index Scale Score at 6 Weeks
NCT01896700 (8) [back to overview]	Change From Baseline in Automatic Postural Response (APR) Latency at 6 Weeks
NCT01896700 (8) [back to overview]	Change From Baseline in Vestibular-Ocular Reflex (VOR) Gain at 6 Weeks
NCT01896700 (8) [back to overview]	Change From Baseline in Vestibular Ocular Reflex (VOR) Phase (in Degrees) at 6 Weeks
NCT01896700 (8) [back to overview]	Change From Baseline in Vestibular Ocular Reflex (VOR) Asymmetry (Percentage Asymmetric) at 6 Weeks
NCT01896700 (8) [back to overview]	Change From Baseline in Timed Up and Go (TUG) Test Time at 6 Weeks
NCT01907360 (6) [back to overview]	PK Parameters for Rate and Extent of Absorption of MPH in Plasma: Plasma Concentration-time Curve
NCT01907360 (6) [back to overview]	PK Parameters for Rate and Extent of Absorption of MPH: Lag Time
NCT01907360 (6) [back to overview]	PK Parameters for Rate and Extent of Absorption of MPH: Cmax
NCT01907360 (6) [back to overview]	PK Parameters for Rate and Extent of Absorption of MPH: AUC0-tz
NCT01907360 (6) [back to overview]	PK Parameters for Rate and Extent of Absorption of MPH: AUC0-inf
NCT01907360 (6) [back to overview]	PK Parameters for Rate and Extent of Absorption of MPH: Tmax
NCT01912352 (2) [back to overview]	Change From Baseline ADHD Rating Scale-IV Scores at 8 Weeks
NCT01912352 (2) [back to overview]	Clinical Global Impression-Improvement Scale at 8 Weeks
NCT01933217 (3) [back to overview]	Parent Outcome-Behavior Rating Inventory of Executive Functioning (BRIEF)
NCT01933217 (3) [back to overview]	Neuropsychological Outcome- Wechsler Intelligence Scale for Children, 4th Edition Processing Speed Index (WISC-IV-PSI)
NCT01933217 (3) [back to overview]	Parent Outcome-Vanderbilt ADHD Parent Rating Scales (VADPRS)
NCT01933880 (29) [back to overview]	WCST: Percentage of Correct Responses (Rc%)
NCT01933880 (29) [back to overview]	WCST: Percentage of Perseverative Error Responses (Rpe%)
NCT01933880 (29) [back to overview]	WCST: Perseverative Error Responses (Rpe)
NCT01933880 (29) [back to overview]	WCST: Perseverative Responses (Rp)
NCT01933880 (29) [back to overview]	Wisconsin Card Sorting Test (WCST): Administered Responses (Ra) of Completed Examination
NCT01933880 (29) [back to overview]	WCST: Percentage of Conceptual Level Responses (Rf%)
NCT01933880 (29) [back to overview]	Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 2
NCT01933880 (29) [back to overview]	Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale at Week 12
NCT01933880 (29) [back to overview]	Academic Achievement
NCT01933880 (29) [back to overview]	Change From Baseline in Completion Time of Stroop Color-word Test at Week 12
NCT01933880 (29) [back to overview]	Change From Baseline in Digit Span Test Total Score at Week 12
NCT01933880 (29) [back to overview]	Change From Baseline in I/O Score of IOWA Conners Behavior Rating Scale at Week 12
NCT01933880 (29) [back to overview]	Change From Baseline in Inattention/Overactivity With Aggression (IOWA) Conners Behavior Rating Scale - I/O Score at Week 1
NCT01933880 (29) [back to overview]	Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 12
NCT01933880 (29) [back to overview]	Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 3
NCT01933880 (29) [back to overview]	Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 7
NCT01933880 (29) [back to overview]	Change From Baseline in Total Scores of Digit Span Test at Week 12
NCT01933880 (29) [back to overview]	Coding Test
NCT01933880 (29) [back to overview]	Number of Participants Compliant With Treatment
NCT01933880 (29) [back to overview]	Number of Participants With Clinical Global Impression - CGI Scale Score
NCT01933880 (29) [back to overview]	Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale.
NCT01933880 (29) [back to overview]	Stroop Color Word Naming Test
NCT01933880 (29) [back to overview]	WCST: Completed Categories (Cc)
NCT01933880 (29) [back to overview]	WCST: Correct Responses (Rc)
NCT01933880 (29) [back to overview]	WCST: Error Responses (Re)
NCT01933880 (29) [back to overview]	WCST: Failure to Maintain Set (Fm)
NCT01933880 (29) [back to overview]	WCST: First Response (Rf)
NCT01933880 (29) [back to overview]	WCST: Learning to Learn (L-C)
NCT01933880 (29) [back to overview]	WCST: Non-Persistent Error Responses (nRpe)
NCT01993108 (4) [back to overview]	Reaction Time on the Multi-Source Interference Task
NCT01993108 (4) [back to overview]	Characterize the Effects of Methylphenidate and Naltrexone on Neural Circuits in Prefrontal Cortex Associated With Top-down Control.
NCT01993108 (4) [back to overview]	Accuracy on the Multi-Source Interference Task
NCT01993108 (4) [back to overview]	Reaction Time Variability on the Multi-Source Interference Task
NCT02039908 (3) [back to overview]	Endpoint Medication Dose
NCT02039908 (3) [back to overview]	Time to First Dose Increase
NCT02039908 (3) [back to overview]	Number of Dose Changes Required Per Protocol
NCT02051452 (2) [back to overview]	Number of Participants With Adverse Events
NCT02051452 (2) [back to overview]	Time to Emergence From General Anesthesia
NCT02096952 (1) [back to overview]	Change in Adult ADHD Investigator Symptom Report Scale (AISRS) Score
NCT02153944 (28) [back to overview]	Measure of Heart Rate
NCT02153944 (28) [back to overview]	Reaction Time to Stimuli: Threat Condition - 3BACK - Run 1
NCT02153944 (28) [back to overview]	Reaction Time to Stimuli: Threat Condition - 3BACK - Run 2
NCT02153944 (28) [back to overview]	Magnitude of Startle Reflex During Safe Condition
NCT02153944 (28) [back to overview]	Magnitude of Startle Reflex During Threat Condition
NCT02153944 (28) [back to overview]	Measure of BOLD Response in Brain Cluster - Threat Condition - 1BACK
NCT02153944 (28) [back to overview]	Measure of BOLD Response in Brain Cluster - Threat Condition - 3BACK
NCT02153944 (28) [back to overview]	Measure of BOLD Response in Brain Clusters - Safe Condition - 1BACK
NCT02153944 (28) [back to overview]	Measure of BOLD Response in Brain Clusters - Safe Condition - 3BACK
NCT02153944 (28) [back to overview]	Reaction Time to Stimuli: Safe Condition - 3BACK - Run 1
NCT02153944 (28) [back to overview]	Reaction Time to Stimuli: Safe Condition - 1BACK - Run 2
NCT02153944 (28) [back to overview]	Proportion of Correct Responses in the Working Memory Task (N-back): Safe Condition - 1BACK - Run 2
NCT02153944 (28) [back to overview]	Measure of Heart Rate
NCT02153944 (28) [back to overview]	Measure of Level of Anxiety
NCT02153944 (28) [back to overview]	Measure of Level of Anxiety
NCT02153944 (28) [back to overview]	Proportion of Correct Responses in the Working Memory Task (N-back) - Safe Condition
NCT02153944 (28) [back to overview]	Proportion of Correct Responses in the Working Memory Task (N-back) - Threat Condition
NCT02153944 (28) [back to overview]	Proportion of Correct Responses in the Working Memory Task (N-Back): Safe Condition - 1BACK - Run 1
NCT02153944 (28) [back to overview]	Proportion of Correct Responses in the Working Memory Task (N-back): Threat Condition - 3BACK - Run 2
NCT02153944 (28) [back to overview]	Proportion of Correct Responses in the Working Memory Task (N-back): Threat Condition - 3BACK - Run 1
NCT02153944 (28) [back to overview]	Proportion of Correct Responses in the Working Memory Task (N-back): Threat Condition - 1BACK - Run 2
NCT02153944 (28) [back to overview]	Reaction Time to Stimuli: Threat Condition - 1BACK - Run 2
NCT02153944 (28) [back to overview]	Proportion of Correct Responses in the Working Memory Task (N-back): Threat Condition - 1BACK - Run 1
NCT02153944 (28) [back to overview]	Reaction Time to Stimuli: Threat Condition - 1BACK - Run 1
NCT02153944 (28) [back to overview]	Reaction Time to Stimuli: Safe Condition - 3BACK - Run 2
NCT02153944 (28) [back to overview]	Proportion of Correct Responses in the Working Memory Task (N-back): Safe Condition - 3BACK - Run 1
NCT02153944 (28) [back to overview]	Proportion of Correct Responses in the Working Memory Task (N-back): Safe Condition - 3BACK - Run 2
NCT02153944 (28) [back to overview]	Reaction Time to Stimuli: Safe Condition - 1BACK - Run 1
NCT02178995 (20) [back to overview]	Symbol-digit Matching Test (Double-blind Portion)
NCT02178995 (20) [back to overview]	Neuropsychiatric Questionnaires
NCT02178995 (20) [back to overview]	CPT Scores (Double-blind Portion) (Secondary Variables)
NCT02178995 (20) [back to overview]	CPT Outcomes (Secondary Variables) (Open-label Portion)
NCT02178995 (20) [back to overview]	Conners' Continuous Performance Test (CPT) (Double-blind Portion, Primary Variables)
NCT02178995 (20) [back to overview]	Conners CPT Outcomes (Primary Variables) (Open-Label Portion)
NCT02178995 (20) [back to overview]	Symbol-digit Matching Test (Open Label Phase)
NCT02178995 (20) [back to overview]	Adverse Events Profile (Open-Label)
NCT02178995 (20) [back to overview]	Stimulant Side-effects Checklist
NCT02178995 (20) [back to overview]	Seizure Frequency (Open-label Portion)
NCT02178995 (20) [back to overview]	QOLIE-89 Aggregate Score
NCT02178995 (20) [back to overview]	MCG (Open-label Portion)
NCT02178995 (20) [back to overview]	Hit Reaction Time (Open-Label)
NCT02178995 (20) [back to overview]	Hit Reaction Time (Double Blind)
NCT02178995 (20) [back to overview]	Remaining CPT Variables (Open-label)
NCT02178995 (20) [back to overview]	Remaining CPT Variables (Double-blind Portion)
NCT02178995 (20) [back to overview]	QOLIE-89 Selected Cognitive Subscales (Open-label)
NCT02178995 (20) [back to overview]	Seizure Frequency/Severity (Double-blind Portion)
NCT02178995 (20) [back to overview]	MCG Paragraph Memory Test (Double-blind Portion)
NCT02178995 (20) [back to overview]	QOLIE-89 Additional Subscales (Open-label)
NCT02204410 (2) [back to overview]	Emotional Control Subscale of the Behavior Rating Inventory of Executive Function - Parent Form (BRIEF-Parent)
NCT02204410 (2) [back to overview]	Clinical Global Impression (CGI) Improvement for Deficient Emotional Self-Regulation (DESR)
NCT02225106 (1) [back to overview]	Perceptual Organization and Processing Speed Index
NCT02255513 (1) [back to overview]	SKAMP
NCT02255565 (3) [back to overview]	Clinical Global Impressions-ADHD - Severity
NCT02255565 (3) [back to overview]	Clinical Global Impression - Improvement (CGI-I)
NCT02255565 (3) [back to overview]	ADHD Rating Scale - IV
NCT02293655 (10) [back to overview]	Parent Ratings of Emotional Regulation
NCT02293655 (10) [back to overview]	Spatial Working Memory
NCT02293655 (10) [back to overview]	Written Expression
NCT02293655 (10) [back to overview]	% Time on Task
NCT02293655 (10) [back to overview]	Barkley Sluggish Cognitive Tempo (SCT) Ratings
NCT02293655 (10) [back to overview]	Inhibitory Control Reaction Time Variability (SD of the Reaction Time)
NCT02293655 (10) [back to overview]	Parent ADHD Total Symptom Scores
NCT02293655 (10) [back to overview]	Math Reasoning
NCT02293655 (10) [back to overview]	Math Computation - Number of Problems Completed Correctly
NCT02293655 (10) [back to overview]	Reading Comprehension
NCT02327195 (3) [back to overview]	Emergence Time
NCT02327195 (3) [back to overview]	Number of Participants That Experienced Postoperative Nausea and Vomiting
NCT02327195 (3) [back to overview]	Opioid Dose Escalation Prevention
NCT02346201 (2) [back to overview]	Neuropsychiatric Inventory (NPI)
NCT02346201 (2) [back to overview]	Percentage of Participants With Change in Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (CGIC)
NCT02470234 (10) [back to overview]	AUC(0-t)
NCT02470234 (10) [back to overview]	Tmax
NCT02470234 (10) [back to overview]	V(Dss)/F
NCT02470234 (10) [back to overview]	T1/2
NCT02470234 (10) [back to overview]	Cmax/Dose
NCT02470234 (10) [back to overview]	Cmax
NCT02470234 (10) [back to overview]	Kel
NCT02470234 (10) [back to overview]	CL/F
NCT02470234 (10) [back to overview]	AUC/D
NCT02470234 (10) [back to overview]	AUC(0-inf)
NCT02493777 (2) [back to overview]	Parent Rating of Evening and Morning Behavior Revised, Morning Subscale (PREMB-R AM).
NCT02493777 (2) [back to overview]	Swanson, Kotkin, Agler, M-Flynn and Pelham Combined Score (SKAMP CS) - Model-adjusted Average of All Post-dose Time Points Assessed During a Laboratory Classroom Test Day (Visit 9).
NCT02502799 (4) [back to overview]	Mean Youth Self-Report of Functional Impairment
NCT02502799 (4) [back to overview]	Mean Youth Self-Report of Disruptive Behaviors
NCT02502799 (4) [back to overview]	Mean Youth-Report of Parent-adolescent Conflict
NCT02502799 (4) [back to overview]	Mean Youth Self-Report of Likelihood of Future Substance Use
NCT02520388 (2) [back to overview]	Before School Functioning Questionnaire (BSFQ) Total Score
NCT02520388 (2) [back to overview]	Attention Deficit Hyperactivity Disorder Rating Scale Based on DSM-IV Criteria (ADHD-RS-IV) Total Score.
NCT02536105 (4) [back to overview]	Maximum Drug Concentration Observed (Cmax) for Three Methylphenidate Hydrochloride Extended-release Drug Products
NCT02536105 (4) [back to overview]	Time to Reach Cmax (Tmax) for Three Methylphenidate Hydrochloride Extended-release Drug Products
NCT02536105 (4) [back to overview]	Permanent Product Measure of Performance (PERMP) for Three Methylphenidate Hydrochloride Extended-release Drug Products
NCT02536105 (4) [back to overview]	Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Rating Scale for Three Methylphenidate Hydrochloride Extended-release Drug Products
NCT02630017 (1) [back to overview]	Number of High-effort Selections in the Effort-based Decision Making Task
NCT02638168 (12) [back to overview]	Pittsburgh Side Effects Rating Scale
NCT02638168 (12) [back to overview]	Affective Reactivity Index (ARI)
NCT02638168 (12) [back to overview]	Length of Wakings
NCT02638168 (12) [back to overview]	Parent Rated 10-item IOWA
NCT02638168 (12) [back to overview]	Number of Wakings
NCT02638168 (12) [back to overview]	Night to Night Variability (Weekends & Weekdays) - in Sleep Onset Latency Measured by Actigraphy
NCT02638168 (12) [back to overview]	Wake After Sleep Onset (WASO)
NCT02638168 (12) [back to overview]	Total Sleep Time
NCT02638168 (12) [back to overview]	Sleep Onset Latency (SOL), Defined as Time in Bed Until Sleep by Actigraphy
NCT02638168 (12) [back to overview]	Sleep Onset Latency (SOL) as Reported on the Parent Completed Sleep Log
NCT02638168 (12) [back to overview]	Sleep Offset
NCT02638168 (12) [back to overview]	Sleep Efficiency
NCT02683265 (5) [back to overview]	Attention Deficit Hyperactivity Disorder Rating Scale - 4th Edition (ADHD-RS-IV) Preschool Version Inattention Subscale Score Change From End of Open Label Phase (Baseline) to End of Double Blind.
NCT02683265 (5) [back to overview]	Attention Deficit Hyperactivity Disorder Rating Scale - 4th Edition (ADHD-RS-IV) Preschool Version Hyperactivity-Impulsivity Subscale Score Change From End of Open Label Phase (Baseline) to End of Double Blind.
NCT02683265 (5) [back to overview]	Attention Deficit Hyperactivity Disorder Rating Scale - 4th Edition (ADHD-RS-IV) Preschool Version Total Score Change From End of Open Label Phase (Baseline) to End of Double Blind.
NCT02683265 (5) [back to overview]	Conners Early Childhood Behavior - Parent (Short) (EC BEH-P(S)) Change in T-score From End of Open Label Phase (Baseline) to End of Double Blind
NCT02683265 (5) [back to overview]	Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind.
NCT03185065 (4) [back to overview]	Acceptability of Treatment as Assessed by a Single Question Questionnaire
NCT03185065 (4) [back to overview]	Epworth Sleepiness Scale (ESS) Score
NCT03185065 (4) [back to overview]	Modified Fatigue Impact Scale (MFIS) Score
NCT03185065 (4) [back to overview]	Quality of Life in Neurological Disorders (Neuro-QoL) Item Bank - Fatigue Score
NCT03811847 (3) [back to overview]	Feasibility of a Virtual Multicrossover Randomized Control Trial Design as Measured my Completion Rates and Medication Compliance.
NCT03811847 (3) [back to overview]	Cognition as Measured by the Repeatable Battery for the Assessment Neuropsychological Status-Update (RBANS)
NCT03811847 (3) [back to overview]	Cognition as Measured by Daily, Home-based Brain Games (Lumosity, Lumos Labs, Inc.)
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (0 mg) Maintenance.
NCT04178993 (36) [back to overview]	Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.
NCT04178993 (36) [back to overview]	Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.
NCT04178993 (36) [back to overview]	Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.
NCT04178993 (36) [back to overview]	Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (60 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (40 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (20 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (0 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (60 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (40 mg) Maintenance.
NCT04178993 (36) [back to overview]	Snaith-Hamilton-Pleasure Scale to Measure Anhedonia (Inability to Experience Pleasure)
NCT04178993 (36) [back to overview]	Temperature After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.
NCT04178993 (36) [back to overview]	Temperature After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (20 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (60 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (40 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (20 mg) Maintenance.
NCT04178993 (36) [back to overview]	Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (0 mg) Maintenance.
NCT04178993 (36) [back to overview]	Reinforcing Effects of Methamphetamine Following Methylphenidate (60 mg) Maintenance.
NCT04178993 (36) [back to overview]	Reinforcing Effects of Methamphetamine Following Methylphenidate (40 mg) Maintenance.
NCT04178993 (36) [back to overview]	Reinforcing Effects of Methamphetamine Following Methylphenidate (20 mg) Maintenance.
NCT04178993 (36) [back to overview]	Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance.
NCT04178993 (36) [back to overview]	Heart Rate After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.
NCT04178993 (36) [back to overview]	Heart Rate After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.
NCT04178993 (36) [back to overview]	Heart Rate After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.
NCT04178993 (36) [back to overview]	Heart Rate After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.
NCT04178993 (36) [back to overview]	Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.
NCT04178993 (36) [back to overview]	Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.
NCT04178993 (36) [back to overview]	Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.
NCT04178993 (36) [back to overview]	Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.
NCT04178993 (36) [back to overview]	Delay Discounting for Money
NCT04178993 (36) [back to overview]	Delay Discounting for Methamphetamine
NCT04178993 (36) [back to overview]	Attentional Bias
NCT04178993 (36) [back to overview]	Temperature After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.
NCT04178993 (36) [back to overview]	Temperature After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.
NCT04349917 (7) [back to overview]	Task-Based Brain Network Organization
NCT04349917 (7) [back to overview]	Resting State Brain Network Organization
NCT04349917 (7) [back to overview]	Drug-induced Normalization
NCT04349917 (7) [back to overview]	Go/No-go (GNG) Commission Rate
NCT04349917 (7) [back to overview]	Go/No-go (GNG) Omission Rate
NCT04349917 (7) [back to overview]	Go/No-go (GNG) Response Time Variability
NCT04349917 (7) [back to overview]	Rest-Task Reconfiguration
NCT04507204 (9) [back to overview]	Healthcare Resource Utilization (HCRU)
NCT04507204 (9) [back to overview]	Change in ADHD-Rating Scale 5 (ADHD-RS-5) Total Score From Baseline to Month 2 Among Patients Treated With Adhansia XR
NCT04507204 (9) [back to overview]	Assessment of Clinical Global Impression-Severity (CGI-S)
NCT04507204 (9) [back to overview]	Assessment of Clinical Global Impression-Improvement (CGI-I)
NCT04507204 (9) [back to overview]	Adult ADHD Quality of Life Scale - Revised (AAQoL-R)
NCT04507204 (9) [back to overview]	Difference in Time Sensitive ADHD Symptom Scale (TASS) Between Treatment Groups to Establish Non-inferiority
NCT04507204 (9) [back to overview]	Work Productivity and Activity Impairment (WPAI) Questionnaire
NCT04507204 (9) [back to overview]	Patient Sleep Quality as Measured by the Pittsburgh Sleep Quality Index (PSQI)
NCT04507204 (9) [back to overview]	Assessment of Treatment Satisfaction

Classroom Behavior

Daily records of percentage of assigned problems completed by children in a 60-minute classroom period. (NCT00050622)
Timeframe: Daily for 45 days

Intervention	Percentage of Work Completed (Mean)
No Treatment	37
Low Dose Medication Only	53
Medium Dose Medication Only	57
Higher Dose Medication Only	61
Low Intensity BMOD Only	53
Low Intensity BMOD + Low Dose Medication	67
Low Intensity BMOD + Medium Dose Medication	72
Low Intensity BMOD + Higher Dose Medication	75
High Intensity BMOD Only	58
High Intensity BMOD + Low Dose Medication	72
High Intensity BMOD + Medium Dose Medication	75
High Intensity BMOD + Higher Dose Medication	76

Intervention	Number of Observed Behaviors (Mean)
No Treatment	73.32
Low Dose Medication Only	45.41
Medium Dose Medication Only	28.41
Higher Dose Medication Only	15.08
Low Intensity BMOD Only	27.06
Low Intensity BMOD + Low Dose Medication	13.70
Low Intensity BMOD + Medium Dose Medication	9.27
Low Intensity BMOD + Higher Dose Medication	4.28
High Intensity BMOD Only	20.23
High Intensity BMOD + Low Dose Medication	7.61
High Intensity BMOD + Medium Dose Medication	4.08
High Intensity BMOD + Higher Dose Medication	2.49

Intervention	Units on a scale (Mean)
	Physical Summary Score	Psychosocial Summary Score
Amphetamine + SPD503	0.22	11.56
Methylphenidate + SPD503	-0.38	8.98

Intervention	Units on a scale (T-scores) (Mean)
MPH Trial-Placebo Week	70.1
MPH Trial: Low Dose Week	64.9
MPH Trial: Med Dose Week	62.3
MPH Trial: High Dose Week	59.9

Intervention	Units on a scale (T-scores) (Mean)
MPH Trial-Placebo Week	72.8
MPH Trial: Low Dose Week	63.1
MPH Trial: Med Dose Week	63.6
MPH Trial: High Dose Week	61.5

Intervention	Total Errors (Mean)
MPH Trial-Placebo Week	2.75
MPH Trial: Low Dose Week	1.11
MPH Trial: Med Dose Week	1.18
MPH Trial: High Dose Week	1.24

Intervention	units on a scale (Mean)
	Block 1 Baseline Week 0	Block 1 End of Treatment Week 6	Block 2 Baseline Week 8	Blocks 2 End of Treatment Week 14
Atomoxetine Then Methylphenidate	11.2609	10.6889	9.7108	10.9886
Methylphenidate Then Atomoxetine	10.6905	10.8257	10.1400	10.9286

Intervention	units on a scale (Mean)
	Block 1 Baseline Week 0	Block 1 End of Treatment week 6	Block 1 End of Treatment Week 8	Blocks 2 End of Treatment Week 14
Atomoxetine Then Methylphenidate	.3224	.2386	.3526	.2118
Methylphenidate Then Atomoxetine	.3385	.1978	.3078	.2304

Intervention	units on a scale (Mean)
	Block 1 Baseline Week 0	Block 1 End of Treatment Week 6	Block 2 Baseline 8	Blocks 2 End of Treatment Week 14
Atomoxetine Then Methylphenidate	16.56	7.82	13.99	6.67
Methylphenidate Then Atomoxetine	17.31	7.24	14.80	8.87

Intervention	percentage of participants (Number)
	Treatment Preference of ATX	Treatment Preference of MPH
Atomoxetine Then Methylphenidate	41.8	50.5
Methylphenidate Then Atomoxetine	27.4	51.9

Intervention	participants (Number)
Osmotic-Release Methylphenidate (OROS-MPH)	25
Osmotic-Release Methylphenidate (OROS-MPH) - Placebo	28

Intervention	DSM IV ADHD Score (Mean)
Osmotic-Release Methylphenidate (OROS-MPH)-Baseline	38.4
Osmotic-Release Methylphenidate (OROS-MPH) - Placebo-Baseline	36.6
Osmotic-Release Methylphenidate (OROS-MPH)-Week 11	16.4
Osmotic-Release Methylphenidate (OROS-MPH) - Placebo-Week 11	24.2
Release Methylphenidate (OROS-MPH)-Week 4	20.4
Osmotic-Release Methylphenidate (OROS-MPH) - Placebo-Week 4	27.2
Release Methylphenidate (OROS-MPH)-Week 7	20
Osmotic-Release Methylphenidate (OROS-MPH) - Placebo-Week 7	24
Release Methylphenidate (OROS-MPH)-Week 9	17.3
Methylphenidate (OROS-MPH) - Placebo-Week 9	23.9

Intervention	mg/L (Mean)
Placebo- Placebo	0.00
IR-MPH + OROS MPH	15.06
IR-MPH +IR-MPH	25.34
OROS-MPH+OROS-MPH	20.34
OROS-MPH+ IR-MPH	28.79

Intervention	units on a scale (Mean)
	change from baseline to endpoint in total score	change from baseline to endpoint in inattention	change from baseline to endpoint in hyperactivity
Open Label PR OROS MPH	-1.9	-1.0	-0.9

Intervention	participants (Number)
	at least one AE	at least one SAE	at least one severe AE	at least one AE leading to permanent stop	at least one AE leading to temporary stop	at least one AE with concomitant therapy	at least one AE at least possibly related
Active	7	0	0	0	0	0	3
Open Label PR OROS MPH	126	12	27	15	23	93	62
Placebo	8	1	3	0	2	4	5

Intervention	units on a scale * weeks (Mean)
	Fatigue right now	Worst fatigue last 24 hours	Fatigue interference with general activity	Fatigue interference with mood	Fatigue interference with walking ability	Fatigue interference with normal work	Fatigue interference with relations with others	Fatigue interference with enjoyment of life
Methylphenidate	179.96	144.59	187.60	205.31	210.09	179.94	224.72	194.15
Placebo	174.94	126.36	171.06	220.29	206.46	168.84	243.87	184.12

Intervention	units on a scale * weeks (Mean)
	Overall QOL	Mental well-being	Physical well-being	Emotional well-being	Social activity	Spiritual well-being
Methylphenidate	204.21	227.04	188.13	203.65	189.68	231.24
Placebo	201.34	226.40	191.07	215.65	177.34	255.88

Intervention	units on a scale (Mean)
	Nervousness	Appetite decrease	Sex drive	Abdominal pain	Dizziness	Shakiness	Heartbeat	Vomiting	Headaches	Trouble sleeping	Fatigue distress	Fatigue control satisfaction
Methylphenidate	-2.7	-5.2	-0.9	-3.5	-2.2	-0.6	-2.0	-0.8	-0.8	10.6	22.9	28.0
Placebo	9.5	6.6	9.8	3.6	2.1	1.4	-1.6	0.4	3.9	11.1	15.8	23.2

Intervention	number of sister chromatoid exchanges (Mean)
	Baseline	At the end of treatment i.e. Week12
Behavior Therapy	7.533	7.303
Ritalin LA Plus Behavior Therapy	7.807	7.213

Intervention	number of abnormalities (Mean)
	Baseline	At the end of treatment i.e. week12: Mean
Behavior Therapy	0.75	0.41
Ritalin LA Plus Behavior Therapy	1.05	0.53

Intervention	number of micronuclei per 1000 binucleat (Mean)
	At Baseline	At the end of treatment i.e. Week 12
Behavior Therapy	5.71	4.19
Ritalin LA Plus Behavior Therapy	5.76	3.63

methylphenidate

Description

Cross-References

Synonyms (94)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (3)

Protein Targets (14)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (148)

Molecular Functions (61)

Ceullar Components (42)

Bioassays (122)

Research

Studies (7,354)

Market Indicators

Research Demand Index: 122.09

Study Types

Clinical Trials (408)

Trial Overview

Trial Outcomes

Classroom Behavior

Social Behavior-Negative Verbalizations

Treatment Satisfaction

Days to Remission of Depression

Change From Baseline in Child Health Questionnaire-Parent Form (CHQ-PF50) Scores at 6 Weeks

Number of Participants With Improvement on Parent Global Assessment (PGA) Scores

Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores

Change From Baseline in the Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Total Score at 6 Weeks

Change From Baseline in Conner's Parent Rating Scale-revised Short Version (CPRS-R) Total Score at 6 Weeks

Mean Conners' Parent ADHD Index T Score by Week

Mean Conners' Teacher ADHD Index T Score by Dose

Mean Continuous Performance Test (CPT)-Commission Errors by Dose

Cigarette Smoking

Assessment of Affective Range (AAR)

Child Conflict Index (CCI)

Children's Sleep Questionnaire

Clinical Global Impressions (CGI)- Severity

Continuous Performance Test (CPT)

Social Skills Rating Scale (SSRS)- Parent Version

Tics: Total Impairment

Tics: Total Motor

Tics: Total Phonic

Vital Signs - Diastolic Blood Pressure

Vital Signs - Pulse

Vital Signs - Systolic Blood Pressure

ADHD - H/I

ADHD-RS Inattention

ADHD-RS Total Score

Treatment Preference Survey

Prolonged Abstinence

Diagnostic and Statistical Manual-IV(DSM-IV) ADHD Rating Scale

Point-prevalence Abstinence

Swanson, Nolan, and Pelham Questionnaire (SNAP-IV)

Children's Global Assessment Scale (C-GAS)

Clinical Global Impressions-Severity (CGI-S)

ADHD Severity

OROS-MPH Abuse Liability

Substance Use

Substance Use Outcomes

Peak Plasma Concentration of d-Methylphenidate

Change From OL Baseline in Clinical Global Impression Scale (CGI-S) Score at OL Endpoint

Change From OL Baseline in Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Score at OL Endpoint

Change From OL Baseline to OL Endpoint in Conners' Adult ADHD Rating Scale (CAARS) Total and Subscale Scores

Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs)

Change From DB Baseline to DB Endpoint in CGI-S Score

Change From DB Baseline to DB Endpoint in CAARS Self Rated Scale (CAARS-S:S) Total Score

Change From DB Baseline in Conners' Adult ADHD Rating Scale (CAARS) Total Score at DB Endpoint

AUC of Sleep Quality as Measured by the Pittsburgh Sleep Quality Index at Baseline and at Weeks 1-4

AUC of Vitality as Measured by the Short Form-36 Vitality Subscale at Baseline and at Weeks 1-4

Intervention	score on a scale (Median)
Methylphenidate (MP) + Nursing Telephone Intervention (NTI)	4.00
Methylphenidate (MP) + Control Telephone Intervention (CTI)	7.00
Placebo (PL)+ Nursing Telephone Intervention (NTI)	8.50
Placebo (PL) + Control Telephone Intervention (CTI)	5.00

Intervention	score on a scale (Median)
Methylphenidate (MP) + Nursing Telephone Intervention (NTI)	-3.00
Methylphenidate (MP) + Control Telephone Intervention (CTI)	-1.00
Placebo (PL)+ Nursing Telephone Intervention (NTI)	-2.00
Placebo (PL) + Control Telephone Intervention (CTI)	-2.00

Intervention	Units on a scale (Mean)
Very Light Breakfast (VLB) Treatment Group	1.15
Standard Breakfast (SB) Treatment Group	1.11

Intervention	Units on a scale (Mean)
Very Light Breakfast (VLB) Treatment Group	3.49
Standard Breakfast (SB) Treatment Group	3.56

Intervention	Problems attempted (Mean)
Very Light Breakfast (VLB) Treatment Group	116.3
Standard Breakfast (SB) Treatment Group	118.1

Intervention	Problems solved (Mean)
Very Light Breakfast (VLB) Treatment Group	106.7
Standard Breakfast (SB) Treatment Group	108.6

Intervention	units on a scale (Least Squares Mean)
	Total ADHD-RS Score	Inattentive Subscale	Hyperactive Impulsive Subscale
Estimated Difference Between DMPH and Placebo	-7.99	-4.10	-4.0
Estimated Difference Between Guan and Placebo	-7.77	-4.14	-3.73
Estimated Difference Between Placebo and Combo	-10.66	-5.89	-5.10

Intervention	Participants (Number)
	0 (no evidence of irritation)	1 (minimal erythema)	2 (definite eythema)	3 (erythema and papules)	4 (definite edema)	5 (erythema, edema, and papules)	6 (vesicular eruption)	7 (strong reaction beyond test site)	No dermal evaluation
Daytrana	46	97	151	6	3	0	0	0	2

Intervention	units on a scale (Mean)
Placebo Both Conditions	116.4
Active Drug/Active Therapy	120.5
Active Drug/Placebo Therapy	114.1
Placebo Drug/Active Therapy	118.1

Intervention	units on a scale (Mean)
Placebo Both Conditions	51.3
Active Drug/Active Therapy	51.8
Active Drug/Placebo Therapy	51.9
Placebo Drug/Active Therapy	57.2